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ABSTRACT
Epidemiological studies have observed a lower risk of coronary heart disease 
(CHD) in individuals consuming a diet high in monounsaturated fatty acids (MUFA), 
however, an understanding of the effects of MUFA on postprandial lipoprotein 
metabolism is currently lacking. In this thesis, the effects of acute and chronic MUFA 
intake, as n-9 oleic acid, on postprandial lipoprotein metabolism, especially 
chylomicron (CM) metabolism was studied.
To determine the effects of acute test meals of varying MUFA content on CM 
metabolism, triacylglycerol (TAG), apolipoprotein (apo) B-48 and retinyl ester (RE) 
were measured in plasma, triacylglycerol-rich lipoprotein (TRL) and triacylglycerol- 
poor lipoprotein (TPL) fractions. Fifteen healthy young men were recruited to 
consume the 12%, 17% and 24% test meals on 3 separate occasions and their 
metabolism of intestinally derived lipoproteins, was investigated by determining the 
time to reach peak concentration and area under the curve (AUC) for the RE, apo B-48 
and TAG parameters. On increasing the MUFA content of the test meals, the 
individual volunteer time to peak for the plasma RE and apo B-48 responses were 
significantly later than that of the TAG response (24% MUFA meal, mean (SD), TAG 
266 (126) minutes, apo B-48 293 (75) minutes (P < 0.05) and RE 428 (60) minutes 
(P < 0.05)). The lipoprotein lipase (LPL) activity, following a bolus injection of 
heparin, was significantly lower after an overnight fast compared with the activities 9 
hours following consumption of the 3 test meals (P < 0.05).
The metabolism of CM particles was also compared in 16 Northern (UK and 
Ireland) (N.E.) and 16 Southern (Greece) European (S.E.) volunteers following the 
same 3 MUFA test meals. Although there were no significant differences in the fasting 
TAG and apo B-48 responses, there was a significant difference in the pattern of 
postprandial curves (P < 0.0001), with a more rapid entry and clearance in the S.E. 
volunteers. This was possibly caused by significantly higher hepatic lipase (HE) 
activities in the S.E. volunteers (P < 0.01). The S.E. volunteers showed a different 
pattern of NEFA suppression following the meal compared with the N.E. volunteers 
(P < 0.0001). There was a significantly higher fasting glucose dependent
insulinotrophic polypeptide (GIF) level and significantly different postprandial insulin 
and GIF time response curves (P < 0.001) in the S.E. volunteers.
A 2 month random cross-over study investigated the effect of increasing the 
MUFA content of the background diet of individuals in the U.K. Thirteen healthy 
young men were recruited with a close family history of CHD. No significant 
differences were found in the fasting lipoprotein levels, but there was a greater decline 
in total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) following 
the MUFA-enriched compared with the control diet. Similar postprandial responses 
were observed following the 2 diets, with a tendency for the lipoprotein and hormonal 
responses to begin to mimic those of the S.E. responses, with an earlier entry of TAG 
and apo B-48 and higher peak insulin and GIF responses. Lower LPL and HL 
activities were observed following the MUFA-enriched compared with the control 
diet.
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Chapter 1
General Introduction
1.1 Introduction
Many lines of evidence suggest that adverse dietary habits are a contributory 
factor in coronary heart disease (CHD) (Department of Health (DOH), 1994). The diet- 
heart disease hypothesis states that dietary fat, particularly elevated intakes of saturated 
fatty acids (SFA), raise plasma cholesterol and low density lipoprotein (LDL) 
cholesterol concentrations, which in turn is associated with an increased risk of CHD. 
Almost all of the epidemiological evidence has been determined from fasting lipoprotein 
concentrations. However, individuals spend a large proportion of the day in the 
postprandial state where the lipid transport has been challenged by the absorption of 
intestinally derived lipoproteins following the consumption of a fat containing meal. 
Recent evidence indicates that the magnitude and duration of postprandial lipaemia is 
dependent on fatty acid composition of chylomicrons (CM) and their remnants (Sethi et 
al, 1993). This is important since these lipoprotein particles have been implicated in the 
pathogenesis of CHD (Zilversmit, 1979). Therefore changing the fatty acid composition 
of the diet provides a useful tool for changing the lipoprotein profile in the population 
and so modifying their inherent CHD risk.
1.2. Postprandial lipoprotein metabolism
Plasma lipoproteins are macromolecules representing complexes of lipids such 
as triacylglycerols (TAGs), cholesterol and phospholipids and one or more specific 
proteins referred to as apolipoproteins (Figure 1.1). They are involved in the transport of 
water insoluble nutrients throughout the bloodstream from their site of absorption or 
synthesis to peripheral tissue. For the correct targeting of lipoproteins to sites of 
metabolism, the lipoproteins rely heavily on the apolipoproteins associated with their 
surface coat. This is crucial since it has been shown that abnormal production and 
packaging of the apolipoprotein results in a high frequency of lipid disorders (Havel and 
Kane, 1989).
The liver and intestine are the primary sites of lipoprotein synthesis and the two 
major transported lipid components, TAG and cholesterol, follow two separate fates. 
TAGs, (stabilised by apolipoprotein B (apo B)), are shuttled primarily to adipose tissue 
and muscle where fatty acids are stored and oxidised for energy. Cholesterol, in contrast,
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Figure 1,1 Generalised structure o f  a lipoprotein particle (From Devlin, 1992)
is continuously shuttled among the liver, intestine and other extrahepatic tissues in the 
form of a complex containing apo A-L In the evolution of plasma lipoprotein, it is 
thought that metabolic links between these two pathways must have developed allowing, 
among other things, the exchange of TAG and cholesterol esters between the apo B and 
apo A-I transport systems. This was later found to be the cholesterol ester transfer 
protein (CETP) (Fielding and Fielding, 1991).
Human plasma lipoproteins are divided into five major classes according to their 
flotation density (Table 1.1). The density of the particles is inversely related to their 
sizes, reflecting the relative amounts of low density, nonpolar lipid and high density 
surface protein present. The two largest lipoproteins contain mainly TAGs within their 
core structures. These are CMs, secreted by enterocytes, and very low density
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lipoprotein (VLDL), secreted by hepatocytes. Intermediate density lipoprotein (IDL) 
contain appreciable amounts of both TAGs and cholesterol esters in their core. The two 
smallest lipoprotein classes, low density lipoprotein (LDL) and high density lipoprotein 
(HDL), contain mainly cholesterol esters in their core structures and the mature forms of 
these particles are not secreted directly from cells but are produced by metabolic 
processes within blood plasma. LDL are produced as end products of the metabolism of 
VLDL, whereas components of HDL are secreted with chylomicrons and VLDL.
The lipid metabolic pathways can be divided into the exogenous and endogenous 
cycle, which are responsible for the transport of dietary and hepatically derived lipids 
respectively (Schneider, 1991)
1.2.2 Exogenous pathway 
Digestion o f dietary fa t
The small intestine, in Western adult populations, is presented with 
approximately 100 g of dietary fat per day, comprising TAGs, phospholipids and 
sphingolipids. The composition of the dietary fat is mostly long chain fatty acids 
consisting mainly of saturated fatty acids (palmitic and stearic acids) and unsaturated 
fatty acids (linoleic and oleic acids) (Redgrave, 1983). Dietary fat is metabolised 
primarily by 3 enzymes : -
a) pancreatic lipase and its colipase are responsible for the major lipolytic activity 
involved in the sequential hydrolysis of TAGs where one fatty acid is removed in each 
step, yielding sn-\ and sn-2> diacylglycerols in the upper small intestine and then sn-2 
monoacylglycerols. The latter is usually absorbed although it can be isomerised to the 
sn-1 position and hydrolysed (Bracco, 1994).
b) pancreatic cholesterol esterase, in the intestinal lumen, hydrolyses cholesterol ester to 
yield cholesterol and fatty acids
c) phospholipases.
The products of lipid hydrolysis are absorbed following solubilisation with bile acids. 
The fate of fatty acids once inside the enterocyte is dependent on their chain length. 
Short and medium chain fatty acids (up to 10-12 carbon atoms) are not re-esterified but 
enter the portal vein, and, bound to albumin, are transported to the liver and other
tissues. In contrast, long chain fatty acids and cholesterol are re-esterified to TAG and 
cholesterol esters in the enterocyte (Sethi et al, 1993).
Chylomicron formation and metabolism
Following the digestion of dietary fat in the small intestine, the long chain fatty 
acids are absorbed by the enterocyte. At the apical surface, the fatty acids undergo 
protonation and dissociate from the bile salt micelles and diffuse with other lipolytic 
products across the microvillus membrane. At the apical brush border, two fatty acid 
binding proteins have been proposed to mediate the transport of the fatty acids to the 
endoplasmic reticulum for incorporation into TAG, phospholipid and cholesterol esters. 
The majority of the fatty acids are incorporated into TAGs via the monoacylglycerol 
pathway and to a lesser extent by the phosphatidic acid pathway (Levy et al, 1995). Apo 
B-48, the unique apolipoprotein of CMs, along with apo A-I, and A-IV, are synthesised 
in the rough endoplasmic reticulum (Levy et al, 1995). The components of the CM 
particle are packaged together in the smooth endoplasmic reticulum before migration to 
the Golgi apparatus for final assembly. The Golgi secretory vesicles, filled with pre­
chylomicrons, then migrate under the control of the microtubular apparatus towards the 
basolateral region of the enterocyte. The Golgi vesicles fuse with the plasma membrane 
enabling entry of the CMs into the intercellular space and subsequently into the 
lymphatics before entering the circulation via the thoracic duct and subclavian vein. The 
nascent CM particle consists of a core of TAG (84-89% of the mass), cholesterol ester 
(3-5%) and on the surface free cholesterol (1-2%) and on the surface phospholipids (7- 
9%) and apolipoproteins B-48, A-I, A-II, A-IV, C-III and E (1.5-2.5%) (Devlin, 1992).
Following secretion, an exchange of apolipoproteins between CMs and HDL 
takes place, and the amount of apo C (apo C-II and C-III) and apo E on the CMs is 
increased. During this exchange, there is a decrease in the phospholipid content of the 
particle with a simultaneous increase observed in the free cholesterol content (Oliveira et 
al, 1993). Apo C-II activates the enzyme lipoprotein lipase (LPL) (which is bound to the 
luminal surface of endothelial cells in adipose tissue and muscle) and removal of 
approximately 70-90% of the TAG produces a cholesterol ester rich lipoprotein particle 
termed a CM remnant (Redgrave, 1983). As the core of the CM remnant particle
becomes smaller, surface materials, phospholipids, cholesterol and apolipoproteins (C-II 
and C-III) are transferred to HDL to maintain the stability of the particle. The CM 
remnant particle retains apos B-48 and E on its surface. Uptake of these particles from 
the circulation probably requires interaction with hepatic lipase (HL) which is situated in 
the liver. HL further hydrolyses TAG and phospholipid before uptake by a receptor 
mediated process in the liver which is dependent on apo E (Brasaemle et al, 1993). The 
proposed receptor mediated processes include the LDL receptor, also known as the apo 
B, E (LDL) receptor or the LDL receptor related protein (LRP) (Bradley and Gianturo, 
1990). The remnants are endocytosed and catabolised in lysosomes from which 
cholesterol can enter metabolic pathways in hepatocytes, including excretion into the 
bile (Figure 1.2).
1.2.3 Endogenous pathway 
VLDL-IDL-LDL cascade
The formation of VLDL in hepatocytes resembles that of CMs in intestinal 
absorptive cells. VLDL provides a pathway for the exit of TAGs from the liver to the 
peripheral circulation. In humans, the liver synthesises a larger form of apo B, apo B- 
100, than the intestine and also synthesises apos E and Cs, which enter the bloodstream 
with nascent VLDL. Two subclasses of VLDL are released from the liver, VLDLj (large 
triacylglycerol-rich lipoprotein (TRL) particles) and VLDL2  (smaller, denser particles). 
LPL in the capillary bed extracts TAG from the secreted VLDLj, but less efficiently 
when compared to CMs (i.e. LPL has a lower affinity for VLDL^ particles) (Karpe and 
Hultin, 1995a; Bjorkegren et al, 1996). LDL receptors on the surface of hepatocytes 
recognise apo E on VLDL2  particles (or VLDL remnants) and mediate the endocytosis 
of a fraction of the particles. Prolonged residency of some of the VLDL particles 
(namely VLDL2 ) in the plasma results in their further metabolism by LPL and to some 
extent HL, to form higher density IDL. HL, present on the surface of hepatocytes, 
further hydrolyses IDL and eventually LDL are formed (Griffin and Packard, 1994). 
LDL exists as a heterogeneous population consisting of larger LDL species (LDL-I and 
LDL-II subclass) and smaller denser LDL particles (LDL-III) (Griffin, 1995). LDL can 
be taken up by LDL receptors present on the surface of hepatocytes and on extrahepatic
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Figure 1.2 : Simplified Overview of Lipoprotein Metabolism in Man.
Abbreviations : Apo, apolipoprotein; C, cholesterol; CE, cholesterol ester; CETP, cholesterol ester transfer 
protein; CM, chylomicron; CM-R, chylomicron remnant; HDL, high density lipoprotein; HL, hepatic 
lipase; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LDL-R, low density 
lipoprotein receptor; LPL, lipoprotein lipase; LPR, low density lipoprotein receptor related protein; VLDL, 
very low density lipoprotein.
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cells.
Reverse cholesterol transport
HDL are heterogeneous and can be classified into the larger, less dense HDL2  
(HDL2 a and HDL2 b) or smaller denser HDL3 (HDLg ,^ HDLgy and HDL^j (Skinner,
1994). A fimction of HDL is to trigger the flux of cholesterol fi*om peripheral cells and 
from membranes undergoing turnover to the liver for excretion. There is uncertainty 
about whether or not the transfer of cholesterol from the cell surface to the HDL particle 
requires an apolipoprotein cell binding site or receptor. An HDL binding protein has 
been described and isolated (Aviram et al, 1989). It shows broad ligand specificity and 
promotes the efflux of cholesterol fi*om intracellular pools of cholesterol laden cells.
The process of reverse cholesterol transport is mediated by an enzyme, LCAT 
bound to species of HDL particles. It acts by trapping cholesterol into the apolar core of 
pre-p-HDL following interaction of this particle with a cell surface protein. The 
cholesterol is then transferred to HDL3 , which in turn is converted to HDL2  (von 
Eckardstein et al, 1994). This particle can then follow one of two pathways (direct or 
indirect) to deliver the cholesterol to the liver (Tall, 1993). In the direct pathway, the 
HDL2  is removed via receptor mediated endocytosis by the LDL receptor or via 
selective uptake of CE fi-om the HDL particle by the liver. CETP, is involved in the 
indirect pathway, to transfer cholesterol ester to lower density apo B containing 
lipoproteins, VLDL and CMs, in return for TAG, followed by their uptake by the liver 
(Tall et al, 1987).
This balance between the forward (i.e. endogenous and exogenous pathways) 
and the reverse pathways, which is tightly regulated by the secretion rates of the 
lipoproteins, determines the concentration of cholesterol in plasma.
1.3. Apolipoproteins
1.3.1 Introduction.
During the 1980's, genes for the apolipoproteins were isolated, sequenced and 
localised in the human genome. The principal apolipoproteins include apo A-I, apo A-II,
apo A-IV, apo C, apo C-II, apo C-III, apo B-48, apo B-lOO and apo B. Important 
functions include (Erkelens, 1989) :-
a) Maintenance of the structure and size of lipoproteins,
e.g. apo B-lOO for LDL 
apo A for HDL
b) Regulation of the movement of particular lipids through the cellular membranes from 
inside to outside,
e.g. apo B-48 for CMs 
apo B-lOO for VLDL
c) Acting as ligands to specific high affinity receptors and guiding the lipoproteins to 
sites of catabolism (i.e. hepatic and peripheral cells),
e.g. apo B-lOO to LDL receptor
apo E to the LDL receptor and apo E receptor
d) Cofactors for enzymes involved in lipid transport,
e.g. apo A-I for LCAT 
apo C-II for LPL
e) Inhibition of catabolic pathways,
e.g. apo C-III for TRLs such as CMs and VLDL
1.3.2 Classes of Apolipoproteins 
Apolipoproteins A
This class of apolipoproteins (apo A-I, apo A-II and apo A-IV) are common 
constituents of HDL, with apo A-I being the main apolipoprotein. They are secreted 
from the liver (apo A-I and II) and intestine (apo A-I, IV)
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Apo A-I
The sequence of this apolipoprotein has been described (Brewer et al, 1978) and 
consists of a single polypeptide of 243 amino acids. Its functions include:-
a) cofactor for LCAT (Glomset, 1970) and so participates in both TAG and cholesterol 
transport.
b) facilitates CM metabolism by mediating transfer of apo C-II from the HDL2  particle. 
Apo A-II
Apart from its structural role, it is not known to have a specific function in HDL 
metabolism. Apo A-II, unlike apo A-I, remains bound to the HDL with which it is 
secreted and cannot transfer readily between native HDL particles (Fielding and 
Fielding, 1991). Apo A-II has been shown to be an activator of HL activity (Mowri et al,
1992).
Apo A-IV
Apo A-IV shares a number of functions with apo A-I. The majority of apo A-IV 
is found in plasma and in vitro studies have shown it to be a potent activator of LCAT 
(Mahley et al, 1984).
Apolipoproteins B
Apo B play a pivotal role in intracellular transport and the cellular delivery of 
cholesterol. This is achieved since apo B is :-
a) important in the biosynthesis and secretion of chylomicrons and hepatogenous VLDL.
b) the principal structural apolipoprotein on CMs, CM remnants, VLDL, IDL and LDL.
c) Functions as a ligand on LDL that interacts with the LDL receptor, and so initiates 
absorptive endocytosis and cellular uptake.
Genetic alteration of the apo B gene can lead to the impaired ability of truncated 
forms of apo B to assemble and secrete lipoproteins from both liver and intestine 
(Young, 1986). In the absence of the apo B gene as in the disease abetalipoproteinemia, 
TAG is trapped inside the intestinal and liver cells. This results in the absence of CMs, 
VLDL and LDL in the blood. The selective and concomitant impairment of apo B and
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TAG secretion supports an essential role for apo B in the assembly and secretion of 
lipoproteins.
In 1980, Kane and colleagues reported the presence of 2 primary forms of apo B 
in human plasma and thoracic duct lymph. To describe these proteins a centile system of 
nomenclature was established (Kane, 1983a) that is based on the relative apparent 
molecular weights estimated by sodium-dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). In this system, the molecular weight of each form of apo 
B is expressed as a percentage of the largest form. The largest, and normally most 
abundant form, apo B-lOO, is found on lipoproteins of hepatic origin. The intestine- 
derived species is termed apo B-48 since the smaller polypeptide displays an apparent 
molecular weight of approximately 48% of that of apo B-100. In humans, apo B-48 and 
apo B-100 were considered to be metabolically distinct since they were synthesised 
independently and generally experience separate metabolic fates. They also appeared to 
be structurally and functionally related (Hardman et al, 1987a).
More recently, lipoprotein(a) (Lp(a), has also been found to contain apo B-100 as 
the sole form of apo B-apolipoprotein species (variant of LDL). Apo(a) is a large 
glycoprotein which is structurally related to plasminogen and becomes associated with 
apo B-100 by the formation of disulphide bridges. A strong correlation exists between 
the plasma level of Lp(a) and the risk of developing coronary heart disease (Brown and 
Goldstein, 1987; Liu and Lawn, 1994; Maher and Brown, 1995). The cause of its 
atherogenicity is under intense investigation since it is thought that it may relate to its 
potential of inhibiting thrombolytic mechanisms (particularly in coronary arteries). One 
line of evidence suggests that the pathogenicity of Lp(a) is modulated by elevated LDL 
cholesterol levels (Maher and Brown, 1995).
Apolipoproteins C
These are represented by three low molecular weight apolipoproteins designated 
apo C-I, II and III. The role of C apolipoproteins is associated 'with their ability to 
redistribute among lipoprotein classes (i.e. in the fasting state they are associated with 
HDL and on absorption of dietary fat they become associated with CM and VLDL).
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Apo C-I
This is the smallest of C apolipoproteins and has been shown to activate LCAT 
in vitro (Soutar et al, 1975). In this manner, apo C-I may participate in the remodelling 
of HDL. Apo C-I has also been shown to inhibit the binding of TRLs to the LRP 
(Weisgraber et al, 1990).
Apo C-II
The prime metabolic function is associated with its ability to act as a cofactor in 
activating LPL (Mahley et al, 1984).
Apo C-III
This apolipoprotein circulates in the plasma associated with TRLs and HDL. It 
has been shown to inhibit apo C-II activation of LPL (although a large excess is 
required) (Beckenbridge et al, 1978) and decrease the apo E mediated uptake of remnant 
particles (van Barlingen et al, 1996).
Apolipoproteins E
This is the constituent of many lipoproteins including CMs, CM remnants, 
VLDL and HDL. This apolipoprotein displays a complex isoform pattern that is due to 
the presence of multiple, genetically determined alleles (s2, s3, s4) at a single locus 
(Zannis et al, 1982). The three major isoforms are apo E2, apo E3 and apo E4. Each of 
the isoforms have different affinities for the apo E receptor with apo E4 binding the best, 
followed by apo E3 (most common phenotype in the population) and apo E2 binding 
insufficiently (associated with Type III hyperlipoproteinaemia) (Mahley, 1986).
Primary functions of apo E include:-
a) Cholesterol transport and metabolism,
b) Receptor-mediated uptake of specific lipoproteins (LDL receptors in hepatic and 
extrahepatic tissues by apo E)
c) Heparan binding (important physiological mechanism for lipoprotein binding to 
endothelial surfaces),
d) Formation of cholesterol ester-rich particles,
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e) Lipolytic processing of hepatic 13-VLDL from patients with Type III 
hyperlipoproteinaemia
f) Inhibition of mitogenic stimulation, and
g) Expanded role for apo E metabolism suggested by unique tissue distribution, 
especially in the brain (Mahley, 1984).
Minor apolipopoproteins
Other proteins associated with circulating lipoproteins include apo D, apo H and 
apo J (Patsch and Gotto, Jr, 1996).
Apo D is a member of the lipocalin super family of proteins which possess 
binding sites for small hydrophobic ligands. It has been speculated that this 
apolipoprotein may have a higher affinity for haem-related proteins than for cholesterol 
ester.
Apo H (2-glycoprotein I) is a negative acute phase protein which may be 
involved in inhibition of the coagulation pathway.
Apo J (clusterin) has been shown to play a role in maintaining endothelial 
integrity through inhibition of complement-mediated cell lysis
1.4. Apolipoprotein B
1.4.1 Apolipoprotein B-100
Apo B-100 is the hepatic form of apo B and one of the largest monomeric 
proteins known. Major insights into the understanding of the structure and function of 
apo B-100 were achieved by the elucidation of the complete sequence of apo B-100 
(Knott et al, 1986; Law et al, 1986; Yang et al, 1986; Oloffsson et al, 1987). This was 
carried out primarily by sequence analysis of 30 overlapping partial cDNA clones and 
also intron-exon organisation of the apo B gene (Blackhart et al, 1986). The single gene 
for the apo B gene is located on chromosome 2, spanning 43 kilobases (kb) and contains 
29 exons (Blackhart et al, 1986). A single exon, exon 26, is 7572 base pairs (bp) and 
contains over half of the coding sequence. The distribution of the introns is asymmetrical 
with most of them located in the 5' terminal one-third of the gene. Human apo B-100
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Apo B-100 is essential for the assembly of the triglyceride-rich VLDL and the 
resultant metabolite, which is relatively enriched in cholesterol ester, LDL. LDL 
possesses apo B-100 as its exclusive apolipoprotein constituent and is the principal 
cholesterol transporting lipoprotein in human plasma (i.e. > 60% of the plasma 
cholesterol is present in LDL). Plasma levels of LDL are controlled by the rate of 
synthesis of VLDL and the catabolism of these lipoproteins by the LDL receptor in the 
liver. Epidemiological, pathological and genetic studies have established a positive 
correlation between the amount of LDL cholesterol in the plasma and accelerated CHD 
(Brown and Goldstein, 1984).
1.4.2 Apolipoprotein B-48
Apo B-48 has a molecular weight of approximately 241 kilodaltons (kDa) and is 
synthesised in the small intestine enterocytes. It was first isolated in 1980 by Kane and 
was found to be a marker for intestinally derived lipoprotein particles. Existing evidence 
suggests that only one apo B-48 molecule is associated with the CM particle (Elovson et 
al, 1988) and unlike other apolipoproteins associated with the particle, it does not 
exchange onto other lipoprotein particles.
Although data predicts that the small intestine synthesises predominantly apo B- 
48, the work by Glickman et al (1986) demonstrated that both apo B-100 and apo B-48 
are produced in the human jejunum during gestation. However, they agree that only apo 
B-48 is produced by the tissue in the adult. Recent studies have shown that the colonic 
carcinoma cell line (CaCo-2), which behaves like foetal small intestine, produces mainly 
apo B-100 and small quantities of apo B-48 (Hughes et al, 1987). This work was 
supported by Hoeg and coworkers (1990) who found that although apo B-48 was the 
principal isoform, apo B-100 was also synthesised and secreted by human intestinal 
organ cultures with 16% of the intestinal apo B mRNA coding for apo B-100. The 
synthesis of apo B-100 by the intestine has pathological implications for the 
development of diet-induced atherosclerosis.
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1.4.2.1 Origin of apo B-48
Antibody and peptide mapping, protein sequencing and amino acid composition 
studies suggested that apo B-48 was colinear with the amino terminal of apo B-100 
(Hardman and Kane, 1986; Olofsson et al, 1987). This was consistent with the observed 
size of apo B-48 on SDS-PAGE (Knott et al, 1986) since its glycosylation pattern had 
been shown to be similar to apo B-100 (Sasak et al, 1991). In addition, the amino acid 
composition of apo B-48 was similar to that of apo B-100 between residues 1 and 
approximately 2200 (Hardman and Kane, 1986).
In 1987, the mechanism for the formation of apo B-48 was simultaneously 
determined by Powell et al, Chen et al and later by Hospattankar et al. They 
demonstrated that apo B-48 is produced from the apo B-100 gene by a novel mechanism 
involving mRNA editing. From experiments involving the sequencing of apo B cDNA, 
they found that intestinal apo B cDNA contained a thymine (T) at the position 6 , 6 6 6  in 
contrast to the cytidine (C) at that position in the liver apo B cDNA clones. This 
substitution of the T for a C at nucleotide 6 , 6 6 6  yields an in-frame stop codon (TAA) 
that replaces the CAA codon specifying apo B-100 amino acid glutamine (Gin) at 
position 2153. This substitution at the nucleotide 6 6 6 6  was present in the intestinal 
mRNA but not in the genomic DNA so it was clearly the result of a specific form of 
post-translation editing of the intestinal apo B mRNA. The location of the stop codon 
predicts that apo B-48 found in the plasma would contain the amino terminal 2152 
amino acids. Protein sequencing by Chen et al (1986) and by Hardman et al (1987b) 
pointed to the possibility that in certain tissues, the carboxyl terminal isoleucine is 
partially cleaved post-translationally by the enzyme carboxypeptidase A and that 2151 
amino acids with methionine as the terminal carboxyl residue is the length of the mature 
protein.
Recent work has expanded the understanding of how the editing of apo B mRNA 
takes place, how it is controlled and its physiological role. The production of apo B-48 is 
under tissue-specific, developmental and hormonal control:-
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Tissue-specific
The proportion of apo B transcripts that is edited varies considerably in tissues 
ranging from 2% to 99% editing. In the cell line, CaCo-2, before and after differentiation 
to an enterocyte-like state, editing rose from below 5% to over 50% (Bostrom et al,
1990).
Developmental
Editing activity is induced during the development of human enterocytes and 
unedited apo B mRNA (>99%) is expressed early in development (Teng et al, 1990). 
The physiological relevance of the developmentally regulated increase in apo B mRNA 
editing remains unknown. In the small intestine there maybe a selective advantage in 
restricting apo B-100 production since its overproduction is associated with the risk of 
premature coronary artery disease (Teng et al, 1990). Recently rat studies have 
suggested that augmenting lipogenesis favours production of the edited apo B mRNA 
and this may be important in the developmental switch in apo B synthesis observed in 
the foetal small intestine (Baum et al, 1990). (It is important to note that in man and the 
rat there is a difference in the specificity for the site of production of apolipoproteins B- 
48/B-lOO). These changes probably represent the true developmental pattern rather than 
responses to changing hormonal and nutritional status, a view supported by the induction 
of the apo B editing upon differentiation of the cell line CaCo-2 (Bostrom et al, 1989).
Hormonal and nutritional regulation
Thyroid hormone induces editing of apo B mRNA in rat liver, possibly 
secondary to an effect of lipogenesis (Davidson et al, 1988). Fasting induces a modest 
decrease in editing and refeeding with carbohydrate dramatically increases lipogenesis 
and editing is nearly complete. Therefore modulation of apo B mRNA editing in 
response to nutritional and hormonal influences a potent stimulus to hepatic lipogenesis 
and TAG accumulation (Baum et al, 1990). Insulin has also been demonstrated to 
modulate mRNA editing and lipid assembly in rat hepatocytes (Thomgate et al, 1994).
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Mechanism of Editing
Important conclusions by Hodges and Scott (1992) were drawn on this 
mechanism and these include;-
a) the product of RNA editing is a simple uridine base,
b) the editing reaction does not involve excision. At present there is no known 
polymerase that can remove a nucleotide and add a new nucleotide in its place without 
replacing the 5'-phosphate with the donors phosphate. The editing reaction most 
probably involves site-specific cytidine deamination of RNA. Recent work has cloned a 
27 kDa catalytic subunit of the editing enzyme and identified it to be a zinc-containing 
cytidine deaminase. The apo B mRNA editing enzyme catalytic polypeptide-1 
(APOBEC-1) and additional complementation factors, originally cloned from the rat 
small intestine, has been cloned from human intestinal cells by Teng et al (1993) and 
shown to be the catalytic subunit of the apo B mRNA enzyme complex (Davidson et al,
1995). The major source of gene expression is the mature villus cells in the rat, although 
this has not yet been confirmed in the human small intestine (Giannoni et al, 1996). The 
catalytic subunit is thought to be guided to the editing site by a second targeting subunit 
which is part of a motif downstream of the editing site that is essential for editing (Scott 
et al, 1994). Recent studies have indicated that the zinc co-ordinating region of 
APOBEC-1 may be involved in the binding to the substrate apo B mRNA (McGinnitie 
et al, 1995). However, Nassir et al (1996) have observed that the altered ratios of serum 
isoforms of apo B observed in rats during zinc deficiency were not mediated through 
changes in the hepatic or intestinal editing of the mRNA. These findings are yet to be 
confirmed in humans.
Definition of target site.
The apo B sequence can be transferred into other mRNAs and edited in vitro in 
transfected cells. The length of apo B sequence that can be successfully edited varies in 
different RNA contexts. The optimal size is 55 bases or more but in vitro, 26 bases in the 
core sequence are highly conserved among mammalian apo B sequence. A hypothesis 
suggests that a specific RNA editing process would require conservation of the 
nucleotide sequence surrounding nucleotide 6 , 6 6 6  through evolution. This is shown
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from studies of the apo B gene in which the sequence of the region flanking nucleotide 
6 , 6 6 6  is highly homologous (90%) among the mouse, rat, rabbit and human genes 
(Davies et al, 1989). Site-directed mutagenesis of the editing site has been used to define 
the sequence requirement for editing. In the nine nucleotides surrounding the edited 
cytidine, 2 0  out of 2 2  mutations allow efficient editing in vitro so suggesting that the 
sequence is lax (Chen et al, 1990). A preliminary hypothesis is that the editing enzyme 
recognises a downstream binding site and then searches for a cytidine at a fixed distance 
upstream.
Recently, Navaratanum et ûf/ (1991), has discovered a second RNA editing site in 
human apo B mRNA. Cytidine 6802 is edited in vitro with about 15% of the efficiency 
of the primary editing site cytidine 6 6 6 6 . From intestinal cDNA libraries, two of 11 apo 
B cDNAs had a thymidine at site 6802 (all containing T at the primary editing site) 
demonstrating that editing at this site occurs in vivo. Since this second editing site is 
within the 3' untranslated region of apo B-48 mRNA, it is unclear what effect editing 
would have.
1.4.3 Importance of the presence of two forms of apo B
The principle domain present in apo B-100 and absent from apo B-48 is the LDL 
receptor binding region which mediates the clearance of LDL from the blood by the 
LDL receptor pathway. The half life of LDL in the circulation is approximately one to 
three days in comparison to CM remnants (which are apo E rich) whose contents are 
delivered promptly to the liver within two to three hours.
Removal of the LDL receptor domain from apo B-48 therefore facilitates the 
rapid delivery of lipid soluble substances such as retinol, vitamin E and lipid soluble 
coenzymes to the liver (Scott et al, 1989). These compounds have a critical function in 
maintaining the integrity of LDL apo B against free radical attack. In LDL that has 
become depleted of antioxidants, apo B-100 becomes fragmented and the LDL receptor 
binding domain destroyed. If intestinal apo B was solely in the form of apo B-100 then 
the delivery of lipid soluble antioxidants to the liver would be markedly reduced or 
would not occur (Young, 1991). Another suggestion is that the truncated form of apo B,
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apo B-48, allows maximal exposure of TAG to LPL which therefore allows deposition 
of dietary fat in the adipose tissue.
1.5 Factors determining postprandial lipaemia
The magnitude and duration of postprandial lipaemia is determined by a number 
of factors including lipolytic enzymes, LPL, HL and LCAT, and CETP. The importance 
of lipases, for lipid transport and lipoprotein interconversions is clearly demonstrated by 
the major derangements of lipoprotein metabolism defects (Eckel, 1989).
1.5.1 LPL
LPL is the key enzyme responsible for the hydrolysis of TAG from the cores of 
CM and VLDL particles to form CM remnants and LDL respectively (Nilsson-Ehle, 
1980; Eckel, 1989). Attention was drawn to this enzyme by Hahn in 1943 who 
demonstrated that injections of heparin into the blood of an animal with high levels of 
CMs led to the rapid clearance of plasma turbidity. LPL is synthesised primarily in the 
adipose tissue and muscle where it is bound to the luminal surface of capillary 
endothelial cells via heparan-sulphate proteoglycan (HSPG) molecules and also via a 
recently discovered specific 116 kDa heparin sensitive binding protein (Stins et al,
1993). LPL is a 55 kDa glycoprotein which is synthesised in the endoplasmic reticulum 
as an inactive monomer and maturation of the protein occurs in the Golgi apparatus. 
Recent evidence suggests that potentially active LPL, following synthesis, is stored in a 
cryptic state, in association with heparan sulphate molecules, in vesicles before secretion 
and localisation on the surface of parenchymal cells (Pradines-Figueres et al, 1990).
The fimctional domains of LPL have been determined by site-directed 
mutagenesis, specific proteolytic cleavage and fragment analysis and inhibition of LPL 
by serine inhibitors. The three dimensional structure of pancreatic lipase has provided 
fiirther knowledge of the structure of LPL through the close homology of these enzymes 
(Winkler et al, 1990). The catalytic function has been localised in the aminoterminal 
region of the enzyme which contains a triad of catalytic residues, serine, aspartate and 
histidine. The functional role of the carboxylterminal remains to be established. 
However, recent studies have demonstrated that this region may be responsible for the
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binding of LPL to lipoproteins via lipid substrates. LPL contains a Tid’ which covers the 
catalytic site and allows repositioning to allow access of the substrate to the catalytic 
domain. Based on the structure of pancreatic lipase, the following mechanism has been 
proposed for the interaction of the LPL active site with TRLs. In its inactive state, the lid 
remains closed. Initial interaction of LPL with the TRL, mediated by the carboxyl 
terminal domain, results in the conformational change that leads to opening of the lid 
and exposure of the active site (Santamarina-Fojo and Dugi, 1994).
LPL shows a strong positional specificity for the primary ester bonds in TAGs 
and is responsible for the removal of 70-90% of TAGs fi*om CMs to form the remnant 
particle (Eckel, 1989). Apo C-II is an important apolipoprotein required for the 
activation of LPL and recently, apo C-III has been shown to be a potent inhibitor of LPL 
activity (McConathy et al, 1992). The composition of the substrate, the core structure of 
TRLs as well as the fatty acid chain length has also been demonstrated to affect the 
catalytic rate (Demel and Jackson, 1985).
Enzymatic action of LPL on TRLs results in the generation of mono- and di­
acylglycerols as well as free fatty acids which are used as fiiel for energy or re-esterified 
for storage in peripheral cells. The key role of LPL in lipoprotein metabolism was 
determined in 1960 by Havel and Gordon who demonstrated the slow clearance of CMs 
in LPL deficiency which was restored following the injection of heparin. The catabolism 
of large VLDL, but not small VLDL, is impaired in cynamologous monkeys when LPL 
was inhibited by a monoclonal antibody (Goldberg et al, 1996). Therefore it appears that 
LPL is involved in the VLDL-IDL-LDL delipidation cascade as well as CM 
metabolism. This evidence was supported by individuals with apo C-II deficiency.
Combined studies suggest a dual role of LPL in the pathogenesis of 
atherosclerosis. LPL mediated lipoprotein uptake by the liver may result in enhanced 
catabolism of atherogenic lipoproteins and so reduced atherosclerosis, whereas synthesis 
of LPL by cells present in the arterial wall may promote atherogenesis. Therefore, the 
site of expression of LPL may dictate the ultimate role of LPL in the development or 
protection against atherosclerosis (Santamarina-Fojo and Dugi, 1994).
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1.5.2 HL
HL is a glycoprotein synthesised by liver parenchymal cells which is bound to 
endothelial cells lining the sinusoidal cavities of the liver, including the Space of Disse, 
via heparan sulphate-like ligand. Catalytic activity for HL has also been detected in the 
adrenal gland and in the ovary (Doolittle et al, 1987).
HL is a glycoprotein with an apparent mass of 53 kDa on SDS-PAGE and is 
thought to be an oligomer in its active state. The catalytic domains of HL have been 
studied using the construction of a chimeric lipase consisting of the 329 N-terminal 
amino acids of rat HL linked to the C-terminal 136 residues of human LPL (Wong et al,
1991). The chimera hydrolysed both short chain and long chain TAG substrate with 
enzymatic characteristics of those of native HL. The use of monoclonal antibodies to 
LPL led to the conclusion that HL has a 2 domain structure. An aminoterminal domain 
which contains the active site and is responsible for the catalytic efficiency (Aggerbeck 
et al, 1988). Also, a smaller carboxylterminal domain which modulates substrate 
specificity (i.e. interaction and hydrolysis of long chain fatty acid substrates) and heparin 
binding (Innerarity et al, 1984). This enzyme exhibits a broad substrate specificity and 
hydrolyses mono-, di-, and TAGs, phospholipids and long chain acyl CoA thioesters 
(Enholm and Kussi, 1986). This substrate specificity can be modified by the addition of 
apolipoproteins. It has been demonstrated by Thuren and coworkers (1991) that HL is 
very sensitive to the physical state of the monolayer lipid films commonly used as a 
substrate. Apolipoproteins A-I, A-II, C-I, C-II and E have also been shown to block the 
hydrolysis of HDL2  TAGs and so it appears that these apolipoproteins act to alter the 
interfacial properties of lipoproteins. Conversely, apo E has recently been shown to 
activate the HL catalysed phospholipid hydrolysis suggesting that for apo E enriched 
HDL2 , phospholipid is the preferred substrate for HL (Thuren et al, 1992).
Previous animal studies have directed the action of HL towards the metabolism 
of small VLDL, IDL and HDL (Daggy and Bensadoun, 1986). Recently, HL has been 
implicated Avith CM remnant metabolism, especially phospholipolysis of CM and CM 
remnants. This work implied that HL action is an obligatory metabolic step before 
particles are taken up and degraded by the liver (Griglio et al, 1992). This was confirmed 
by Sultan et al (1990), who demonstrated, following the administration of anti-HL
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antibodies into rats, that these antibodies caused the accumulation of CM remnants, LDL 
and HDL2  particles. Mechanisms whereby HL facilitates remnant uptake is/are not clear. 
Borensztajn and coworkers (1988) have shown that recognition of remnants by the liver 
receptors is improved after hydrolysis of phospholipids by HL. A recent paper by 
Brasaemle et al (1993) indicates that HL treatment of remnants increases the exposure of 
apo E and so increases their binding efficiency to the cell surface receptors. HL is also 
involved in altering the particle size distribution of HDL particles, whereby HL 
promoted a marked reduction in HDL particle size (i.e. HDL2  conversion to HDL3 
subfiraction) (Barrans et al, 1994). In vivo, the concentration of larger, less dense HDL2  
subffaction correlates positively with the postheparin LPL but negatively with that of 
HL (Patsch, 1987). Therefore, it is hypothesised that decreased LPL activity leads to 
pronounced postprandial triacylglycerolaemia, which through the action of CETP 
increases the TAG content of LDL and HDL2  resulting in the formation of atherogenic 
small dense LDL and HDL3 by the action of HL.
1.5.3 LCAT
LCAT is secreted by the liver and circulates in plasma attached to HDL particles. 
This is in contrast to LPL and HL which are primarily bound to the endothelial surface 
(Applebaum-Bowdon, 1995). It has an estimated molecular weight of 59 kDa and is 
present as a monomer in solution. LCAT acts preferentially on smaller HDL particles 
including pre-beta HDL and HDL3 and requires apo A-I and apo A-IV for optimal 
activity.
LCAT is responsible for the formation of cholesterol esters found in human 
plasma by transferring fatty acids from lecithin to the hydroxyl group of cholesterol 
(Nilsson-Ehle, 1980). Once synthesised, cholesterol ester moves into the interior of HDL 
particles and some is exchanged for TAG in other lipoprotein particles by CETP. The 
transferred cholesterol ester accumulates in LDL and cells which require cholesterol 
acquire this via the LDL receptor pathway. Therefore LCAT helps HDL accept 
additional cholesterol either fi*om cell membranes or from other lipoproteins which 
allows further estérification and eventual formation of larger cholesterol ester-rich HDL2
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particles. Thus LCAT is considered to have a anti-atherogenic role via integration in the 
HDL carrier system.
1.5.4 CETP
CETP, also referred to as the lipid transfer protein 1, is a plasma glycoprotein 
which is responsible for the transfer of TAG and cholesterol esters among lipoproteins 
(Tall, 1994). It is a hydrophobic glycoprotein with a molecular mass of 66 to 74 kDa and 
catalyses the transfer of cholesterol esters, TAGs, retinyl esters (RE) and phospholipids 
between lipoproteins. In vivo, CETP is responsible for most of the neutral lipid transfer 
activity (Hesler et al, 1988). CETP mRNA is expressed in liver, spleen, muscle and 
adipose tissue and lower amounts in small intestine, heart and kidney. The functionally 
important region of the CETP molecule has been recognised as the 26 C-terminal 
residues of the protein. This region has been identified using monoclonal antibodies, 
some of which inhibit the neutral lipid transfer (Swenson et al, 1989).
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1.6. Chylomicron Remnants and their relation to Coronary Heart
Disease
1.6.1 Coronary heart disease
CHD is a condition in which the main coronary arteries supplying the heart are 
no longer able to supply sufficient blood and oxygen to the heart muscle 
(myocardium). The main cause of reduced fiow is the accumulation of plaques, mainly 
in the intima of the arteries, a disease known as atherosclerosis. This disease is 
associated with a variety of biologically based risk factors including hypertension, 
diabetes, elevated levels of plasma lipids in plasma and genetic predisposition.
1.6.2 Atherosclerosis
Atherosclerosis is a disorder of the arterial wall characterised by the 
accumulation of cholesterol esters in cells derived from the monocyte-macrophage 
line, smooth muscle proliferation and fibrosis. The development of atherosclerosis is 
thought to be a two stage process, the immune response to injury of the arterial vessels 
followed by the accumulation of lipoproteins, in particular apo B containing 
lipoproteins, into the arterial wall (Ross, 1993). Atherosclerotic plaques develop in 
regions in which the endothelial cells are exposed to high blood pressure, namely 
branch points of the arteries. Repeated exposure of the endothelial cells to injury 
causes them to dysfunction leading to an increase in endothelial turnover, increased 
macromolecular permeability, increased exposure to circulating lipoproteins and also 
an increase in the expression of surface molecules pivotal for monocyte cell 
recruitment (Henry et al, 1995).
The initial step in atherosclerosis development involves the influx of 
lipoproteins into the arterial wall where they interact with a variety of proteoglycans 
and matrix proteins in the subendothelial space. Following the accumulation of lipid in 
the arterial wall, monocytes are attracted to the artery wall as a result of the injury to 
the endothelial surface. Initially, the monocytes adhere to the arterial wall followed by 
migration across the arterial wall where they differentiate into macrophages. 
Macrophages are responsible for the removal of noxious materials and provide a 
source of regulatory growth molecules and cytokines, therefore acting as an
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inflammatory mediator in the developing atherosclerotic plaque. Macrophages contain 
both scavenger receptors/oxidised LDL receptors and since scavenger receptors do not 
contain sterol regulatory sequences in their promoter sequence they are not down 
regulated by the accumulation of lipid (Ross, 1993). Prolonged residence time of apo 
B containing lipoproteins in the circulation makes them prone to modification in the 
arterial wall by endothelial cells, smooth muscle cells and macrophages (Steinberg, 
1987). These modified lipoproteins are now totally unrecognisable by the normal 
receptor mediated mechanisms and so eventually form atherogenic particles. These 
particles are then cleared by unregulated scavenger receptors on the surface of 
macrophages and endothelial cells. If the oversupply of the modified lipoproteins 
becomes chronic the macrophages can no longer remove the cholesterol ester from the 
artery wall but turn into lipid droplet full “bags” called foam cells which eventually 
lyse and spill out their lipid contents. In an advanced lesion, the endothelial layer 
covering the streaks retracts and the platelets are now able to adhere to the surface of 
the endothelial denuded areas. The original inflammation like defense mechanism has 
now become chronic and so provokes degeneration. The expression of leukocyte 
adherence molecules on the surface of the endothelial cells and the release of 
cytokines and growth factors leads to proliferation and migration of the smooth 
muscle cells from the media to the injured intimai site. Finally, the growing lesion 
begins to impinge upon the lumen and this causes blood fiow to be altered. Fissures 
cause bleeding into the vessel walls and thrombi begin to form which eventually 
causes total occlusion of the artery. The resulting hypoxia leads to CHD and so results 
in eventual myocardial infarction (Stary et al, 1994).
Role of oxidised LDL
Reduced uptake of apo B containing lipoproteins by normal receptor mediated 
mechanisms, i.e. liver and peripheral cells, results in the prolonged residence time in 
the circulation and so uptake by the arterial wall. Lipids deposited in atherosclerotic 
plaques are primarily cholesterol and cholesterol ester derived from circulating LDL 
particles. CM remnants have also been implicated in the aetiology of atherosclerosis. 
However, evidence for their direct uptake into the arterial wall remains controversial.
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Many lines of evidence suggest that LDL is correlated with the mortality and 
morbidity from CAD (Brown and Goldstein, 1986). Small dense LDL particles have 
been implicated in particular since these are prone to oxidative modification in the 
circulation and arterial wall (Blinder and Walldius, 1994). Once LDL particles have 
been sequestered in the arterial wall, they are oxidised by endothelial cells, smooth 
muscle cells and macrophages mediated by lipoxygenases and cytokines. Oxidised 
LDL (ox-LDL) inhibits the mobility of macrophages and so traps them in the 
subendothelium of the artery, resulting in the further recruitment of macrophages to 
the arterial lesion. Other factors contributing to the in vivo oxidation of LDL include 
exogenous compounds that promote free radical formation and the extent of damage 
of the endothelial barrier (Shireman, 1996).
Animal and human studies have shown that ox-LDL contributes to the 
development of atherosclerosis (Steinberg et al, 1989) (Figure 1.3). Antibodies against 
epitopes of ox-LDL have been isolated in atherosclerotic plaques but not in normal 
arteries and also in the plasma of Watanabe heritable hyperlipidaemic (WHHL) rabbits 
which have a severe deficiency of LDL receptors. Involvement of ox-LDL in 
atherosclerosis is also supported by the regression of fatty streaks on treatment with 
antioxidants. Antioxidants are chemical compounds which readily accept unpaired 
electrons characteristic of free radicals in order to neutralise them. LDL particles 
enriched with antioxidants vitamin E, vitamin C and the drug probucol have been 
shown to increase the resistance of the LDL particles to oxidation. Vitamin E, in 
particular, has been shown to inhibit LDL oxidation in vitro and in vivo and this has 
been attributed to the lipid soluble moiety of the antioxidant (Jialal and Devaraj, 
1996). The fatty acid composition of the LDL particle is also another determinant of 
the resistance of the particle to oxidation. Diets high in monounsaturated fatty acid 
(MUFA) have been shown to be less prone to oxidation than those high in 
polyunsaturated fatty acids (PUFA) (Thomas and Rudel, 1996). This is also in 
agreement with individuals consuming a Mediterranean diet high in MUFA and 
antioxidants, vitamin C and E (O’Keefe et al, 1995).
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Role of LPL
In 1979, Zilversmit implicated local LPL activity in atherosclerotic lesions in 
the formation of atherogenic remnants from circulating CMs. Recent evidence has 
shown the presence of LPL gene expression by macrophages in the vessel wall. LPL 
located within the arterial wall has been implicated in the retention of lipoproteins, in 
particular LDL, within the endothelial matrix rather than catabolism of TRL particles. 
It has been proposed that LPL acts as a link between matrix proteoglycans and the 
lipoprotein particles by using its heparin and lipoprotein binding domains (Saxena and 
Goldberg, 1994).
Recently evidence has implicated LPL in the pathogenesis of atherosclerosis 
either located on endothelial cells or within in the arterial wall associated with 
macrophages (Goldberg, 1996). LPL has been shown to be involved in the hydrolysis 
of TAG-rich lipoproteins (TRL), CMs and VLDL, and uptake of remnants directly via 
the arterial wall. The availability of substrate at the arterial wall is a determinant of the 
efficiency of removal of postprandial lipoproteins by LPL located in adipose tissue 
and muscle. Therefore remnants can be taken up as a result of lipolysis on the 
endothelial surface and direct uptake as a result of smaller particle size. Studies in 
transgenic mice, overexpressing apo C-II but deficient in apo E, lead the authors to 
suggest that apo E anchors TRLs to HSPG in close proximity to LPL to enable 
catabolism (Shachter et al, 1994). A second protein hrp-116 has also been implicated 
along with HSPG to enable interaction of LPL with the endothelial surface (Sivaram 
etal,\992).
Genes for LPL are known to be expressed in the human monocyte macrophage 
cell lines. LPL in macrophages has been suggested to be responsible for the uptake of 
lipoprotein lipid and fat soluble vitamins involved in the formation of fatty acids for 
energy requirements of the cells. It has been demonstrated that macrophage LPL 
enhances CM uptake via apo E on the surface of these lipoprotein particles (Lindqvist et 
al, 1983) and also LDL. However, the mechanism of uptake is presently controversial 
since different in vitro techniques have been used as model systems. Under some 
incubation conditions (i.e. presence of antibiotics, antioxidants and proteinase 
inhibitors), LPL has been shown to increase LDL uptake via the LDL receptor and under
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other conditions LDL uptake occurred in the absence of LDL receptors (Tangirala et al,
1996). It has been postulated that LPL may be involved in the uptake of LDL through 
the association of LPL with HSPG so increasing the proximity of the lipoprotein to the 
receptor (Goldberg, 1996)
1.7. Atherogenicity of chylomicron remnants
1.7.1 Catabolism of chylomicron remnants
CMs are too large to cross the endothelial barrier, therefore prior lipolysis to 
form CM remnants, serves a dual function, i) the transport of energy and ii) decrease in 
size to facilitate terminal catabolism (Schneider, 1991). The requirement to produce 
small, TAG-poor, cholesterol ester-rich remnant particles capable of rapid removal by 
the liver is strongly supported by experimental work in rat hepatocytes and perfused rat 
livers (Arbeeny and Rifici, 1984). Studies have also suggested that CM remnant 
transport into the liver is mediated by the cell surface receptor, likely to function 
similarly to the LDL receptor (Bradley and Gianturo, 1990).
Since CM remnants do not contain the receptor binding region of the apo B 
gene, which is present in apo B-lOO, it indicates that apo E is the surface component 
which targets the chylomicron to their site of uptake. Evidence has indicated that an 
additional lipoprotein receptor on liver membranes maybe involved in CM remnant 
uptake since:-
a) Hepatic removal of CM remnants is normal in patients with familial 
hypercholesterolaemia and in WHHL rabbits which do not express or have a severe 
deficiency of LDL receptors (Kita et al, 1982; Demacker et al, 1992).
b) Antibodies directed against the hepatic LDL receptor have failed to inhibit binding of 
chylomicron remnants (Nagata et al, 1988).
c) Evidence that interventions that affect the number of LDL receptors seems to have 
little effect on CM remnant removal has proved to be controversial. Two papers 
published recently (Windier et al, 1988; Jackie et al, 1992) suggest that the LDL 
receptor is partly responsible for the uptake of CM remnants. This was demonstrated by 
infusions of oestradiol, known to increase the number of hepatic LDL receptors, which 
increased the rate at which the remnants were removed (Jackie et al). It also remarked on
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the fact that down regulation of the receptor, as a result of cholesterol feeding, did not 
significantly affect uptake. Due to the binding of apo E on the LDL receptor it can only 
be postulated that the LDL receptor may make an important contribution to the hepatic 
uptake of remnants.
The hunt for the elusive CM remnant receptor has been centred on the evidence 
that CM remnants are dependent on the presence of apo E for their receptor mediated 
uptake by the liver. The most likely candidate for the CM remnant receptor is the LRP 
which mediates the uptake of apo E enriched lipoproteins (Cowel et al, 1989). LRP, a 
member of the LDL receptor family, is an integral membrane glycoprotein of 4526 
amino acids containing 31 repeats of the type found in the binding domain of the LDL 
receptor. LRP is a multifunctional receptor which is responsible for the internalisation of 
many ligands including the a 2 -macroglobulin/protease complex, apo E, LPL, HL and 
the receptor-associated protein (RAP) (inhibitor of receptor activity). The LRP is 
expressed in a number of cell types, including macrophages, fibroblasts, hepatocytes, 
smooth muscle cells, astrocytes and neurones (Strickland et al, 1995).
Evidence for the fimction of the LRP as a possible receptor for CM remnants 
was determined in 1988 by Willnow and coworkers who investigated normal mice and 
those lacking the LDL receptor. These mice were genetically engineered to overexpress 
the RAP protein and so inhibit the activity of the LRP. Lipoproteins of the CM remnant 
density range were shown to accumulate in the plasma of the LDL receptor deficient 
mice, however, in the normal mice, there was only a minor effect on the uptake of CM 
remnants (Willnow et al, 1994). Van Dijk et al (1991) has demonstrated that the in vivo 
clearance of CM remnants can be inhibited by lactoferrin. Although this protein is an 
inhibitor of the LRP, it does not however inhibit LDL receptor activity and so provides 
strong evidence for the major role of the LRP as the remnant receptor. However, this is 
in disagreement with de Faria et al (1996), who postulated that the LDL receptor was the 
main receptor responsible for the removal of CM remnants and that the LRP plays only a 
minor role. Although the contribution of the 2 receptors for the uptake of CM remnants 
remains controversial, this agrees with the 2 receptor hypothesis suggested by Ishibashi 
et al (1994) who states that both receptors have the ability to remove remnants and that 
they will compensate in the absence of the other receptor.
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Although the LDL receptor and LRP are the main receptors for uptake of CM 
remnants, even when both of these receptors are inhibited there is significant uptake of 
CMs which suggests that one or more additional pathways are available (Hilpert et al,
1995). The lipolysis stimulated receptor (LSR) has also been proposed since this 
receptor is able to bind apo E containing lipoproteins (Yen et al, 1994). This receptor is 
present in LDL receptor deficient fibroblasts and rat hepatocytes. This receptor is 
activated by oleate. The authors proposed that LSR was responsible for the mediation of 
intestinal CMs and that the free fatty acids released by the hydrolysis was a signal for 
this receptor. However, the contribution of this receptor to remnant uptake is currently 
unknown.
Apart from the uptake of CM remnants via hepatic receptors, they can be taken 
up by mononuclear cells (i.e. which recognise apo E) leading to the accumulation of 
esterified cholesterol and formation of foam cells (Mahley et al, 1983). These foam cells 
are thought to be analogous to those found in atherosclerotic lesions. Recent evidence 
has identified the presence of the LRP receptor mRNA in smooth muscle cells and 
macrophages in the atherosclerotic lesion. Since this receptor does not contain a sterol- 
dependent response element in the LRP promoter, it enables the accumulation of 
cholesterol when the LDL receptor has been downregulated. Therefore the LRP may 
contribute towards the development of CHD through the uptake of circulating CM 
remnants.
1.7.2 Mechanism for the receptor mediated uptake of CM remnants.
Following a fat containing meal, large quantities of CM remnants are generated 
which are rapidly cleared from the circulation. This has suggested that these remnants 
are removed by high affinity, capacity sites. Recent evidence has indicated that the 
mechanism for the receptor mediated uptake of remnants depends not only on the 
receptors but also the hepatocyte surface itself (Herz and Willnow, 1995). Several 
factors are known to influence remnant metabolism at the hepatocyte cell surface 
including HSPG, apo E and the lipases, LPL and HL.
The original secretion recapture model was first proposed by Brown and 
coworkers (1991). Before the remnants are taken up by the liver, they accumulate in the
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Space of Disse, which is the region containing proteoglycans and a high concentration of 
apo E. Remnant lipoproteins can then be taken up by a number of mechanisms : -
a) Initial sequestration of the particle by the HSPG by the apo E apolipoprotein on its 
surface. This role of the proteoglycans was demonstrated in the mouse by injection of 
heparinase. This resulted in the accumulation of CM remnants and apo E (Ji et al, 1995). 
This enables further enrichment of the particle for uptake by the LDL receptor or LRP.
b) Following hydrolysis of TAG by LPL, the surrounding concentration of fatty acids 
causes the LPL enzyme to dissociate from the endothelial lining and remain attached to 
the lipoprotein particle. LPL is a ligand for the LRP and enables its direct internalisation.
c) HL is also required for the uptake of remnants and this is demonstrated from animal 
experiments whereby CM remnants have accumulated in the circulation following the 
injection of anti-HL antibodies (Sultan et al, 1990; Shafi et al, 1994). HL is not only 
involved in the final remodelling of the remnant particles by increasing the exposure of 
apo E (Brasaemle et al, 1993) but also by enhancing the association of the remnant 
particles with HSPG, thereby increasing the enrichment of the particle with apo E (de 
Faria et al, 1995). Recent evidence has indicated that the mechanism of uptake is not 
dependent on the enzyme activity but due to the C-terminal region of HL. The receptor 
which is responsible for uptake of the HL binding protein has been determined to be the 
LRP (Krapp et al, 1996).
The “two compartment” model for the uptake of CM remnants, which involves 
the interplay of the HSPG in the Space of Disse as binding sites and enrichment sites of 
the remnants before internalisation, contrasts with the uptake of LDL by the LDL 
receptor which is dependent on the direct binding to the receptor without prior 
interaction with the hepatocyte surface. This therefore may provide an explanation for 
the rapid removal of the remnants by binding to the HSPG which is able to bind the 
remnants even when the LDL receptor has been downregulated, since HSPG is not 
regulated by the cellular sterol content. However, the rate of internalisation differs, with 
a faster rate being demonstrated by direct uptake by the receptors and a slower pathway 
via the adherence to HSPG (Herz and Willnow, 1995)(Figure 1.4).
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a) ONE COMPARTMENT MODEL
apo B-lOO
Circulation
Endothelial cell
Space of Disse proteoglycan
LDL receptor
hepatocyte
b) TWO COMPARTMENT MODEL
ap oE
Circulation
Endothelial cell
c
Æ \/
Space of Disse
LDL receptor LRP
t #  t
hepatocyte
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Figure 1.4 : One- and two-compartment models for hepatic lipoprotein uptake, (a) and 
(b), respectively (adapted from Herz and Willnow, 1995). Abbreviations : CR, chylomicron 
remnant; HL, hepatic lipase; LDL, low density lipoprotein; LPL, lipoprotein lipase; LRP, low density 
lipoprotein receptor related protein
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1.7.3 Atherogenicity of chylomicron remnants.
Temporary accumulation of CM remnants capable of infiltrating the arterial wall 
is a characteristic of postprandial lipaemia. Three possible reasons exist for the 
association of CMs with CHD
a) small dense remnants in the fasting state promote accumulation of cholesterol ester in 
macrophages,
b) elevated concentrations of CMs is a determinant of the postprandial response and so 
residence time of the particles in the circulation
c) elevated levels of CMs alters the number, size and composition of HDL which is the 
anti-atherogenic lipoprotein (Clifton, 1994).
A vast amount of work regarding the association of TRLs with CHD has been carried 
out in the fasting state, where their metabolism and lipid transport has reached an 
equilibrium. However, individuals spend a large proportion of the day in the 
postprandial state in which the postprandial exogenous pathway is superimposed on the 
endogenous pathway.
Two teams of investigators have determined postprandial lipaemic responses in 
individuals who had CHD and demonstrated that they had a more pronounced and 
prolonged postprandial lipaemia after a fat containing meal compared with the controls. 
It was interesting to note that in all cases the CHD positive individuals had a higher 
fasting TAG concentration and also higher TAG concentrations in the late postprandial 
phase (Groot et al, 1991; Patsch et al, 1992). This latest observation has provided 
evidence that the delayed uptake of small CM remnants is associated with the 
progression of atherosclerosis (Karpe et al, 1993, 1994). This agreed with observations 
by Simons and coworkers (1987) who observed that the apo B-48 to apo B-lOO ratio 
was elevated in patients with CHD compared with controls. This finding is consistent 
with long standing theories that postprandial lipoproteins must be atherogenic 
(Zilversmit, 1979).
A report published by Slypher (1992) examined the development of 
atherosclerosis related to postprandial accumulation of CM remnants (atherogenic 
remnant hypothesis). Accumulation of CM remnants results in the development of 
hyperlipidaemia whose causes are classified into many types:-
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i) Type I  - Two genetic forms are known and these are LPL deficiency (inability to 
process CMs after a fatty meal) and apo C-II deficiency. These patients have 
exceedingly high plasma TAG levels (>1000 mg/dl (11 mmol/1)) and suffer firom 
eruptive xanthomas and pancreatitis.
ii) Type II - this results firom abnormalities of apo E, which interfere with receptor- 
mediated uptake of CM remnants and so these patients have an increased risk of 
atherosclerosis.
iii) Type IV  - like Type I, associated with CM TAG levels, pancreatitis and eruptive 
xanthomas. This type of hyperlipidaemia results in an excessive postprandial TAG 
response (especially VLDL-TAG) to a meal high in fat due to an overproduction of 
CMs, or to inadequate lipolysis, or to abnormalities in the metabolism of remnant 
lipoproteins resulting in their accumulation (Weintraub et al, 1987).
The mechanism whereby CM remnants provide the building blocks of arterial 
lesions are :-
a) circulating CM remnants may bind and penetrate the arterial surfaces just in the same 
way as plasma LDLs, therefore the rate of atherogenesis should be proportional to the 
plasma remnant concentrations, and
b) CMs may be absorbed and then degraded to remnants at the arterial surface 
(Zilversmit, 1979).
In each instance, the reaction leading to the endocytosis of remnants by smooth 
muscle cells may take place at sites where local injury has removed the endothelium. If 
these cells contain LPL, it acts to degrade the CMs to give CM remnants. Fielding 
(1978) has demonstrated a reduced uptake of CM cholesterol ester by the rat heart when 
perfused with heparin. Such an inhibition could be due to the displacement of LPL from 
the artery or could be a result of reduced CM remnant binding to the arterial surface.
The magnitude of postprandial lipaemia, with respect to the individuals TAG 
metabolic capacity, is dependent on a number of factors including LPL activity, receptor 
mediated uptake of the remnants and hormonal effects, in particular, the influence of 
insulin resistance. Accumulation of CM also has an indirect effect on endogenous 
lipoproteins known to be atherogenic, in particular the transfer of TAG from CMs to 
LDL and HDL and a reciprocal transfer of cholesterol ester to the CMs by the CETP.
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The transfer of cholesterol ester makes the TRLs resistant to lipase action which 
impedes the normal metabolism of TRLs and cholesterol enriched CM remnants are 
taken up by the macrophages in the arterial lesion. LDL and HDL on the other hand, 
become suitable substrates for LPL and HL and so results in the reduction in the size of 
these particles. This results in the development of an atherogenic lipoprotein profile in 
which the TRLs become cholesterol ester enriched, LDL size is reduced and HDL-C 
concentrations are reduced. The small dense nature of the LDL makes it unrecognisable 
by the LDL receptors in the liver and so it is removed by the scavenger receptor, 
contributing to the formation of foam cells. (Meisenbock and Patsch, 1992).
Recent evidence has suggested that although TRL remnants are larger than LDL, 
they have been isolated from atherosclerotic plaques (Demacker, 1995). On analysis of 
the origin of these lipoproteins, the TRLs isolated from the plaque did not contain apo 
B-48 but apo B-lOO containing particles. This implies that the atherogenic nature of CM 
remnants may lie in their effect on other lipoprotein classes. However, the method used 
to isolate TRLs from human atherosclerotic plaques was performed using anti-apo B 
immunosorption which may have resulted in the loss of apo B-48 containing TRLs from 
the plaques (Karpe and Hamsten, 1995). Although more research to determine the 
atherogenic nature of CM remnants is required, there is at present considerable evidence 
that the accumulation of remnant lipoproteins is an important factor in the aetiology of 
CHD.
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1.8 Methods to monitor the metabolism of intestinally derived 
lipoproteins
CMs are synthesised in the intestinal enterocyte following consumption of a fat 
meal. Abnormal clearance of CMs and CM remnants have been suggested to be directly 
involved in the deposition of cholesterol into the arterial wall and so be involved in the 
onset of atherosclerosis (Zilversmit, 1979; Mahley, 1982). This association has 
highlighted the need for a specific method to characterise the clearance of intestinally 
derived lipoproteins.
Separation of lipoproteins by sequential ultracentrifugation is dependent on their 
flotation densities. The particle density is inversely related to size reflecting the relative 
amounts of low density, nonpolar lipid and high density surface protein present. Since 
the size and composition of CMs and large and small VLDL and CM remnants are 
similar, they cannot be separated from each other exclusively without contamination. 
Currently two methods are available for the measurement of CMs and their remnants 
during postprandial lipaemia and these include : -
a) Indirect labelling of CMs with an ester of vitamin A, retinyl palmitate (RP), via 
incorporation of RP with a test meal.
b) Measurement of the unique structural protein of intestinally derived lipoproteins, apo 
B-48.
1.8.1 Vitamin A (RP) loading
Vitamin A is a fat soluble vitamin which is involved in a number of biological 
processes including differentiation of epithelial cells, functioning as a chromophore in 
the visual process and in fetal development.
In 1935, Drummond, Bell and Palmer reported that the structure of vitamin A 
resembled that of cholesterol and that they were incorporated into the core of the CM 
along with cholesterol ester. Unlike cholesterol, REs are not resecreted by the liver 
(Goodman, 1965).
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1.8.1.1 Metabolism of RP labelled CMs
Following ingestion of a fat meal containing RP, the meal is broken down into 
fatty globules in the stomach before entry into the duodenum. In the presence of bile 
salts, these globules are broken down into smaller lipid congregates which are more 
easily digested by pancreatic lipase. The RP is catabolised by long chain RE hydrolase 
which is situated on the brush border membrane of the intestinal enterocyte (Rigtrup et 
al, 1994). Specific binding proteins (cellular retinol binding protein (CRBPII)) carry the 
lipid soluble retinol through the membrane and into the intestinal enterocyte (Ong et al, 
1993; Herr et al, 1993). The retinol is then re-esterified with long chain fatty acids to 
form the predominant ester, RP, together with small quantities of retinyl stearate and 
retinyl oleate by 2 enzymes acyl CoA : retinol acyltransferase and lecithin : retinol 
acyltransferase (Huang and Goodman, 1965). The esterified retinol together with large 
amounts of TAG, some phospholipid, cholesterol and apolipoproteins (B-48 and apo A) 
are released into the lymph in the form of CMs from the basolateral surface of the 
intestinal enterocyte. Almost all of the retinol absorbed into the enterocytes is 
incorporated into the CM. Once in the liver the unesterified retinol has 2 fates, one of 
these is storage in the stellate cells and/or delivery to the peripheral tissues together with 
a specific protein which is synthesised in the liver, retinol binding protein (RBP). 
Whereas dietary retinol is transported to the liver largely as an ester in CMs, the 
mobilisation of vitamin A fi*om the liver stores to the peripheral tissue (for example, 
bone marrow), occurs as the parent compound, retinol, bound to RBP.
In 1976, Hazzard and Bierman introduced a method of indirect labelling of CMs 
and their remnants using vitamin A. Since then, it has become a popular method used in 
a number of dietary studies to date in animals (Ross and Zilversmit, 1977; Kita et al, 
1982) and humans (Berr and Kem, 1984; Cortner et al, 1987; Weintraub et al, 1987; 
Krasinski et al, 1990a, b; Ruotolo et al, 1992). The following rationale have been 
accepted for the use of RP loading studies and these include : -
a) incorporation of REs selectively into the core of the CM prior to its secretion from the 
enterocyte
b) negligible intravascular hydrolysis of the RE or extrahepatic removal of the labelled 
CM remnants
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c) low transfer of RE to other lipoproteins
d) complete plasma clearance of RE by hepatocytes
e) no resecretion of RE by the liver
Q virtually no background levels of plasma RE in fasting humans.
Recently, Krasinski and coworkers (1990b) have highlighted limitations of the 
use of REs as markers of CM remnants. These include : -
i) delay in the postprandial RE response in comparison with TAG and apo B-48 
responses in the plasma and TRL fractions.
Krasinski attributed this to the differences in the metabolism of TAG and RE in 
the lipoprotein particles. TAG is hydrolysed by LPL whereas RE remains in the core 
until uptake. Therefore conservation of RE and lack of conservation of TAG would 
result in the delay in the response. However, this would be also the case for apo B-48 
since this is an integral component of the lipoprotein particle and remains with the 
particle until uptake by a receptor mediated process.
Krasinski also hypothesised that the delay observed may be due to the rate/order 
in which the TAG and RE are packaged during synthesis in the enterocyte since early 
CMs are rich in TAG whereas late CMs are rich in RE. Recent evidence from studies in 
patients with LPL deficiency has demonstrated that in these individuals TAG and RP 
clearance curves were coincident compared with the dissociaton in normal individuals 
(Sprecher et al, 1991). They attributed this to the transfer of REs from CMs to the non- 
CM fraction through the action of CETP since accelerated cholesterol ester transfer has 
been demonstrated in diabetic individuals (Bagdade et al, 1991).
The delayed appearance of the RP peak compared with that of the TAG and apo 
B-48 responses is not a consistent finding in the literature (Table 1.2). In most cases, the 
peak concentrations of TAG and RP/E are reached at approximately the same time. 
Recently, in studies where the apo B-48 response has been determined, the pattern of 
response has been simultaneous with that of TAG and not with that of RP/E (Cohn et al, 
1989; Krasinski et al, 1990 a, b; Demacker et al, 1991; Jackson et al, 1995; Karpe et al, 
1995b). A criticism of the literature reviewed is that the time interval of the blood
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sampling varied between one and three hours, and so the longer the time interval, the 
more the apparent consistent timing of the peak concentrations of the analytes. It is 
interesting to note that in most cases where there is a delay, non water miscible RP was 
used in the test meal (Cohn et al, 1989; Krasinski et al, 1990 a, b; Cohn et al, 1993; 
Jackson et al, 1995; Karpe et al, 1995). The composition of the test meal did not seem to 
affect the timing of the peak responses, since delays were observed if the meal was 
mixed or of a liquid composition. However, it has been the type of fat incorporated into 
the test meal which has been questioned, since PUFAs have been suggested to delay the 
absorption of vitamin A (Karpe et al, 1995b).
ii) presence of RE-label detected in other lipoprotein fractions, namely LDL and 
HDL, 9-12 hours following consumption of the meal
Similar observations were demonstrated by Wilson (1983) and Berr and Kem 
(1984), although only a insignificant amount was detected in the LDL fraction compared 
with that detected at the peak in the TRL and plasma fractions. Cortner et al (1987) has 
also demonstrated an increase of 75% of RE is seen in the IDE and LDL lipoprotein 
classes in the late postprandial period. Analysis of apo B-48 content of lipoproteins in 
these fractions, using SDS-PAGE with Coomassie Blue for detection of bands, indicated 
that no apo B-48 containing lipoproteins were present in the IDL fraction, LDL bands 
thus excluding the possibility that RE present in these fractions represents intestinally- 
derived remnant particles. One possibility is that RE transfers to IDL and LDL, through 
exchange of the neutral lipid components. However, recent work by Hoeg et al (1990) 
has demonstrated that the human intestine has the capacity to synthesise apo B-lOO 
containing lipoproteins similar to VLDL. The amount and contribution of these 
intestinal lipoproteins is unknown or even if these lipoproteins are assembled and 
secreted. However, if this were the case, delipidation of intestinally-derived RP 
containing VLDL would result in the appearance of RP in IDL and LDL. Recently 
Karpe and coworkers (1995b), investigated the contribution of hepatic and intestinal 
lipoproteins to alimentary lipaemia following a test meal containing RP by analysing the 
apolipoprotein content of the isolated lipoproteins. The number of RP molecules per apo 
B-48 containing TRL was determined based on the following assumptions; a) the
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intestine was not producing a significant amounts of apo B-lOO containing lipoproteins, 
and b) there was negligible transfer between lipoprotein classes. The large CMs, 
Sf > 400, contained between 2000 and 4000 RP molecules whereas the CM remnant 
fraction, Sf 20 to 400, contained between 100 and 600 molecules. The authors 
determined that the RP labelled remnants were not derived totally from the large CMs 
otherwise their content of RP would be similar to the “parent” particle, but that the 
intestine releases a heterogeneous range of CM sizes, including those in the density 
range of remnants. The authors hypothesised that the intestine continuously releases 
lipoproteins in the fasting state which did not relate to the massive demand for TAG 
transporters from the intestine that occurs following fat intake.
Studies in WHHL rabbits (Beaumont and Assadollahi, 1990; Demacker et al, 
1991) have indicated the delayed clearance of RE and appearance of REs in higher 
density lipoproteins up to 24 hours following administration of RP. The authors 
implicated the down regulation or absence of LDL receptors in the delay of remnant 
clearance since similar findings were shown in cholesterol fed rabbits. It is well known 
that rabbits have a higher CETP activity than humans and so the appearance of REs in 
higher density lipoprotein fractions may be a result of in vivo transfer from intestinally 
derived lipoproteins (Tall, 1993). Since HDL is involved in reverse cholesterol transport, 
lipoprotein constituents are transferred between HDL and TRLs (i.e. CMs and VLDL) 
during lipolysis mediated by CETP in normal humans (Tall et al, 1986). Similar 
observations were described by Krasinski et al (1990) which indicate that transport of 
REs to HDL may be possible. It cannot be ruled out that some of the lipoproteins found 
in these fractions may be small or very small CM remnants, although presence in the 
circulation up to 24 hours after consumption of RP may indicate transfer mechanisms 
which may occur through the action of CETP. On the other hand, recent work in our 
laboratory which has identified CM remnants in the LDL particle density region, 
suggests that CM remnants are a population of heterogenous particles ranging in size 
and density and that their appearance in LDL and possibly HDL fractions cannot be 
ruled out (Isherwood, 1996). Alternatively, the appearance of REs in higher density 
fractions may be due to the incorporation of REs into HDL directly in the intestine 
during synthesis which slow release into the circulation. This hypothesis comes from
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research carried out in patients with abetalipoproteinaemia (a genetic disorder where 
HDL is the sole lipoprotein class since apo B containing lipoproteins cannot be 
synthesised) (Schaefer et al, 1982; Patsch et al, 1983) whereby ingestion of RP in 
patients has shown elevated levels of REs in HDL.
Recent evidence suggests that the apo E polymorphism influences the 
postprandial RP as well as TAG concentration (Boerwinkle et al, 1994; Weintraub et al, 
1987). Apo E exists as three major isoforms, E2, E3 and E4, with each one having 
different affinities for the apo E and LDL. RP profiles were shown to be significantly 
different among the apo E isoforms with E2 exhibiting a greater more prolonged 
residence time of the TRLs (determined from the AUCs) compared with the E3 and E4 
isoforms. These differences were not demonstrated in the postprandial TAG (plasma and 
TRL) and apo B-48/ B-lOO ratios.
In the rationale, one of the assumptions is that the RE enriched CM remnants are 
cleared exclusively by the liver. Recent evidence suggests that REs may be taken up by 
adipose tissue during LPL hydrolysis of CMs (Wolf, 1994; Blomhoff, 1994; Blaner et 
al, 1994). Makover and coworker (1989) detected substantial amounts of retinol binding 
protein in adipose tissue and later work by Blaner et al (1994) suggest that the source of 
this retinol was REs contained in CMs since animal studies had detected retinoid in 
adipose tissue in the form of retinol and RE on excess retinol diets. The mechanism by 
which this is thought to occur is through the hydrolysis of RE by LPL and uptake of the 
retinol by the adipocytes. This possibility of the uptake and storage of retinol and REs in 
other tissues was demonstrated by Skrede et al (1992) who observed uptake of REs from 
CMs by leukocytes and myeloid leukemic cells. A similar observation was shown in 
children with acute myeloid leukaemia where treatment with high doses of retinol has 
resulted in remission. The authors based the remission on the uptake of CM-bound REs 
by the leukaemic cells (Lie et al, 1988). However, this does not discount the fact that on 
feeding of high doses of vitamin A, CM remnants and LDL become enriched in REs and 
that it may be due to the uptake of these particles by the bone marrow rather than direct 
uptake of the RE from the CM particles themselves.
This uptake of REs by adipose tissue must therefore have an impact on the 
kinetic studies of the clearance of postprandial lipids through an overestimation of the
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catabolic rate of the CM remnants. This, therefore, adds to the questionable validity of 
the use of REs as markers for CM metabolism during postprandial lipaemia, although 
they provide a useful tracer substance for the core component of these lipoproteins.
1.8.1.2 Analysis of retinyl esters in postprandial samples
Analytical methods for the measurement of postprandial RP and RE 
concentrations are reviewed in chapter 2 , section 2 .2 .1 .
1.8.2 Apolipoprotein B-48
1.8.2.1 Analysis of apo B-48 containing lipoproteins
CMs are exclusively associated with apo B-48 and so a direct, specific method 
for their measurement would be targeted to their structural apolipoprotein. The potential 
for using apo B-48 has been demonstrated by experiments performed by Hardman and 
Kane (1986). Determination of the distinct forms of apo B, apo B-lOO and apo B-48, is 
difficult since i) apo B-48 is identical to the N terminal 2152 amino acid residues of apo 
B-lOO, ii) the concentration of apo B-48 is very low in plasma and iii) expression of the 
apo B epitope on the lipoprotein particle will depend on the lipid or apolipoprotein 
content of the particle (Karpe et al, 1996). Separation and quantitation has relied on 
difference in the molecular size and physical characteristics of the 2 apo B proteins. The 
most popular method involves the measurement of apo B-48 levels following 
consumption of a test meal by applying lipoproteins isolated by sequential 
ultracentrifugation (which is dependent on the flotation densities of the lipoproteins) 
onto an SDS-PAGE gel (Poapst et al, 1987; Zilversmit and Shea, 1989; Peel et al, 
1993b; Karpe et al, 1994). The separated bands are then visualised using Coomassie 
Blue staining and the differences in the chromatogenicity of the 2 apo B containing 
lipoproteins is determined by densitometry scanning of the gels. Recently, disagreement 
has arisen over the amount of variation in the Coomassie blue dye taken up by the apo 
B-48 and apo B-lOO containing lipoproteins. The identical peptide chain of these 2 
lipoproteins should in theory interact with the dye in an identical manner in the 
delipidated protein. Zilversmit and Shea (1989) and Karpe and Hamsten (1994) have 
both found that there was no difference in the chromogenicity of the 2 apo B isoforms,
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however, the chromatogenicity of apo B-lOO derived from larger particles was shown to 
be higher than that of apo B-48 by Poapst et al (1987). They also determined that there 
was also a non linear response between intensity of dye uptake and apolipoprotein mass. 
The differences between the methods used is that 2 different types of SDS-PAGE gels 
were used, with slab gels being used by Karpe and Hamsten (1994) and rod gels by 
Poapst and coworkers (1987). Rod gels, unlike slab gels, require the application of 10 
times more material and so this may account for the variation in the amount of 
Coomassie blue dye taken up by the lipoproteins when large amounts of apo B-48 and 
apo B-lOO are added to the gel. Karpe and coworkers (1994) postulated that the 
difference was due to the low concentration of apo B-100 in the TRL compared with the 
concentration seen in LDL, therefore underestimating the apo B-lOO containing particles 
when the gel is overloaded with the sample. A recent publication by Kotite et al (1995) 
has described the use of SDS-PAGE to quantify apo E along with that of apo B-48 and 
apo B-lOO in various lipoprotein fractions. This has an advantage over the other SDS- 
PAGE methods mentioned in that apo E can be simultaneously quantitated in 
postprandial samples.
A HPLC method has been described to quantify apo B-lOO and apo B-48 
(Hidaka et al, 1990). The method uses a silica gel column in which retention times of the 
apo B lipoproteins are 12.1 and 16.9 minutes respectively. Quantitation of 
postabsorptive samples has yielded an apo B-48 concentration which is seven fold 
higher than that measured by slab SDS-PAGE, although the percentage of apo B-48 was 
correlated with that analysed using SDS-PAGE. The discrepancy was attributed to the 
solubility of the sample before it is applied to the column and to the generation of 
cystine from oxidation of the stored samples which increases the absorbance measured at 
280 nm.
Due to the structural similarity of the 2 apo B isoforms, polyclonal and 
monoclonal antibodies raised to apo B-48 have cross-reacted with apo B-100. Recently, 
a polyclonal antiserum has been raised against apo B-48 following injection of New 
Zealand rabbits with a synthetic peptide consisting of the seven terminal amino acid 
residues of apo B-48 attached to an N terminal cysteine residue. This has been used in 
the quantification of apo B-48 following separation on an SDS-PAGE gel and
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immunoblotting of the nitrocellulose filter (Peel et al, 1993 a, b). This specific antiserum 
has therefore increased the sensitivity and specificity of the quantitation of apo B-48 
compared with using Coomassie Blue staining, although reproducibility of the SDS- 
PAGE method is a problem.
A semi-quantitative apo B-48 ELISA has been reported by Brasaemle et al 
(1993) using a nonspecific antiserum to apo B-100, with affinity purified antibodies 
against apo B-48 being used in the ELISA format. It was reported that the purified 
antisera was 50 % reactive with apo B-100 in the samples. Lovegrove and coworkers 
(1996) have recently used the specific antiserum raised by Peel et al (1993a) in the 
development of a specific apo B-48 ELISA. This enables the measurement of apo B-48 
containing lipoproteins in TRL postprandial samples which is not easily performed 
using SDS-PAGE due to the low concentrations of apo B-48, compared with apo B-100 
containing lipoproteins during the postprandial timecourse. The sources of error which 
occur in the other quantitative methods for the measurement of apo B-48 (extensive 
ultracentrifugation of plasma samples, delipidation and SDS-PAGE) are reduced 
considerably in the ELISA format since there is no prior preparation of the samples 
before analysis. The ELISA therefore provides a rapid, simple, specific alternative for 
the measurement of intestinally derived lipoproteins following consumption of standard 
test meals and also the screening of individuals to determine their risk of the 
development of CHD.
In conclusion, apo B-48 is currently being recognised as a specific marker for 
CMs and their remnants. It provides a sensitive, specific alternative to the use of vitamin 
A loading studies whose limitations are currently being recognised.
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1.9 Effects of dietary fatty acids on serum lipoproteins and
postprandial lipaemia
Fatty acids are the basic units of fats and comprise of saturated fatty acids (SFA), 
PUFA and MUFA. Numerous animal, human and epidemiological studies have 
indicated that diet may influence serum levels of cholesterol and lipoproteins which may 
be causative in the development of atherosclerosis (Stone, 1990). This hypothesis has 
generated a lot of research to determine the types of dietary fat which should be 
increased in the diet to reduce the amounts of SFAs.
1.9.1 Saturated fatty acids
The principle dietary SFAs are lauric acid (Ci2 :o), myristic (C1 4 .0 ), palmitic acid 
(Ci6 ;o) and stearic acid (Cig.q). Numerous epidemiological and experimental evidence 
suggests that a diet high in SFAs is associated with raised serum cholesterol 
concentrations, especially LDL cholesterol, and in turn is related to a higher incidence of 
CHD (Keys, 1970; Stone, 1990; Ulbright and Southgate, 1991). The involvement of 
SFAs in atheroma development is thought to be a result of the uptake of ox-LDL by 
macrophages in the arterial wall as a result of the suppression of the LDL receptor by 
SFAs (Woollett and Dietshy, 1994).
Originally it was thought that all SFAs were hypercholesterolaemic, but recent 
evidence suggests that stearic acid is not hypercholesterolaemic compared with other 
shorter chain SFAs (Bonanome and Grundy, 1988; Kris-Etherton et al, 1993; Nagaya et 
al, 1994). Stearic acid is also thought to exhibit the equivalent effects on LDL 
cholesterol concentrations as oleic acid, however, similar effects for these two fatty acids 
were not observed for HDL-C concentrations (Katan et al, 1995).
1.9.2 Polyunsaturated fatty acids
PUFAs can be divided into the «-3 (eicosapentaneoic acid (EPA), 
docosahexaenoic acid (DHA) and linolenic acid) and the n-6 oils (i.e. linoleic acid). 
Early studies indicated that n-6 PUFAs elicited a hypocholesterolaemic effect when 
substituted for SFAs (Kinstell et al, 1953; Hegsted et al, 1965). Recent postprandial
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studies have enlightened on earlier hypocholesterolaemic effects of PUFAs. Harris et al 
(1988) observed that a lower postprandial TAG response was observed when PUFAs 
were substituted for SFAs. Further studies on the effects of acute and chronic 
substitution of PUFAs («-3 and n-6) for SFAs on fasting and postprandial lipoproteins 
were carried out by Weintraub and coworkers (1988). Using RP loading studies, n-6 and 
n-3 were shown to dramatically reduce the postprandial response compared with SFAs 
in the acute and chronic situations. The authors concluded that the response observed 
was due to the fatty acid composition of the diet which was chronically fed, which may 
in turn affect the synthesis of endogenously synthesised lipoproteins (i.e. VLDL) and so 
reduce competition for catabolism by LPL. These similar plasma and CM-TAG 
responses following consumption of 3 test meals (mixed oil, «-3 and n-6) was observed 
by Zampelas and coworkers (1993). Lowest postprandial responses were again seen with 
n-3 PUFA, with mixed oils (fatty acid composition similar to current UK intake) 
showing the greatest TAG response. Postheparin plasma LPL activities, measured 9 
hours following the test meal, supported the postprandial lipid responses and so were 
postulated to explain the lower TAG response by «-3 PUFAs. CM-TAG and apo B-48 
responses were measured following consumption of diets rich in n-6 PUFAs or SFAs by 
subjects for 2 weeks (Demacker et al, 1991). Incremental areas under the apo B-48 
response curves were lower on the diets enriched with n-6 PUFAs despite the 
comparable fasting TAG values. However, it should be noted that TAGs and apo B-48 
were measured in response to meals containing the fat represented in the background 
diet. For this reason the reduced lipaemia and apo B-48 concentrations may reflect the 
effects of the meal itself, adaptive effects to the background diet or both. Many studies 
have shown that inclusion of long chain «-3 PUFA in the background diet, at levels as 
low as 2-3 g per day can significantly reduce postprandial lipaemia in response to a 
standard test meal (Harris, 1989; Sanders, 1989; Blonk et al, 1990; Brown and Roberts. 
1991). Although there is some evidence that effects of «-3 PUFA may be due to 
enhancement of the lipolytic cascade, recent work by Harris (1993), suggests 
supplementation with fish oils does not increase clearance and their action may lie in the 
synthesis/production of CMs in the enterocyte rather than their clearance.
51
1.9.3 Monounsaturated fatty acids and the Mediterranean diet 
1.9.3J . Monounsaturatedfatty acids
A detailed review of the effects of MUFAs on fasting lipoproteins and 
postprandial lipaemia is given in the introductions of chapters 3, 4 and 5. Although there 
is a vast amount of data on the effects of MUFA-enriched diets on fasting lipoproteins, 
there is at present a lack of information regarding the effects of MUFA on postprandial 
lipaemia. At present there are three possible hypotheses which explain the effects of the 
Mediterranean-style diet (with high levels of MUFA) in the prevention of CHD : -
Cholesterol hypothesis
Do MUFAs act by directly lowering LDL cholesterol concentrations and so in 
turn reducing the risk of CHD ?
Antioxidant hypothesis
Does the high intake of antioxidants in the Mediterranean diet, through the 
consumption of a large amount of fruit and vegetables reduce LDL oxidation and so 
reduce the risk of CHD ?
TAG intolerance hypothesis
Does MUFA or another constituent of olive oil reduce postprandial lipaemia and 
thus indirectly reduce the number of small dense LDL remnants so reducing CHD ?
It is impossible at this time to highlight one of these hypotheses as an explanation for the 
actions of MUFAs, because although fasting analytes have been measured in the Greek 
population, detailed postprandial analysis has not yet been completed on the population 
as a whole or in comparison with populations whose CHD risk is higher, e.g. Northern 
Europeans.
1.9.3.2. Mediterranean diet
Interest in the Mediterranean diet is derived directly from the results of the Seven 
Countries study which demonstrated that the mortality rate from CHD in Southern
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Europe was two- to three-fold lower than in Northern Europe and the USA. In the study, 
12,770 men were studied, aged between 40 to 59, in 11 cohorts; two in Finland, three in 
Yugoslavia, two in Italy, two in Greece and two in Japan. The incidence of CHD was 
shown to be the lowest in the cohort from Crete and this was surprising since the intake 
of dietary fat was high and serum cholesterol concentrations were similar to those of 
other cohorts in the Mediterranean and Northern Europe (Keys, 1970). A fifteen year 
follow up of the participants, indicated that the death rates were positively correlated 
with the average percentage dietary energy from SFAs and negatively with percentage 
dietary energy from MUFAs. It also indicated that in the cohorts where MUFA was the 
principal dietary fat, the type of MUFA accounted for the differences in the mortality 
rates (Keys, 1986).
Further evidence for the beneficial components of the Mediterranean diet was 
supported by an additional study on dietary intake in Europe carried out between 1963 
and 1965. The European Atomic Energy Commission (EURATOM) examined the 
household food consumption in 3725 families in 11 regions (nine in northern Europe 
and two in southern Europe) in 6  countries in Europe. The purpose of the study was to 
identify commonly consumed foods which may be a source of radioactive contaminants 
(Ferro-Luzzi and Branca, 1995). The Cretan Mediterranean diet of the 1960s, had a high 
abundance of plant foods, fruit, vegetables, breads, other forms of cereals and fish and a 
low abundance of meat, dairy foods, eggs and sweets. The fat intake was principally 
from olive oil compared with butter and margarine consumed in Northern Europe. The 
total fat intake is approximately 40% of total dietary energy, but the MUFA to SFA ratio 
is elevated and is usually > 2. The high intake of vegetables and cereals guarantee a high 
intake of p-carotene, vitamin C, vitamin E and non-nutrient substances such as 
flavonoids and polyphenols (Trichopoulou et al, 1994).
Olive oil contains a high proportion of MUFA, is relatively low in SFA and is a 
source of antioxidants including vitamin E. Recent evidence has indicated that olive oil 
may be a preferable fat for human diets because : -
i) In contrast with diets high in PUFA, MUFA rich diets decrease the susceptibility of 
LDL to undergo lipid peroxidation implicated in the pathogenesis of atherosclerosis
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(Reaven et al, 1991; Pagnan, 1993). Evidence indicates that dietary olive oil reduces the 
uptake of LDL by macrophages (Aviram and Eias, 1993).
ii) Dietary substitution of SFA by MUFA has shown to be as effective as diets rich in 
PUFA in lowering LDL-C concentrations. However, MUFA rich diets maintain the 
beneficial HDL concentrations compared with PUFA rich diets (Mattson and Grundy, 
1985; Mensink and Katan, 1989; Wardlow and Snook, 1990). Substitution of olive oil 
for carbohydrates has shown an increase in HDL cholesterol concentrations without the 
typical rise in LDL cholesterol concentrations seen when carbohydrates are replaced by 
other fats (Grundy, 1986, Mensink and Katan, 1987). The effects of MUFA substitution 
especially oleic acid, in the diet on plasma lipid and lipoproteins (including postprandial 
lipoproteins) are reviewed in greater detail chapter 3.
iii) Oleic acid is considered antithrombotic compared with SFAs. In comparison with 
PUFA, MUFAs inhibit platelet aggregation but not to the same extent (Ulbricht and 
Southgate, 1991).
iv) Olive oil has been consumed in large quantities as the major dietary fat in 
Mediterranean countries for many years with no evidence of harmful effects.
During the past 30 years, the traditional Mediterranean diet has been modified 
according to altered work habits, commercial trends and changing cultural norms. 
Evidence from recent dietary surveys suggest that dietary patterns are changing 
throughout the region and generally in an undesirable direction. The total serum 
cholesterol concentrations have been reported to have risen 25% over the concentrations 
recorded in the 1960s. The life expectancies in Greece have dropped slightly and this has 
been attributed to the recent dietary practices. Kafatos et al{\99\) has reported that there 
has been an increase in the intake of meat, fish and cheese with a decrease in the intake 
of bread, fruit, potatoes and olive oil compared with the dietary data collected by Keys 
during the Seven Countries study in the 1960s. Recent data has shown that the level of 
consumption of the olive oil has fallen from 32.6% of total dietary energy to 25% in the 
Cretan diet and this has been reflected in an alteration in the adipose tissue fatty acid 
composition of the population (Kafatos and Comas, 1990). Epidemiological studies in 
other Mediterranean countries in southern Italy and Spain where abandonment of the 
traditional diet, in particular the reduction in olive oil intake, has been linked vdth higher
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serum cholesterol concentrations and in turn an increased incidence of CHD. Changes in 
dietary habits have also been linked with the increase in other chronic diseases including 
hypertension, diabetes and cancer. These trends support well established patterns 
between diet and chronic disease risk.
In summary, several dietary factors have been recognised which may be 
implicated in the development of CHD, two have been identified as promoters, SFAs 
and thrombogenic SFA. Five have been identified as protective, PUFA of the n-6 
(linoleic) acid series, PUFA of the «-3 (EPA and DHA) fatty acid series, MUFA, dietary 
fibre, and antioxidants (Ulbricht and Southgate, 1991). Although it is customary to 
consider the factors independently, the response of these dietary factors is an integrated 
one. One such example is the ‘French paradox’ in which the French demonstrate a low 
incidence of CHD even though they consume a substantial amount of SFA, coupled with 
appreciable smoking and wine consumption. Wine has been shown to be modestly 
protective against CHD and that consumption of wine and vitamin E (a-tocopherol 
isomer) have approximately the same inverse strength of association with CHD across 
Europe (Rimm and Ellison, 1995). A recent article by Fielding (1995) highlights that 
there are many inconsistencies in our understanding of CHD not only in the area of 
dietary fat but also intake of alcohol. Fielding suggests that secular trends may be a great 
influence on CHD mortality which tend to be ignored in cohort studies unless they help 
to account for unexpected outcomes. This stems from evidence as early as 1952 in 
California where there was a secular decline in CHD rate well before the public were 
aware of the CHD epidemic. This was supported by evidence from a study in Iceland 
where leveling off of CHD rate occurred well before the decline in dietary fat began. It 
was determined that there was a time lag of 13 years between diet change and decline in 
CHD. Although many lines of epidemiological evidence suggests that dietary factors, in 
particular fat intake are linked with the incidence of CHD, their relations appear to be 
more complex than the current lipid hypothesis (Esrey et al, 1996).
1.10 Aims of the study
The main objective of the study was to investigate the effects of varying acute 
and chronic intake of MUFA on the clearance of CMs and CM remnants. The first aim
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was to compare the conventional method of RP labelling of CMs with a novel 
immunoassay for the measurement of their structural protein, apo B-48, as an in vivo 
marker of dietary lipids. This was determined by analysing RE, TAG and apo B-48 
responses in young men from the UK following 3 test meals of vaiying MUFA content 
(chapter 3). The next stage was to determine postprandial and hormonal responses to the 
same 3 test meals in young men from Northern Europe (UK and Ireland) with those 
from Southern Europe who habitually consume different amounts of MUFA in their 
background diet (chapter 4). The final aim was to substitute dietary saturated long chain 
fatty acids with MUFA {n-9 oleic acid) in the usual diet of young men from the UK, 
with a close family history of CHD. The level of MUFA intake will reflect the intake 
currently consumed in Crete and other Mediterranean countries (approximately 18-23% 
dietary energy). The postprandial responses in the young men following the chronic 
intake of MUFA were determined using a high MUFA test meal (chapter 5).
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Chapter 2
Materials and Methods
2.1 Collection and treatment of blood samples
Blood samples were collected into lithium heparin coated blood tubes (L.LP. 
Ltd., Shipley, UK) and spun immediately for 1700 g.min in a bench centrifuge. For the 
analysis of glucose concentrations, blood was collected into fluoride oxalate tubes (L.LP. 
Ltd., Shipley, UK) and spun as above. The plasma was removed using a plastic Pasteur 
pipette, aliquotted and stored at -20°C. To protect apo B-48 from proteolytic cleavage, a 
preservative cocktail was added to the plasma, triacylglycerol-rich lipoprotein (TRL) and 
triacylglycerol-poor lipoprotein (TPL) samples before storage (Edelstein and Scanu, 
1986).
2.1.1 Preparation of the apo B-48 preservative 
Materials
Reagent Grade Supplier
EDTA Analar Fisons Scientific Equipment,
NaCl Loughborough, UK.
NaOH
Aprotinin Analar Sigma Chemical Company,
Benzamidine St Louis, USA
Chloramphenicol
Gentamicin sulphate
Sodium azide
Procedure
NaCl, 8 . 8  g, and 1.2 g of EDTA were weighed into a 100 ml beaker. Forty ml of 
distilled water was added with continual mixing. NaOH, 3M, was added dropwise to 
adjust the pH to 7.4 to enable the solids to dissolve. One hundred mg of sodium azide, 
2.75 mg of aprotinin, 80.0 mg of chloramphenicol, 80.0 mg gentamicin sulphate and 160 
mg of benzamidine were weighed out and added to the solution. The volume of the 
mixture was made up to 50 ml with distilled water and mixed for 2 hours at room 
temperature (RT). The solution was then transferred to a 100 ml glass bottle and stored 
at RT in the fume cupboard.
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The preservative was added to the apo B-48 tubes before addition of the plasma 
samples in order to have a final concentration of 5% (v/v).
2.1.2 TRL and TPL separation
TRL (flotation density d < 1.006 g/ml) and TPL (flotation density d > 1.006 
g/ml) fi’actions were prepared by following the procedure of Grundy and Mok (1976) 
with a few modifications. Blood was collected into 10 ml heparinised blood tubes and 
spun immediately at 1700 g.min in a bench centrifuge. Five ml of plasma was 
transferred to a 10 ml glass bottle containing no anticoagulant and stored at 4°C 
overnight. Plasma, 3.5 ml, was overlayered with 3.5 ml of saline solution (d = 1.006 
g/ml) using an automated Finnpipette (Lifesciences International, UK). The saline was 
prepared by dissolving 9.6 g NaCl (Fisons Scientific Equipment, Loughborough, UK) in 
1 litre of distilled water and the density was adjusted using an automated density meter 
(Paars Ltd., UK). Thick walled polycarbonate tubes, 38 ml, (Beckman, UK) were 
ultracentrifuged in a 50.2 Ti rotor (Beckman, UK) at 4.83 x 10^  g^ax-min in a Beckman 
L7-65 ultracentrifuge (MSE Scientific Instruments, UK) at 24°C. TRL (creamy layer 
floating on the surface), 1.2 ml, was isolated carefully using a glass Pasteur pipette and 
aliquotted into LP3 tubes (L.LP. Ltd, Shipley, UK) for different analyses. If the amount 
of TRL removed was greater than 1.2 ml, the volume was noted and the remaining 
solution, termed TPL, was made up to 5.8 ml with saline. The TPL was mixed 
thoroughly and aliquotted into appropriately labelled LP3 tubes for different analyses 
before being stored at -20°C. To protect the apo B-48 fi*om proteolytic cleavage, a 
preservative cocktail was added at a concentration of 5% (v/v) of the apo B-48 
containing sample.
2.1.2.1 TRL and TPL separation in Dublin and Crete
Exceptions to the above method carried out in the U.K. are described below : -
Dublin
Samples for the separation of plasma into the TRL and TPL fractions were 
carried out in duplicate. Plasma, 1.75 ml, was overlayered vdth 1.75 ml of saline
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solution (d = 1.006 g/ml) using an automated Gilson pipette. Quick seal polyallomer 
tubes, 5.1 ml, were ultracentrifuged in a TLA-100 rotor at 9.38 x 10^  g^ax-min in a TL- 
100 bench top ultracentrifuge at 4°C. TRL, 0.6 ml, was removed from each of the 
duplicate tubes using tube slicing and mixed thoroughly before being aliquotted into 
LP3 tubes for different analyses.
Crete
Plasma, 3.0 ml, was overlayered vvdth 3 ml of saline solution (d = 1.006 g/ml) 
using an automated Gilson pipette. 6  ml bell top quick seal tubes were ultracentrifuged 
in a 50.4 Ti rotor at 8.05 x 10^  g^ax-min in a Beckman LX-90 ultracentrifuge at 4°C. 
TRL, 1 ml, was removed carefully using tube slicing and aliquotted into LP3 tubes for 
different analyses. If the amount of TRL removed was greater than 1 ml, the volume was 
noted and the remaining TPL solution, was made up to 5 ml with saline.
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2.2 Retinyl Ester Analysis
2.2.1 Analysis of retinyl esters in postprandial samples.
2.2.1.1 Retinyl esters
In concentrated solutions, retinol and its esters are yellow oils which are readily 
miscible in organic solvents. They are particularly sensitive to oxidation by air and light 
but are quite stable when bound to proteins in plasma. REs possess a characteristic ultra 
violet (UV) absorption spectrum at 330 nm. Since other fluorescent materials are present 
in biological fluids (e.g. B-carotene) some prior purification of the samples must occur 
(de Leenheer et al, 1993). Retinol and its esters are closely related compounds and so 
chromatography is the method of choice for their separation. The main REs include 
RP(Ci6 ;o), retinyl stearate (C^ g-o), retinyl oleate (RO)(Cig.J and small amounts of retinyl 
linoleate (Cig.2 ).
2.2.1.2 Analytical methods
Chromatography is a physical method of separation in which the components to 
be separated are distributed between 2  phases of which one is stationary while the other 
is mobile. Chromatographic processes occur as a result of repeated interactions with 
mobile phase on movement through the stationary phase and the resultant separation is 
due to the differences in the distribution constants of the individual sample components 
(Poole and Poole, 1991). Initial analytical methods used to separate and quantify REs 
include column chromatography, in which alumina and silica acid stationary phases 
were used (Zile and Deluca, 1968). However, this method caused destruction of the REs. 
Thin layer chromatography (TLC) was used by Huang and Goodman (1965) but this 
proved to be a lengthy method which involved 2  steps, involving initial separation of the 
REs followed separation according to chain length and saturation. A gas liquid 
chromatography method was also used which involved saponification of flree fatty acids 
followed by conversion to methyl esters and chromatography on polar columns. 
Problems with these methods include poor resolution and destruction of the REs.
To overcome these technical problems and to increase sensitivity and specificity, 
HPLC was used. This enables the addition of an internal standard which is closely 
related to the compounds of interest but which is not found in biological samples. This
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therefore compensates for any losses in the extraction step and/or adsorption losses on 
the column. The first reported method was in 1978 when de Ruyter and de Leenheer 
developed a reverse phase HPLC procedure capable of resolving individual long chain 
esters of retinol on a reverse phase column (containing octadecasilyl groups as bonded 
phase) with on-line UV detection. The principle of reverse phase HPLC is that retention 
is not due to the favourable interaction with the stationary phase but the effect of the 
mobile phase forcing the compound to the hydrocarbon stationary phase. Use of 
methanol as the mobile phase enabled the resolution of individual saturated retinyl esters 
although RO and RP coeluted as a single peak. Abe et al (1977) also developed 2 
methods for determining retinol and RP, one based on reverse phase 
(isopropanol/ethanol/water as mobile phase using fluorimetry for detection) and the 
other based on adsorption chromatography (with fluoresence detection). The 
assumptions of Abe and coworkers cannot be verified since they did not determine the 
capacity ratios, in particular the retention times of the REs. Also the use of fluorimetric 
detection ran into problems since an endogenous fluorescent compound, phytochrome, is 
known to interfere with the assay.
In 1979, de Ruyter and de Leehneer reported an improved method for the 
resolution of individual long chain retinyl esters. By inclusion of silver ions in the 
mobile phase, separation is determined according to chain length and unsaturation. 
These associate with the double bonds and so decrease their retention time compared 
with similar sized esters without affecting the saturated esters. Therefore RP elutes later 
than RO enabling their separation. A disadvantage of using silver ions remains a 
problem since use over a long period of time causes precipitation of silver ions on the 
column and in the pumping equipment. To overcome this problem, Ross (1981) used a 
HPLC column with bonded phases containing octyl or phenyl substituents which 
enabled long chain retinyl esters to be separated and quantitated in a single isocratic 
elution or more rapidly with a 2 step discontinuous gradient elution. Reverse phase 
HPLC is a popular method for the separation of REs but reported retention times for 
these methods vary between 2 0  and 80 minutes for the complete separation and small 
concentrations of REs are difficult to detect (de Ruyter and de Leenheer, 1978, 1979; 
Cortner et al, 1987). Also, lipid fi*actions need to be extracted desiccated and
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resolubilised in mobile phase buffer before application onto the column. While one 
advantage of reverse phase HPLC is the ability to resolve different esters of retinol most 
of the studies that use HPLC reported data for the concentration of the major peak 
corresponding to RP.
Recently, research groups have adopted the measurement of total REs rather than 
the separate esters of retinol (Bankson et al, 1986; Cohn et al, 1988; Krasinski et al, 
1990a, b). The use of normal phase HPLC (i.e. in which the largest retinyl esters elute 
first) with a 2 solvent gradient system elutes all esters of retinol into a single peak. The 
stationary phases are usually silica packing which contains active "silanol" groups 
(hydroxyl functions on the silicon atoms). The mobile phase consists of hexane Avith a 
low percentage of polar solvents (acetonitrile and chlorobutane). The silica packing 
reacts weakly with acidic compounds and so basic compounds are strongly retained or 
even irreversibly adsorbed. Addition of a base, acetonitrile, reduces tailing of basic 
compounds and addition of an acid, acetic acid, reduces trailing of acidic compounds. 
The use of ethanol/hexane as precipitating and extraction agents has generally been 
reported to have a reproducible and have a high extraction recovery for retinol and its 
esters since there is no need for an evaporation or resuspension step. These normal phase 
HPLC methods have the advantage of decreasing the elution time and increasing the 
sensitivity due to the elution of the REs in a single peak but a disadvantage in that the 
method requires extensive processing time. Recently, Ruotolo et al (1992) have reported 
a method which does not involve desiccation of the lipid extract prior to injection onto 
the column. The advantage of this method over that of previously reported normal phase 
chromatography methods is that only one pump is required, together with a simple 
preparation procedure and resolution times of the REs are less than 10 minutes.
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Principle of the retinyl ester assay
The vitamin A loading method is an indirect method used to determine the 
clearance of intestinally derived lipoproteins since the REs are transported around the 
circulation incorporated in the core of lipoprotein particles (Goodman, 1966). Once in 
the liver, the no^v unesterified retinol is either stored or transported to peripheral tissues 
bound to retinol binding protein. Therefore REs measured in postprandial samples are 
thought to be associated only with CMs and their remnants and not vdth other 
lipoprotein classes. The normal phase HPLC procedure described by Ruotolo and 
coworkers (1992) with a few modification by Ah-Sing in our laboratory, has been used 
in the analysis of REs in the circulation. Three peaks are observed following resolution 
which correspond to REs (predominantly RP along with retinyl stearate and oleate), RA 
(internal standard) and retinol.
2.2.2 Materials
Laboratory reagents and equipment were obtained fi*om the following suppliers
Reagent Grade Supplier
Retinyl Palmitate 
Retinyl Acetate
All-trans (RP crystalline purity and RA synthetic). 
Sigma Chemical Company, St Louis, U.S.A.
Hexane
1-Chlorobutane
HPLC
HPLC
Sigma-Aldrich, Dorset, U.K.
Methanol 
Acetonitrile 
Acetic acid
HPLC
HPLC
Analar
Fisons Scientific Equipment, Loughborough, U.K.
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Instrumentation
Equipment Description
Pump Severn Analytical Model SA 6480 (Severn Analytical, U.K.)
Autosampler Gynotek GINA Model 160 Precision Autosampler (Severn 
Analytical, UK)
Column Hichrom Spherisorb S5W (5 pm, 25 cm x 4.6 mm ID 
(Hichrom, U.K.)
Detector RAPISCAN SA6508 multiple wavelength UVWIS (Severn 
Analytical, UK)
Injection volume 50 pi
Flow rate 1 ml/min
Detection UV 330 nm
Integrator Model 160 Serial Chromatography Signal Interface 
(Autochrom Incorporated, U.K.)
Computer software Apex Software model 625-1 (integration) and Quattro Pro 
(spreadsheets)
Retention times RP = 2.55 (SD 0.08) minutes 
RA = 3.47 (SD 0.09) minutes 
Retinol = 8.62 (SD 0.05) minutes
Preparation of Mobile Phase Buffer
The constituents of the mobile phase buffer (MPB) are hexane, 1-chlorobutane 
and acetonitrile (82:13:5 by volume with 10 pi acetic acid (per 270 ml of hexane)). 
Before use, the mobile phase is sonicated under vacuum to displace the air. The MPB is 
made up fresh daily.
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Standard solutions
Stock solution (0.5 mg/ml) of RP and RA (internai standard) are prepared in 
MPB and stored at 4°C for two weeks. Standard solutions are prepared daily, in fresh 
MPB, from the stock solutions. The standards used for TRL measurement, are 25 pg/ml 
RP and 2.5 pg/ml RA and for plasma and TPL, 12.5 pg/ml RP and 1.25 pg/ml RA 
respectively.
Standard Curve Preparation
The following amounts of RA and RP are mixed to give a standard curve which 
ranges from 1.25 to 10 pg/ml of RP : -
RP standard 
(pg/ml)
RA (2.5 pg/ml) 
pi
RP (25 pg/ml) 
pi
MPB
pi
1.25 50 5 445
2.50 50 1 0 440
5.00 50 2 0 430
10.00 50 40 410
The peak area ratio (RP/RA) is plotted against the RP concentration to check for the 
linearity of the standard curve.
Extraction of standard and postprandial samples
The extraction procedure for the 3 fractions (plasma, TRL and TPL) was 
described by Ruotolo and coworkers (1992) and is summarised in Table 2.1. Briefly 100 
pi of plasma / TRL or 300 pi of TPL was pipetted into a 2 ml glass tube with a push-on 
lid. 400 pi of saline was then added to plasma / TRL or 300 pi to TPL followed by the 
addition of 500 pi of methanol, 50 pi of RA (2.5 pg/ml for TRL or 1.25 pg/ml for 
plasma / TPL) and 450 pi of MPB. The tubes were then mixed gently by placing on a 
rotary wheel for 10 minutes before being centrifuged at 1700 g.min in a Beckman J- 6  
(Beckman, UK). 200 pi of the clear upper phase were pipetted into an autosampler vial 
and 50 pi was injected onto the column.
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A standard curve of spiked plasma, TRL or TPL (fasted samples) was extracted 
alongside the postprandial samples to enable determination of their concentrations. Two 
quality control samples (freshly prepared MPB and RP spiked fasted samples (3 x
1.25 pg/ml or 2.5 pg/ml depending on the concentration of RA)) were also run to ensure 
efficiency of the extraction procedure. A data handling software package (Apex 
Chromatography) was used to integrate the chromatograms and to determine the
Table 2.1 : Extraction procedure for standard and postprandial samples
RPStd.
(pg/ml)
Plasma/TRL 
(TPL) pi
Saline
pi
Methanol
pi
RApl
*
RPpl
**
pi MPB
Blank 100
(300)
400
(200)
500 500
Blank + 
RA
100
(300)
400
(200)
500 50 450
1.25 RP 100
(300)
400
(200)
500 50 5 445
2.50 RP 100
(300)
400
(200)
500 50 10 440
5.00 RP 100
(300)
400
(200)
500 50 20 430
10.00 RP 100
(300)
400
(200)
500 50 40 410
The volumes shown are for plasma and TRL samples. Where the volumes differ for the TPL 
samples, these are given in parenthesis ( ).
* RA concentration for TRL is 2.5 pg/ml or 1.25 pg/ml for plasma and TPL 
** RP concentration for TRL is 25 pg/ml giving standard concentrations ranging from 1.25 to 
10 pg/ml RP or 12.5 pg/ml for plasma / TPL giving standard concentrations ranging from 0.625 
to 5 pg/ml.
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peak area ratios of the RP and the RA peaks. This data was then transferred to Quattro 
Pro spread sheets to enable calculation of the RE concentrations of the test samples from 
the response factor which was determined from the slope of the standard curve. Internal 
standard calibration was done by the addition of a known amount of a reference sample 
(RA) to both standards and samples. Since the integrated amount of the internal standard 
was always the same, a change in the internal standard response indicates a change in the 
chromatogram. This is reflected in the calculation by taking the ratio of the RP 
concentration to the RA concentration (internal standard) and of the RP peak area 
response to the RA peak area response (internal standard). Since the spiked RP standard 
curve was directly proportional to the RP/RA ratio, a single level calibration can be used 
to determine the amounts of RE in postprandial samples. The following equation was 
used to calculate the response factor and so the RE concentration from the standard 
curve:
Response factor (Rf) = RA peak area x RP concentration
RP peak area RA concentration
Since the absorbance of REs is only determined by the retinyl content, the concentration 
of RE is given by :
Concentration (pg/ml) = Rf (mean) x RA concentration x RE response
RA response
2.2.3 Validation Experiments
In order to determine the accuracy and reliability of a new method in the 
laboratory, it must first be validated. This involves measurement of the linearity, 
precision, reproducibility and the percentage recoveiy following the extraction 
procedure. This ensures that the results obtained are accurate and can be accepted. A 
typical chromatogram is shown in Figure 2.1(a). The three retinol peaks are well 
separated.
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Linearity
The linear correlation observed between 5 standards of different concentration of 
RP was determined by plotting their concentration against the ratio of the peak areas of 
RP against RA. Regression analysis was performed by measuring the regression 
coefficient, slope and intercept of the straight line drawn through the points. A 
regression coefficient (r) close to 1 indicates good linearity. This will be investigated by 
comparison of the slope and regression coefficients of the standard curves obtained 
during the validation experiments. The regression correlation, r, slope and the intercept 
were calculated using LINCAL for the linearity validation experiments.
The linearity of the assay was determined from plotting known standard RP 
concentrations against the peak area ratios obtained (Figure 2.1(b)). RP standard curves 
ranging from 1.25 to 10 pg/ml and a RA concentration of 2.5 pg/ml were found to have 
a mean r value of 0.9996, SD 0.0003, n=10. The slope had a mean value of 0.2369 (SD 
0.029), n=10. Linearity following extraction of plasma and TRLs (i.e. fasted samples 
spiked with a known concentration of RP) was shown to have a mean r value 0.9971 
(SD 0.004) and the slope a mean of 0.2391 (SD 0.031), n=10.
Precision
Injection precision of the autosampler onto the column is important to ensure 
that all samples are analysed under the same conditions. To investigate this, multiple 
injections were made from single standards and the peak area ratios obtained were 
assessed using statistical analysis, namely the coefficient of variation (CV).
Variability of the automated injected samples (intra-assay) was observed to be 
less than 5% Avith a mean value of 0.439 (SD 0.005), n= 6  and CV of 1.2%.
Reproducibility
The within- and the between-day reproducibility of the extraction and sampling 
procedure were assessed by preparation of multiple standards on the same and different 
days. Their reproducabilities were determined from the CV obtained for both days. This 
was determined in test samples (a subject from the MUFA study (chapter 3)) extracted 
on different days.
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Figure 2.1. a) A typical chromatogram of REs extracted from plasma and b) standard 
curve for RP spiked plasma samples. Values in the standard curve are the RP/RA ratios 
plotted against the concentrations of RP.
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The intra-assay and interassay variations for the multiple spiked samples (n=10) were 
assessed using the CV. The results are shown below in Table 2.2.
Table 2.2 Reproducibility of RE spiked plasma samples.
RP Standard (pg/ml) Intra-assay CV (%) Interassay CV (%)
1.25 3.9 5.0
2.50 3.0 4.4
5.00 1.9 2 . 2
1 0 . 0 0 1 . 2 3.2
The reproducibility between test samples (subject from the MUFA study) extracted on 
consecutive days is shown in figure 2.2. The mean CYs for the RE concentrations 
obtained at each time point was 10.3 % (SD 10.2) with percentage CV differences being 
greatest at earlier timepoints (i.e. 60 - 180 minutes post meal). To minimise inter-assay 
variability each subjects postprandial samples were extracted and analysed in batches.
i
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Figure 2.2. Reproducibility of test samples extracted on consecutive days. Analysis of 
postprandial samples using the method by Ruotolo et al (1992) on 2 consecutive days. 
Postprandial samples were firozen between analyses. Values represent RP/RA ratios for 
each timepoint read off a prepared standard curve
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Storage
The stability of the stock solution stored at 4°C and RT was determined from the 
regression components of the standard curve following storage for 1 day and 1 week in 
the dark. The effect of storage of the extracted samples at 4°C (0, 6  and 24 hours 
following extraction of REs) was determined to investigate the stability of the extracted 
REs.
Following the storage of the RP stock solution (0.5 mg/ml) for 1 week at 4°C 
and RT, the linearity of the standard curve was found to be y = 0.1921x + 0.030, r = 
0.9999 for RT and y = 0.2312x + 0.001, r = 1.000 for 4°C. The observed fall in peak 
area was seen for the stock solution stored at RT and this was indicated by the fall in the 
slope of the standard curve. The extracted RE samples demonstrated a minimal 
progressive fall on storage at 4°C over 24 hours. The CVs for the RE concentrations 
obtained for the postprandial samples stored at 4°C for 6  hours and 24 hours 
demonstrated a change from the original timepoints of 2.6 % (SD 2.4) and 4.8 % (SD 
3.6) respectively. The slope of the standard curve following storage for 24 hours was y = 
0.2249x + 0.2734, r = 0.9805 compared with y = 0.2228x + 0.1788, r = 0.9914 at 0 
hours. The stock solutions were therefore stored for 1 week at 4°C.
Percentage recovery following extraction
This was determined by comparison of spiked fasted plasma, TRL and TPL 
samples with corresponding samples made up in MPB from the stock solutions. The 
peak area ratios obtained from the extracted samples were read off the standard curve 
prepared from the stock solutions to determine their concentration. The value obtained 
was divided by the concentration of RP which was used to spike the fasted samples to 
determine the percentage recovery.
The percentage recoveries for RP concentrations ranging from 1.25 to 10 pg/ml 
were 92.1 % (SD 15.1) for 1.25 pg/ml, 96.9 % (SD 22.61) for 2.5 pg/ml, 98.7 % (SD
11.4) for 5 pg/ml and 99.9 % (SD 9.63) for 10 pg/ml.
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2.3 Apolipoprotein B-48 analysis
Principle
A  competitive ELISA was used to analyse apo B-48 concentrations in 
postprandial samples according to Lovegrove et al (1996) and the principle of the 
ELISA is shown in figure 2.3. An heptapeptide-thyroglobulin conjugate consisting of 
the terminal residues of the apo B-48 molecule is used as the coating material in this 
ELISA format. Postprandial plasma samples were incubated with the specific antisera to 
apo B-48 before addition to the ELISA plate. An horse radish peroxidase (HRPO)- 
conjugated antibody is used to detect antibodies attached to the coating material through 
its action with the TMB substrate. Absorbance measured at 450 nm is inversely 
proportional to the concentration of apo B-48 in the postprandial samples.
2.3.1 Materials
Reagent Grade Supplier
Disodium hydrogen orthophosphate Analar Fisons Scientific Equipment,
Dimethylformamide (DMF) Loughborough, U.K.
Gelatine
Hydrogen peroxide
Hydrochloric acid
Potassium chloride
Potassium dihydrogen
orthophosphate
Sodium hydrogen carbonate
Sodium carbonate
Sodium chloride
Citric acid Analar BDH Limited, Poole, U.K.
Human serum albumin (HSA) Analar Sigma Chemical Company, St Louis,
(Fraction V 96-99% purity) U.S.A.
Tween 20
3, 3’, 5, 5’-Tetramethylbenzadine Boehringer Mannheim GmbH, Germany.
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Figure 2.3. Principle of the apo B-48 ELISA
ELISA well
Hapten {thyroglobulin - peptide conjugate)
After Blocking, Addition of a 
Pre-incubated sampie i.e. Antibody 
raised to Apo B-48 and a 
Postprandiai Sampie (A = Low Apo 
B-48 and B = High Apo B-48 content)
1
1 1
1 1
Incubation with 
Enzyme-labelled Antl-IgG
1 1
1
1
Enzyme Substrate (TMB) 
Added
Opticai Density Measured is inverseiy Proportionai to the 
Concentration of Apo B-48 in the Postprandiai Sampies. 
(After each stage the ELiSA piates were washed and dried)
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Coating conjugate
A heptapeptide consisting of the N-terminal cysteine residue attached to the C- 
terminal hexapeptide equivalent to residues 2147-2152 of apo B-48 (HgN^-Cys-Leu- 
Gln-Thr-Tyr-Met-Ile-COO') was custom synthesised at the National Institute of Medical 
Research (Mill Hill, London, UK). In order to absorb the heptapeptide to the microtitre 
plate it was conjugated to thyroglobulin using succinimidyl 3-(2 -pyridyldithio) 
propionate (See section 2.3.2). This was stored at -20 °C and diluted in coating buffer at 
a dilution of 1:80,000 for use in the ELISA format.
Assay standard - Lymph samples E and H
Human thoracic duct lymph from a patient undergoing thoracic surgery, who 
suffered chylo thorax, was kindly supplied by Dr J. Wright (Royal Surrey County 
Hospital, Guildford, UK). The lymph samples were treated with the apo B-48 
preservative 5% (v/v), according to the method of Edelstein and Scanu (1976) (see 
section 2.1.1) and stored in aliquots at -20°C. We are indebted to Dr Frederik Karpe at 
the Karolinska Institute, Sweden for quantitating the absolute amount of apo B-48 and 
apo B-lOO within the lymph standard sample using SDS-PAGE separation followed by 
Coomassie blue staining (Karpe and Hamsten, 1994). The values for the apo B-48 and 
apo B-lOO within the 2 standard lymph samples used were 19.1 pg/ml and 42.9 pg/ml 
(lymph E) and 12.7 pg/ml and 37.0 pg/ml (lymph H) respectively
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Quality controls
Pooled plasma samples were collected from fasting individuals, for the low 
concentration of apo B-48 QC and postprandial samples for the medium and high apo B- 
48 QC samples. These were aliquotted and stored at -20°C.
Buffers
Reverse osmosis distilled water is used in the preparation of all of the buffers
Coating buffer -carhonate/bicarbonate buffer pH  9.6, 0.1 M  
3.18gNa2C0g 
5 .8 8 gNaHC0 3
Dissolve both salts in distilled water and make up to 1 litre. Check pH and store 
at4°C
Stock buffer - Phosphate buffer saline (PBS) pH  7.4, 0.2 M  
160 g NaCl 
58gNa2HP04 
4gKCl 
4gKH2P04
Dissolve in distilled water and make up to 2 litres. Check pH and store at RT. 
PBS was in fact made up as a 10 fold stock solution (i.e. 0.2 M) and on the day 
of use, the required amount was removed and diluted 1 : 1 0  with distilled water to 
give 0.02 M PBS.
Wash and diluent buffer (PBS-GT) - 0.02 MPBS, 0.05% Tween 20 and 0.1% 
gelatin, pH  7.4.
100 ml PBS 0.2 M
1 . 0  g gelatin 
0.5 ml Tween 20
Make up 0.02 M PBS (100 ml of 0.2 M PBS added to 900 ml of distilled 
water) remove 1 0 0  ml and add 1 . 0  g gelatin with heating and stirring to ensure
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that all of the gelatin dissolves. Add the Tween 20, mix and then add back to the 
rest of the PBS to give the working solution.
Standard diluent - human serum albumin (HSA)
35 mg HSA
Dissolve HSA in 1 ml of 0.02 M PBS. Prepare not more than one hour before 
use.
Substrate buffer - Citrate phosphate buffer, pH  5.0 for TMB substrate 
3.55gNa2HP04 
2.61 g citric acid
Dissolve both in 500 ml of distilled water. Check pH and store at 4°C.
Substrate stock - 3, 3 \5 ,5 ’ Tetramethylbenzidine (TMB)
20 mg TMB 
Make up in 1 ml of DMF
TMB Substrate
2 0  ml substrate buffer (citrate phosphate buffer)
1 0 0  pi substrate stock 
16 pi H2 O2  
Make up within 15 minutes of usage.
Stop solution -1 MHCl
50 ml concentrated HCl 
Add to 500 ml of distilled water.
Procedure 
Day 1
Coating conjugate, 100 pi, made up in coating buffer, pH 9.6 was placed into the 
inner 60 wells of a flat bottomed polystyrene microtitre plate (Nunc, Roskilde,
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Denmark). The plates were placed into a damp storage box and stored for 16 hours at 
4°C.
Day 2
The plates were washed three times with PBS GT using an automated microplate 
washer (Lifesciences International, UK) and banged diy on paper towels several times to 
remove washing buffer before addition of 150 pi of PBS-GT. The plates were then 
incubated for 1 hour at 37°C to block the unbound sites in the wells and to prevent non­
specific binding.
The plates were washed as previously described. An 8  point standard curve and a 
zero standard were prepared using the lymph standard and standard diluent. A T. 125,000 
dilution of apo B-48 antisera in PBS-GT was prepared and an equal volume was added 
to the lymph standards, QCs (low, medium and high apo B-48 containing plasma 
samples) and test samples (i.e 250 pi of antisera was added to 250 pi of samples), 
vortexed and incubated at RT for 1 hour. 100 pi of the standards, QCs and samples were 
added in duplicate to the plate and incubated for 2 hours at 37°C. The plates were then 
washed as before.
A 1:40,000 dilution of donkey-anti rabbit HRPO-antisera was prepared in PBS- 
GT and 100 pi was added in duplicate and incubated for 2 hours at 37°C. Plates were 
washed 3 times with PBS-GT followed by the addition of 100 pi of TMB substrate. The 
bound antisera was incubated with TMB at 37°C for approximately 30 minutes until a 
dark blue colour had developed. The reaction was terminated by the addition of 50 pi of 
the stop solution (1.0 M HCl) and the yellow product was read at 450 nm using an 
automated plate reader (Multiskan Biochromatic plate reader, Lifesciences International, 
UK). A standard curve was drawn and the concentrations of apo B-48 in the postprandial 
samples were determined using Genesis software (Lifesciences International, UK). A 
typical standard curve is shown in figure 2.4. Postprandial responses to each test meal 
were analysed on separate plates for each subject.
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Figure 2.4. A typical lymph standard curve prepared by diluting human lymph in assay 
diluent (neat, 1:2,1:4,1:8,1:16,1:32,1:64,1:128,1:256).
2.3.2 Optimisation and validation of the ELISA format.
The ELISA was optimised and validated in conjunction with 2 colleagues 
(Lovegrove ûr/, 1996)
2.3.2.1 Optimisation experiments
The optimum incubation temperature and time, buffers, plates and analyte 
concentrations were determined at each step of the competitive ELISA development.
Optimisation of the concentration of new donkey anti-rabbit HRPO conjugate
The concentration of the new detecting antisera was determined by running a 
series of concentrations of the antisera and comparing the shape of the lymph standard 
curves. It is important that the absorbances for the standard curve provide a good range.
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starting very low (i.e. 2 SDs above zero) and the top standard having an absorbance 
between 1 and 1.5. In this ELISA format, the optimal concentration of the new detecting 
antisera was 1:40,000.
2.3.2.2 Validation experiments
All routine validation tests were carried out and these included parallelism, intra- 
and interassay reproducibility, sensitivity (2 SD from the background absorbance), 
parallelism, recovery of a known amount of apo B-48 from a spiked sample and cross­
reactivity/interference of other materials.
Validation of a new lymph sample. Lymph H
The human thoracic duct lymph, used as the standard in the ELISA format, was 
kept in a number of alphabetically labelled plastic containers. The concentration of 
Lymph E was analysed previously by Dr Frederik Karpe and determined to be 19.1 
pg/ml. Recent apo B-48 quantitation of all of the lymph samples by Dr Karpe has 
determined the concentration of lymph E to be 21.4 pg/ml and that of lymph H to be
14.9 pg/ml. Since the newly analysed concentration of lymph E was similar to that 
previously analysed, it was decided that the concentration of Lymph H could be 
calculated from the lymph E standard curve in the ELISA format. Lymph H was 
determined to have a mean concentration of 12.7 pg/ml (SD 0.55, n = 12).
Lymph H was chosen as the replacement standard since its apo B-48 
concentration encompassed the apo B-48 concentrations in fasting and postprandial 
plasma, TRL and TPL samples. The new lymph H sample was analysed and shown to 
give a comparable standard curve to Lymph E (Figure 2.5a) and to be parallel to the 
original standard (Figure 2.5b).
Parallelism
This is an important tool for monitoring any changes in the assay performance 
due to reagents. Ideally, the shapes of the standard and the sample matrix should be 
similar. Any test sample which is diluted before analysis should yield the same final 
concentration after interpolation from the standard curve following correction for the
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specimen dilution. Plasma, TRL and TPL fractions were tested by double diluting the 
samples in the assay diluent and analysing the samples in the ELISA format.
In general, the samples tested ran parallel to the standard and examples are 
shown in figure 2 .6 ).
Sensitivity and recovery of a known amount of apo B-48 from a spiked sample
The sensitivity of an ELISA is defined as 2 SDs above the background (zero) 
absorbance and in this ELISA format has been determined to be less than 37 ng/ml by a 
colleague.
The recovery of samples spiked vrith apo B-48 containing fractions in the range 
of 19.1 to 5.7 pg/ml was performed by a colleague and shown to be 102 % (SD 10)
Crossreactivity
Crossreactivity was investigated using ovalbumin, the carrier protein used to 
raise the antisera, from 1 mg/ml to 3.9 pg/ml; HSA, which is structurally similar to 
ovalbumin and the most abundant protein in plasma, from 70 mg/ml to 0.27 mg/ml; 
thyroglobulin, the protein used to produce the coating conjugate, from 1 mg/ml to 3.9 
pg/ml; apo B-lOO, since it is identical to 2152 amino acids of apo B-48, from 50 pg/ml 
to 0.2 pg/ml within the assay. Intralipid (Kabi Pharmaceuticals, Milton Keynes, UK) 
was used to determine whether there was interference by lipid particles in the range from 
20 mg/ml to 78 pg/ml.
Negligible crossreactivity to these proteins/particles and interference by a lipid 
emulsion was observed in the ELISA format.
Intra- and inter-assay reproducibility
The CV of the newly prepared low, medium and high QCs were used to 
determine the intra- and inter- assay variation. 12 samples of each QC were analysed on 
one plate and this was repeated on the same day and then on three successive occasions. 
The results are shown in Table 2.3.
As an additional test of reproducibility, TRL samples from 6  postprandial time 
courses, each with 1 2  time points, were analysed on two separate occasions in the
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Figure 2.5. Validation of the new lymph standard. Lymph H. a) lymph standard curve 
comparison and b) parallelism of the new lymph H standard with the original lymph E 
standard.
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Figure 2.6. Parallelism of plasma, TRL and TPL samples with the lymph H standard 
curve. Dilutions of plasma, TRL and TPL samples were made with the assay diluent and 
analysed in the ELISA format.
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ELISA format. An example of a postprandial time course from a subject is shown in 
figure 2.7. The mean correlation coefficient, r, was 0.94 (SD 0.07) and the level of 
significance was P < 0.001 (Pearsons parametric correlation) (Table 2.4).
Table 2.3 Intra-assay and inter-assay coefficient of variation of the three quality
control samples in the apo B-48 ELISA
QC sample apo B-48 
concentration 
(fxg/ml)
Intra-assay
CV(%)
apo B-48 
concentration 
(pg/ml)
Inter-assay
CV(%)
LOW 2.239(0.116) 5.2 2.376 (0.223) 9.4
MEDIUM 2.885 (0.121) 4.2 2.587 (0.212) 8 . 2
HIGH 4.186(0.159) 3.8 3.903 (0.296) 7.6
Values for the apo B-48 concentration are represented as mean (SD)
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Figure 2.7. Apo B-48 postprandial profile for TRL samples from a subject (subject 12) 
determined using the apo B-48 ELISA on 2 separate occasions. The subject was a young 
male who consumed a 42 g fat meal following a 12 hour overnight fast.
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Table 2.4. The correlation coefficient, r, between the postprandial TRL apo B-48 
concentration measured by the ELISA on 2 separate occasions in 6 subjects (each 
with 12 timepoints over a 9 hour period).
Subject number Correlation coefficient (r)
1 0.98
4 0.94
6 0.80
9 0.94
1 2 0.99
15 0.99
2.3.3 Preparation of the new heptapeptide-SPDP-thyroglobulin coating conjugate
The coating conjugate, prepared by a co-worker, used in the ELISA format 
(Lovegrove et al, 1996) had run very low and so it was decided to prepare a new 
conjugate to enable the remaining apo B-48 containing samples to be analysed. 
Laboratory reagents were obtained from the following suppliers : -
Reagent Grade Supplier
EDTA
Dimetbylformamide (DMF) 
Disodium hydrogen orthophosphate 
Potassium chloride 
Sodium chloride
Analar Fisons Scientific Equipment, 
Loughborough, UK.
Mercaptoethanol 
Porcine thyroglobulin
Sigma Chemical Company, St 
Louis, USA.
N-Succinimidyl 3 -(2-pyridyldithic) 
propionate (SPDP)
Fluka Biochimika, Buchs, 
Switzerland.
Heptapeptide (cys-apo B-48 residues 
2147-2152)
National Institute of Medical 
Research, Mill Hill, London, UK
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2.3.3.1 Materials
Solution A  -0.1 M  sodium phosphate solution 
1.42gNa2HP04 
0.9gNaCl 
20 mg KCl 
Dissolve in 100 ml of distilled water
Solution B - 0.1 M  potassium phosphate solution 
1.35gKH2P04 
0.9gNaCl 
20 mg KCl 
Dissolve in 100 ml water
Solution C -0.1 M  sodium phosphate solution with 5 mM EDTA 
0.186 g EDTA (5 mM)
Dissolve in 100 ml of solution A
Solution D -0.1 M  potassium phosphate solution with 5 mMEDTA 
0.186 g EDTA 
Dissolve in 100 ml of solution B
Procedure
The heptapeptide (cys-(apo B-48 residues 2147-2152) was conjugated to porcine 
thyroglobulin activated with SPDP following the method of Carlsson and coworkers 
(1976).
A 0.1 M phosphate buffer, pH 8-8.5, was prepared by adding solution A to B 
until the desired pH was obtained. Solution C was then added to D to prepare a 0.1 M 
phosphate buffer containing 5 mM EDTA, pH 6 .6 6 . Porcine thyroglobulin, 20 mg, was 
weighed out and added to 2 mis of 0.1 M phosphate buffer, pH 8-8.5 and stirred for 20 
minutes. SPDP, 1 mg, was dissolved in 100 pi of DMF and 30 pi of this solution was 
then added dropwise to the porcine thyroglobulin dissolved in phosphate buffer. This
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solution was stirred at RT for 1 hour. 470 pi of 0.1 M phosphate buffer, pH 8-8.5 was 
added to bring the volume of the solution to 2.5 mis.
A PD-10 column (Sephadex G-25 M; Pharmacia Biotech AB, Uppsala, Sweden) 
(used to separate the activated carrier from the unreacting conjugate) was equilibrated 
using 25 mis of 0.1 M phosphate buffer containing 5 mM of EDTA, pH 6 .6 6 . 2.5 mis of 
the thyroglobulin-SPDP solution in phosphate buffer was added to the column and 1 ml 
fractions were collected following the addition of 10 mis of 0.1 M phosphate buffer 
containing 5 mM EDTA, pH 6 .6 6 . The presence of protein was determined by reading 
the absorbance of the fractions at 280 nm and the three fractions with the greatest 
absorbances were pooled and the combined volume and absorbance determined.
Estimation o f the number o f SPDP conjugated to thyroglobulin
17 pi of 2-mercaptoethanol was added to 5 mis of 0.1 M phosphate buffer, pH 
8.0-8.5 to give a 0.012 M 2-mercaptoethanol solution. 900 pi of distilled water was 
transferred to a cuvette and 100 pi of the 0.012 M 2-mercaptoethanol solution (blank) 
was added. 2 0 0  pi of the pooled fraction was then transferred to a second cuvette 
containing 700 pi distilled water and 100 pi of the 0.012 M solution of 2- 
mercaptoethanol was then added. The quantity of 2-thiopyridone liberated, which is 
directly proportional to the introduced thiopyridyl groups, was calculated using s = 8000 
M'  ^ cm'  ^ by measuring the absorbance at 343 nm after 1 hour. The difference in the 
absorbances between these cuvettes gave the amount of SPDP bound and was used to 
calculate the ratio of SPDP which had reacted with the porcine thyroglobulin. This was 
used to determine the amount of peptide to add, since a ratio of 1:1 with SPDP is 
required.
Conjugation o f the peptide
An excess of the heptapeptide was added to the porcine thyroglobulin-SPDP 
solution, i.e. 0.5 mg of peptide dissolved in 15 pi of DMF, and stirred for 3 hours at RT. 
The amount of peptide attached to the SPDP was determined by reading the absorbance 
of the solution at 343 nm. The absorbance obtained enabled the amount of the
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heptapeptide attached to the thyroglobulin to be calculated. The conjugate was then 
dialysed for 24 hours in distilled water at 4°C and aliquots of 50 pi were stored at -20°C.
2.33.2 Optimisation of the new coating conjugate
The concentration of coating conjugate required in the ELISA format was 
determined by coating ELISA plates with a range of concentrations of the new conjugate 
and comparing the absorbances and the shape of the lymph standard curves with the 
original conjugate (Figure 2.8). A dilution of 1:80,000 in coating buffer was preferred 
for the new coating conjugate.
I
I
2.01
Original conjugate 
New conjugate 1:60K 
New conjugate 1:80K 
New conjugate 1:120K
0.5-
0.0
1 0 0101.1.01.001
Apo B-48 Concentration(ug/ml)
Figure 2.8. Optimisation of the new coating conjugate. A range of concentrations of the 
new conjugate were coated onto an ELISA plate and the lymph standard curves 
compared with that of the original conjugate.
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2.4 Lipoprotein and Hepatic lipase activities
Principle
LPL and HL activity were measured according to the method described by 
Nilsson-Ehle and Schotz (1976) with a few modifications. The principle of this method 
is the liberation of labelled oleic acid fi*om a tritium labelled triolein emulsion which is 
extracted by nonpolar solvents to measure the activity of the enzymes in postheparin 
plasma samples.
2.4.1 Materials
Laboratory reagents were obtained from the following suppliers : -
Reagent Grade Supplier
Glycerol Tri (9,10(n)-'*H) Oleate 
370-1100 MBq/mol, 5mCi/ml
Amersham International pic, UK
Bovine albumin (essentially fatty 
acid free)
Heparin-sodium salt (grade II) 
Heptane
L-a-phoshatidylcholine 
Triolein (Cl8:1, cis-9)
Trizma base
HPLC
Sigma Chemical Company, St Louis, 
USA
Boric acid 
Potassium carbonate
Analar BDH Limited, Poole, UK
Chloroform 
Glacial acetic acid 
Glycerol 
Methanol
Optiphase Safe (Wallac Scintillation 
products)
Analar Fisons Scientific equipment, 
Loughborough, UK.
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Assay reagents
Assay diluents - low and high NaCl solutions
Low salt - 50 mmol Tris (pH 8.1), 0.2 M  NaCl and 2 U/ml heparin
11.69 g NaCl
6.06 g Trizma base
1 2 . 0  mg heparin
Dissolve in 900 mis of distilled water. Adjust pH to 8.1 using 0.1 M HCl 
and make volume up to 1 litre with distilled water. Store at 4°C
High salt - 50 mmol Tris (pH8.1), 4.0 MNaCl and2 U/ml heparin
116.9 g NaCl
6.06 g Trizma base
1 2 . 0  mg heparin
Add to 900 mis of distilled water and warm to dissolve (up to 60°C).
Cool and adjust pH to 8.1 using 0.1 M HCl. Make up volume to 1 litre 
and store at 4°C.
Tris-BSA -3% fatty acidfree BSA added to assay diluent 
30 mg BSA
Diluted with 10 ml of the appropriate assay diluent (low or high salt)
Milk quality controls -1:10 and 1:4 diluted solutions o f prepared skimmed milk 
20 mis of raw fresh milk (Loseley, Guildford, UK) was centrifuged at 3000 rpm 
for 1 0  minutes in a bench top centrifuge and the skimmed milk was decanted 
from the cream by piercing the cream layer with a pipette. The skimmed milk 
which was filtered through glass wool and stored at 4°C was prepared by a 
colleague. Dilutions of skimmed milk are made at 1:4 and 1:10 with 50 mM Tris 
buffer, pH 8.1 (Low salt assay diluent) :
1:4 20 ml skimmed milk added to 60 ml Tris buffer
1:10 10 ml skimmed milk added to 90 ml Tris buffer.
Aliquots of 1 ml are stored at -80°C.
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Milk standard quality control -1:10 skimmed milk standard diluted 1:3 with 
low salt assay diluent
2 0  ml 1 : 1 0  skimmed milk standard 
Add 40 ml of low salt assay diluent. Store 500 pil aliquots at -80°C.
Apolipoprotein C-II source - human serum
Blood from volunteers was collected into plain glass tubes and allowed to clot at 
RT for 2 hours and then spun at 1700 g.min. Serum is removed and incubated at 
62°C for 10 minutes (to inactivate lipases) and 500 pi is aliquotted into 
microcentrifuge tubes. Store at -80°C.
Potassium carbonate - 0.1 M, pH  10.5 
13.82gK2C03
Make up to 1 litre with distilled water. Adjust pH to 10.5 'with boric acid. Store 
at4°C
Organic solvent - chloroform, heptane and methanol (1.25:1:1.41)
250 ml chloroform 
2 0 0  ml heptane 
282 ml methanol 
Ensure thorough mixing of organic solvents.
Scintillation cocktail -Optiphase Safe and glacial acetic acid 
4 ml Optiphase Safe 
80 pi glacial acetic acid 
Carefully add Optiphase Safe and glacial acetic acid to the individual 
scintillation vials (Wallac UK, Milton Keynes, UK) using the appropriate 
dispenser. Prepare on day of use and store in dark until use.
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2.5.2 Procedure
a) Preparation of the tritium labelled triolein emulsion
50 pi Triolein
250 pi Triolein
80 pi L-a-phosphatidylcholine
5 ml Glycerol
Triolein, triolein and L-a-phosphatidylcholine were pipetted into a sonicating 
vial, mixed and blown down to dryness under N2  in a dark fume cupboard for 2  hours. 
Glycerol, pre-warmed at 37°C, was added and vortexed to ensure thorough mixing. The 
emulsion was produced by sonicating for 1 0 - 2 0  second intervals using a soniprobe at an 
amplitude setting of 2-4. Between sonications, the emulsion was vortexed well and kept 
on ice. The emulsion was sonicated until fat globules were no longer visible on its 
surface and then transferred to a clean glass bottle wrapped in aluminium foil for storage 
at RT. The emulsion was stable for a maximum of six weeks.
The quality of the emulsion was determined by preparing a milk standard curve 
using dilutions of the 1:10 and 1:4 skimmed milk standards.
b) Assay for the analysis ofpostheparin LPL and HL activities.
Blood samples were collected 5 and 15 minutes following the injection of 7500 
lU of heparin, 9 hours following each test meal and following a 12 hour overnight fast. 
In the assay format, all samples were analysed in duplicate and carried out using a low 
salt assay diluent (total lipase determination) and a high salt assay diluent (HL 
determination). A milk standard QC was included in each assay.
Plasma samples stored at -80°C were defrosted and centrifuged at 1000 g.min. 
The working substrate emulsion was prepared using the low salt and high salt assay 
diluents by adding 500 pi of human serum, 500 pi tritiated glycerol emulsion and 2 mis 
of Tris-BSA (0.2 M and 4 M NaCl) to a 5 ml plastic tube (L.I.P. Ltd; Shipley, UK). This 
solution was mixed thoroughly and incubated at 37°C for 10 minutes. An outline of the 
assay protocol is shown in Table 4. Briefly, total, blank and sample tubes were prepared 
in 15 ml opaque centrifuge tubes (Sarstedt Ltd, Leicester, UK). 100 pi of working
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substrate emulsion was added to each centrifuge tube and vortexed thoroughly. The 
tubes were capped and placed in a shaking water bath; incubated at 37°C for 30 minutes. 
The tubes were then placed on ice and 3.25 ml organic solvent and 1.05 ml 0.1 M 
K2 CO3 were added to all tubes except for the totals tubes. Following thorough mixing, 
the tubes were centrifuged at 1700 g.min. 500 pi of the upper aqueous layer was 
removed and placed into an appropriate scintillation vial and vortex mixed. The vials 
were left to stand for 1 hour before being counted using a WALLAC 1410 scintillation 
counter (WALLAC UK, Milton Keynes, UK). Due to the large number of tubes 
involved in the lipase assay, only samples from 1 subject were analysed in each assay.
The intra- and inter-assay variation of the assay was determined by analysing 10 
milk standard QCs in one assay and then in successive assays. The CV were 5.2% and
9.3 % respectively.
Table 2.5 : Lipase assay protocol
Reagents Tubes
Totals Blanks QC Plasma
Assay diluent (low 
or high salt)
2.45 ml 1 0 0  pi 80 pi
QC - - 1 0 0  pi -
Plasma - - 2 0  pi
Substrate
emulsion
1 0 0  pi 1 0 0  pi 1 0 0  pi 1 0 0  pi
Vortex mix and incubate at 37°C for 30 minutes
K2CO3 - 1.05 ml 1.05 ml 1.05 ml
Organic solvents - 3.25 ml 3.25 ml 3.25 ml
Mix and centrifuge 1700 g.min
The data was handled in the following manner. The results from the blanks tube 
were subtracted from all of the results for the postheparin plasma samples. Enzyme 
activity (pmol oleate released per minute) at 37°C was calculated by :
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(DPM-blank) x J_ x ______1___________  x 3 x 4.9 x ^
30 specific activity of triolein 0.76
Where:
specific radioactivity of triolein = 2170617.8 dpm / pmol 
30 = incubation time of 30 minutes 
3 = 3 mol oleate liberated from 1 mol of triolein
4.9 = only 0.5 ml of aqueous methanolic layer was sampled from a total volume 
of 2.45 ml
1/0.76 = extraction efficiency of oleate into the aqueous methanolic phase. 
Conditions allowing quantitative oleate recovery would also extract some 
triolein and partial glycerides.
Enzyme activity is expressed in mU/ml of plasma which is equivalent to 1 nmol of 
oleate released per min at 37°C.
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2.5 Automated analysis on the Cobas Mira Plus
These analyses were carried out by co-investigators. TAG, NET A, glucose and 
HDL-C were analysed using an automated COBAS Mira plus (Roche Diagnostics Ltd, 
Welwyn Garden City, UK) in fasting and postprandial samples by enzymatic reactions. 
TAG was measured in plasma and also TRL and TPL fractions obtained following 
ultracentrifugation. NEFA and glucose were measured in plasma. Postprandial HDL-C 
were measured in the TPL fraction obtained follovring ultracentrifugation. HDL-C and 
HDL3 -C were measured in fasting plasma, with the difference between these 2 
concentrations being used to determine HDL2 -C levels. LDL-C levels were determined 
using the Friedewald equation (Friedewald et al, 1972) using concentrations of TC and 
TAG.
For each analyte, all the samples from one subject were measured in the same 
batch. QC samples were measured 'within each batch to ensure assay conditions were 
consistent in each run.
2.5.1. Analysis of TAG
The working reagent (Unimate 5 TRIG reagent kit) and calibrator (Lipid control 
serum) were supplied in kit form from Roche Diagnostics Ltd, Welwyn Garden City, 
UK. The QC (Seronorm lipid) was supplied by Nycomed, Birmingham, UK.
Principle
The concentration of TAG was determined using an enzymatic colorimetric 
assay involving the use of enzymes LPL, glycerol kinase, glycerol phosphate oxidase 
and peroxidase : -
TAG glycerol + fatty acids
glycerol + ATP -> glycerol-3-P + ADP
glycerol-3-P + 0 2 ^  dihydroxyacetone phosphate + H2 O2
H2 O2  + 4-chlorophenol + 4-aminophenazone -> quinoneimine
derivative
95
The intensity of the red quinoneimine derivative end product is proportional to the 
concentration of TAG when measured spectrophotometrically at 550 nm.
The assigned value for Seronorm lipid QC was 2.2 mmol/1. The mean intra-assay 
CV for this QC was 1.5% (n=6 ) and the inter-assay CV was 4.5% (n=60). The linearity 
limit of the assay was 8  mmol/ 1  and any samples with concentrations greater than this 
were diluted with 0.9% saline.
2.5.2 Analysis of TC
The reagents (Unimate 5 CHOL reagent kit), calibrater (Control serum N) and QC (lipid 
control serum) was supplied by Roche Diagnostica Ltd., Welwyn Garden City, UK.
Principle
The concentration of TC in plasma was determined using an enzymatic 
colorimetric assay involving the enzymes cholesterol esterase, cholesterol oxidase and 
peroxidase : -
Cholesterol ester + H2 O -> Cholesterol + fatty acids
Cholesterol + O2  -> D^ -^cholesten-3 -one + H2 O2
H2 O2  + phenol + 4-aminophenazone —> quinoneimine derivative.
The colour intensity of the end product is proportional to the concentration of HDL-C 
when measured spectrophotometrically at 500 nm.
The assigned cholesterol value for the lipid control serum was 2.24 mmol/1. The 
mean intra-assay CV was 2.8% (n=6 ) and 4.2% (n=15).
2.5.3 Analysis of HDL-C
2.5.3.L Fasting and postprandial HDL-C concentrations used in chapters 3,4and 5.
The reagents (HDL reagent and Unimate 5 CHOL reagent kit), calibrator 
(Control serum N) and QC (lipid control serum) were supplied by Roche Diagnostica 
Ltd., Welwyn Garden City, UK.
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Principle
To remove the apo B containing lipoproteins from the TPL samples they were 
precipitated using the HDL reagent which contained phosphotungstic acid and 
magnesium chloride. Afrer centriftigation the HDL remain in the supernatant and the 
VLDL, IDL and LDL were pelleted. The concentration of HDL-C in the clear 
supernatant was determined using an enzymatic colorimetric assay involving the 
enzymes cholesterol esterase, cholesterol oxidase and peroxidase as shown above for the 
measurement of TC.
The colour intensity of the end product is proportional to the concentration of 
HDL-C when measured spectrophotometrically at 500 nm. The standard for this assay 
must be diluted with saline to allow for the dilution of the HDL-C due to the 
precipitation reagent. The QCs are treated in the same way as the samples. The assigned 
cholesterol value for the lipid control serum was 2.24 mmol/1. The mean intra-assay CV 
was 2.8% (n=6 ) and 4.2% (n=15).
2.5.3,2. Fasting HDL2  andHDL3  concentrations used in chapter 5.
The reagents (Quantilip A (total HDL) and Quantilip B (HDL3 )) and calibrator 
(Immunolip) were supplied by Immuno Ltd, U.K. Unimate 5 CHOL reagent kit, 
calibrator (Control serum N) and QC (lipid control serum) were supplied by Roche 
Diagnostica Ltd., Welwyn Garden City, UK.
Principle
To remove the apo B containing lipoproteins from the plasma samples they were 
precipitated using the appropriate HDL reagents; Quantilip A precipitates LDL and 
VLDL leaving total HDL subclasses whereas Quantilip B precipitates LDL, VLDL and 
HDL2  enabling HDL3  determination. After centrifugation the HDL subclasses remain in 
the supernatant and the concentration of HDL-C in the clear supernatant was determined 
using an enzymatic colorimetric assay involving the enzymes cholesterol esterase, 
cholesterol oxidase and peroxidase as shown above for the measurement of TC (2.5.2). 
The content of HDL2 -C was obtained by calculating the difference between total HDL-C 
and the HDL3 -C subclass concentrations.
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2.5.4. Determination of LDL-C
The Friedewald equation was used to determine LDL-C concentrations from 
knowledge of TAG and HDL-C levels (Friedewald et al, 1972). This formula applies if 
the serum TAG concentrations are less than 4.5 mmol/1 since at this concentration, the 
quantity of cholesterol in VLDL has a fairly linear relationship with TAG concentration.
TC and TAG were determined enzymatically as described in sections 2.5.1. and
2.5.2 respectively and the fasting concentrations were used to determine LDL-C levels 
using the following formula : -
LDL-C = TC - (HDL-C + plasma TAG) mmol/1
2.2
2.5.5 Analysis of NEFA
The working reagent (Wako NEFA C test kit), calibrator (NEFA C standard) and 
QC (NEFA C kit) were supplied in kit form manufactured by Wako and supplied by 
Alpha laboratories, Eastleigh, UK.
Principle
Measurement of NEFA concentrations in plasma samples involves the enzymes 
acyl-CoA synthetase, acyl-CoA oxidase and peroxidase. : -
NEFA + ATP + CoA + Mn^  ^ acyl CoA + AMP + PPi 
acyl-CoA + 0 2 ^  2,3 - trans-Enoyl-CoA + H2 O2  
H2 O2  + 3-methyl-N-ethyl-N-(p-hydroxyethyl)-aniline
+ 4-aminoantipyrine purple coloured adduct
The purple coloured end product is measured spectrophotometrically at 550 nm. 
Ascorbic acid is removed from the reaction mixture with ascorbate oxidase since it 
reacts with the hydrogen peroxide generated in the reaction.
The value for the NEFA-C kit QC was 0.50 mmol/1. The intra-assay CV for this 
quality control was 1.7% (n=6 ) and inter-assay CV was 6.7% (n=60).
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The use of plasma collected in lithium heparin coated tubes is not recommended 
for the measurement of NEFA since the heparin stimulates the activity of LPL in blood 
resulting in the generation of more NEFA. However, since a large number of analytes 
are being measured from the blood samples collected during the postprandial study day, 
heparin coated blood tubes were used. The assay was validated by a colleague who 
collected blood samples in EDTA and heparin coated tubes and showed no significant 
differences between the NEFA levels observed.
2.5.6 Analysis of glucose
The working reagent (Unimate 5 glucose hexokinase reagent kit), calibrator (1; 
lyophilized horse serum) and QC (control serum N) were supplied in kit form from 
Roche Diagnostics Ltd, Welwyn Garden City, UK.
Principle
The assay of glucose in plasma samples is an enzymatic assay involving the 
enzymes hexokinase and glucose-6 -phosphate dehydrogenase: -
D-glucose D-glucose-6 -P + ADP
D-glucose-6 -P + NAD^ D-gluconate-6 -P + NADH + H^
The NADH formed during the reaction is directly related to the glucose concentration 
and is measured photometrically at 340 nm.
The value for the glucose QC was 4.09 mmol/1. The intra-assay CV for this 
quality control was 0.5% and inter-assay CV was 1.05% (n=60).
2.6 Analysis of insulin
Principle
Insulin was measured by a colleague according to the RIA method, involving an 
accelerated double antibody separation stage, originally described by Albano et al 
(1972) with modifications by Flatt and Bailey (1981). The method is a double antibody
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RIA technique in which plasma samples are incubated with an antiserum raised to 
porcine insulin in the guinea pig and a fixed amount of radiolabelled insulin. 
Competition occurs between the radiolabelled and the unlabelled insulin, where the level 
of the radiolabelled insulin bound to the insulin antibody is proportional to plasma 
insulin concentrations. The separation step is initiated by the addition of a guinea pig 
IgG antiserum which causes a precipitation of the antigen-antibody complex which is 
accelerated by the presence of polyethylene glycol (PEG).
Procedure
Briefly, insulin antiserum and assay diluent were mixed with the standard and 
plasma samples and incubated for 24 hours at 4°C. On the following day, ^^ I^ (ICN 
Biomedicals, UK) labelled insulin was added and incubated at 4°C for 24 hours. On the 
third day, normal guinea pig serum, a donkey anti-guinea pig antiserum and PEG were 
added and incubated for 2 hours at 4°C. The tubes were centrifuged at 1500 g.min in a 
Beckman J-6 B centrifuge (Beckman, UK), the resulting supernatant was removed and 
the level of radioactivity counted on a Wallac 1260 Multigamma II counter (Wallac, Oy, 
Finland). Insulin concentrations were expressed as pmol/1. A QC was run in each assay. 
The intra-assay CV was 9.03% at 35 pmol/1 (n=8 ). The inter-assay CV was 10.7% at 35 
pmol/ 1  (n=1 0 ).
2.7 Measurement of GIF in plasma
Concentrations of GIP in plasma were determined by a co-investigator using a 
radioimmunoassay technique based on the method described by Morgan, Morris and 
Marks (1978). The principle of the RIA assay involving precipitation of the antibody 
bound to antigen by a second antibody and PEG, as described for the measurement of 
plasma insulin concentrations.
Procedure
In the RIA, an antiserum raised in rabbits against porcine GIP was radiolabelled 
with ^^ I^ (ICN Biomedicals, UK) in the assay format. In this assay format, the purified 
labelled GIP was incubated for 48 hours at 4°C before the separation stage on the fourth
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day of the assay. GIP concentrations were expressed in pmol/1. A QC was run in the 
assay and the inter-assay CV was 8.0% at 360 pmol/1 (n=10).
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Chapter 3
Effects of acute substitution of 
monounsaturated fatty acids for 
saturated fatty acids on 
postprandial lipaemia in healthy
young men
3.1 Introduction
Effects of monounsaturatedfatty acids on postprandial lipaemia
Individuals living in industrialised nations, spend the majority of their time in the 
postprandial state, in which CMs and their remnants transport dietary fats around the 
circulation. Although the effects of SFAs and PUFAs on postprandial lipaemia have 
been investigated previously, the effects of the acute and habitual consumption of 
MUFA’s on postprandial lipid metabolism have not been extensively studies. One study 
compared the consequences of MUFAs (canola and olive oils) and PUFA (com oil) on 
fasting and postprandial lipoproteins (Lichenstein et al, 1993). Volunteers received diets 
meeting the National Cholesterol Education Program Step 2 criteria (fat intake limited to 
< 30% of calories in which SFA represent < 7% of calories) in which % of the fat 
calories were derived from canola, com or olive oil in the randomised diets for a period 
of 32 days. Similar responses were observed in the fasting and postprandial states, with a 
characteristic decline seen in both LDL-C and apo B concentrations with all of the oils 
investigated.
Studies by de Bmin et al (1993) and Brouwer et al (1993) have investigated the 
clearance rates, in the postprandial state, of PUFA (soybean oil) and MUFA (olive oil) 
meals and intravenously administered emulsions. Comparison of the clearance rates of 
CMs and their remnants, using the vitamin A loading technique and apo B-48 as 
markers, indicated the faster assimilation of PUFA-enriched compared to the MUFA- 
enriched intestinally derived lipoproteins. Following introduction of the MUFA- 
enriched emulsion, the HDL-C was shown to be conserved during the postprandial 
period in comparison with the decrease observed with the PUFA-enriched emulsion. 
Since TAG and HDL-C responses have been shown to be inversely related in the 
postprandial state (Patsch, 1994), further investigation of these responses is required to 
determine whether there are beneficial effects of MUFA-enriched diets on CM and CM 
remnant metabolism.
Methods for the measurement of CM and CM remnant metabolism
Evidence, as early as the 1980s, has implicated raised levels of CMs and CM 
remnants, which circulate following consumption of a meal, in the aetiology of
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atherosclerosis (Stender and Zilversmit, 1982; Mahley et al, 1982; Brown and Goldstein, 
1983). Postprandial studies conducted by Weintraub et al (1988) and Demacker et al 
(1991) have highlighted the importance of the measurement of intestinally derived 
TRLs, in determining the effects of dietary fatty acids in the diet.
Currently there are two methods available for the measurement of CMs and their 
remnants during postprandial lipaemia : -
a) Indirect labelling of CMs with an ester of vitamin A, by incorporation of RP into the 
test meal (Hazzard and Bierman, 1976). This method relies on the hydrolysis of RP to 
retinol and its reformation into REs in the intestinal enterocyte. The REs are then 
incorporated into the core of the CM where they remain with the particle until uptake by 
the liver. Therefore, the RE concentration reflects the balance between input of RE- 
labelled CMs into plasma and the formation and elimination of CM remnants. However, 
Krasinski and coworkers (1990b) have highlighted limitations of the use of REs as 
markers of CM remnants. These include a delay in the postprandial RE response in 
comparison with TAG and apo B-48 responses in the plasma and TRL fractions and also 
the presence of RE label in other lipoprotein fractions (LDL and HDL), 9 to 12 hours 
following the meal.
b) Direct measurement of apo B-48. It is hypothesised that each CM particle contains 
one apo B-48 molecule (Elovson et al, 1987) and since apo B-48 is not exchanged with 
other lipoprotein classes, the concentration of apo B-48 is a direct measure of the 
number of CM particles in the circulation at that time. Most workers measure the 
concentration of apo B-48 following a standard test meal by analysing lipoproteins 
prepared by sequential ultracentrifugation using SDS-PAGE. The bands are then 
visualised with Commassie blue staining. Long ultracentrifugation spins, low sensitivity 
and interference with albumin in plasma samples limits its use for postprandial studies. 
A specific antisera to apo B-48 has been raised in our research group and this has been 
used in the development of a competitive ELISA for the measurement of apo B-48 in 
TRL samples (Lovegrove et al, 1996). This method provides a rapid, simple, specific 
alternative for the measurement of intestinally derived lipoproteins following 
consumption of standard test meals.
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A review of the current literature employing TAG, RE and apo B-48 as markers 
for CMs and their remnants following standard test meals is included in the general 
introduction (1.8.1.1). The method for RE analysis varies between different research 
groups and in general, the extent of the delay in the RE response is dependent on the 
type of RP used in the test meals to label the CM particles, with the oily and tablet forms 
causing the greatest delay. A criticism of many of the studies reviewed is that in the 
majority of them, sampling is only every 2 to 3 hours which does not allow for the 
accurate comparison of peak REs and apo B-48. TAG and apo B-48 both return to 
fasting concentrations at the end of the postprandial test period which is not observed 
with the RE response. This evidence has highlighted apo B-48 as a more specific marker 
for the metabolism of intestinally derived lipoproteins.
Aims of this study
This present study is designed to investigate the effects of the acute substitution 
of SFAs by MUFAs (18:1, n-9 oleic acid), within a mixed meal on the postprandial 
responses (lipids, lipoproteins, metabolites and hormones) to meals of varying MUFA 
content in the U.K. population whose habitual consumption of MUFA is approximately 
12% of dietary energy (DOH, 1994). Acute test meal studies will be discussed further in 
chapter 4 in individuals who habitually consume different amounts of MUFAs (People 
in Ireland, like the U.K. habitually consume 12% MUFA, people in Greece (excluding 
Crete) 17% MUFA and people in Crete 24% MUFA) in their diet.
Another aim of this study is to compare the use of the vitamin A loading 
technique and apo B-48 as markers for intestinally derived lipoproteins in plasma, TRL 
and TPL fractions, using meals of different fatty acid composition.
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3.2 Study design
3.2.1 Subject recruitment
Eight healthy young males aged between 18-30 and with a body mass index 
(BMI) of between 19-26 kg/m^ were recruited via colleagues and from within the 
university population. Subjects were excluded if they were
• smokers
• vegetarians
• heavy exercisers (> 3 x 30 minutes of aerobic exercise per week)
• heavy drinkers (>30 units of alcohol per week)
• diagnosed as diabetic or other another endocrine/liver disease
• trying to lose weight
• taking dietary fatty acid supplements
• on a habitual diet high in MUFAs, or were consciously trying to increase dietary 
MUFA intake.
Recruitment was made following screening of : -
a) blood for the measurement of fasting TAGs (< 2.3 mmol/1), cholesterol (< 6.5 
mmol/1) and glucose (< 6 . 2  mmoFl)
b) dietary history, by a 24 hour recall, to ensure habitual fat intake reflected usual U.K. 
intake (i.e. 35-45 % energy as fat with approximately 17% from SFA, 12% from MUFA 
and 5% from PUFA).
The study was approved by the ethics committees of the University of Surrey and the 
Royal Surrey County Hospital and all subjects gave informed consent.
3.2.2 Test Meal Composition
Subjects were randomly allocated to consume 3 acute test meals of varying 
MUFA content (12,17,24 % of energy) which were presented in the form of :-
• a milkshake consisting of skimmed milk powder (40 g, Tesco’s, U.K.), Nesquik (40 g. 
Nestle U.K. Ltd., Surrey) and test oil (40 g),
• jam sandwiches (thick white bread, 135 g and strawberry jam, 36 g, Tesco’s, U.K.)
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• water (200 mis, Evian).
RP (oil form) (100 mg, 170,000 I.U., Roche Products Ltd., Herts.) was weighed 
out onto a plastic spoon and placed into the milkshake. The energy content of the meal 
was 4.18 MJ (997 kcal) of which 55% of dietary energy was derived from carbohydrate, 
8 % from protein and 35% from fat. The mixture and the fatty acid composition of the 
test oils in the three meals are shown in Tables 3.1 and 3.2 respectively.
Table 3.1 : Oil mixture for the different test oils
Test meal Coconut oil Palm oil Olive oil Sunflower oil
12% MUFA 16 8 1 2 4
17% MUFA 8 8 2 2 2
24% MUFA 40
Figures denote g o f  oil used in the test meals.
Table 3.2 : Test meal fatty acid composition as a percentage of total energy (%E)
Test Meal SFA (% E) MUFA(%E) PUFA (%E)
12% MUFA 17.2 1 2 . 0 5.0
17% MUFA 12.3 17.1 4.6
24% MUFA 5.4 24.1 4.6
In each case the fatty acids contributed approximately 35% o f the total energy o f  the test meal
3.2.3 Study Day Procedure
Subjects arrived at the Royal Surrey County Hospital Investigation unit 
following an overnight 12 hour fast on 3 separate occasions. (Fasting was defined as no 
food and the only fluids allowed included sugar free (< 1 kal) decaffeinated drinks and 
water. Alcohol was not permitted to be consumed 24 hrs prior to the test meal). An 
indwelling cannula was inserted into the antecubital vein of the forearm and 2  fasting 
blood samples (timepoints - 1 0  and 0  mins) were taken.
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The test meal was given immediately after the second fasting blood sample was 
taken and the meal was consumed within 20 minutes. Every 2 hours, 200 ml of 
decaffeinated, sugar-free drinks were consumed and no food was allowed during the 
nine hour test period. Blood was collected every hour until 9 hours after the meal. At the 
end of the test period, 7500 I.U. of heparin was injected into the contralateral arm and 
two blood samples were taken at 5 and 15 minutes following the injection for analysis of 
LPL and HL activities. Blood samples for the analysis of fasting postheparin lipase 
activities were collected on a different occasion, following a 1 2  hour overnight fast, at 
least 7 days after the third acute test meal.
3.2.4. Plasma separation and analytical methods 
Plasma separation
Plasma was separated by spinning at 1700 g.min using a bench centrifuge, 
aliquotted into LP3 tubes for different analyses and stored at -20°C (samples for lipase 
analysis were stored at -80°C). TRL and TPL fractions were prepared from plasma 
stored overnight at 4°C by following the procedure of Grundy and Mok (1976) as 
described in chapter 2 (section 2.1.2). To protect apo B-48 from proteolytic cleavage, the 
preservative cocktail (section 2.1.1) was added at a concentration of 5% (v/v) of the apo 
B-48 containing sample. Samples for the analysis of REs were covered with aluminium 
foil to protect them from degradation by light.
Analytical methods
The methods employed for the analyses of various analytes were described in 
chapter 2  :-
• RE concentrations in plasma, TRL and TPL fractions were measured using normal 
phase chromatography (Ruotolo et al, 1992)(section 2.2),
• Apo B-48 concentrations in plasma, TRL and TPL were analysed using a competitive 
ELISA method (Lovegrove et al, 1996)(section 2.3)
• Postheparin LPL and HL activities were determined by the method based on the 
release of labelled fatty acids from a ^H labelled triolein emulsion (Nilsson-Ehle and 
Schotz, 1976) (section 2.4).
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The following assays were carried out by other workers:-
• TAG concentrations in plasma, TRL and TPL fractions were measured using an 
automated enzymatic colorimetric test (section 2.5.1).
• HDL-C in TPL postprandial samples was measured following precipitation using an 
automated enzymatic assay (section 2.5.3.1).
• GIP and insulin responses in plasma were measured using established 
radioimmunoassay techniques involving double antibody separation (sections 2.7 and
2 . 6  respectively).
• Postprandial plasma glucose responses were measure using an automated hexokinase 
method (section 2.5.5).
• NEFA were determined using an automated colorimetric method (section 2.5.4).
3.2.5. Statistical Analysis
Results presented for the time response curves and total and incremental area 
under the curves (AUCs and lAUCs respectively) are given as mean values with their 
standard error of the mean (SEM). AUCs (total and incremental) were calculated using 
the trapezoidal rule on Excel spreadsheets (Matthews et al, 1990). In tables, data is 
presented as mean values with their standard deviation (SD). Analysis of variance was 
applied to the responses of the subjects to the three acute test meals and the differences 
were identified using the statistical package Instat (Macintosh version 2, San Diego, 
USA). Statistical differences were then allocated using the Student-Newman-Keuls 
multiple comparisons post test. Repeated measures analysis of variance were performed 
using Data desk 4.1 (Data description Inc, USA). Data was checked for normality and 
transformed before statistical analysis was performed. Values of P < 0.05 were taken as 
significant.
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3.3. Results
3.3.1 Subject information
Eight subjects were successfully recruited with a mean age of 22.5 (SD 3.6) 
years, BMI of 22.6 (SD 2.2) kgW  and a habitual fat intake of 37.5 % energy, of which 
14.0 % was derived from SFA, 11.0 % from MUFA and 7.0 % from PUFA (calculated 
from a three day diet diary using the Compeat software programme). The acute test 
meals were consumed within the stated 2 0  minutes and did not elicit any adverse effects.
3.3.2 Fasting concentrations
All of the fasting concentrations for each of the analytes in plasma (PL), TRL 
and TPL were found to be similar and not significantly different among study days for 
each of the test meals (Table 3.3).
Table 3.3 : Fasting lipid and hormone concentrations for each test meal
Parameter
MUFA meal
12% 17% 24%
Apo B-48 (pg/ml) PL 
TRL 
TPL
3.27 ±0.56 
0.42 ± 0.33 
2.95 ± 0.29
3.24 ±0.43 
0.50 ±0.31 
2.84 ±0.65
3.76 ±0.80 
0.48 ± 0.28 
3.06 ±0.70
TAG (mmol/1) PL 
TRL 
TPL
1.07 ±0.32 
0.42 ±0.09 
0.64 ±0.15
1.04 ± 0.35 
0.39 ±0.19 
0.63 ±0.16
1.18 ±0.34 
0.46 ± 0.21 
0.64 ± 0.20
HDL-C (mmol/1) 0.89 ± 0.24 0.84 ± 0.20 0.87 ±0.18
NEFA (mmol/1) 0.38 ±0.17 0.44 ±0.19 0.42 ± 0.20
Glucose (mmol/1) 4.63 ±0.43 4.80 ± 0.52 4.80 ±0.36
GIP (pmol/1) 16.33 ±7.59 17.01 ±5.94 21.45 ±17.15
Insulin (mU/1) 41.64 ±11.52 49.53 ±24.19 47.98 ± 14.42
Values are presented as mean ± SD for fasting lipid and hormone concentrations for 8 subjects. 
Analytes were measured in plasma unless otherwise indicated in the table.
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3.3.3 Triacylglycerol responses
In the plasma and TRL fractions, the TAG concentrations rose following the 
meal and a small peak was reached between 120 and 240 minutes before falling back to 
basal levels after 9 hours. A second major peak was observed with the 24% MUFA meal 
at 360 minutes and between 360 and 420 minutes for the 12% MUFA meal, whereas the 
17% MUFA meal plateaued between 300 and 360 minutes. (Figure 3.1). Essentially, the 
same pattern of response was seen in the TRL as in the plasma fraction, with the TRL 
demonstrating a more marked response in the later postprandial period with the 24% 
MUFA meal. This pattern was not seen in the TPL-TAG responses (Figure 3.1)
No significant differences were observed in the AUCs for the overall TAG 
responses for the three test meals in the plasma, TRL and TPL fractions (Table 3.4), 
however there was a trend for the 24% MUFA to exhibit the greatest response in the 
plasma and TRL fractions.
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Plasma TAG responses
soo 600ZOO 3000
1Z% MUFA meal 
n%  MUFA meal 
24% MUFA meal
Time (mins)
TRL-TAG response
Time (mins)
TPL-TAG responses
12%MUFAmei4 
17% MUFA meal 
24% MUFA meal
Time (mins)
Figure 3.1 : TAG concentrations following consumption of meals of varying MUFA 
content (12%, 17% and 24% MUFA meals) in the plasma, TRL and TPL fractions. 
Values represent mean ± SEM for the 8  subjects. On 3 separate occasions, subjects 
consumed in random order either 12%, 17% or a 24% MUFA meal following a 12 hour 
overnight fast. Postprandial samples were collected over a 9 hour period during which 
subjects consumed 2 0 0  mis of sugar free decaffeinated fluid every 2  hours and 
maintained normal sedentary activities.
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3.3.4 RE response
A significant difference was observed in the AUC for the overall RE responses 
in total plasma, with the value for the 12% MUFA meal being significantly lower than 
that for the 17% MUFA meal (P < 0.05). There were no significant differences observed 
in the AUC for the RE responses for the 3 meals in the TRL and TPL fractions (Table 
3.4).
Plasma RE response
The RE concentrations initially rose at a similar rate, before the major peaks 
were reached at 420 minutes for the 12%, 17% and 24% MUFA meals (Figure 3.2). In 
the earlier part of the postprandial phase (0 to 300 mins), the 17% and 24% MUFA 
meals showed the greatest response with the 12% MUFA meal showing the lowest. At 
the end of the study period (540 mins), the RE concentrations had not returned to 
baseline, with the 12% and 17% MUFA RE concentrations being lower than that of the 
24% MUFA meal RE concentration.
TRL-RE response
For the 3 test meals the RE concentrations initially rose at a similar rate, and a 
small peak concentration was reached at 180 minutes for the 12% and 24% MUFA 
meals before a major peak was reached at 420 minutes for the 24% MUFA meal and 
between 300 and 360 minutes for the 17% MUFA meals (Figure 3.2). With the 12% 
MUFA meal, a plateau RE concentration was reached between 300 and 360 minutes. 
Although there were no significant differences in the AUC, there was a tendency for the 
24% MUFA meal AUC to be greater than those observed with the 12% and 17% MUFA 
meals (Table 3.4). RE concentrations did not return to baseline after 9 hours.
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Figure 3.2 : RE concentrations following consumption of meals of varying MUFA
content (12,17% and 24% MUFA meals) in the plasma, TRL and TPL fractions. Values
represent mean dk SEM for the 8 subjects.
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TPL-RE response
There was a gradual, small increase in TPL-RE concentration which did not 
decline towards baseline even after 9 hours postprandially, when the concentration of 
RE represented 28% of the maximal value seen in the plasma and TRL fractions (Figure 
3.2). There were no significant differences in the AUC for the 3 test meals (Table 3.4)
3.3.5 Apo B-48 responses 
Plasma apo B-48
All of the apo B-48 concentrations rose following the meal and a peak was 
reached at 240 minutes for the 12% and 24% MUFA meals and at 300 minutes for the 
17% MUFA meals. A smaller second peak was observed for the 24% MUFA meal at 
420 minutes which was not observed with the 12% and 17% MUFA meals (Figure 3.3). 
The apo B-48 concentrations following the 3 test meals returned to the fasting baseline 
at the end of the 9 hour test period. No significant differences were observed in the 
AUCs between the 3 test meals, however there was a trend for the 17% MUFA meal to 
show a lower response than the 12% and 24% MUFA meals (Table 3.4)
TRL apo B-48 responses
There was a gradual small increase in TRL apo B-48 concentration following the 
meal which returned to the fasting baseline at the end of the postprandial 9 hour test 
period (Figure 3.3). The AUC were very similar for all of the test meals and no 
significance was observed between them (Table 3.4).
TPL apo B-48 responses
The apo B-48 response curves observed following the 3 test meals were much 
flatter than those exhibited in total plasma (Figure 3.3). A small peak was demonstrated 
between 240 and 300 minutes for the 12% MUFA meal and 300 minutes for the 17% 
and 24% MUFA meals. In the earlier part of the postprandial phase (0-300 minutes), the 
12% and 17% MUFA meals showed the greatest response with the 17% MUFA meal 
showing the least. At the end of the 9 hour test period, apo B-48 concentrations had 
returned to the fasting concentrations.
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Figure 3.3 : Apo B-48 concentrations following consumption of meals of varying
MUFA content (12%, 17% and 24% MUFA meals) in the plasma, TRL and TPL
fractions. Values represent mean ± SEM for the 8 subjects.
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3.3.6 Comparison of apo B-48, RE and TAG responses in the plasma TRL and 
TPL fractions - time to reach peak concentration (minutes)
No significant differences were observed in the time to peak for the individual 
meals for any of the TAG, apo B-48 or RE responses. Significant differences were 
observed in the plasma fraction between the RE and apo B-48 {P < 0.05) time to peak 
for the 24% MUFA meal (Table 3.5). In the TPL fraction, there was a significant 
difference between the RE and the TAG (P < 0.05) time to peak concentration for the 
12% MUFA meal (Table 3.5). No significant differences were obtained in the time to 
reach peak concentration in the TRL fraction between the 3 analytes for the test meals 
(Table 3.5).
Table 3.5 : Individual time to reach peak concentration for the TAG, apo B-48 and 
RE analytes in the plasma, TRL and TPL fractions (minutes)
MUFA meal
Parameter
TAG Apo B-48 RE
Plasma 12% 
17% 
24%
315.0 (89.3) 
277.5 (106.1) 
266.3 (125.7)
330.0 (115.6)
270.0 (101.4) 
*292.5 (74.8)
397.5 (106.1) 
375.0 (76.9) 
*427.5 (59.5)
TRL 12% 
17% 
24%
277.5 (106.1) 
228.8 (93.4)
277.5 (115.4)
307.5 (87.5)
262.5 (110.8) 
240.0 (120.0)
375.0 (53.2)
367.5 (67.6)
367.5 (113.1)
TPL 12% 
17% 
24%
*233.3 (128.8)
253.4 (129.8) 
337.7 (172.2)
296.3 (126.7) 
292.5 (108.5) 
300.0 (64.1)
*480.0 (91.7) 
397.5 (90.4) 
433.3 (93.1)
Values shown are mean (SD) in minutes. P < 0.05, significantly different from the time 
to reach peak concentration for REs.
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3.3.7 Postheparin LPL and HL activities
No significant differences were observed in the 9 hour postprandial LPL and HL 
5/15 minute activity measurements made following the 3 test meals (Figures 3.4 a and
b). However, significant differences were observed in the plasma post-heparin LPL 
activity between fasting measurements and the 9 hour postprandial measurements for the 
12% MUFA and the 17% MUFA meal (P < 0.05) and the 24% MUFA meal {P < 0.01) 
at 15 minutes following the injection of heparin (Figure 3.4a). Enzyme activities were 
determined 5 and 15 minutes following the injection of heparin since at these timepoints, 
maximal activities of the enzymes are displayed, LPL (15 minutes) and HL (5 minutes) 
(Nilsson-Ehle etal, 1980).
3.3.8 Plasma HDL-C responses
Postprandial HDL-C responses are shown in figure 3.5. Plasma HDL-C 
concentrations showed a gradual, small decline following the 3 MUFA test meals with 
the 12% MUFA meal showing the greatest decline in lAUC compared with the 17% and 
24% MUFA meals. A significant difference was not observed in the AUCs or lAUCs for 
the 3 MUFA meals.
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Figure 3.4 : Postheparin lipase activities at 5 (HL) and 15 (LPL) minutes after the 
injection of 7500 lU of heparin following a 12 hour overnight fast and 9 hours after the 
random consumption of the MUFA test meals (12%, 17% or 24%). Values represent 
mean (SEM) for the 8  U.K. subjects. * P < 0.05 and ** P < 0.01, significantly different 
between the 15 minute and fasting LPL activity.
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Figure 3.5 : HDL-C responses in plasma following the consumption of meals of varying
MUFA contents (12%, 17% and 24% MUFA meals). Values represent mean ± SEM for
the 8 subjects.
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3.3.9 Plasma NEFA responses
Following the test meals, NEFA concentrations showed a marked decrease in 
concentration (0 - 1 2 0  minutes) with the levels rising above fasting levels during the later 
postprandial period (Figure 3.6). There were no differences in the AUC for each of the 
test meals, however for the lAUC, there was a trend for the 24% MUFA meal to exhibit 
the greatest decrease compared with that of the 12% and 17% MUFA meals.
3.3.10 GIP responses
Plasma GIP concentrations rose rapidly following the meal and reached a peak 
between 120 and 240 minutes (12% and 24% MUFA at 120 mins and 17% MUFA 
between 120 and 240 minutes). Following the peak, the 12% and 17% MUFA meals 
return slowly towards baseline concentrations, whilst the 24% MUFA meals exhibits a 
smaller second peak. (Figure 3.7a). There were no significant differences between the 
AUC and lAUCs for the GIP responses for the 3 MUFA meals (Table 3.6).
3.3.11 Plasma insulin responses
Postprandial plasma insulin response curves are shown in figure 3.7b. Following 
the meals, insulin concentrations rose sharply to give a major peak between 60 and 1 2 0  
minutes and then fell to fasting concentrations between 240 and 300 minutes, where 
these concentrations were maintained until the end of the test period. Although there 
were no significant differences between the AUC and lAUCs for the 3 MUFA meals, 
there was a strong trend for the 24% MUFA meals to exhibit the greatest response 
(Table 3.6).
3.3.12 Glucose response
Plasma glucose concentrations rose following the meal to a peak at 120 minutes 
before returning to fasting concentrations between 180 and 240 minutes following the 
meal (Figure 3.7c). No significant differences were observed in the AUCs for the 3 
MUFA test meals, although there was a trend for the 24% MUFA meal to show the 
greatest responses when compared with the 12% and 17% MUFA meals. This trend was
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Figure 3.6 : Plasma NEFA responses following the consumption of meals of varying
MUFA content (12%, 17% and 24% MUFA meals). Values represent mean ± SEM for
the 8 subjects.
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Figure 3.7 : a) GIP, b) insulin and c) glucose responses to meals of varying MUFA 
content (12%, 17% and 24% MUFA) in plasma. Values represent mean ± SEM for the 8  
subjects.
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not observed with the lAUC, where the 12% and 24% MUFA meals exhibited the 
greatest responses (Table 3.6).
Table 3.6 : AUC and lAUC for plasma GIP, insulin and glucose responses
MUFA meal GIF (pmol/l.min) Insulin (pmol/l.min) Glucose
(mmol/l.min)
12% AUC 
lAUC
64825 (3760) 
56008 (2532)
117934(14300) 
95448 (12971)
2614.09 (84.8) 
113.21 (49.8)
17% AUC 
lAUC
74369 (3853) 
65182(3580)
111043 (13821) 
84299(11565)
2657.60 (87.5) 
63.9 (65.4)
24% AUC 
lAUC
69758 (3726) 
58174 (2762)
154693 (28976) 
12879 (28029)
2700.14 (65.7) 
109.2 (84.3)
AUC and lAUC values are presented as mean (SEM), n=8 .
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3.4 Discussion
Worldwide studies have shown a link between heart disease and the amount of 
and type of fat in the diet. The strongest links have been made with SFAs and weakest 
with PUFAs and MUFAs. Dietary recommendations suggest that together with the 
reduction in the total fat consumed, PUFAs and MUFAs should be substituted in the diet 
for a large proportion of SFAs. Recent studies, using PUFAs (Demacker et al, 1991; 
Weintraub et al, 1989) have confirmed that the fatty acid composition of CM particles is 
an important determinant of their synthesis and/or removal rate. Therefore, changing the 
fatty acid composition of the diet provides a useful tool to investigate the risk factors for 
developing CHD. Although effects of SFAs and PUFAs on postprandial lipaemia have 
been extensively studied, there is at present a lack of knowledge of the effects of MUFA 
intake on CM synthesis and removal. Recent studies suggest that the metabolism of 
CMs is intimately linked to that of HDL particles by CETP activity (Tall, 1993; Patsch 
etal, 1987).
The olive oil study at the University of Surrey is part of a collaborative project 
with research groups in Dublin and Crete. The fatty acid composition of the test meals 
was modified to provide 12%, 17% and 24% dietary energy as MUFA. The 12% MUFA 
test meal reflects the habitual MUFA intake of the U.K. and Irish populations, 17% that 
of the non-Cretan Greeks and 24% that of the Cretan Greeks (the percentage dietary 
energy derived from MUFAs observed in Crete during the Seven Countries study in the 
1960s). The aim of the study was to determine the effects of acute substitution of 
MUFAs for SFAs in young volunteers from the U.K. who habitually consume 
approximately 12% dietary energy as MUFA on lipoprotein and hormonal responses. 
The appearance and eventual clearance of TRL particles was investigated by analysing 
circulating TAG, RE and apo B-48 responses to the 3 meals of varying MUFA content.
3.4.1. Effects of meal MUFA/SFA content on postprandial lipids, lipoproteins, 
metabolites and hormones
The design of this study was a randomised cross-over in which 15 healthy male 
volunteers received 3 test meals on three separate occasions. Food frequency 
questionnaires and 3 day weighed food intakes were implemented to ensure that their
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diet was representative of the UK population. Significant differences were not observed 
between the fasting analytes for each of the study days and so provided a good index of 
the compliance of the volunteers to the instructions given. Data for only 8  volunteers is 
presented in this chapter since due to time and cost constraints only a limited number of 
apo B-48 samples could be analysed and so are related to the their other postprandial 
responses. Therefore individual variation for the analytes will be greater than if the data 
from 15 volunteers were presented.
Fasting and postprandial TAG concentrations obtained following the 3 test meals 
were comparable with other reported values (Weintraub et al, 1987; Groot et al, 1991; 
O’Meara et al, 1992; Karpe et al, 1995b; Murphy et al, 1996). There were no differences 
in the AUC for the TAG responses for the U.K. subjects in the plasma, TRL and TFL 
fractions to the different meals. However, there was a trend for the 24% MUFA meal to 
show a biphasic response in the plasma and TRL fractions which was not observed with 
the 17% and 12% MUFA meals. A tendency for a longer residence time in the 
circulation was also observed with the 24% MUFA meal in the plasma and TRL 
fractions.
The labelling of CMs using RP was one of the methods used in this study to 
follow the appearance and subsequent clearance of CM remnants. The rationale for the 
use of this method is that RE is incorporated into the CM particle in the same way as 
cholesterol ester and that it remains with the particle until uptake by the liver. The 
methodology used in our laboratory for the determination of total REs agrees with other 
published methods using both normal and reverse phase HPLC (Chapter 1, Table 1.2). It 
has been reported that there is a linear relationship between the amount of vitamin A 
given in an oral lipid load and the concentrations of RP/E in plasma (Weintraub et al, 
1987). The levels of RE measured in the plasma of our subjects following the 3 MUFA 
test meals agree with investigators who use between 100,000 and 120,000 lU of vitamin 
A in the test meal. There was a significant difference observed in the total plasma in the 
AUCs, with the 12% MUFA meal being significantly lower than that of the 17% MUFA 
meal. This, however, was not observed with the plasma TAG and apo B-48 responses. 
No differences were observed in the AUCs for the RE responses in the TRL and TPL 
fractions to the meals of varying MUFA content. There was a tendency however for the
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24% MUFA meal to exhibit the greatest response in the AUC compared with that of the 
12% and 17% MUFA meals in the TRL fraction. In the later part of the postprandial 
period in the plasma and TRL fractions, the 12% MUFA meal response was found to be 
lower than that of the 17% and 24% MUFA meal responses. However, this finding was 
not observed with the apo B-48 responses in the plasma and TRL fractions. At the end of 
the postprandial period, the RE concentrations remained elevated above baseline 
concentrations and this suggests that this may reflect either the composition of the CM 
remnant particle (i.e. TAG depleted RE-enriched particle) rather than their concentration 
in the circulation at that time or possibly transfer of REs to apo B-lOO containing 
lipoproteins.
Another method used to monitor the appearance and eventual clearance of 
intestinally derived lipoproteins is through the measurement of apo B-48 levels. The 
raising of a specific antisera in our laboratory (Peel et al, 1993a) has enabled the 
development of a specific ELISA for the measurement of apo B-48 in the TRL fraction 
(Lovegrove et al, 1996). Since apo B-48 is a structural protein of CMs and their 
remnants, it is now being regarded as a more specific marker than the use of the RP 
loading method. Like the TAG response, no significant differences were observed for 
the AUCs for the three test meals, although there was a tendency for the 24% MUFA 
meal to exhibit the greatest response. A smaller second peak was also demonstrated with 
the apo B-48 response in the plasma fraction which was not confirmed by the 12% and 
17% MUFA meals and this was paralleled by the biphasic TAG response. These 
observations may indicate the later entry of CMs from the gut which may partly explain 
the increase in magnitude of the RE response for the 24% MUFA meal. Overall the 
combined TAG, apo B-48 and RE data suggests that the acute substitution of SFAs by 
MUFAs does not appear to significantly alter the rate of entry or clearance of dietary 
derived lipoproteins.
There were no significant differences in the LPL and HL responses to the 3 
meals at the end of the postprandial period. Therefore this suggests that meal MUFA 
content does not alter postheparin measurements of LPL and HL. However, there was a 
significant increase from fasting postheparin LPL activity to the postheparin LPL 
activities 9 hours after the 3 test meals. One possible explanation for the higher LPL
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activities may be due to the presence in the circulation of more enzyme, through 
stimulation of the enzyme by insulin during the test meal compared, with that of the 
enzyme following an overnight fast. The activity of the HL, which has been implicated 
in the receptor mediated removal of CM remnants from the circulation did not show any 
differences after the 3 test meals. Therefore, an acute substitution of meals of varying 
MUFA content may not be sufficient to cause changes (i.e. increase or decrease in their 
activity) in the lipolytic enzymes. However, postheparin lipase activities can only be 
analysed at the end of the test period since injection of heparin affects the rate of 
catabolism of the TRLs. Therefore differences in activities of LPL and HL may occur at 
earlier time points when the TRLs are being metabolised in the circulation.
The method used in our laboratory to measure the postheparin lipase activities 
was based on the method of Nilsson-Ehle and Schotz, 1976, in which a triolein glycerol 
(TAG) emulsion was used as a substrate and low and high salt assay diluents were used 
to determine total enzyme and HL activities. LPL activity was obtained by subtracting 
HL activity from the total activity. On reviewing current literature, there are a wide 
range of substrates and assay diluents for the selective measurements of LPL and HL. In 
general postheparin lipase activities are measured following a 1 2  hour overnight fast, 
approximately 10 to 15 minutes after the injection of heparin. (Table 3.7). In some of the 
methodology, antibodies raised against LPL and HL, protamine sulphate and SDS rather 
than the use of low and high sodium chloride concentrations are used for their selective 
measurements (Huttunen et al, 1975; Applebaum-Bowden et al, 1985; Groot et al, 1991; 
O’Meara et al, 1992; de Bruin et al, 1993; Brouwer et al, 1993, Karpe et al, 1992, 1993, 
1994a). Also different TAG substrates are used, gum arabic, Triton X-100, 
phoshatidylcholine, glycerol and intralipid, depending on the assay format developed by 
the research groups. Two different emulsions are used by one research group (Karpe et 
al, 1992, 1993, 1994; Mowri et al, 1994) to determine LPL and HL activities therefore 
catering for the different substrate specificities of the 2 enzymes. This, however, 
prevents direct comparison of the 2  enzyme activities since different assay formats have 
been operated. Although our LPL activities are within the range of those published in the 
literature, the HL activities are low in comparison (Table 3.7). One explanation for the 
lower HL activities may be due to our assay procedure, in that it is biased more towards
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the measurement of LPL due to the use of the glycerol TAG emulsion. This is because, 
glycerol-based and phosphatidylcholine-stabilised triolein are more readily attacked by 
LPL and gum arabic and Triton X-100 by HL (Olivecrona and Bengtsson-Olivecrona, 
1992). In the original grant proposal, the determination of fasting and postheparin HL 
activities were not included, however since in our assay format HL activities are 
determined on incubation of the plasma samples with high salt assay diluent, it was 
decided to include their activities in this thesis. Although absolute HL activities were not 
determined, the use of the same assay format used throughout this thesis will enable 
direct comparison of activities presented in Chapter 4 and so may highlight the 
mechanism of action of varying MUFA intakes on postprandial lipaemia.
HDL is the lipoprotein which is responsible for reverse cholesterol transport 
(Tall, 1986). High levels of HDL are associated with a lower incidence of CAD and this 
is thought to be attributed to their association with TAG levels (Meisenbock and Patsch, 
1991). The fasting and postprandial HDL-C concentrations obtained for the 3 test meals, 
are low compared with normal range values quoted by the manufacturers of the HDL-C 
determination kit, for normal healthy males >1.4 mmol/1. In the original grant proposal, 
the analysis of fasting and postprandial HDL-C measurements were not included. 
However, following sample collection, it was decided to include this analysis to enable a 
greater insight into the postprandial lipid and lipase responses following the MUFA test 
meals in our subjects. The most common methods for the measurement of HDL-C 
concentrations involve immediate precipitation from fresh plasma of apo B containing 
lipoproteins yielding a clear supernatant (Bachorik and Albers, 1986). The use of 
samples stored at 4°C or frozen samples has been discounted since this has been shown 
to affect the repeatability of measurement of HDL-C due to the adverse effects of 
freezing on lipoprotein aggregation and precipitation of apo B containing lipoproteins 
(Bachorik et al, 1980; Bachorik et al, 1982). A recent method has shown that when 
immediate precipitation is not possible a modified precipitation method improves 
repeatability and this has shown to be acceptable when TAG concentrations do not 
exceed 2.26 mmol/1 (McNamara et al, 1994). This method has been used in large scale 
epidemiological studies where facilities for precipitation and subsequent processing of 
samples were not available. Their method involves dilution of frozen plasma samples
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with saline, whose TAG concentrations exceeded 2.26 mmol/1, followed by precipitation 
and determination of HDL-C concentrations. Therefore it was decided that it would be 
possible to measure HDL-C concentrations in our postprandial TPL samples since d < 
1.006 g/ml (TRLs) had been separated from the TPL by a short ultracentrifugation step. 
In this method, fasting and postprandial samples were overlayered with an equal volume 
of saline and the TRL fraction was removed following ultracentrifugation to leave TPL 
with a dilution factor of 2.3 times. This therefore provided an ideal sample since the 
concentration of TAG in these samples would be less than 2.26 mmol/1 so preventing the 
potential influences of varying postprandial TAG concentrations but would mean 
increasing the sensitivity of the automated method due to this dilution factor. This 
method would therefore allow HDL-C concentrations to be evaluated in our samples 
following the MUFA test meals although absolute “true” concentrations would not be 
obtained due to the use of frozen samples.
No significant differences were observed with the HDL-C AUC and lAUC for 
the 3 meals, although there was a trend for the 12% MUFA meal to show a larger 
decline in HDL-C during the postprandial period. At the end of the postprandial period, 
there is a tendency for the 24% MUFA meal HDL-C to be higher than that of the 17% 
and 12% MUFA meals. This is interesting since the 12% MUFA meal shows a small 
decline from fasting concentrations whereas the 17% and the 24% MUFA meal shows 
no change, indicating that the amount of MUFA in the diet may directly affect HDL-C 
concentrations. This supports work by de Bruin et al (1993) who investigated 
postprandial lipoprotein responses in young healthy males following soybean oil and 
olive oil emulsions. HDL-C concentrations were shown to be maintained with the olive 
oil emulsion compared with the decrease observed with the soybean emulsion. The 
authors concluded that the clearance of oleic acid enriched CM remnants was inversely 
correlated with HL activity and that competition of the remnants for removal with HDL 
for this enzyme may provide an explanation for the HDL “conserving” effect of olive 
oil. Another explanation of these observations could be due to the size and composition 
of the dietary derived lipoproteins, following the ingestion of the different unsaturated 
fatty acids, and so their availability as an ideal substrate for LPL. Since HL is 
responsible for the final remodelling of remnants before uptake by the liver, the oleic
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acid enriched remnants may require extensive hydrolysis thus preventing the conversion 
of HDL2  to HDL3 ..
NEFAs are free fatty acids bound to albumin which are responsible for the 
transport of lipid-based energy to many organs. Hydrolysis of CMs by LPL results in the 
release of NEFAs and glycerol, with NEFAs being taken up into the adipose tissue 
where they are re-esterifred to form TAGs for storage. This process results in the fall in 
the circulating NEFA levels which is mediated by the rise in insulin concentrations 
following the meal. At the end of the postprandial period, insulin levels have fallen to 
baseline levels, resulting in the release of NEFAs from adipose tissue through the loss of 
inhibition of hormone sensitive lipase by insulin. Fasting and stress also affect the 
activity of hormone sensitive lipase resulting in a greater release of NEFA into the 
circulation. NEFAs exhibited a classic response with concentrations being suppressed 
following the meal and then rising above fasting concentrations in the latter half of the 
postprandial period. Daily typical concentrations in normal subjects range from 0.1 to 
0.7 mmol/1 and this is in agreement with our NEFA concentrations (Frayn et al, 1996). 
Compared with the NEFA responses for the 12% and 17% MUFA meals, the 24% 
MUFA meal response showed a trend for a slower return to fasting concentrations and a 
lower final NEFA concentration. Although significant differences were not observed 
with the lAUCs, there was a stepwise decrease in NEFA-IAUC on increasing the MUFA 
content of the test meal. These trends may help to explain the clearance rates of the CM 
remnants at the end of the postprandial period, since a longer clearance time and 
biphasic peak were observed with the apo B-48 and TAG responses for the 24% MUFA 
meal compared with that of the 12% and 17% MUFA meals. Therefore the high MUFA 
content of the 24% MUFA meal may affect the absorption rate and so entry and resultant 
metabolism of the TRL particles in the circulation.
Plasma glucose, insulin and GIF responses were not found to be significantly 
different for the 3 test meals studied and to be concordant with recently published data 
(Morgan et al, 1988; O’Meara et al, 1992; Schrenzenmeir et al, 1992; Murphy et al, 
1995, 1996). GIF is stimulated in man by fat and also carbohydrate (although not to the 
same extent) following the consumption of a meal. This hormone forms one of the major 
components of the enteroinsular axis which directly affects the insulin secretion induced
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by glucose (Morgan et al, 1988). Whereas the peak insulin and glucose levels are 
reached within 2 hours and then return to basal concentrations, GIF remains elevated 
above baseline concentrations for the whole of the 9 hour test period. Analysis of 24 
hour profiles of circulating gastrointestinal hormones indicated that the profile of GIF 
paralleled that of the TAG (Elliot et al, 1993). This type of evidence has suggested that 
GIF may play a part in TAG disposal and so play a role in lipid metabolism. This is 
interesting since the GIF response for the 24% MUFA meal exhibits a smaller second 
peak at 360 minutes which is also shown in the TAG and apo B-48 responses. The 12% 
MUFA meals shows a trend for the lowest residence time of the hormone and this may 
be a result of programming of the individual’s habitual diet.
The actions of insulin on lipid metabolism are multifactorial. Its main actions 
include, suppression of the NEFA release from adipose tissue, suppression of hepatic 
VLDL-TAG secretion during feeding at the liver and activation of LFL at adipose tissue 
(Frayn, 1996). Following the meal, GIF release stimulates insulin release from the 
pancreatic cells when the blood glucose concentrations rise above fasting levels. 
Therefore the rise in GIF concentrations is paralleled by that of insulin which results in 
the removal of glucose from the circulation. It is interesting to note that the 24% MUFA 
meal shows a trend for the greatest insulin responses in the early part of the postprandial 
period which is not observed with the GIF response. Therefore this pattern of response 
may be a result of the increase in the MUFA content of the meal which is consistent with 
the marginally slower rise of postprandial NEFA levels following the 24% MUFA meal 
compared with the other test meals or due to the variations in the insulin responses to the 
24% MUFA meals of the 8  volunteers. This increase in NEFA levels may have an effect 
on the insulin secretions following the meals since NEFA and glucose are in competition 
for uptake into skeletal muscle during the postprandial phase.
In conclusion, the results of this study demonstrate that substitution of MUFA 
for SFAs at physiological levels does not alter the magnitude of postprandial lipaemia or 
hormonal responses following acute mixed meals in healthy young men from the U.K. 
Increasing the MUFA content of the test meals in volunteers who habitually consume 
12% dietary energy as MUFA may affect the rate of incorporation of the dietary lipids 
into the CM particles and so their resultant metabolism.
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3.4.2. The use of apo B-48/RE as markers of intestinally derived lipoproteins
Comparison of the apo B-48, TAG and RE responses in the plasma, TRL and 
TPL fractions showed a consistent trend for a later time to peak for the REs 
(approximately 6-7 hours) compared with that of the TAG and apo B-48 (approximately 
3-5 hours) responses. However, this trend only reached statistical significance in the 
plasma (24% MUFA meal) and TPL (12% MUFA meal) fractions. Although TAG and 
apo B-48 responses return to baseline at 540 minutes, the RE response remains elevated 
above the baseline. This agrees with work by Krasinski et al (1990b) who hypothesised 
that the RE response does not correlate with the TAG and apo B-48 responses. Two 
possibilities may exist for this observed difference a) that the metabolism of TAG occurs 
during the first half of the postprandial period by virtue of the action of LPL whereas RE 
remains within the core of the CM so becoming more RE rich by the end of the 
postprandial period, and/or b) the rate at which RE is packaged into the core of the CM 
during synthesis may be inversely related to the amount of TAG in the core of the 
lipoprotein particle. The oily preparation used with the test meal to RP load the subjects 
may not be digested easily so resulting in the delay in its incorporation. This delay was 
also observed using RP in tablet form in the test meal (Karpe et al, 1995b). Another 
explanation may be due to the unsaturated nature of the fatty acids incorporated into the 
test meal since polyunsaturated fatty acids have been shown to delay the absorption of 
vitamin A in the circulation (Karpe et al, 1995b). Although slightly different responses 
are observed for RE and apo B-48, with respect to the effects of meal MUFA, they both 
provide markers for intestinally derived lipoproteins. This is with respect to their 
location in the lipoprotein particle since REs, like cholesterol esters, are within the core, 
whereas apo B-48 is present on the surface of the particle and so reflects their 
metabolism and uptake by the liver.
Separation of plasma into the TRL (d < 1.006 g/ml) and TPL (d > 1.006 g/ml) 
fractions enables the postprandial metabolism of CMs and CM remnants to be 
investigated separately. On the study day, three separate aliquots of plasma were frozen 
for analysis of plasma TAG, RE and apo B-48 (the plasma sample for apo B-48 analysis 
is protected from the action of peptidases by the apo B-48 preservative cocktail), 
whereas the aliquot of plasma for ultracentrifugation to prepare the TRL and TPL
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fractions was stored at 4°C overnight. The apo B-48 preservative was not added to this 
sample since this interferes with the enzymatic analysis of TAG. Comparison of the 
AUCs for the apo B-48, TAG and REs time response curves has highlighted that for apo 
B-48 and RE, the recoveries (TRL + TPL = PL) appear to be inconsistent between the 
analytes (see table 3.4). Possible explanations for the recoveries observed for each 
analyte are discussed below:-
a) With the TAG responses, the recovery was good with only a 5 % loss observed 
between the fractions (see figure 3.8). This may be attributed to the losses that occur due 
to the storage of the plasma sample itself or due to the ultracentrifugation method for the 
preparation of the TRL and TPL fractions.
b) With the RE response, the distribution of the REs was greater in the TRL fraction 
(approximately 75%) than in the TPL fraction (approximately 25%). REs are not present 
in detectable amounts in plasma all of the time and so following ingestion of the test 
meal, REs are present exclusively in the TRLs, with only metabolism resulting in the 
appearance of the RE label in TPLs. The sum of the TRL and TPL-AUC for RE 
provides a value about 30% higher than that of the plasma AUC for RE (see figure 3.8). 
The TRL-AUC was found to be equal to or higher than that of the plasma AUC 
following the 3 test meals (see table 3.4). This may be due to the preparation of the 
samples and the analysis using HPLC. Possible explanations for the increased recovery 
include : -
i) analysis of plasma, TRL and TPL samples was carried out separately, with the plasma 
samples being analysed last. Therefore the column will be older and so sensitivity of the 
column will have decreased with respect to differences in concentrations. Therefore 
plasma concentrations may be lower than expected. An internal standard was used to 
correct for this, however, the concentrations observed in plasma were within the lower 
region of sensitivity of the assay standard curve and so may provide an explanation for 
low plasma RE concentrations.
ii) the lipid moiety or low protein content of the TRL samples may result in better 
recovery in this fraction during the extraction procedure. However, during the validation 
of the HPLC method, the recoveries for each of the fractions were very similar (see 
section 2.3).
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iii) the method used in our laboratory was modified from the method by Ruotolo et al 
(1992) and we used the volumes recommended by the authors for the plasma and TRL. 
The concentration of RE labelled intestinally derived lipoproteins will be higher in the 
TRL fraction due to their concentration during the ultracentrifugation step than the 
plasma fraction so perhaps the amount of plasma required in the assay needs to be 
increased.
c) With the apo B-48 response, the distribution of intestinally derived lipoproteins is 
greater in the TPL fraction (about 80%) than the TRL fraction (about 20%). TRLs are 
larger and less dense than the TPLs indicating that there are more apo B-48 containing 
particles in the TPL fraction than the TRL fraction. A low recovery was observed with 
the apo B-48 response with the plasma AUC being approximately 10% higher than that 
of the combined TRL and TPL AUCs. The increase in the TPL and TPL response curves 
are quite gentle and so the rise observed in the plasma response curve cannot be 
explained through the contribution of the TRL or TPLs. Therefore, since the plasma 
samples for apo B-48 analysis are preserved on the study day, it is assumed that this 
represents the most reliable picture of the metabolism of the dietary derived lipoproteins 
following the test meals. The ELISA format used for the analysis of apo B-48 has been 
validated for CM-enriched fraction or TPL. The antisera used in the ELISA has been 
shown to be specific to apo B-48 and not to crossreact with apo B-lOO containing 
lipoproteins (Lovegrove et al, 1996). It was therefore decided that ELISA could be 
utilised for the measurement of apo B-48 containing lipoproteins in plasma and TPL 
fractions. The ‘high’ concentrations in plasma compared with those in the TRL and TPL 
fractions suggests that there is interference in the assay format from some component in 
plasma. Protein content in these samples and/or maybe crossreactivity of the secondary 
antibody with immunoglobulins in plasma may result in higher concentrations being 
observed than expected. Losses over the time response curve were not consistent, with 
the greatest losses observed at timepoints where the plasma is very lipaemic (see figure 
3.8). Therefore degradation of these lipoproteins may have occurred when the plasma 
samples were stored overnight without preservative resulting in lower than expected apo 
B-48 concentrations in the TRL and TPL fractions.
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Figure 3.8. Losses from fractions (TRL and TPL) of the TAG, RE and apo B-48 
concentrations during the postprandial period following consumption of meals of 
varying MUFA content (12%, 17% and 24% MUFA meals). Values represent mean 
concentrations when TRL and TPL fractions have been subtracted from the plasma 
fraction for the 8  subjects.
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The relative distribution of the intestinally derived lipoproteins between the TRL 
and TPL fractions differs between the RE and apo B-48 methods of analysis. Whereas 
the RE label is predominately in the TRL fraction, the greatest number of apo B-48 
containing particles are present in the TPL fraction. A possible explanation for these 
differences observed is due to the principles of the 2 methods used to monitor CMs and 
CM remnants. Apo B-48 containing lipoproteins are present continually in the 
circulation and since these particles are heterogenous they are dispersed between the 
TRL and TPL fractions. Therefore fblloAving the consumption of a fat containing meal, a 
range of particles are released from the enterocyte in which the large TRL predominant. 
Following metabolism by the endothelial lipases, the TRLs become denser and so enter 
the density range of the TPL fraction. The half life of the large TRLs is shorter than that 
of the apo B-48 containing particles in the TPL fraction and so at one time, the number 
of particles will be greater in the TPL fraction compared with those in the TRL fraction. 
The vitamin A loading method relies on the incorporation of REs into the core of the 
CM particle in the same manner as cholesterol esters. Hence, following ingestion of the 
test meal, the RP must be hydrolysed to retinol before its entry into the enterocyte and 
subsequent incorporation into the nascent CM. Normally, REs are present at very low 
concentrations and so detection of RE-labelled TRLs occurs approximately 1-2 hours 
following consumption of the test meal. Therefore it is suggested that the earliest TRLs 
entering plasma are rich in TAG and as absorption proceeds the TRLs decrease in 
number (as indicated by the decrease in apo B-48 concentrations) and become 
increasingly enriched in RE. Since the TRLs are labelled in the enterocyte, presence of 
RE label in the TPL fraction could arise from two sources a) from the metabolism of the 
large TRLs by LPL or b) due to the production of smaller CM particles which directly 
enter into the density range of d > 1.006 g/ml. The discussion in the previous paragraphs 
therefore implies that these two methods are providing different but very useful 
information about the metabolism of the intestinally derived lipoproteins following the 
test meals.
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Chapter 4
Comparison of the effects of meals 
of varying monounsaturated fatty 
acid content on postprandial 
lipaemia in healthy young men 
from Northern and Southern
Europe.
4.1 Introduction
Populations whose diets cause an increase in their blood cholesterol levels (i.e. 
high in SFAs) are thought to be more prone to the development of CHD. Numerous 
clinical trials have tested the hypothesis that when plasma lipids are lowered by diet or 
drugs, the risk of mortality from CHD is reduced. Compared with drug treatment, 
dietary intervention reduces plasma lipid levels but not to the same extent. However, a 
disadvantage of drug therapy is the increase in non-CHD related deaths (Temple, 
1994). Therefore dietary changes provide a safe and potentially effective means for the 
prevention of CHD, assuming a high level of dietary compliance.
Trends in mortality rates from CHD in the European Union (EU) have shown 
marked differences between the 1 2  countries, with mortality rates being greatest in 
Ireland and the U.K. and least in the Mediterranean countries (DOH, 1994). Interest in 
the traditional Mediterranean diet, as protective against CHD, is derived from the Seven 
Countries study, carried out in the 1960s, which indicated that the lowest rates of CHD 
were observed in Mediterranean countries (especially Greece, Yugoslavia and Italy) 
compared with the U.S.A., Finland and the Netherlands (Keys, 1970). The lowest 
prevalence of CHD (i.e. 90% lower than that seen in Western societies) was observed in 
Crete and this was interesting since serum cholesterol levels in this region were 
intermediate, and their total fat intake was among the highest, of the 16 cohorts of 
middle aged men studied. A follow up of participants of the Seven Countries study 
revealed that mortality from all causes was positively associated with the average intake 
of SFAs and inversely associated with MUFAs (Keys et al, 1986).
During the 1970s, risk factors for CHD had risen in Crete (i.e. increase in fasting 
serum cholesterol levels) and this had been attributed to the shift in their diet towards a 
more “Westem-style” diet. Adipose tissue biopsies performed in 1962 and again in 1988 
indicated that SFAs in the adipose tissue had increased by 24.5% whereas PUFAs and 
MUFAs had decreased by 30% and 4% respectively. As a result of these changes, the 
adipose tissue P:S and M:S ratios had decreased in the Cretan population (Kafatos and 
Comas, 1990). Comparable observations were made in Italy where manipulation of the 
habitual diet, through reduction in olive oil consumption for a period of 42 days, gave 
rise to increases in serum cholesterol levels (Ferro-Luzzi et al, 1989).
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Postprandial lipaemia and coronary artery disease
Much of the evidence regarding the effects of TAGs on CHD has been derived 
from epidemiological studies, where blood samples have been obtained following a 1 2  
hour overnight fast. However, individuals in industrialised nations spend a major 
proportion of their day in the postprandial state when the lipid transport system is 
challenged by fat containing meals. The strength of the association between TAGs and 
CHD has been demonstrated in a number of observational studies (Austin, 1991). In 
the Framingham study, individuals were segregated according to their HDL-C levels 
and it was observed that the group with highest TAG levels, combined with a low 
HDL-C concentration, were shown to have the greatest prospective risk for CHD 
(Wilson, 1994). This also agreed with observations by O’Meara and coworkers 
(1992), where the highest magnitude of lipaemia was found in individuals who had 
low HDL-C concentrations. Significantly higher AUC under the TAG response curve 
was determined in the individuals who had a high fasting TAG compared with a lower 
fasting TAG concentration. Although univariate analysis has demonstrated the 
association between TAG concentrations and CHD risk, multivariate analysis, 
including other lipid parameters and especially HDL-C levels, has abolished this 
statistical significance. However, this finding has been controversial since an inverse 
relationship exists between the levels of TAGs and HDL-C levels. Therefore a single 
measurement of these lipid parameters in an individual may not provide sufficient 
information and so underestimate any association between these variables.
Postprandial triacylglycerolaemia has been identified as an important factor in 
relation to CHD. It has been demonstrated that the magnitude and duration of 
postprandial triacylglycerolaemia is positively related to the pathogenesis of 
atherosclerosis (Groot et al, 1991; Patsch et al, 1992). A recent report by Karpe and 
CO workers (1994) has provided evidence that the delayed uptake of small CM 
remnants is associated with the progression of atherosclerosis. Decreased clearance of 
CM and CM remnant after a fat load have been implicated either directly or indirectly 
with the presence of CHD (Patsch et al, 1987). However, the relationship between 
TRLs during alimentary lipaemia and CHD has not been fully elucidated.
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It has recently been suggested that many of the metabolic disturbances, which 
have been related to the development of CHD are associated with insulin resistance 
(Frayn, 1993). Insulin affects endogenous lipid metabolism directly via its ability to 
modulate the expression of enzymes and indirectly via its role in determining the rate 
of delivery of NEFA to the liver. Breakdown of these mechanisms results in a 
deficient response to changes in insulin secretion following the consumption of a meal 
which may directly affect the triacylglycerolaemic response. A recent study has 
suggested that resistance to insulin-mediated glucose uptake provides a good 
predictive index of the postprandial lipaemic response (Jeppesen et al, 1995b).
The Cretan population is of interest from a public health point of view since 
their CHD mortality has been very low, with an annual rate of 13.5 deaths per 10,000 
males compared with 39 per 10,000 in Finland (Keys, 1986). A recent cross-sectional 
study investigated characteristics of ‘metabolic syndrome X’ in a low CHD risk group 
in Crete (Koutis et al, 1992). Syndrome X is characterised by hypertension, central 
obesity, lipid and glucose disturbances, in particular insulin resistance and 
hyperinsulinaemia. Therefore this study was used to establish whether these 
conditions interacted in the same way as those described in higher risk populations 
such as Sweden. Although higher fasting insulin and C-peptide levels were observed 
in the syndrome X individuals, the CHD mortality rate in Crete was lower than that 
observed in the Swedish population, even though serum cholesterol concentrations 
were very similar suggesting that these subjects retain some protection, not measured 
in this study. The authors hypothesised that the lower risk of CHD observed in the 
Cretan population may have been a result of their lower exposure to CHD risk factors 
10-20 years ago, since atherosclerosis requires at least 2 decades to develop. Therefore 
the more recent finding of increased cholesterol level and risk factors in Cretan men, 
suggests that the incidence of CHD in Crete will increase in future years. In the light 
of recent findings regarding the role of postprandial lipoproteins in the aetiology of 
CHD and possible role of insulin resistance with impaired lipaemia, there is a need to 
understand, in more detail, the nature and extent of any differences in postprandial 
lipoprotein (and hormone) responses to meals in groups of subjects with different risks 
of CHD.
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Aims of this study
One opportunity of the EU funded project, collaborating with research groups 
in Ireland and Crete, was to carry out a comparative study of the postprandial 
responses in Greek and Northern European (N.E.) males. It was hoped this study 
might shed some light on the factors responsible for the lower risk of CHD in 
Southern European (S.E.) males. Therefore the aim of the present study is the 
measurement of lipoprotein and hormonal responses to acute test meals of varying 
MUFA (12%, 17% and 24%) content in Greek subjects living in Greece and 
consuming a Mediterranean diet rich in MUFAs, compared with Northern Europeans 
living in Ireland and the U.K. consuming a diet rich in SFAs.
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4.2 Study design
4.2.1 Subject recruitment
Thirty two healthy normolipidaemic young men aged between 18-30 and with a 
BMI of between 19-26 kg/m^ were recruited; 16 from N.E. ( 8  from the U.K., 8  from 
Ireland) and 16 from S.E. ( 8  from Crete and 8  from Greece (excluding Crete)). 
Volunteer exclusion criteria were as described in section 3.2.1.
The studies were approved by the ethics committees of the Federated Dublin 
Voluntary Hospitals in Ireland, the University of Surrey and the Royal Surrey County 
Hospital in the U.K. and the University of Heraklion in Crete. All subjects gave 
informed consent.
4.2.2 Test meal composition
As described in section 3.2.2. RP was not included in the test meals of the Irish 
and Greek volunteers due to ethical constraints. Exactly similar procedures were 
followed for the test meal protocol in each of the 3 centres.
4.2.3 Study day procedure
As described in section 3.2.3.
Transfer of samples from Ireland and Crete to the UKfor analysis
Samples were transferred from collaborating centres by air packaged in dry ice. 
On arrival the samples were stored at the appropriate temperatures.
Dietary analysis for determination of habitualfat intake.
The analysis of the dietary intake of the subjects were determined in the centre 
of recruitment using the following validated questionnaires. Intake was determined 
using computer data bases by a qualified dietitian :
UK
Ireland
Crete
food frequency questionnaire and 3 day diet diaries.
7 day diet diaries and food atlas.
food frequency questionnaire and 24 hour recall.
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4.2.4 Plasma separation and analytical methods 
Plasma separation
Plasma was separated by spinning at 1700 g.min using a bench centrifuge, 
aliquotted into LP3 tubes for different analyses and stored at -20°C (samples for lipase 
analysis were stored at -80°C). This project combines 3 centres to study the effects of 
MUFAs on postprandial lipaemia in individuals who habitually consume varying 
amounts of MUFA in their background diet. Three different ultracentrifuges, tubes, 
gravitational g and methods for separation of the 2  fractions from plasma were used 
(see section 2.1.1). These differences have resulted in unfortunate losses in CM 
particles in the TRL fractions and so the postprandial TAG and apo B-48 
concentrations in the TRL and TPL fractions can therefore not be compared between 
the centres. Therefore statistical analysis will be performed between the N.E. and S.E. 
subjects for the plasma samples only. To protect apo B-48 from proteolytic cleavage, 
the preservative cocktail (section 2.1.2) was added at a concentration of 5% (v/v) of the 
apo B-48 containing sample.
Analytical methods
The methods employed for the determination of various analytes were 
previously described in chapter 2  : -
• Apo B-48 concentrations in plasma, TRL and TPL fractions were analysed using a 
competitive ELISA method (Lovegrove et al, 1996) (Section 2.3).
• Postheparin LPL and HL activities were determined by the method based on the 
liberation of labelled fatty acids from a ^H labeled triolein emulsion (Nilsson-Ehle and 
Schotz, 1976). (Section 2.4)
The following assays were carried out by co-workers : -
• TAG concentrations in plasma, TRL and TPL fractions were measured using an 
automated enzymatic colorimetric method (Section 2.5.1).
• The TAG/apo B-48 ratio was calculated for the 12%, 17% and 24% MUFA test 
meals in the plasma for the N. E. and S. E. subjects. This was performed by dividing
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individual TAG concentrations by those for the apo B-48 levels and calculating the 
mean and SEM for each timepoint of the postprandial period.
• Total cholesterol (TC) concentration in plasma was measured using an automated 
enzymatic method (Section 2.5.2).
• HDL-C in TPL samples was meaured following precipitation using an automated 
enzymatic assay (section 2.3.5.1).
• NEFAs in plasma were measured using an automated colorimetric method (Section 
2.5.5).
• GIF and insulin responses in plasma were measured by established 
radioimmunoassay techniques using a double antibody separation (Section 2.7 and 2.6 
respectively). The GIP and insulin responses were only determined in the S.E. and all 
of the subjects from the UK and for samples from the 12% MUFA meal only.
4.2.5 Statistical Analysis
Postprandial data was expressed in the form of time response curves and total 
and incremental area under the curve. Values in the figures and tables are given as 
mean values with SEM or SD. AUCs were calculated using the trapezoidal rule 
(Matthews et al, 1990). Unpaired Student’s t tests and one way analysis of variance 
were applied to the responses of the subjects to the 3 test meals and the differences 
identified using the Student-Newman-Keuls multiple comparisons post-test using the 
statistical package Instat (Macintosh version 2.01, San Diego, USA). Repeated 
measures analysis of variance was performed using Data desk 4.1 (Data description 
Inc, USA). Data was checked for normality and transformed before analysis if 
necessary. Repeated measures analysis of variance, using centre (N.E. or S.E.) and 
meal as the independent variables, investigated changes in the postprandial response 
for the analytes measured. Values of P < 0.05 were taken as significant.
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4.3. Results
4.3.1 Subject information
Sixteen subjects were successfully recruited each from N.E. (U.K., Ireland) and 
S.E. (Crete and Greece (excluding Crete)) and their details are shown in Table 4.1. 
There were no differences in age and BMI of the subjects in the 2 populations. 
However, the MUFA and PUFA intakes of the S.E. subjects were significantly 
different compared with those of the N.E. subjects (P < 0.002 and P < 0.0001, 
respectively). The acute test meals were consumed within the stated 20 minutes and 
did not elicit any adverse effects.
Table 4.1 : Subject Information
N.E. S.E.
Age (years) 22.4 (2.6) 22.3 (3.0)
BMI (kg/m-^) 22.8(1.7) 23.8(1.5)
Energy (MJ)/d 12.9 (3.6) 11.1 (4.6)
Protein (g)/d 106.3 (31.4) 94.2 (36.4)
Carbohydrate (g)/d 359.9 (115.9) 282.8 (129.0)
Fat (g)/d 
(%E)
133.7(41.5) 
38.5 (4.8)
128.8 (64.5) 
42.9 (9.3)
SEA (%E) 13.6 (3.4) 15.1 (3.4)
PUFA (%E) 7.0 (1.8) *4.3 (2.3)
MUFA (%E) 11.4(2.7) **18.3 (7.4)
Values are presented as mean (SD). * P  < 0.0001 and ** P  <  0.002 represents significant 
differences from N.E. percentage PUFA and MUFA intakes.
4.3.2 Fasting analyte concentrations
Within populations, fasting concentrations for each of the plasma analyte 
concentrations were not significantly different among study days for each of the test 
meals (Table 4.2).
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Table 4.2 : Fasting lipid and hormone concentrations for each test meal in 
subjects from Northern and Southern Europe
MUFA content of meal
Parameter 12% 17% 24%
TAG (mmoI/1) N.E.
S.E.
1.07 (0.33) 
1.02 (0.32)
0.95 (0.32) 
1.12(0.28)
1.12(0.38)
1.17(0.39)
Apo B-48 (pg/ml) N.E.
S.E.
3.57 (0.69) 
*3.01 (0.83)
3.56 (0.91) 
*2.86 (0.71)
3.84(1.04)
3.20(1.22)
TC (mmol/1) N.E.
S.E.
4.24 (0.26) 
4.30 (0.22)
4.24(0.27)
4.14(0.35)
4.15 (0.26) 
4.08 (0.28)
NEFA (mmol/1) N.E.
S.E.
0.61 (0.52) 
0.73 (0.24)
0.52 (0.23) 
0.60 (0.23)
0.42 (0.19) 
0.55 (0.34)
Insulin (pmol/1) U.K.
S.E.
41.64 (11.52) 
***86.00(41.52)
GIP (pmol/1) U.K.
S.E.
16.33 (7.59) 
***70.36 (56.88)
Values are presented as mean ± SD for the fasting lipid and hormone concentrations. Analytes 
were measured in plasma unless otherwise indicated in the table. * P  <  0.05, **P < 0.01, *** P  
<  0.001, concentrations significantly different between N.E. and S.E. populations for the 
analytes shown.
Between populations, the following significant differences were observed
a) Apo B-48, the N.E. apo B-48 concentrations were significantly higher than the S.E. 
concentrations for the 12% MUFA meal (P < 0.05) and the 17% MUFA meal (P < 
0.05).
b) Insulin, the S.E. fasting concentration was significantly higher than the U.K. 
concentration (P < 0.001).
c) GIP, the S.E. fasting concentrations were significantly higher than the U.K. 
concentration (P < 0.001).
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4.3.3 Plasma triacylglycerol responses
Postprandial TAG responses for the 2 populations are shown in figure 4.1. 
Following the test meals, plasma TAG concentrations rose within 2 to 3 hours, with a 
consistent trend for the S.E. subjects to peak earlier than the N.E. subjects. However, 
this only reached significance for the 12% MUFA meal (P < 0.001). Peak 
concentrations were also shown to be higher in the S.E. subjects compared with those 
of the N.E. subjects (Table 4.3). In contrast with the S.E. subjects, the N.E. subjects 
demonstrated a second peak between 360 and 420 minutes before returning to fasting 
concentrations at the end of the 9 hour test period (Figure 4.1). Repeated measures 
analysis of variance demonstrated a significant difference (P < 0.0001) in the patterns 
of the individual subjects postprandial TAG responses between the 2 centres. 
Differences in the pattern of plasma TAG response were most evident for the 24% 
MUFA meal and least for the 17% MUFA meal.
No effect of meal MUFA content was observed in the AUC for the TAG 
responses, with a trend for the AUCs to be higher in the S.E. subjects compared with 
the N.E. subjects (Table 4.4). Pearson product-moment correlation demonstrated that 
the fasting plasma TAG concentrations were significantly correlated ^vith the AUC for 
the postprandial plasma TAG response curve (r = 0.851; P < 0.0001).
4.3.4 Plasma apo B-48 responses
Peak plasma apo B-48 concentrations were found to be similar for the 2 
populations, with a trend for the S.E. subjects to reach peak values earlier than the N.E. 
subjects. (Table 4.3). After reaching the peak value, apo B-48 concentrations returned 
to baseline concentrations although there was a tendency for the N.E. subjects to 
remain elevated for longer during the later part of the postprandial test period before 
returning to fasting concentrations (Figure 4.2). Although there were no significant 
differences observed in the AUCs, there was a trend for the S.E. subjects to show a 
lower AUC compared with the N.E. subjects (Table 4.4). Repeated measures analysis 
of variance demonstrated a significant difference (P < 0.0001) in the patterns of the 
individual subjects postprandial apo B-48 responses between the 2 centres. A
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Figure 4.1. Plasma TAG concentrations following consumption of meals of varying 
MUFA content (12%, 17% and 24% MUFA test meals). Values represent mean ± 
SEM for the 16 N.E. and 16 S.E. subjects. On 3 separate occasions, subjects consumed 
in random order 12%, 17% and a 24% MUFA meal following a 12 hour overnight fast. 
Postprandial samples were collected over a 9 hour period during which subjects 
consumed 2 0 0  mis of sugar free decaffeinated fluid every 2  hours and maintained 
normal sedentary activities.
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Figure 4.2. Plasma apo B-48 concentrations following consumption of meals of
varying MUFA content (12%, 17% and 24% MUFA test meals). Values represent
mean ± SEM for the 16 N.E. and 16 S.E. subjects.
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Table 4.4 : Total area under the curve for the plasma TAG and apo B-48 
responses following meals of varying MUFA content
MUFA meal TAG (mmol/l.mm) Apo B-48 (pg/mLmiu)
1 2 % N.E. 727.42 (229.98) 2575.60 (750.67)
S.E. 738.21 (260.65) 2158.87 (526.42)
17% N.E. 665.04 (165.82) 2514.71 (639.71)
S.E. 786.38 (255.84) 2339.45 (873.68)
24% N.E. 777.43 (78.56) 2595.75 (732.82)
S.E. 786.24 (234.17) 2330.14 (694.78)
AUC values are presented as mean (SD), n=16.
significant difference was not observed for the postprandial apo B-48 responses to the 
individual test meals between the N.E. and S.E. subjects. Pearson product-moment 
correlation demonstrated that the fasting apo B-48 concentration was significantly 
correlated with the AUC for the postprandial plasma apo B-48 response curve (r = 
0.607, P <  0.0001).
4.3.5. Plasma TAG/apo B-48 ratios
Calculated TAG/apo B-48 ratios are shown in figure 4.3. Between populations, 
there was a tendency for the ratios to be higher in the S. E. subjects, with significance 
reached only following the 17% MUFA meal (P < 0.03). Over the postprandial 
timecourse, the ratios remained fairly constant, with a trend for the S. E. subjects to 
exhibit a higher ratio compared with those for the N. E. subjects.
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Figure 4.3. TAG/apo B-48 ratio calculated from the plasma TAG and apo B-48 
concentrations following consumption of meals of varying MUFA contents (12, 17% 
and 24% MUFA meals). Values represent mean ± SEM for the 16 N. E. and 16 S. E. 
subjects.
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4.3.6. Postheparin LPL and HL activities
Postheparin lipase activities 5 and 15 minutes following the injection of 
heparin were measured a) nine hours after meals of varying MUFA content and b) on 
a separate occasion after a 12 hour overnight fast (Figure 4.4). Within populations, 
there was no effect of the MUFA content of the test meals or fasting on LPL and HL 
activity.
Between populations, there was a tendency for the 15 minute LPL activities to 
be higher in the N.E. than the S.E. subjects, with significance reached only for the 
12% MUFA meal (P < 0.01) (Figure 4.4). There was a consistent trend for the fasting 
and 9 hour postheparin HL activities to be higher in the S.E. than the N.E. subjects 
(Figure 4.3b). Fasting postheparin HL activities were significantly lower in the N.E. 
subjects compared with the S.E. subjects (P < 0.004). Postheparin HL activities in the 
N.E. subjects were significantly lower than the S.E. activities for the 12% (P < 0.02), 
17% (P < 0.01) and 24% (P < 0.01) MUFA meals. (Figure 4.8)
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Figure 4.4. Postheparin plasma lipase activities 5 (HL) and 15 (LPL) minutes after 
injection of 7500 lU of heparin 9 hours following a 12 hour overnight fast and 9 hours 
after the random consumption of the MUFA test meals (12%, 17% or 24%). Values 
represent mean (SEM) for the 16 N.E. and 16 S.E. subjects. ** P<  0.02 compared with 
the N.E. LPL activities; * P < 0.01, ** P < 0.02, *** P < 0.001 compared with the S.E. 
HL activities.
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4.3.7. TC responses
Plasma TC responses following the 3 test meals are shown in figure 4.5. There 
were no significant differences observed in the postprandial responses for the 3 test 
meals between the 2 populations. Similar fasting TC concentrations and patterns of 
response were exhibited by the N.E. and S.E. subjects. The AUC and lAUC for the 
postprandial TC responses are shown in table 4.5. Between populations there was a 
tendency for the AUCs to be similar, however this pattern was not demonstrated with 
the I AUCs, which were all negative, where there was a trend for the S.E. response to 
be greater than the N.E subjects response. This reached significance for the 24% 
MUFA meal only (P < 0.03).
Table 4.5. AUC and lAUC (mmol/I.min) for the plasma TC responses in
the N.E. and S.E. subjects.
Meal AUC lAUC
12% MUFA N.E.
S.E.
2237.55 (137.16) 
2196.79 (120.27)
-53.74 (31.21) 
-123.23 (48.27)
17% MUFA N.E.
S.E.
2272.21 (123.78) 
2151.79 (145.53)
-16.55 (62.54) 
-81.83 (84.17)
24% MUFA N.E.
S.E.
2194.45 (141.38) 
2016.85 (146.54)
44.69 (11.17) 
-183.81 (48.21)
Values are presented as mean ± SD. * P  <  0.03, significantly different from the lAUC for the 
S.E. subjects.
160
12% MUFA meal
4 '  ■
NJE.
S.E.
500 600100 200 300 4000
Time (mins)
17% MUFA meal
4^
300 400 500 600100 2000
N£.
SJE.
Time (mins)
24% MUFA meal5
4
3
2
1
0
600400 500200 3001000
N E .
S E .
Time (mins)
Figure 4.5. TC responses in plasma following the consumption of meals of varying
MUFA contents (12%, 17% and 24% MUFA). Values represent mean ± SEM for the
16 N.E. and 16 S.E. subjects.
161
4.3.8 HDL C responses
Postprandial plasma HDL-C responses are shown in figure 4.6. There were no 
significant differences between the 3 MUFA test meals on fasting and postprandial 
HDL-C concentrations for the N.E. and S.E. subjects. Between populations, there was 
a tendency for the N.E. fasting HDL-C concentrations to be higher than that of the 
S.E. concentrations. However, this did not reach significance. The AUCs and lAUCs 
for the postprandial responses are shown in table 4.6. There was a trend towards 
increasing HDL-C AUC with increasing MUFA content of the test meal, with the 24% 
MUFA meal being greater than that of the 12% and 17% MUFA meals. There was 
also a trend for the S.E. AUCs to be lower than that of the N.E. subjects. However, 
these patterns were not seen with the I AUC for HDL-C.
Table 4.6. AUC and lAUC (mmoI/I.min) for the plasma HDL-C responses in
the N.E. and S.E. subjects.
Meal AUC lAUC
12% MUFA N.E.
S.E.
496.85 (135.44) 
509.76 (127.58)
-23.07 (62.47) 
2.29 (59.61)
17% MUFA N.E.
S.E.
509.76 (128.88) 
447.58 (154.13)
0.47 (37.66) 
-10.41 (58.36)
24% MUFA N.E.
S.E.
517.32 (135.06) 
465.76 (119.08)
-4.28 (37.75) 
-8.44 (64.11)
Values are presented as mean ± SD.
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Figure 4.6. Plasma HDL-C responses in plasma following the consumption of meals
of varying MUFA contents (12%, 17% and 24% MUFA). Values represent mean ±
SEM for the 16 N.E. and 16 S.E. subjects.
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4.3,9 NEF A responses
Following the test meals, NEFA concentrations fell during the first two hours 
before rising above fasting concentrations by the end of the 9 hour period (Figure 4.7). 
Repeated measures of analysis demonstrated a significant difference (P < 0.0001) in 
the patterns of the individual subjects postprandial NEFA responses between the N.E. 
and S.E. populations with the decline in postprandial NEFA concentrations being 
significantly less in the S.E. compared with the N.E. subjects. Pearson product- 
moment correlation demonstrated that the fasting NEFA concentration was 
significantly correlated with the AUC for the plasma NEFA response (r = 0.707, P < 
0 .0001).
Significant effects of meal MUFA content were observed within the individual 
populations, for the N.E. subjects, the 24% MUFA meal AUC was significantly lower 
than the 12% and 17% MUFA meals (P < 0.05) and for the S.E. subjects, the 17% and 
24% MUFA meals were significantly lower than the 12% MUFA meal (P < 0.05). No 
significant effects of meal MUFA content were observed with the lAUC for the 
plasma NEFA responses. Between populations, the 12% MUFA AUC for the N.E. 
subjects was significantly lower than the S.E. AUC for the 12% MUFA meal 
(P < 0.01). There was a trend for the U.K. and S.E. AUC-NEFA responses to decrease 
as the MUFA content of the test meals increased (Figure 4.8).
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Figure 4.7. NEFA responses to meals of varying MUFA content (12%, 17% and 24%
MUFA) in plasma. Values represent mean ± SEM for the 16 N.E. and 16 S.E.
subjects.
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Figure 4.8. AUC and lAUC for the plasma NEFA responses to meals of varying 
MUFA content (12%, 17% and 24% MUFA). Values represent mean ± SEM for the 
16 N.E. and 16 S.E. subjects. ** P < 0.01 compared with AUC for the S.E. subjects and 
*P< 0.05 compared with the AUC for 12% MUFA meals for both populations.
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4.3.10 GIF response
Following the meal, GIF concentrations rose with peak concentrations being 
reached at approximately 1 2 0  minutes before returning slowly to baseline 
concentrations (Figure 4.9). Significant differences were observed in the AUC, with 
the U.K. subjects being lower than that of S.E. {P < 0.0001) subjects. No differences 
were observed with the lAUC, although there was a tendency for the U.K. lAUC to be 
lower than that of the S.E. subjects. Repeated measures analysis of variance 
demonstrated a significant difference (P = 0 .0 0 0 2 ) in the patterns of the individual 
subjects GIF responses between the N.E. and S.E. populations. Fearson product- 
moment correlation demonstrated that the fasting GIF concentration was significantly 
correlated with the AUC for the GIF response curve (r = - 0.650, P < 0.001).
4.3.11 Insulin response
Fostprandial insulin responses to the 12% MUFA meal are shown in figure 
4.10. Following the meal, insulin concentrations rose sharply with peak concentrations 
reached at 60-120 minutes for the U.K. subjects and between 60 and 240 minutes for 
the S.E. subjects. Basal concentrations were reached at approximately 360 minutes 
and were maintained until the end of the 9 hour test period. No significant differences 
were observed in the AUC and lAUC for the 2 populations although there was a trend 
for the S.E. subjects to show greater responses than the U.K. subjects (Figure 4.10). 
Repeated measures analysis of variance demonstrated a significant difference 
(P < 0.0001) in the patterns of the individual subjects postprandial insulin responses 
between the 2 centres. The Fearson product-moment correlation demonstrated that the 
fasting insulin concentration was significantly correlated with the AUC for the insulin 
response curve (r = 0.748, P < 0.0001).
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Figure 4.9. GIP response to the 12% MUFA meal in plasma. Values represent mean ± 
SEM for the 8  U.K. and 16 S.E. subjects. *** P < 0.0001 compared with S.E. AUC.
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Figure 4.10. Insulin response to the 12% MUFA test meal in plasma. Values represent 
mean ± SEM for the 8  U.K. and 16 S.E. subjects.
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4.4 Discussion
A relationship between postprandial lipaemia and CHD was hypothesised as 
early as the 1950s and 1960s (Karpe and Hamsten, 1995c). Recent studies, 
investigating postprandial responses in individuals with atherosclerosis, have 
confirmed that an elevated plasma level of intestinally derived lipoproteins is 
associated with CHD (Groot et al, 1987; Karpe et al, 1994). Lipoprotein metabolism 
is a complex integrated system in which the regulation of lipid transport is controlled. 
The metabolism of newly secreted CM and VLDL lipoproteins occur by the same 
lipolytic pathway. Following secretion, the lipoproteins undergo an exchange with 
HDL in which they gain apo C-II, the apolipoprotein required for the activation of 
LPL. This enzyme is involved in hydrolysing core TAGs from the circulating CMs 
releasing fatty acids and glycerol (Bensadoun, 1991). The free fatty acids (NEFA) are 
taken up by tissues locally to meet energy and storage requirements. The resultant 
remnant, depleted of a large proportion of TAG, re-enters the circulation where it is 
further hydrolysed by HL, increasing the exposure of apo E on the surface, before 
uptake into the liver by a receptor-mediated process. The receptors involved include 
the LRP and the LDL-receptor (Beisiegel, 1995). Any disturbance in this system 
results in the accumulation of dietary derived lipoproteins which are now believed to 
contribute to the development of CHD, either directly through TRLs and their 
remnants or indirectly, by affecting other lipoproteins known to be atherogenic (Patsch 
et al, 1987).
The aim of this study was to determine whether there were differences in the 
postprandial processing of dietary fat or in hormone concentrations in individuals who 
consume different amounts of MUFA in their habitual diet, in this case, subjects of 
Northern (UK and Ireland) and Southern (Greece) European origin. The subjects were 
recruited from the university population of each population and were matched for age, 
BMI, biochemical status, exercise level, smoking status and alcohol consumption. 
This was to ensure that that any differences in response to the 3 test meals were due to 
their habitual consumption of dietary MUFA. However, other factors including 
genetic predisposition and lifestyle between the 2  populations could not be controlled 
for and so may provide an explanation for any of the differences observed. Also the
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subjects involved in the study were not recruited from a typical free living population 
but from a resident student population so their dietary habits and attitudes towards 
their diet may not precisely reflect those of the whole population. The percentage 
dietary energy derived from MUFA, as expected, was significantly higher in the S.E. 
subjects. It was interesting to note, that the PUFA content of the N.E. diet was higher 
than that of the S.E. diet and that there was a similar intake of dietary SFA. The fatty 
acid composition of the habitual diets of the subjects was determined using a detailed 
food frequency questionnaire. However, different questionnaires and nutrient analysis 
programmes were used in the 3 centres, although each questionnaire had been 
validated for use on the relevant population. This methodology problem was 
unavoidable since the diets in the three centres differed widely and so therefore it was 
not feasible to assess using a single questionnaire.
In general, the results obtained in this study have indicated that there were no 
differences in the postprandial responses between the 3 MUFA test meals for the 
individual N.E or S.E. populations and confirms the data for the young men from the 
U.K. shown in chapter 3. The percentage MUFA used in the 3 test meals was derived 
from the habitual diet of the N.E. subjects (i.e. approximately 12% MUFA) and the 
S.E. subjects (i.e. approximately 17% MUFA derived from the Greek diet and 24% 
from the Cretan diet). The fat content of the test meal was maintained at 40 g which 
was chosen since this reflected the average fat content of a meal and so enabled 
postprandial responses to be determined following a moderate fat challenge, typical of 
a standard evening meal. The fasting concentrations of the analytes for the 2 
populations were not significantly different on each of the 3 study days, so implying 
good compliance of the subjects during the study period.
The lipaemic responses of the subjects following the test meals was 
investigated using TAG and apo B-48 measurements in plasma and the TRL and TPL 
fractions. Although plasma gives an overall view of the metabolism of TRLs, and in 
the case of apo B-48 intestinally derived lipoproteins, fractionation enables the 
distribution of the TAG-rich (predominately CMs) and TAG-poor particles 
(predominantly CM remnants) to be determined. This is important since CM remnants 
have been implicated in the development of CHD (Karpe et al, 1992). Due to
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methodological differences between the 3 centres involved in this study (section 
2 .1 .1 ), which only became evident following sample collection and sample analysis, it 
is impossible to compare the concentrations obtained in the TRL and TPL fractions 
between the N.E. and S.E. subjects. This is due to the losses in the TRL fraction which 
were shown to have occurred in sample transfer from Crete and Ireland, which when 
added together do not give the TAG and apo B-48 concentrations in plasma (Figures
4.11 and 4.12). A retrospective comparison of TAG and apo B-48 concentrations in 
identical samples spun in the 3 centres confirmed the nature of the methodological 
problem and it was not possible to correct for this in a systematic manner. Losses in 
the fractions may have been a result of the procedures adopted in the centres to isolate 
the TRLs or as a result of storage of the samples during transport between centres. The 
plasma, TRL and TPL data was presented to provide an overview of the patterns of the 
responses and distribution of the particles for the individual centres, but no inferences 
can be drawn from any of the statistically significant findings observed for the TRL 
and TPL for the N.E. and S.E. subjects. Therefore only plasma data has been used to 
compare the responses between the N.E. and S.E. subjects since this was processed 
differently in the individual centres.
Significant differences were observed in the pattern of the lipaemic responses 
(apo B-48 and TAG) in plasma between the 2 populations. Although there were no 
differences in the fasting TAG concentrations for the 2 groups, there were significant 
differences in the patterns of TAG response with the S.E. subjects demonstrating an 
earlier and greater rise in TAG concentrations following the meal. In contrast, the N.E. 
subjects demonstrated biphasic responses, with higher TAG concentrations being 
reached approximately 6-7 hours following the meal. Furthermore, with the S.E. 
subjects, the plasma TAG concentrations returned rapidly to fasting values in the later 
part of the test period, whereas the N.E. subjects this concentration remained elevated 
for most of the postprandial period, and only returned to fasting concentrations 9 hours 
following the meal.
Different postprandial TAG responses were also observed by Patsch et al 
(1992), who measured TAG levels following a fat containing meal in individuals with 
and without CHD. They observed that although fasting TAG concentrations were
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Figure 4.11. Losses from fractions (TRL and TPL compared with those of total 
plasma) for the TAG concentrations during the postprandial period following 
consumption of meals of varying MUFA content (12%, 17% and 24% MUFA meals). 
Values represent mean concentrations when the TRL and TPL concentrations have 
been subtracted from those in plasma for the 16 N.E. and 16 S.E. subjects.
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Figure 4.12. Losses from fractions (TRL and TPL compared with those for total 
plasma) for the apo B-48 concentrations during the postprandial period following 
consumption of meals of varying MUFA content (12%, 17% and 24% MUFA meals). 
Values represent mean concentrations when the TRL and TPL concentrations have 
been subtracted from those in plasma for the 16 N.E. and 16 S.E. subjects.
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similar for the 2 groups, the postprandial TAG concentrations following the meal 
discriminated between the normals and the CHD subjects who had elevated 
concentrations late in the alimentary phase. They suggested that there was a direct 
relationship between the levels of plasma lipoproteins in the postprandial state and the 
development of CHD. This therefore highlights the use of fasting TAG concentrations 
together with postprandial TAG measurements to evaluate the risk of an individual for 
the development of CHD.
The apo B-48 concentrations were investigated to determine the contribution 
of the dietary derived lipoproteins to the postprandial lipaemic response. There was a 
significant difference in the pattern of the apo B-48 response following the 3 test 
meals between the N.E. and S.E. subjects. There was a trend for an earlier rise and 
lower peak number of the CM and CM remnants observed with the S.E. subjects. 
Furthermore, the S.E. returned rapidly to fasting concentrations whereas the N.E. 
subjects remained elevated during the latter half of the postprandial test period. Again 
the N.E. subjects demonstrated a biphasic response. These results are in good 
agreement with the TAG data, whereby the N.E. subjects apo B-48 concentrations 
remain elevated at the end of the postprandial period compared with that of the S.E. 
subjects. Possible explanations for the different patterns of response for the lipaemic 
responses (TAG and apo B-48) between the N. E. and S. E. subjects could be as a 
result of : -
a) entry of larger CMs earlier in the postprandial period which have been shown to be 
a favourable substrate for LPL (Bensadoun, 1991). This is illustrated in the TAG to 
apo B-48 ratios, which is calculated to determine the TAG enrichment of the CM and 
CM remnant particles, whereby the S. E. subjects show a higher ratio over the 
postprandial period for the 3 test meals (see 4.3.5). The higher TAG/apo B-48 ratio 
observed in the S.E. subjects compared with that of the N.E. subjects suggests that the 
S.E. intestinally derived lipoproteins are more enriched with TAG and so may provide 
an explanation for the rapid removal of these lipoprotein particles. It would have been 
useful to have measured apo B-lOO concentrations in the TRL and TPL fractions to 
confirm the intestinal rather than hepatic origin of the late postprandial TAG.
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b) differences in the gastrointestinal handling of food, e.g. stomach emptying between 
2 populations. However, since this was not measured we can only speculate that the 
S.E. volunteers may have a higher rate of stomach emptying and so entry of lipid into 
the circulation. This therefore implies that the S.E. subjects, habituated to a high 
MUFA diet, may digest and absorb fat more quickly. The gastrointestinal handling of 
food may also be affected by different eating patterns between the populations.
c) increased hydrolysis of CM particles due to the higher concentrations of GIP and 
insulin during the early postprandial period which has been demonstrated to be 
synergistic in stimulating LPL activity (Knapper et al, 1996b). At this present time we 
can only speculate on the activity of LPL during the postprandial period since only 
postheparin LPL activities were measured.
Lipase activities are important determinants of the postprandial processing of 
lipoproteins (Olivecrona and Bengttson-Olivecrona, 1990). LPL and HL activities 
were measured 9 hours following the test meal after a bolus injection of heparin and 
blood samples are collected at 5 and 15 minutes. The LPL activities were highest in 
the N.E. subjects and HL activities highest in the S.E. subjects. This is surprising since 
a favourable lipoprotein phenotype for a lower risk of CHD, is one in which there is a 
high LPL activity and a low HL activity (Karpe et al, 1993). Decreased LPL activity 
leads to pronounced postprandial lipaemia, which, through the action of CETP, 
increases the TAG content of HDL2 , allowing conversion of HDL2  to HDL3 by HL, 
resulting in low HDL levels (Patsch et al, 1983). HL plays a key role in the turnover 
of potentially atherogenic lipoprotein remnants and in determining the distribution of 
the HDL subclasses, namely HDL2 , which has been demonstrated in individuals with 
HL deficiency. Karpe and coworkers (1993) investigated the relationships of plasma 
levels and composition of light (TAG-rich) and dense (TAG-poor) LDL subfractions 
to postprandial TRLs and postheparin lipase activities in young male post-infarction 
patients. LPL activity was demonstrated to be associated with LDL particle 
distribution between the light and dense subfractions. The activity of HL was found to 
be inversely proportional to the plasma level of the light TAG-rich LDL subclass.
The postheparin lipase data obtained was unexpected since the pattern of the 
TAG and apo B-48 responses appeared to differ between the N. E. and S. E. subjects.
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A possible explanation for the lipase activities obtained from blood samples collected 
9 hours following the meal is that they provide a snapshot at that timepoint of the 
exposure of the enzymes to their optimal substrates. At the end of the postprandial 
period, the TAG concentrations in the N.E. subjects were higher than those of the S.E. 
subjects so increasing the exposure of this enzyme to its substrate. Since HL is 
involved in the removal step, it is possible that the higher HL activities resulted in 
clearance of the TRLs in the S.E. occurs earlier and at a faster rate than that of the 
N.E. subjects. This therefore implies that the postheparin enzyme activities are giving 
an indication of the postprandial state of the individuals 9 hours following the meal. 
However, lipase activities may have varied during the earlier portion of the 
postprandial period when the TRLs were being actively metabolised in the circulation 
and so may have provided more information about the effects of the 3 MUFA test 
meals in the 2 populations on lipase activities during postprandial lipaemia. This is 
consistent with the peak LPL levels which are co-incident with the peak levels of TAG 
in plasma in the postprandial period (Frayn, 1993). These possible postprandial 
changes in LPL activity cannot be measured since heparin cannot be given 
intermittently during the study test period since heparin itself can affect the 
postprandial processing of lipoproteins through its effect on LPL activity. This 
indicates the importance of measuring pre-heparin LPL activities to determine 
postprandial lipase activities. Karpe et al (1992) have determined that plasma 
activities of LPL but not those of HL were influenced by an oral fat load.
The levels of NEFAs in the circulation are as a result on the physiological state 
of the individual. During fasting there is an increase in the release of NEFA from 
adipose tissue through the action of HSL. On feeding, NEFA release is suppressed and 
adipose tissue is involved in the clearance of dietary TAG through the action of LPL 
for estérification and storage (Frayn et al, 1996). Within populations, significant 
differences were observed in the AUC, with the 24% MUFA meals being significantly 
lower than the 12% MUFA meal in the N.E. subjects and being significantly lower 
than the 12% and 17% MUFA meals in the S.E. subjects. This pattern of response was 
reflected in the lAUC, where there was a trend for the 24% MUFA meal to be lower 
than that of the 12% and 17% MUFA meals. Therefore, it appears that the NEFA
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response in the N.E. and S.E. subjects is influenced by the MUFA content of the test 
meals and also the habitual consumption of the subjects, since the AUC was greater in 
the S.E. subjects. The meal MUFA content also demonstrated a progressive decrease 
in lAUC in both populations. Since the TAG responses did not differ between the 3 
test meals, this finding suggests that there was a tendency for the 24% MUFA TRLs to 
be hydrolysed and removed more efficiently from the circulation compared with the 
12% and 17% MUFA meal TRLs. Therefore, since the SFA content of the test meals 
was substituted by MUFA with PUFA being maintained, it would suggest that the 
decrease of SFA or increase in MUFA may account for the differences observed.
The NEFA data has also shown a significant difference in the pattern of 
response following the meal between the 2 populations. In particular, the lower NEFA 
suppression and a faster return to basal concentration in the S.E. subjects on increasing 
the MUFA content of the test meals. The increased amount of NEFA during the 
earlier part of the postprandial period demonstrated in the S.E. subjects may be a result 
of the faster TRL-TAG hydrolysis by LPL on the endothelial surface. Therefore 
release of TAG from TRLs during the post meal NEFA suppression may contribute to 
the resultant plasma NEFA concentration in the early part of the postprandial period. It 
has recently been suggested that greater than 50% of the NEFA released firom the CM 
particle is released directly into the circulation (Frayn et al, 1996). Alternatively, the 
higher insulin concentrations in the S.E. subjects may cause the subjects to be less 
responsive to the antilipolytic actions of insulin therefore enabling further hydrolysis 
of CM particles by LPL.
The hormones, GIP and insulin have demonstrated differences in the patterns 
and extents of response between the N.E. and S.E. subjects. Although the GIP 
concentrations were analysed for the samples collected fi*om the U.K. subjects, the 
data generated from the initial acute phase suggested that GIP and insulin secretions 
may differ in individuals who consume varying amounts of MUFA in their 
background diet. Only samples collected following the 12% MUFA meal were 
analysed for their insulin and GIP concentration due to analytical and financial 
restrictions. The S.E. subjects show a higher fasting GIP and insulin concentrations, in 
combination with significantly higher AUCs compared with that of the U.K. subjects.
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This may be in agreement with the insulin AUC /IAUC data for the U.K. subjects 
following the high 24% MUFA meal which demonstrated a tendency for higher 
concentrations. Possible explanations for the higher secretion of GIP and insulin in the 
S.E. subjects could be a result of : -
a) the higher habitual fat intake in this population. An increase in GIP release has been 
demonstrated on increasing fat intake in man (Morgan et al, 1988). The elevated GIP 
concentrations maybe a result of the rapid entry and hydrolysis of the TRLs since GIP 
secretion is regulated by dietary fat and CM formation. A biphasic insulin response 
was observed in the S.E. subjects which was not demonstrated in the N.E. subjects and 
this may be due to the continual high secretion of GIP during the postprandial period 
which is known to directly affect the secretion and synthesis of insulin. Therefore the 
rapid clearance of the TRL TAG and return to fasting levels may be a result of the 
synergistic action of GIP and insulin on LPL activity during the postprandial test 
period. At present this is only suggestive since there is no direct evidence for this 
hypothesis.
b) Elevated insulin concentrations may be as a result of the elevated NEFA levels (i.e. 
decreased suppression) following the test meals, since competition exists between 
NEFA and glucose for uptake by the surrounding tissues. Therefore more insulin 
would have to be released in order to enable uptake of the circulating glucose levels by 
the surrounding tissues. Unfortunately due to financial constraints, fasting and 
postprandial glucose concentrations was only measured in the U.K. and Irish subjects 
and so a comparison between Northern and Southern Europeans could not be made to 
help explain the responses observed.
c) The easily absorbable nature of olive oil may also be involved in the stimulation of 
GIP release (Kafatos and Comas, 1990).
In conclusion, some of the lipid and hormonal responses obtained for the S.E. 
compared with that of the N.E. population were unexpected in light of their lower 
CHD risk. In comparison, the S.E. subjects exhibited : -
• an earlier entry and clearance of TRLs
• lower postheparin LPL activity
• significantly higher postheparin HL activity
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• similar TC concentration
• lower NEFA suppression in the earlier part of the postprandial period
• significantly higher fasting insulin and GIP concentrations
However, this is the first cross-cultural comparison of postprandial responses to meals 
of varying MUFA content and so the responses observed may not be representative of 
the lipid and hormonal indices of the two populations. This study has highlighted 
important differences in the magnitude and duration of postprandial lipaemia between 
these 2 distinct populations. However, it is difficult to ascertain whether the 
differences observed are a result of the genetic make-up or the high dietary 
consumption of MUFAs in these populations. This study does suggest that a lower 
incidence of CHD in the S.E. population may be a result of a more efficient processing 
of dietary fat. The extent of this effect and the role of a high intake of olive oil remain 
to be elucidated.
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Chapter 5
Effects of chronic 
monounsaturated fatty acid intake 
on postprandial lipaemia in 
healthy young men with a family 
history of coronary heart disease.
5.1. Introduction
Monounsaturated fatty acids
A recent COMA report, on the nutritional aspects of cardiovascular disease, has 
indicated that the mortality rates for this disease in the U.K. exceed those of other 
Western nations (DOH, 1994). The British “Western style” diet is high in total fat, 
especially SFAs (approximately 16% of dietary energy) and cholesterol. 
Epidemiological studies have shown high intakes of SFAs to be correlated with an 
elevated total cholesterol in plasma (Keys, 1965; Keys, 1970). The COMA report 
recommends that the average contribution of total fat to dietary energy should be 
reduced from current levels of intake (38%) to approximately 35%, with 10% being 
derived from SFAs and 6 % being derived from PUFAs. However, there are currently no 
specific recommendations regarding the intake of MUFAs and their effects on 
cholesterol concentrations and their potential as a means of preventing cardiovascular 
disease.
Olive oil, which is consumed in large quantities in Mediterranean countries, is 
rich in MUFA namely oleic acid (approximately 75%), together with a small percentage 
of SFAs (palmitic and stearic acids, approximately 14%) and essential PUFAs (LA and 
a-LLA, approximately 11%). It also contains antioxidants including tocopherols and 13- 
carotene which may have an important role in modifying an individual’s susceptibility to 
atherosclerosis (Kafatos and Comas, 1990). Data concerning the effects of MUFAs in 
the diet are equivocal. Original dietary studies carried out in the 1960s reported that 
MUFAs had a “neutral” effect with regard to their cholesterol lowering properties (Keys 
et al, 1965; Hegsted et al, 1965). Recent studies involving replacement of fats containing 
a high proportion of SFAs (approximately 16 to 18% of dietary energy) with MUFAs 
(especially oleic acid), have demonstrated that MUFAs like PUFAs, lower LDL-C (and 
apo B) but not to as great an extent as PUFAs. In addition, and unlike PUFAs whose 
action was associated with a fall in HDL-C, most studies showed that HDL-C was 
maintained or increased after SFAs were substituted with MUFAs (Becker et al, 1983; 
Mattson and Grundy, 1985; Mensink and Katan, 1989; Trevisan et al, 1990; Berry et al, 
1991; Kris-Etherton et al, 1993; Temme et al, 1996). However, reductions in HDL-C 
have also been observed with MUFAs (Sirtori et al, 1986; Dreon et al, 1990;
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Lichtenstein et al, 1993; Nydahl et al, 1994; Choudray et al, 1995; Howard et al, 1995) 
(a summary of results is shown in Table 5.1). A possible explanation for this decrease 
maybe due to the low fat content of the diets studied (i.e. approximately 30% of dietary 
energy). This is supported by the decline in HDL-C observed in individuals consuming 
low fat diets (Knuiman et al, 1987). Comparisons of feeding different levels of PUFAs 
and MUFAs indicated that PUFAs exhibited their greatest cholesterol-lowering effects 
when the test diet contained the highest percentage of dietary energy derived from 
PUFAs (i.e 17%). However, when dietary energy of PUFAs was between 6 % and 10%, 
the percentage dietary energy recommended by the COMA report, similar effects were 
observed with the diets enriched with MUFAs (Howard et al, 1995).
It has also been demonstrated that a diet high in MUFA was as effective as low 
fat, high fibre diets in the lowering of LDL-C without also causing the decrease in HDL- 
C observed with low fat diets (Sirtori et al, 1985; Grundy, 1986; Garg et al, 1988). 
Further evidence has indicated that diets high in MUFA are more favourable than diets 
high in carbohydrate (Grundy, 1989). Although high carbohydrate diets were associated 
with a decrease in LDL-C levels, they were also associated with an increase in serum 
TAG levels and a decrease in HDL-C when compared with a diet high in MUFAs.
Although olive oil is currently the principal dietary source of MUFAs, other 
sources which are available include; canola oil (zero-erucic acid rapeseed oil) and oleic 
acid-enriched variants of sunflower oils or safflower oil. Unlike olive oil, zero-erucic 
acid rapeseed oil consists mainly of oleic acid (approximately 60%) with a moderate 
content of essential LA (approximately 22%) and a-LLA (approximately 11%). 
Although the fatty acid composition of these oils are similar, they differ in the amount of 
plant sterols they contain. A recent study compared the effects of olive oil and oleic acid- 
enriched sunflower oil on the lipoprotein concentrations in normolipidaemic young men 
(Perez-Jimenez et al, 1995). Although both diets resulted in an increase in HDL-C and 
apo A-I, the oleic acid-enriched sunflower oil resulted in a greater decrease in LDL-C 
and apo B concentrations when compared with the diet high in olive oil. The authors 
attributed these responses to the differences in the plant sterol composition (avenasterol, 
p-sitosterol, campesterol and stigmasterol) and non-fatty acid constituents (squalene and 
tocopherol) in the oleic acid-enriched oils.
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The effect of the isomers of oleic acid, cis (natural) and trans (hydrogenated 
form, elaidic acid) were recently investigated to determine their effects on serum lipids. 
Compared with the cis isomer, trans-elaidic acid was found to increase total cholesterol 
and LDL-C although to a lesser degree than SFAs. This response was attributed to the 
increase in CETP activity detected following consumption of elaidic acid compared with 
that of oleic acid (Abbey and Nestle, 1994; Judd et al, 1994). CETP plays an important 
role in determining the size and composition of lipoprotein particles by redistributing 
cholesteryl ester firom HDL to lower density lipoproteins, CM and VLDL (Tall, 1993). 
This increase in activity of CETP and paralled increase in LDL-C concentrations with 
dietary trans fatty acids may therefore contribute to a less favourable atherogenic 
lipoprotein profile.
Another source of MUFA, zero-erucic acid rapeseed oil, has been studied by 
Seppanen-Laakso and colleagues (1993). MUFA substitution of SFAs Avith zero-erucic 
acid rapeseed oil, caused a reduction in LDL-C and an increase in HDL-C whereas 
HDL-C remained unchanged with olive oil substitution. These actions of zero-erucic 
acid rapeseed oil were suggested to be attributable to the LA and a-LLA constituents 
which prevent the excessive reduction of LA in plasma phospholipids as a result of the 
preferential metabolism of the a-LLA in plasma phospholipids to EPA. High intakes of 
dietary LA are considered to be beneficial since the proportion of LA in adipose tissue 
has been shown to be inversely related to the risk of development of CHD (Reimersma 
et al, 1986).
The LDL-C lowering effects by MUFAs and PUFAs has recently been 
investigated by Brousseau and coworkers (1993) in Cynomologus monkeys. They 
postulated that the LDL-C lowering properties occurred by different mechanisms. Both 
fatty acids were thought to affect apo B-lOO synthesis, whereas PUFAs are thought also 
to affect the catabolic rate of apo B-lOO containing lipoproteins. This effect of MUFAs 
was also observed by Woollett and Dietschy (1994) who stated that the decrease in 
LDL-C levels caused by MUFAs was due to their effect in restoring LDL receptor 
activity, which is suppressed by SFAs, and in lowering of apo B-lOO production. In 
contrast, the trans isomer of oleic acid was shown to have no effect on the LDL receptor 
activity nor on circulating LDL-C levels.
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Family history of coronary heart disease
The development of early atherosclerotic lesions between 6  and 30 years of 
age, is associated with the following risk factors, elevated total plasma cholesterol, 
increase in total TAG and a low level of HDL-C concentrations, obesity, high blood 
pressure and high major apolipoproteins, apos A-1, B and E (Kwiterovich, Jr, 1993). 
Elevated plasma cholesterol concentrations have been associated with high 
concentrations observed in their parents or first degree relatives as a result of shared 
genetic and environmental factors. A recent epidemiological study has shown that a 
family history of CHD is an independent predictor of the development of CHD in the 
offspring (Jousilahti et al, 1996). The aim of this latter study was to determine the 
association between parental history of premature CHD and the risk of acute 
myocardial infarction in the Eastern Finnish population which has an exceptionally 
high incidence of CHD. The risk associated with positive paternal history was similar 
for both men and women, however, positive maternal history was associated with a 
higher risk in women.
Apo A-I, apo B and plasma lipid levels have been investigated in the offspring 
of adults with CHD. Significantly higher levels of plasma total cholesterol, LDL and 
apo B and lower levels of HDL-C and apo A-I were observed in the children with a 
family history of CHD (Morrison et al, 1982; Murkherjee and Dastur, 1994).
Postprandial lipoprotein metabolism has been implicated in the development of 
atherosclerosis (Zilversmit, 1979). This is supported in individuals with familial 
dysbetalipoproteinaemia, whereby they develop premature CHD as a result of the 
derangement of the metabolism of TRLs in plasma (Hazzard and Bierman, 1976). A 
recent report by Karpe et al (1994) has provided evidence that the delayed uptake of 
small CM remnants is associated with the progression of atherosclerosis. This agreed 
with observations by Simons and coworkers (1987) who found that the apo B-48 to 
apo B-lOO ratio was elevated in patients with CHD compared with matched controls. 
Uiterwaal and coworkers (1994) investigated the lipoprotein response in young men 
with a family history of CHD in the fasting state and following an oral fat load 
containing RP. Prolonged postprandial hypertriglyceridaemia was observed in the 
sons of the men with CHD compared with the controls 8-12 hours following the lipid
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load. This was shown to be a better discriminator of familial risk since fasting lipid 
and lipoprotein levels were similar between the 2 groups. Plasma RP levels were also 
shovm to be higher during the latter half of the postprandial period although this was 
not shown to be statistically significant. Therefore this suggests that individuals with a 
family history of CHD exhibited a delayed clearance of TRLs which have been 
associated with the development of CHD.
Aims of this study
The aim of this present study is to investigate the effects of the substitution of 
long chain dietary SFAs by MUFA in the usual diet of young healthy men from the 
U.K. with a close family history of CHD. The level of MUFA intake will reflect the 
intake currently consumed in Crete and other Mediterranean countries (approximately 
18-23% dietary energy). The effects of this diet will be compared with a control of the 
current U.K. fatty acid profile on fasting and postprandial lipoprotein metabolism 
(apolipoproteins, lipids, metabolites and hormones) following the consumption of a 
24% MUFA test meal.
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5.2 Study design
5.2.1 Subject recruitment
Thirteen male subjects with a family history of CHD, in a first degree relative, 
aged between 18-45 years and with a BMI of between 20-30 kg/m^ were recruited 
from local GP practices in the Guildford area. Subjects were excluded if they : -
• have suffered from a myocardial infarction
• have had drug treatment for hyperlipidaemia or any other drug treatment which 
would affect their plasma lipid levels
• were heavy drinkers (assessed by gamma GT)
• were taking dietary supplements
• were travelling often or going on holiday during the intervention period
• were smokers
• were vegetarian or on calorie restricted diets or had other food intolerances or 
dietary restrictions
• were partaking in regular or vigorous exercise (>3 x3 0  minutes of aerobic exercise 
per week) or participating in team sports only for one arm of the study.
• have a dietary MUFA intake greater than 12% as energy and an average total dietary 
fat intake greater than 35-45% of total energy (~ 18% SFA, 8 % PUFA)
• were not normally consuming 3 meals/day plus snacks for an average of 5 out of 7 
days
• were having business lunches and/or socialising more than once per week
• have had inadequate storage (fridge-freezer) and cooking facilities at home.
Recruitment was made following screening of :-
a) blood for measurement of fasting total cholesterol (< 6.5 mmol/1), TAG (<2.3 
mmol/1), glucose (< 6.2 mmol/1), haemoglobin (> 13 g/1) and gamma GT (< 1601.U.).
b) anthropometric measurements (weight, height and waist and hip circumference - 
waist-hip ratio)
c) lifestyle questionnaire to obtain information on dietary and lifestyle habits and a 7 
day dietary history following interview with a registered dietitian, to ensure that a 
minimum of 5 meals were consumed per week at home and to ensure habitual fat
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intake reflected usual U.K. intake (35-45% energy as fat with approximately 18% 
from SFA, 12% from MUFA and 8 % from PUFA).
The study was approved by the ethics committees of the University of Surrey and the 
Royal Surrey County Hospital and all subjects gave informed consent.
5.2.2 Dietary intervention design
The chronic intervention study was a randomised cross-over design comprising 
2 months control and 2 months MUFA-enriched diets. The study design of the chronic 
intervention was to replace long chain SFAs by MUFA in the subjects’ usual diet, 
whilst maintaining their total dietary fat intake within the range of 38-40% as energy. 
Subjects were asked to maintain their usual lifestyle during the study. A standard test 
meal was given at the end of each dietary period in order to assess postprandial 
lipaemic responses.
5.2.2.1 Dietary intervention
Cretan olive oil was supplied by Elais (Unilever, Greece) and transferred to 
Vandenberg foods for blending to produce the test and control oils and margarine 
spreads. Some of the oils and spreads were sent to food manufacturers (Diet and 
Health Ltd and Sainsburys, pic) to be incorporated into, for example, biscuits, recipe 
meals, garlic breads, cakes. Low fat foods were supplied by Heinz and Sainsburys to 
which the test oils and spreads could be added to at the subjects’ homes.
The dietary intervention target was 38-40% energy as fat, comprising 10% 
SFA, 22% MUFA and 8 % PUFA. The average intake of MUFA was 40 g/day and this 
was implemented as a unit system, i.e. 1 unit = 5 g MUFA = 8  g oil or 10 g spread. 
The average target was approximately 8  units/day depending on the individual 
subjects habitual diet. The aim was to replace the subjects’ usual evening meal vrith a 
MUFA-enriched recipe/low fat meal for 5 days each week of the dietary periods. Two 
of the main meals of the week were termed “free days”, however, the subjects’ were 
instructed by a registered dietitian regarding suitable free-choice foods.
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Two weeks prior to the start of the study, the subjects attended an open 
evening at the university where the study design and dietary intervention were 
explained and a back-up video and handbook describing the method of dietary 
intervention, filling in diet diaries and body weight measurements were supplied for 
home use. Body weight was recorded every week with scales which were provided 
and individual allowances of food were adjusted to minimise weight changes. The 
subjects attended a special room in the department every fortnight to provide a fasting 
blood sample and receive a 14 day supply of food, coded A or B, which was requested 
from a list of available recipe meals provided to the subjects a week prior to 
collection. The subjects were free to contact the dietitians by phone if they had any 
problems with fulfilling the requirements of the dietary intervention.
S.2.2.2 Nutritional intake and compliance
Nutritional assessment was achieved using a 3 day weighed food intake, 2 
study (control and MUFA-enriched dietary periods) and one free day consecutively, 
performed on 2  occasions during the dietary periods.
The information obtained was analysed using the FOODBASE data base (Institute of 
Brain Chemistry and Human Nutrition, Queen Elizabeth Hospital, U.K.) and data was 
analysed using the diet diaries.
Compliance was assessed using a questionnaire incorporating a linear- 
analogue scale filled in during each of dietary periods.
5.2.3 Blood sample collection
5.2.3.1 Fasting blood samples
Blood samples were collected following a 12 hour overnight fast prior to the 
start of the intervention period as well as 2 and 4 weeks within each arm. Plasma was 
collected by centrifugation at 1700 g.min in a bench centrifuge and stored at -20°C. 
Analytical methods for the measurement of TC, TAG, NEFA, HDL-C, glucose, GIP 
and insulin are described in section 5.2.4. Fasting HDL-C, HDL2 -C and HDL3 -C 
concentrations in plasma were determined following precipitation using an automated 
enzymatic assay (2.5.3.2).
194
S.2.3.2 Postprandial blood sample collection 
Test meal composition
Postprandial responses to a standard test meal, the 24% MUFA test meal, were 
determined at the end of each arm of the study, i.e. control and MUFA-enriched diets 
(week 8 ) (see section 3.2.2).
Study day procedure
See section 3.2.3. Only the 24% MUFA meal was used to determine the 
subjects’ postprandial responses.
5.2.4 Plasma separation and analytical procedures 
Plasma separation
Plasma was separated by spinning at 1700 g.min using a bench centrifuge, 
aliquotted into LP3 tubes for different analyses and stored at -20°C (samples for lipase 
analysis were stored at -80°C). TRL and TPL fractions were prepared from plasma 
stored overnight at 4°C by following the procedure of Grundy and Mok (1976) as 
described in chapter 2, section 2.1.2. To protect apo B-48 from proteolytic cleavage, 
the preservative cocktail (2.1.1) was added at a concentration of 5% (v/v) of the apo 
B-48 containing sample.
Analytical methods
The methods employed for the analysis of various analytes were described in 
chapter 2  :-
• Apo B-48 concentrations in plasma, TRL and TPL were analysed using a 
competitive ELISA method (Lovegrove et al, 1996) (2.3)
The following assays were carried out by coworkers :-
• TAG concentrations in plasma, TRL and TPL fractions were measured using an 
automated colorimetric method (2.5.1)
• TC concentrations in plasma were determined using an automated enzymatic assay 
(2.5.2)
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• HDL-C concentrations in TPL postprandial samples were measured following 
precipitation using an automated enzymatic assay (2.5.3.1)
• LDL-C levels were determined from the total cholesterol and HDL-C concentrations 
using the Friedewald equation (2.5.4).
• Postprandial plasma glucose responses were measured using an automated 
hexokinase method (2.5.6)
• NEFA was determined using an automated colorimetric method (2.5.5)
• GIP and insulin responses in plasma were measured using an established 
radioimmunoassay technique involving a double antibody separation (2.7 and 2.6 
respectively)
• Postheparin LPL and HL activities were determined by the method based on the 
release of labelled fatty acids from a ^H labelled triolein emulsion (Nilsson-Ehle and 
Schotz, 1976) (2.4).
5.2.5 Statistical analysis
Results presented as time response curves and total and incremental area under 
the curves (AUCs and lAUCs respectively) are given as mean values with their 
standard error of the mean (SEM). AUCs (total and incremental) were calculated using 
the trapezoidal rule on Excel spreadsheets (Matthews et al, 1990). In Tables, data are 
given as mean values with their standard deviation (SD). Unpaired Student t tests and 
one way analysis of variance were applied to the responses of the subjects to the 2  
dietary periods using the statistical package Instat (Macintosh version 2.01, San 
Diego, USA) and repeated measures analysis of variance was performed using Data 
desk 4.1 (Data description Inc, USA). Data was corrected for normality and 
transformed before analysis if necessary. Repeated measures of analysis using subject 
and dietary period (control or MUFA-enriched) as the independent variables, 
investigated changes in the postprandial response for the analytes measured. Values of 
P < 0.05 were taken as significant.
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5.3. Results
5.3.1. Subject information
Thirteen subjects were successfully recruited with a mean age of 33.0 (SD 5.5) 
years, and BMI of 24.4 (SD 2.8) kglm . Two dietary periods were completed by all of 
the subjects and the composition of the diets are shown in table 5.2. There were no 
differences in the energy intake or the percentage energy derived from fat between the 
control and MUFA-enriched diets. However, the SFA and MUFA intakes of the 
MUFA-enriched diet were significantly different compared with the control diet, with 
a 6 % decrease observed in the SFA intake (P < 0.0001) and 5.3% increase observed in 
the MUFA intake (P < 0.0001). Body weight remained stable during the dietary 
periods with a 0.6 and 0.9 kg increase over the control and MUFA-enriched diets 
respectively, however this did not reach significance compared with the weights on 
entry to the diets (Table 5.3).
On the postprandial study day, the acute test meal was consumed within the 
stated 2 0  minutes and did not elicit any adverse effects.
Table 5.2. Composition of the control and MUFA-enriched diets
Control diet MUFA-enriched diet
Energy (MJ)/d 1 1 . 1  ( 1 .1 ) 1 1 .2 (0 .8 )
Protein (g)/d 81.3 (13.2) 79.4 (10.0)
Carbohydrate (g)/d 309.4 (53.5) 316.2(45.8)
Fat (g)/d 
%E
119.2(13.2) 
40.6 (3.5)
117.8 (12.6) 
39.8 (3.6)
SFA (%E) 16.5(1.8) *10.6(1.5)
MUFA (%E) 13.4 (1.5) *18.7(1.7)
PUFA (%E) 7.0 (1.0) 7.2 (0.3)
Values are presented as mean (SD), * P < 0.0001 represents significant differences from the 
control diet percentage SFA and MUFA intakes.
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Table 5.3. Body weight changes (kg) during the control and MUFA-enriched
diets
Baseline 2  wks 4 wks 8  wks
Control diet 
MUFA-enriched diet
76.5(12.1) 
75.8 (12.2)
76.4(11.7)
75.7(11.6)
76.3(11.8)
76.0(12.1)
77.1 (12.4) 
+ 0 . 6  kg 
76.7(11.9) 
+ 0.9 kg
Values are presented as mean (SD) for the 13 subjects. Values in bold represent the change in 
weight of the subjects during the 8  week dietary periods.
5.3.2. Fasting analyte concentrations
Fasting plasma lipid and hormone concentrations collected at baseline, 2 
weeks, 4 weeks and at the end of each of the dietary periods (week 8 ) are shown in 
table 5.4. Baseline concentrations for each of the analytes were not significantly 
different between the control and MUFA-enriched dietary periods apart from the 
fasting NEFA response (P < 0.02). Between diets the following responses were 
observed : -
a) TAG
During the dietary periods, the fasting TAG concentration at 2, 4 and 8  weeks 
were elevated above the baseline concentrations, although this did not reach 
significance for any of the visits (Table 5.4). For the control diet, TAG concentrations 
remained very similar with a decrease observed at 8  weeks, whereas during the 
MUFA-enriched diet TAG concentrations rose steadily during 8  week intervention 
period.
b) TC
Total cholesterol concentrations were, in general, lower compared with 
baseline concentrations during the 2 dietary periods. There was a tendency for the 
cholesterol concentrations to be higher during the MUFA-enriched diet which resulted 
in a greater decrease (1 2 %) during the diet, but this did not reach statistical 
significance (Table 5.4).
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c) HDL-C, HDL2-C and HDL3-C
Similar HDL concentrations were observed between the 2 diets, however, the 8  
week HDL concentration were higher at the end of the MUFA-enriched diet compared 
with the control diet which was significantly lower than the baseline concentration (P 
< 0.01). During the diets, there was a progressive but not significant decrease in HDL- 
C and HDL3 -C concentrations during the MUFA-enriched diet, but during the control 
diet, the HDL3 -C concentration at 8  weeks was significantly lower than the baseline 
concentration (P < 0.02). HDL2 -C concentrations rose 2 weeks following the start of 
the diets which was maintained at 4 weeks and fell below baseline concentrations at 8  
weeks (Table 5.4).
d) LDL-C
Although the fasting LDL-C level was higher at the beginning of the MUFA- 
enriched diet, there was a consistent trend for the levels to be lower during the MUFA- 
enriched diet compared with those of the control diet. During the 8  week dietary 
period, LDL-C concentrations remained very similar during the control diet with only 
a minimal decline (2%) compared with the fall observed during the MUFA-enriched 
diet (17%). However, this did not reach significance.
e) NEFA
There was a trend for the baseline NEFA concentrations to be significantly 
higher before the MUFA-enriched diet compared with the control diet (P < 0.02). For 
the control diet, NEFA concentrations were similar between 2 and 4 weeks with a 
higher concentration at 8  weeks which was significantly higher than the baseline 
concentration (96%). In contrast, the NEFA concentration showed a progressive fall in 
concentration until 4 weeks with an increase observed at the end of the MUFA- 
enriched dietary period (Table 5.4). Eight week NEFA concentrations were similar for 
both of the diets.
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f) Glucose
There was a consistent trend for the glucose concentrations to be lower during 
the MUFA-enriched diet compared with the control diet. For both diets, there was a 
small increase in concentration after 2  weeks which decreased during the dietary 
period. In contrast to the control diet, there was a tendency for the 8  week fasting 
glucose concentration to be lower than the baseline concentration (3%) for the MUFA- 
enriched diet (Table 5.4).
f)GIP
Fasting GIP concentrations were similar during the 2 dietary periods (Table 
5.4). For both the control and MUFA-enriched diets, GIP concentrations remained 
similar during baseline to 4 weeks, with a significant rise observed at 8  weeks. For the 
control diet, the 8  week concentration was significantly higher than the baseline and 2  
week concentration (P < 0.05) whereas, with the MUFA-enriched diet, the 8  week GIP 
concentration was significantly higher than the baseline, 2 and 4 week concentrations 
(P < 0.05). There was a trend for the 8  week GIP concentration to be higher following 
the control compared with the MUFA-enriched diet, however, this did not reach 
significance.
g) Insulin
Similar insulin concentrations were observed between the 2 diets, with a trend 
for the insulin concentrations to be lower during the 8  week period (Table 5.4.). 
During the dietary periods, insulin responses were maintained until 4 weeks with an 
increase observed at 8  weeks.
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Postprandial lipid and hormonal responses
5.3.3 Triacylglycerol responses
In the plasma and TRL fractions, the TAG concentrations rose following the 
meal reaching an initial peak between 120 and 240 minutes and returning slowly to 
baseline concentrations. An initial plateau was observed following the control diet 
which demonstrated a later major peak between 360 and 480 minutes before returning 
to baseline concentrations (Figure 5.1). Essentially the same pattern of response was 
seen in the TRL fraction as in the plasma fractions, with the TRL demonstrating a 
biphasic response in the later postprandial period with the MUFA-enriched diet. This 
pattern was not seen with the TPL TAG responses (Figure 5.1).
No significant differences were observed with the AUCs for the overall TAG 
responses for the control and MUFA-enriched diets (Table 5.5). Pearson product- 
moment correlations demonstrated that the fasting plasma, TRL- and TPL-TAG 
responses were significantly correlated with the AUC for the postprandial TAG 
response curves (r = 0.953, 0.846 and 0.879 respectively, P < 0.0001).
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Figure 5.1 : TAG concentrations following consumption of the 24% MUFA test meal 
in the plasma, TRL and TPL fractions following the control and MUFA-enriched 
dietary periods. Values represent mean ± SEM for the 13 subjects. Subjects consumed 
the test meal following a 12 hour overnight fast. Postprandial samples were collected 
over a 9 hour period during which subjects consumed 200 mis of sugar free 
decaffeinated fluid every 2  hours and maintained normal sedentary activities.
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5.3.4 Apo B-48 responses 
Plasma apo B-48 responses
Following the meals, apo B-48 concentrations rose and a small peak was 
reached before the concentrations returned to baseline concentrations for the control 
and MUFA-enriched diets (Figure 5.2). There was a tendency for the apo B-48 
concentrations to peak earlier following the MUFA-enriched diet and for the peak 
value to be lower compared with the control diet. However, this did not reach 
significance (Table 5.5). There were no significant differences in the AUC for the 
plasma response between the 2  diets, there was a consistent trend for a lower response 
to be demonstrated following the MUFA-enriched diet (Figure 5.2).
TRL apo B-48 responses
There was a gradual small increase in TRL apo B-48 concentrations following 
the meal which returned to fasting concentrations at the end of the 9 hour postprandial 
test period (Figure 5.2). The AUCs were very similar following the control and 
MUFA-enriched diets and no significance was observed (Table 5.5).
TPL apo B-48 responses
Apo B-48 concentrations rose following the standard test meal with a peak 
being reached between 180 and 300 minutes for the MUFA-enriched diet before 
returning to baseline concentrations at the end of the 9 hour test period (Figure 5.2). In 
contrast, the control diet showed a minimal increase in apo B-48 concentrations which 
remained elevated at the end of the postprandial test period. Repeated measures 
analysis of variance demonstrated a significant difference {P < 0.02) in the patterns of 
the individual subjects postprandial TPL apo B-48 responses between the control and 
MUFA-enriched diets. Although there were no significant differences in the AUCs, 
there was a trend for the MUFA-enriched diet to show a lower AUC compared with 
the control diet (Table 5.5).
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Figure 5.2 : Apo B-48 concentrations following consumption of the 24% MUFA test
meal in the plasma, TRL and TPL fractions following the control and MUFA-enriched
dietary periods. Values represent mean ± SEM for the 13 subjects.
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Pearson product-moment correlations demonstrated that the fasting plasma 
TRL and TPL apo B-48 concentrations were significantly correlated with the AUC for 
the postprandial apo B-48 response curves (r = 0.98, 0.895 and 0.801 respectively, 
P <  0.0001).
5.3.5. Postheparin LPL and HL activities
Postheparin lipase activities 5 and 15 minutes following the injection of 
heparin 9 hours after the standard test meal are shown in figure 5.3. There were no 
significant differences in the LPL and HL activities following the control and MUFA- 
enriched diets. However, there was a tendency for the lipase activities to be higher 
following the control than the MUFA-enriched diet.
300-1
I
I
200
1 0 0
Postheparin LPL and HL activities
LPL HL
■  Control 
□  MUFA-enriched
Figure 5.3. Postheparin plasma lipase activities 5 (HL) and 15 (LPL) minutes after the 
injection of 7500 I.U. of heparin 9 hours following the consumption of the 24% 
MUFA test meal following the control and MUFA-enriched dietary periods. Values 
represent mean (SEM) for the 13 subjects
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5.3.6 HDL C responses
Postprandial HDL-C responses are shown in figure 5.4. Repeated measures 
analysis of variance demonstrated a significant difference (P < 0.02) in the patterns of 
the individual subjects postprandial plasma HDL-C responses between the control and 
MUFA-enriched diets. There were no significant differences in the fasting 
concentrations between the control and MUFA-enriched diet. There was a tendency 
for the fasting concentrations to be higher following the control diet, although this did 
not reach significance. The AUCs and lAUCs for the postprandial HDL-C responses 
are shown in figure 5.4. There was a trend for a higher AUC and lAUC with the 
MUFA-enriched diet compared with the control diet, although this did not reach 
significance. Pearson product-moment correlations demonstrated that the fasting 
plasma HDL-C concentrations were significantly correlated with the AUC for the 
postprandial plasma HDL-C response (r = 0.674, P < 0.002).
5.3.7 TC responses
Plasma TC responses following the control and MUFA-enriched dietary 
periods are shown in figure 5.5. Repeated measures analysis of variance demonstrated 
a significant difference (P < 0.04) in the patterns of the individual subjects’ 
postprandial plasma TC responses between the 2 diets. There were no significant 
differences observed in the fasting TC concentrations and in the patterns of the 
postprandial responses between the 2 diets. The AUC and lAUC for the plasma TC 
responses are shown in figure 5.5. Between the 2 diets there was a tendency for the 
AUCs to be higher following the control diet, however, this pattern of response was 
not demonstrated with the lAUCs. There was a trend for the lAUC following the 
control diet to be negative, whereas, the lAUC following the MUFA-enriched diet was 
positive. Pearson product-moment correlation demonstrated that the fasting TC 
concentration was significantly correlated with the AUC for the postprandial plasma 
TC response curve (r = 0.959, P < 0.0001).
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Figure 5.4. Plasma HDL-C responses to the 24% MUFA test meal following the
control and MUFA-enriched dietary periods. Values represent mean ± SEM for the 13
subjects
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Figure 5.5. Plasma TC responses to the 24% MUFA test meal following the control
and MUFA-enriched dietary periods. Values represent mean ± SEM for the 13
subjects.
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5.3.8. NEFA responses
Following the meal, NEFA concentrations fell during the first 2 hours before 
rising above fasting concentrations by the end of the 9 hour period (Figure 5.5). There 
were no significant differences in the AUCs and lAUCs between the 2 diets, although 
there was a trend for lower responses to the standard test meals following the MUFA- 
enriched diet (Figure 5.6).
5.3.9 GIF response
Plasma GIF responses rose rapidly following the meal and reached a peak at 
120 minutes for the MUFA-enriched diet and between 120 and 240 minutes for the 
control diet (Figure 5.7a). The MUFA-enriched diet showed a tendency for a higher 
peak concentration following the standard test meal, however, this did not reach 
significance. Following the peak, the GIF concentrations returned slowly towards 
baseline concentrations, with a small plateau observed between 300 and 360 minutes. 
There were no significant differences between the AUC and lAUC for the 2 diets, 
however, there was a tendency for the volunteers to show a higher response on the 
MUFA-enriched diet (Table 5.6).
5.3.10 Insulin responses
Postprandial insulin responses are shown in figure 5.7b. Following the meal, 
insulin concentrations rose sharply to give a peak at 60 minutes for the MUFA- 
enriched diet and 1 2 0  minutes for the control diet and then fell to fasting 
concentrations at approximately 300 minutes, where these were maintained until the 
end of the test period. Although there were no differences between the AUCs and 
lAUCs for the 2 diets, there was a trend for the volunteers to exhibit a higher response 
on the MUFA-enriched diet (Table 5.6).
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Figure 5.6. Plasma NEFA responses to the 24% MUFA test meal following the
control and MUFA-enriched dietary periods. Values represent mean ± SEM for the 13
subjects.
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Figure 5.7. a) GIF, b) insulin and c) glucose responses in plasma to the standard test
meal following the control and MUFA-enriched dietary periods. Values represent
mean ± SEM for the 13 subjects.
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5.3.12 Glucose responses
Plasma glucose responses rose following the standard test meal, reaching a 
peak at 60 minutes for the MUFA-enriched diet and between 60 and 180 minutes for 
the control diet (Figure 5.7c). A smaller second peak was observed at 240 minutes 
following the MUFA-enriched diet and the levels fell below baseline concentrations 
before returning to it by 9 hours following the test meal. In contrast, the control diet 
returned to fasting concentrations 240 minutes following the meal. No significant 
differences were observed in the AUCs and I AUCs for the 2 diets, although there was 
a tendency for the MUFA-enriched diet AUC to be lower than that of the control diet. 
This trend was not observed with the lAUCs, with the MUFA-enriched diet lAUC 
being higher than that of the control diet (Table 5.6)
Table 5.6 : AUC and lAUC for the glucose (mmoI/I.min), GIF (pmoI/l.min) and 
insulin (mU/ml.min) following the control and MUFA-enriched diets
Analyte Control diet MUFA-enriched diet
AUC lAUC AUC lAUC
glucose 2673.5 (816.2) 97.3 (246.0) 2857.9 (252.8) 64.3 (238.4)
GIF 129608 76807 136407 96266
(21373) (45117) (2188) (20707)
insulin 125481 92499 162969 115312
(55220) (40459) (113189) (26718)
Values are presented as mean (SD).
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5.4 Discussion
The aim of the dietary intervention study was to evaluate the effects on plasma 
and hormonal concentrations, of an intervention for 8  weeks with a MUFA-enriched 
diet high in olive oil, in a group of healthy young male volunteers with a family 
history of CHD. This volunteer population was chosen since evidence has shown that 
males, with a family history of CHD, are a ‘high’ risk group, especially if their plasma 
lipid levels are elevated (Murkherjee and Dastur, 1994; Uiterwaal et al, 1994; 
Jousilahti et al, 1996). The target of the dietary intervention target was to maintain the 
percentage dietary energy derived from fat at between 38 and 40%, with 10% from 
SFA, 22% MUFA and 8 % as PUFA. In contrast, the target for the control diet was 
20% SFA, 11% MUFA and 8 % PUFA. On analysis of the diet diaries recorded during 
the control and MUFA-enriched dietary periods, the percentage dietary energy derived 
from SFA and MUFA was significantly different between the 2 diets with total fat 
intake and calories being maintained at around 40% dietary energy (Table 5.2). This 
was mirrored by the maintenance of body weight during both the control and MUFA- 
enriched diets. This was imperative since any differences observed in the hormonal 
and lipoprotein parameters measured during the study could be attributed to the 
predominant fat in the diet rather than changes in body weight of the volunteers. A 
random cross-over design was employed for this study, in which the foods and oils 
were supplied labeled as either A or B corresponding to the control or MUFA- 
enriched products. Fourteen volunteers were initially recruited from the local 
Guildford area, with only one dropping out prior to screening due to work 
commitments. The study population chosen was free-living and this design was 
chosen since compared with a residential study, it provided an opportunity to 
determine whether increasing the MUFA content of the UK population was feasible 
and acceptable. The disadvantage of this sort of study design is that it results in less 
frequent contact with the volunteer group, difficulties in sample collection and 
distribution of the food supplies often causing a reduction in the compliance of the 
volunteers (Fairweather-Tait, 1996). A pilot study was initially carried out in our 
research group and this highlighted that to maintain motivation of the volunteers, there 
needed to be close contact with the study co-ordinators, who were also registered
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dietitians, and for there to be a wide variety of foods available (Tredger et al, 1995; 
Knapper et al, 1996a). Although the dietary fats from other food sources had been 
restricted, volunteers were allowed 2  free days from the dietary intervention where the 
restrictions was relaxed and they were, for example, allowed to have a meal in a 
restaurant. This therefore enables flexibility and variability of the diet and helped the 
volunteers to remain motivated.
Two methods of evaluation were used to determine the effects of the dietary 
intervention of MUFA-enriched products in the U.K. population. Fasting blood 
samples were collected at 4 times during the eight dietary periods to evaluate lipid and 
hormonal changes. Postprandial measurements were made at the end of the 2 dietary 
periods and involved the volunteers consuming a standard test meal, representing the 
typical fatty acid composition of the traditional Cretan Greek diet, and the collection 
of blood samples for a period of 9 hours. This was conducted in order to assess the 
changes in lipid and lipoprotein responses during the 2  diets and to determine if any 
effects were observed in the composition, size and clearance of dietary derived 
lipoproteins. Postheparin lipase activities were also determined to explore possible 
mechanisms responsible for any lipid changes observed during the postprandial state.
Fasting plasma lipid and hormonal analytes
In general, there were no significant differences in the fasting lipid and 
hormonal responses between the control and MUFA-enriched diets. Baseline 
concentrations were not significantly different between the two dietary periods, 'with 
the exception of the NEFA levels, which were significantly higher before the start of 
the MUFA-enriched diet. Evidence has shown that NEFA concentrations vary 
considerably between individuals and this is thought to be due to a number of factors 
including stress levels and exercise (Frayn et al, 1996). Therefore an explanation for 
the higher fasting levèls may be a result of the stress levels of the volunteers in 
expectation of the venepuncture and possibly due to the additive effect of the 1 2  hour 
overnight fast on their levels. The similar concentrations of the lipid and hormonal 
parameters between the control and MUFA-enriched diets suggests that the four week 
wash-out period was sufficient in order to return lipid and hormone responses to their
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original concentrations. This also indicated the level of compliance of the volunteers 
with maintenance of their habitual diets during the wash-out periods.
A trend towards a greater decline in TC during the eight week period was 
observed with the MUFA-enriched (10%) compared with the control diet (7%) and 
this supports earlier findings by other research groups outlined in table 5.1., where a 
decrease in TC was observed following the substitution of SFAs by MUFAs. This was 
paralleled by the LDL-C concentrations whereby there was a 17% decrease during the 
MUFA-enriched diet compared with the 2% decrease with the control diet. This is in 
agreement with the literature reviewed in table 5.1 with a percentage decrease ranging 
from 6  to 19%, being observed over a range of fat intakes varying from 29% to 40% 
dietary energy derived from fat and suggests that MUFAs, when substituted for SFAs, 
are responsible for the hypocholesterolaemic effect rather than the amount of energy 
derived from fat. An increase in fasting TAG levels was observed during the MUFA- 
enriched dietary period and supported earlier findings by Lichtenstein et al, 1993; 
Seppanen-Laakso et al, 1993; Abbey et al, 1994; Howard et al, 1995; Temme et al, 
1996. It appears that the increase in TAG observed during high MUFA intake is 
determined by the total percentage energy derived from fat and the age of the 
volunteers, with a higher fat intake and the older age group having increases in the 
fasting TAG concentrations (Table 5.1).
Similar HDL-C and subclass levels were observed during the dietary periods. 
Although, levels were maintained during the first 4 weeks of every diet, there was an 
unexpected decrease observed at 8  weeks in the total HDL-C concentration which was 
significant for the control diet. In order to provide a more informative HDL profile of 
the volunteers during each diet, HDL2  and HDL3 subclasses were measured. It has 
been proposed that HDL2  represents lipolysis products and so provides an indication 
of the efficiency of the TAG transport system, whereas HDL3 provides a more reliable 
CHD risk indicator (Skinner, 1995). The principle of the method for the measurement 
of HDL-C and subclass concentrations is the precipitation of two aliquots of plasma 
using different solutions, Quantilip A and B, is described in section 2.5.2. 
Unfortunately due to the large number of samples prepared on the postprandial study 
day (week 8  of the dietary intervention periods), precipitation of plasma sample
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occurred the following day using plasma stored overnight at 4°C. Therefore, 
precipitation may have resulted in the removal of more than the apo B containing 
lipoproteins, resulting in lower HDL-C concentrations than expected in the 
supernatant. Although HDL-C has been shown to be maintained or increased 
following a MUFA-enriched diet compared with a diet enriched with SFAs, it is 
difficult to ascertain whether the HDL-C would have been maintained at 8  weeks if 
the sample preparation had been carried out on fresh samples. Since the percentage 
energy derived from the test diets was set at 40%, it is likely that the HDL-C 
concentration would have been maintained, however, this is only speculation based on 
the data shovm in table 5.1.
Fasting NEFA concentrations were higher on the eight week plasma sample 
compared with the baseline and 2 and 4 week samples during both diets. As 
mentioned in the previous paragraph, the postprandial study day coincided with the 
eight week blood sample, where on these occasions, a cannula was inserted into the 
arm of the volunteers using a local anaesthetic to enable multiple blood samples to be 
taken compared with a single venepuncture carried out on the normal fasting blood 
sample collection day. Evidence has shown stress to increase circulating NEFA 
concentrations through the action of catecholamines on HSL resulting in adipose 
tissue TAG hydrolysis (Frayn et al, 1996). In combination with the stress level, the 
nutritional status of the individuals may provide an explanation for the elevated NEFA 
levels since they had fasted for 1 2  hours prior to the postprandial study day.
The two hormones measured, insulin and GIF, were similar during the first 
month and then elevated at the end of the dietary period, which reached significance 
for the GIF response only. Since this happened at the end of both the control and 
MUFA-enriched diets, it tends to suggest that it may be as a result of the postprandial 
study day rather than the intervention diets. However, we can only speculate about 
this.
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Postprandial lipid and hormonal responses.
In general, the results from this study have indicated that there were no 
significant differences in the postprandial responses to the standard test meal 
following the 8  week control and MUFA-enriched dietary periods.
The lipaemic responses of the volunteers were evaluated using TAG and apo 
B-48 measurements in plasma, TRL and TPL fractions to provide an opportunity to 
determine the contribution of the TAG-rich and TAG-poor particles to the overall total 
plasma responses. No significant differences were observed in the lipaemic responses 
between the control and MUFA-enriched diets, although, there was a tendency for the 
TAG and apo B-48 responses, in the 3 fractions, to peak earlier following the MUFA- 
enriched diet compared with the control diet. However, this did not reach significance. 
A trend was also observed for a higher peak TAG concentration and apo B-48 
concentration for the MUFA-enriched diet and this is in agreement with the acute test 
meal studies outlined in chapter 3, where the peak concentrations were higher and the 
time to reach peak concentration were earlier following consumption of the 17% and 
24% MUFA meals for the TAG and apo B-48 responses compared with the 12% 
MUFA meal. Earlier times to reach peak TAG and apo B-48 concentration were also 
demonstrated by the Southern Europeans, habituated to a diet rich in MUFA, 
compared with the Northern European volunteers. Although higher peak 
concentrations were observed for the TAG concentrations by the Southern European 
volunteers, peak apo B-48 concentrations were lower compared with the Northern 
European volunteers described in chapter 4.
While there were no significant differences in the patterns of the apo B-48 
responses in the plasma and TRL fractions, there was a significant difference in the 
pattern in the TPL fraction between the intervention diets. However, this was not 
demonstrated in the TPL-TAG pattern of response. The TAG-poor CM remnants 
predominate in the TPL fraction, whose concentration at the end of the postprandial 
period has been implicated in the development of CHD (Karpe et al, 1994). The 
circulating fasting and 9 hour TPL apo B-48 concentration was higher for the control 
diet compared with the MUFA-enriched diet and this tends to suggest that MUFA- 
enriched CM remnants may be cleared more quickly from the circulation by the liver
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and peripheral tissues. Therefore a MUFA-enriched diet may affect the rate and 
packaging of the components of the CM particle in the intestinal enterocyte and so 
determine the size of the particles. This in turn may affect the specificity of these 
particles for the lipolytic enzymes LPL and HL which determines the clearance of the 
intestinally derived lipoproteins from the circulation.
LPL and HL activities were measured 9 hours following the consumption of 
the standard test meal, with blood samples being collected at 5 and 15 minutes after a 
bolus injection of heparin. There were no significant differences in the LPL and HL 
activities between the control and MUFA-enriched diets, however, there was a 
tendency for activities to be higher following the control diet. Although the AUC and 
9 hour plasma TAG and apo B-48 concentrations were similar, there was a tendency 
for the pattern of the lipaemic responses following the 2  dietary periods to differ 
during the postprandial test period. Although the LPL and HL activities measured 9 
hours following the meal reflect the lipolytic activities at this timepoint it does not 
discount the possibility that activities may have varied during the postprandial period 
when the TRLs were being actively metabolised in the circulation.
The concentration of HDL-C has been shown to be inversely correlated with 
the risk of development of CHD (Miller and Miller, 1975). A direct anti-atherogenic 
role of HDL has been assumed because of its ability to trigger the efflux of cholesterol 
from peripheral tissues to the liver and also its ability to interfere with the oxidation of 
LDL (Skinner, 1995). As expected, there was a trend towards higher AUC and lAUC 
for the plasma HDL-C levels following the MUFA-enriched diet, with a significant 
difference being observed in the pattern of the response in comparison with the 
postprandial HDL-C responses of the control diet (Figure 5.4). In order to enable the 
HDL-C concentrations to be comparable for those measured in chapter 3 (acute test 
meals) and 4 (comparison of Northern and Southern Europeans), frozen TPL samples 
were precipitated in order to isolate the total HDL. Cholesterol concentrations were 
determined in the supernatant and a dilution factor was used to convert to the 
concentration of HDL per ml of plasma. Compared with the young healthy males 
recruited for the acute test meal studies, the fasting HDL-C concentrations were lower 
in the young men with the family history of CHD compared with the young men from
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the U.K. and Greece. This may therefore reflect the increased risk of these individuals 
for the development of CHD. However, the concentrations for the healthy young men 
from the U.K. and Southern Europe are very low for normal individuals, normal 
fasting range 0.9-1.4 mmol/1, and this may have been a result of the use of the dilute 
TPL fraction to determine HDL-C (see chapter 2, section 2.5.4).
Cholesterol is carried primarily in the plasma in LDL particles and a positive 
relationship exists between this lipoprotein and the risk of development of CHD 
(Brown and Goldstein, 1986). It is interesting to note, that as 'with the fasting data, 
there was a trend for cholesterol concentrations to be lower following the MUFA- 
enriched diet during the postprandial test period compared with the control diet. This 
supports earlier findings by Lichtenstein and coworkers (1993), where decreases in 
fasting cholesterol responses were paralleled in the postprandial cholesterol responses 
following an olive oil-enriched diet.
The NEFA data has shown no significant differences between the control and 
MUFA-enriched diets. NEFAs exhibited a classic response with concentrations being 
suppressed following the meal and then rising above fasting concentrations in the 
latter half of the postprandial period. Although the NEFA responses were 
superimposable during the postprandial period, there was a tendency for NEFA 
concentrations to be higher for the control diet 8  and 9 hours following the meal. This 
trend may explain the clearance rates of the CM remnants at the end of the 
postprandial period, since higher TAG and apo B-48 concentrations were observed 6  
to 9 hours following the meal after the control diet. Therefore the high MUFA content 
of the intervention diet may affect the absorption rate and so entry and resultant 
metabolism of the TRLs in the circulation.
Plasma glucose, GIF and insulin responses were not significantly different 
between the responses to the standard test meal following the intervention diets. A 
trend for higher GIF concentrations were observed during the early part of the 
postprandial period following the MUFA-enriched diet, with superimposable 
responses being observed with the control diet between 6  hours and the end of the 
postprandial test period. This is in agreement with the plasma TAG data, with
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concentrations being higher during the first 6  hours of the postprandial period 
following the MUFA-enriched diet.
As with the GIF response, there was a trend for the peak insulin concentration 
to be higher and for the insulin response to be more prolonged during the early part of 
the postprandial period after the MUFA-enriched diet. This agrees with the acute test 
meals studies described in chapter 3 where the 24% MUFA test meal exhibited the 
greatest insulin response and in chapter 4 where the Southern Europeans demonstrated 
a greater response compared with the Northern Europeans. An explanation for the 
increased secretion of insulin may be due to the higher secretion of GIF during the 
early part of the postprandial period since insulin secretion has been shown to be 
modified by GIF in the postprandial environment (Morgan et al, 1988). Also, the 
glucose concentration in the circulation rises following consumption of the acute test 
meal with a biphasic response being demonstrated by volunteers following the 
MUFA-enriched diet compared with the control diet which returns to fasting 
concentrations following an initial peak. Therefore a more prolonged stimulus for 
insulin secretion will be required to ensure uptake of glucose into the peripheral 
tissues.
In conclusion, a population of healthy males with a family history of CHD, 
consumption of a MUFA-enriched diet in comparison with the control diet rich in 
SFA, resulted in the following trends : -
Fasting responses
• a greater decrease in fasting TC and LDL-C concentration
• maintenance of HDL-C concentrations for the first four weeks of the intervention 
period followed by a non-significant decrease at 8  weeks
• greater increase in fasting TAG concentration
Postprandial responses
• earlier time to peak, with a higher peak concentration for the TAG and apo B-48 
responses
• lower postheparin LFL and HL activities
222
• lower plasma cholesterol response
• maintenance of the HDL-C concentration
• higher peak GIF concentration
• higher peak insulin concentration with a more prolonged secretion during the early 
part of the postprandial period
• biphasic glucose response
The greater decline in TC and LDL-C concentrations during the MUFA-enriched diet 
occurred over a range of fat intakes in the diets and suggests that the substitution of 
long chain SFAs by MUFAs may be responsible for these observations. Recent 
evidence has indicated that TC and LDL-C concentrations are regulated by receptor- 
mediated processes responsible for their uptake, especially the LDL receptor. Diets 
rich in SFAs have been shown to increase TC levels through reduction in the number 
of receptors available. In contrast, FUFAs and MUFAs have been shown to restore 
receptor activity and reduce circulating TC and LDL levels (Woollett and Dietschy, 
1994). Therefore MUFAs may act at the cellular level affecting receptor activity 
and/or reducing apo B-lOO containing lipoprotein synthesis.
Although no significant differences were observed between the lipid and 
hormonal responses between the diets, patterns following the single standard test meal 
did highlight differences between the 2 diets. The data presented in this chapter is part 
of a larger study in which an identical study was carried out by a collaborating group 
in Ireland. On collation of the data, i.e. increasing the number of volunteers from 13 to 
24, significant differences were observed in the fasting and postprandial lipaemic 
responses, which were not detected when the 2  centres were considered individually. 
Interestingly, the earlier time to peak with a higher peak concentration illustrated by 
the lipaemic responses, lower TC responses and higher peak insulin and GIF 
responses suggest that the MUFA-enriched diet causes a shift in these responses in the 
direction of those demonstrated by the S.E. volunteers. This was a pleasing response 
in view of the short 8  week intervention time compared with the responses of the 
young S.E. males habituated to a diet high in MUFA.
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This study therefore illustrates that dietary interventions can be performed in 
free-living populations, using commercially available foods enriched with MUFAs 
and provide a suitable option for the provision of energy when replacing SFA in the 
diet, especially for individuals with elevated lipids who are at a higher risk of the 
development of CHD.
224
Chapter 6
General Discussion
The highest morbidity and mortality rates from CHD have been observed in 
the Western industrialised nations compared with the rest of the world (DOH, 1994). 
This has prompted the need for a change in the lifestyle, especially attitudes towards 
diet, of these populations in an attempt to reduce risks of the major cause of premature 
death.
Early dietary studies carried out between 1950 and 1970, concentrated on 
PUFAs as the major fatty acid for the partial replacement of SFA in the diet as a 
preventive measure against CHD. A 1% reduction in plasma cholesterol levels was 
associated with a reduced CHD mortality of 2%, with PUFAs being regarded as an 
ideal fatty acid for substitution at the expense of SFAs in the diet (Heyden, 1994). 
However, MUFAs were regarded as ‘neutral’ with respect to changing the lipoprotein 
profile of an individual and so were not initially favoured as a beneficial fatty acid for 
prevention of CHD. Evidence from the Seven Countries Study, conducted in the 
1960s, indicated that Mediterranean countries had a lower risk of CHD and that this 
was positively associated with the type of fat consumed by these populations (Keys, 
1970). MUFAs are predominately consumed in this region, compared with SFAs 
consumed in the Westem-style diet. Although there was some evidence that the 
cardioprotective effect of high MUFA diets were related to cholesterol reduction, this 
evidence was conflicting and other protective mechanisms were sought. Recently 
emphasis has been placed on adverse effects of elevated postprandial lipoproteins and 
indicated a clear need to ascertain effects of diet on these lipoprotein classes. The main 
theme of this thesis was to investigate the effects of acute and chronic ingestion of 
MUFA, n-9 oleic acid, on postprandial lipoprotein metabolism, especially dietary 
derived lipoproteins.
Chapter 3 addresses two objectives, one of which determines the influence of 
acute meals of varying MUFA content on postprandial lipoprotein metabolism in 
young men from the U.K. The oral fat load used was a mixed meal including a 
strawberry-flavoured milkshake, which contained a mixture of oils and was used to 
represent the habitual MUFA intake of the UK (12%), Greece (17%) and the 
traditional Cretan Greek diet observed in the 1960s (24%). Sunflower, com, palm and 
olive oil were used to provide a representative fatty acid intake of the 3  populations.
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with increasing MUFA content at the expense of SFAs. A jam sandwich was also 
included in the test meal and this was to ensure that it provided carbohydrate, 
representative of a typical meal, to elicit insulin, glucose and gut hormone responses. 
After an overnight fast, the test meals were presented in random order on 3 separate 
occasions and blood samples were collected over a 9 hour period. There were no 
significant differences in the fasting and postprandial lipoprotein and hormonal 
responses following ingestion of the 3 test meals, which indicates that, within a meal, 
substitution of SFA by MUFA does not significantly alter the rate of entry or 
clearance of dietary-derived lipoproteins.
A second objective of chapter 3 was to compare the use of the two commonly 
used methods to monitor the metabolism of CMs and their remnants, the vitamin A 
loading method and measurement of apo B-48. Intestinally derived lipoproteins have 
been implicated with the aetiology of atherosclerosis as early as the 1980s and this 
emphasises the importance of a reliable method for their measurement (Zilversmit, 
1979; Stender and Zilversmit, 1982). This is especially important in light of recent 
findings by Krasinski et al (1990b), who highlighted limitations with the use of REs 
as markers for CMs and their CM remnants. They observed a delay in the entry of RE 
labeled intestinally derived lipoproteins into plasma compared with that of TAG and 
apo B-48 responses and also the presence of the RE label in the HDL and LDL density 
fraction following ultracentrifugation, 9 to 12 hours after the test meal. The delay in 
the RE response still remains controversial since the study day procedures and blood 
sampling intervals differ significantly between research groups. The timing of blood 
sample collection is crucial during postprandial studies, with more fi*equent sampling 
providing a greater insight into the metabolism of the TRL particles during the time 
period. However, a detailed study requires a number of experienced investigators and 
equipment to cope with a large number of samples collected.
It has also been demonstrated that the type of test meal used in an oral fat load 
determines the postprandial response, in particular the form of the meal and also the 
amounts of protein and carbohydrate in the meal. This may account for the 
disconcordent responses in the literature with liquid, emulsion and mixed meals being 
used by different investigators (Table 1.5). The dose and the type of RP administered
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in the test meal is not standardised within this research area, with a range of between 
100,000 and 350,000 LU., and the use a RP in the form of oils, aqueous emulsions and 
tablets being used. However, Krasinski has suggested that the incorporation of RP into 
the nascent CM particle should not differ between the different forms of RP, if the 
individuals are normal and healthy without any disturbances in fat absorption and 
metabolism (Krasinski et al, 1990b). Weintraub et al (1988) has also postulated that 
there is a linear relationship between the amount of RP administered and the RP/E 
concentrations in plasma. Therefore, the amount of RP needed in the test meal, may be 
dictated by the sensitivity of the HPLC method available for analysis.
An antibody has recently been raised in our research group which has been 
incorporated into a novel ELISA for the measurement of apo B-48 (Peel et al, 1992, 
1993; Lovegrove et al, 1996). In order to determine the contribution of CMs and their 
renmants to the total plasma response, a single, short ultracentrifugation step was used 
to separate TRLs (predominately CMs) from TPLs (CM remnants). Since it has been 
proposed that each CM particle carries only one molecule of apo B-48, the ELISA 
determines the number of intestinally derived particles in the plasma and isolated 
fractions. However, with the vitamin A loading method, RP is incorporated into the 
core of the nascent CM particle, in the same way as cholesterol ester, and it is thought 
to remain in the core of the CM particle until uptake of the CM/CM remnant by the 
liver. Therefore, the RE response indicates the entry of the particles into the 
circulation of intestinally derived lipoproteins following a meal and their subsequent 
metabolism in the plasma without taking into account their baseline circulating 
concentrations.
In these studies, the TAG and apo B-48 responses had returned to baseline 
fasting concentrations at the end of the 9 hour postprandial test period, whereas the RE 
response in the plasma and TRL fractions remained elevated above baseline 
concentrations. The circulating concentrations 6  to 9 hours following the meals, has 
been deemed to represent the exchange of RE to the endogenous lipoproteins, LDL 
and HDL from CM remnants by the action of CETP. Although since the rationale for 
using RP as a marker for CM metabolism is that the RE acts in the same way as a core 
lipid cholesterol ester, then it might be expected that RP will be subject to exchange
228
like cholesterol ester to LDL and HDL by CETP. However, on the other hand, recent 
evidence from our laboratory has detected the presence of apo B-48 containing 
lipoproteins in the LDL density range (d = 1.063 g/1) using both the apo B-48 ELISA 
and SDS-PAGE followed by Western blot. This finding implies that the presence of 
REs 6  to 9 hours postprandially may in fact represent RE-enriched CM remnants 
(Isherwood, 1996). This therefore requires further investigation to determine the origin 
and lipoprotein class of these particles in order to determine the specificity of the 
vitamin A loading method as a marker of intestinally derived lipoproteins.
In our study, on increasing the MUFA content of the test meals from 12 to 
24% MUFA, the time to reach peak RE concentration appeared to be delayed 
compared with the TAG and apo B-48 responses. Although no significant differences 
were observed in the apo B-48 and RE responses, the trends observed suggest that the 
MUFA content of the test meal may affect the rate of incorporation of RE into the core 
of the CM particle and hence its entry and metabolism in the circulation. This would 
therefore suggest that the increase in MUFA or decrease in SFA in the test meal may 
result in changes in CM synthesis in the enterocyte. The rate of entry of the fatty acids 
to the enterocyte and their effect on the processing and packaging of the components 
of the nascent CM particles may result in alteration in core lipids such as cholesterol 
ester. In conclusion, the measurement of both REs and apo B-48 provide useful 
markers to monitor the metabolism of CM particles in the circulation. Although apo 
B-48 is seen as the more specific marker, the vitamin A loading method provides 
information regarding the entry and residence time of these particles and may lend 
insight into the incorporation of cholesterol ester into the CMs. In combination they 
provide a substantial amount of information about the metabolism of CM particles 
following an oral fat load.
Chapter 4 addresses the differences in the postprandial processing of the 3 
MUFA test meals, used in chapter 3, in young healthy men fi*om Northern and 
Southern Europe. The EC funded project provided an opportunity to study volunteers 
in the U.K., Dublin and Greece and so compare populations with vastly different heart 
disease risks, in an attempt to determine the protective mechanisms of the 
Mediterranean diet in the S.E. population. Exactly the same procedures were carried
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out in the 3 centres and the test meals were randomly consumed on 3 separate 
occasions to determine their effects on lipoprotein and hormonal responses. 
Differences were observed in the entry and clearance of the TRLs demonstrated by the 
Greek volunteers compared with their N.E. counterparts whose TAG and apo B-48 
responses were elevated in the latter half of the postprandial period. The large increase 
in TAG during the early part of the postprandial period by the S.E. volunteers, 
suggests that they rapidly secrete larger CM particles enriched with TAG than the 
N.E. volunteers. Since larger CM particles have been shown to more susceptible to 
hydrolysis by LPL (Olivecrona and Bengtsson-Olivecrona, 1990), these CM remnants 
would be taken up faster by the liver. The significantly higher HE activity in the S.E. 
subjects suggests that HE may be responsible for the quick removal of the CM 
remnants. The involvement of HE in the clearance of CM remnants is at present 
controversial since HE is also involved in the metabolism of HDL and the VLDL- 
IDL-LDL cascade to produce small dense HDL3 and LDL. The levels of these 
lipoproteins have both been correlated with the presence of CHD and suggests that a 
high HE activity may result in an increased risk of CHD development.
The rapid entry and removal of TRLs from the circulation in the S.E. 
population may be as a result of the higher postprandial GIPs and insulin during the 
early part of the postprandial period. Recent evidence has implied that both insulin and 
GIP act synergistically increasing the activity of LPL, the enzyme responsible for the 
initial hydrolysis of the TRL particles (Knapper et al, 1996b). Surprisingly, low 
postheparin LPL activities were demonstrated in the S.E. volunteers despite the rapid 
clearance of the TRLs. Since a single measurement at 9 hours following the meal 
provides only a snapshot of the activities of these enzymes, it sheds doubt on the 
usefulness of this measurement. At the end of the postprandial period, the TRLs have 
been metabolised and the TAG and apo B-48 responses are returning to baseline 
concentrations. Our results suggest that our measurements are descriptive of the TRL 
metabolism in the circulation nine hours following the test meal, with a higher 
circulating concentration resulting in a higher LPL enzyme activity. A more 
informative profile would be the use of preheparin measurements, since peak LPL 
activity has been determined to be at the peak lipaemic responses, approximately 4 to
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6  hours postprandially. However, preheparin activities are very low and their 
measurement would require a very sensitive assay which was not available at the time 
of analysis of our samples. The elevated insulin and GIP responses of the S.E.s 
combined with the higher fasting and postprandial NEFA responses would initially 
suggest that the population possess the profile of insulin resistance. However, this 
syndrome is also normally associated with hypertriglyceridaemia which was not 
evident in the healthy young male population studied. In view of the increasing CHD 
risk in the Greek population, it would be interesting to conduct a similar comparison 
of responses in the same volunteers in 5 to 10 years time to determine the changes in 
the lipoprotein profiles of the two groups.
A surprising observation was the lower fasting and HDL-C concentration of 
the S.E. volunteers compared with that of the N.E. volunteers. Evidence from the 
Seven Countries Study observed higher HDL-C concentrations in the Mediterranean 
region compared with the Western industrialised cohorts studied. However, this study 
was conducted in the 1960s when a traditional Mediterranean diet was being 
consumed in Crete. The volunteers used in this study were recruited from the student 
population and so their attitudes towards their diet may not be representative of the 
S.E. population as a whole. A study by Mensink and Katan (1989) compared the lipid 
levels of young male children in Crete consuming a diet high in olive oil with that of 
middle-aged men and women from the Netherlands. They determined that the LDL-C 
and HDL-C profile of the Cretan children was not protective against the development 
of CHD. Unfortunately, the heart disease risk in Crete has increased since the 1960s 
and so the profile of our S.E. subjects may represent their current lipoprotein profile, 
in view of their increased risk. However, the HDL-C levels measured in this study 
may not be a true representative of actual levels, since the levels are lower than those 
quoted for the normal range in the manufacturers instructions of the kits used. An 
explanation for the lower concentrations may be a result of the transfer of the samples 
from Crete which may have resulted in damage of the samples due to freeze-thawing. 
Also, a single ultracentrifugation step was carried out in order to isolate TRLs from 
plasma, leaving a TPL fraction rich in the higher density lipoproteins. After collection 
of the samples, it was discovered that different procedures were implemented to
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isolate the TRLs with different tubes, ultracentrifiigal g, temperature and method of 
isolation of TRLs. Therefore this may have resulted in losses of the HDL particles 
through the use of the lower temperature (4°C) during the ultracentrifugation 
procedure.
The objective of chapter 5 was to determine the effects of increasing the 
MUFA content of the diet, of individuals in the U.K., to those observed in the 
Mediterranean diet. The population chosen were healthy young men who had a family 
history of heart disease (first degree relative) in an attempt to ascertain whether this 
could provide a safe dietary intervention to modify their lipoprotein profile and so 
reduce their risk of developing CHD later in life. The design of this study was a 
randomised cross-over in which the young men consumed a control diet representative 
of the typical U.K. diet and a MUFA-enriched diet, each for a period of two months. 
Collaborative links were made with major food companies to provide ready-made 
meals and snacks during the dietary periods in an attempt to allow the volunteers to 
maintain their normal lifestyle habits. Four fasting blood samples were collected 
during the 8  week dietary periods and postprandial blood samples were collected 
following an oral fat load representing the fatty acid composition of the traditional 
Cretan diet at the end of both the control and MUFA-enriched diets. This was 
proposed to determine the effects of the MUFA-enriched diet on lipoprotein classes 
and on the mechanisms involved in the metabolism of dietary derived lipoproteins.
Our study has shown that there were no significant differences in the responses 
of the volunteers between the control and MUFA-enriched diet. There was a tendency 
however, for the postprandial responses following the MUFA-enriched diet to begin to 
adopt the patterns of those demonstrated in the S.E. volunteers, although this is only 
speculative. Although only minor changes in pattern were observed, it was a pleasing 
observation in view of the short intervention period used and so does not discount the 
possibility that a longer intervention period may further modify the postprandial 
pattern to that observed in the young S.E. men. Since there were no differences in the 
responses to the diets it suggests that the MUFA-enriched diet provides a safe 
alternative to the SFA-rich U.K. diet, with no detrimental effects on the lipoprotein 
profile of the individuals.
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The individuals used in chapter 5 differed from those used in chapters 3 and 4 
in that they had a family history of CHD and so an increased risk of development of 
CHD in later life (Murkheijee and Dastur, 1995; Uiterwaal et al, 1994). Comparison 
of the lipoprotein profiles, for the 24% MUFA test meals following the control diet, 
with those in chapter 3 indicate
• higher fasting plasma and postprandial TAG concentrations
• lower fasting and postprandial plasma apo B-48 response
• lower LPL and higher HL activity.
These profiles tend to suggest an overall trend for an increased CHD risk, although the 
differences are not significant, we can therefore only speculate on their inherent risk. 
These observations agreed with those of Uiterwaal et al (1994), who determined an 
increased magnitude and duration of plasma TAG, especially in the latter half of the 
postprandial period, in the individuals with a family history of heart disease compared 
with controls. Although the young men recruited in chapter 5 were termed ‘young 
men’ their mean age was in fact 33 years compared with 22.5 years for the young 
healthy men studied in chapter 3. Therefore, differences observed in the lipaemic and 
lipase activities may be a result of the differences in age of the volunteers, since age 
has been shown to affect the rate at which the TRLs enter and leave the circulation 
(Krasinski et al, 1990a). It would have been interesting to compare the lipoprotein 
profile of young Greek men with a family history of heart disease with that of the men 
studied in chapter 5 to determine if these males had an altered lipoprotein profile 
compared to that of the young men in chapter 4. However, a recent paper by Koutis 
and CO workers (1992) compared a group of individuals with characteristics of 
‘metabolic syndrome X’ in Crete with a group in Sweden. The lower CHD incidence 
in the Cretan group was thought to be a combination of the diet, genetic make-up and 
lifestyle of the population.
The results from chapter 5 suggest that habitual MUFA intake of the S.E. 
population may be one of the factors responsible for their lower CHD risk. However, 
the Mediterranean diet is not made up wholly of MUFA. They also have a high intake 
of fresh fruit and vegetables, fish and a moderate red wine intake. In addition to the 
oleic acid content of olive oil, it also contains a number of plant sterols and
233
antioxidants (including vitamin E). These additional compounds have been associated 
with effects on lipoprotein metabolism and so may be responsible for some of the 
differences observed. A recent study by Perez-Jimenez et al (1994) has highlighted 
differences in the plant sterol composition present in different MUFA-rich oils, with 
an oleic acid enriched sunflower oil causing a greater reduction in TC and increases in 
apo A-I and HDL-C compared with olive oil. The authors attributed the responses 
observed in the p-sitosterol content to the sunflower enriched olive oil. This suggests 
that a number of factors may contribute to the lower incidence of heart disease in 
Mediterranean countries and indicates the complex effects of an individual’s habitual 
diet on their lipoprotein profile. This makes it difficult to isolate only one component 
of the diet since synergistic relationships may exist between nutrients in the 
Mediterranean diet which may not be expressed in isolation. The lifestyle of the S.E. 
populations differs from that of the N.E. population, with for example, different eating 
habits, with usually a midday rest following consumption of lunch and the main meal 
of the day being consumed much later in the evening. Also, the working day is usually 
split into 2  halves, resulting in an extended working day until approximately 9  to 1 0  
pm, which together with these different eating habits, may result in different circadian 
rhythms of hormones and enzyme activities compared with the N.E. population which 
is more sedentary in the early evening. This may therefore provide a partial 
explanation for the different responses observed to the 3 test meals between the 2 
populations, which were consumed at approximately 8  am in the morning.
Although many dietary studies have been conducted on the effects of the 
substitution of SFAs by MUFA on lipoprotein metabolism, the present work 
highlights that more extensive work is required in this area to determine the beneficial 
properties of the Mediterranean diet in an attempt to explain their lower heart disease 
risk. A number of questions regarding the effects of MUFA on the formation and 
release of CM particles into the circulation will need to be addressed to determine the 
mechanism of action of this fatty acid. In chapter 3, there was a trend for an increased 
residence time of the 24% MUFA test meal in the apo B-48 and TAG responses and 
an interesting observation was made for the RE data, where there was a later time to 
peak on increasing the MUFA content of the test meals. The young men studied, from
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N.E., were programmed to a high habitual SFA intake and so the effect of the 
increased MUFA or decreased SFA intake may have disrupted the packaging of the 
nascent lipoprotein particles in the enterocyte and hence their release and metabolism 
in the circulation. The size of the particles may have differed according to the 
predominant fatty acid incorporated into the core of the particle and so their 
metabolism by the lipase enzymes, programmed to smaller SFA enriched TRL 
particles, may have been retarded due to the expression and or number of lipase 
molecules present on the surface of the capillaries in adipose tissue and skeletal 
muscle. In chapter 4, all of the TRLs produced following the 3 test meals were 
metabolised more efficiently in the S.E. compared with the N.E. population. If the 
habitual MUFA intake was responsible for this phenomenon, it would suggest that the 
S.E. population receive the components of the CM particle quicker than that of their 
N.E. counterparts. A recent review has indicated that olive oil has a mild laxative 
effect and that the rate at which the stomach empties may be quicker following a meal 
due to their effect on gastric hormones (Kafatos and Comas, 1990). If the capacity to 
make apo B-48 was the same in both populations, the enterocyte may be programmed 
to produced larger TAG-rich particles due to the predominant MUFA intake and this 
agrees with the TAG/apo B-48 ratio, which was higher for the S.E. compared with the 
N.E. volunteers.
Overall, the use of fasting and postprandial studies to investigate the effects of 
acute and chronic ingestion of MUFA on postprandial lipaemia has provided a greater 
insight into the whole body metabolism of olive oil. Postprandial lipoprotein 
metabolism is a complex inter-related process which is dependent on the absorption 
and digestion of dietary fat, TRL formation in the enterocyte and liver, metabolism by 
LPL and HL and their receptor mediated uptake mainly by the liver and other 
peripheral tissues. Any disturbance in the process would result in an increased 
residence time of the TRLs and so increase the time of exposure of these particles to 
the arterial wall and the risk of development of atherosclerosis. If the present study 
had employed the use of only the traditional fasting plasma parameters it would not 
have revealed the differences in the handling of dietary lipids between the N.E. and 
S.E. populations. This therefore highlights the need for more frequent use of
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postprandial measurements in epidemiological studies in order to represent a more 
accurate picture of the whole body metabolism of dietary fat.
In conclusion this thesis has addressed two important issues, one of which 
concerns the effects of MUFAs on postprandial lipoprotein metabolism and has 
highlighted that there were
• no significant effects of the 3 meals of varying MUFA content on postprandial 
lipoprotein or hormonal responses in any of the young men.
• important differences in the postprandial processing of dietary fat in the S.E. 
compared with the N.E. population.
The feasibility of conducting a dietary intervention study in fi-ee-living individuals 
conducted in collaboration with the food industry was also demonstrated.
A second issue was to compare two methods used to monitor the metabolism 
of dietary derived lipoproteins. The specific apo B-48 antiserum raised in our research 
group has provided us with a unique opportunity to determine the limitations of the 
vitamin A loading method in comparison with our apo B-48 ELISA. Although the 
time to reach peak concentration was later than that of apo B-48 and TAG, it only 
reached significance on increasing the MUFA content of the acute test meals. This 
therefore suggests that the RE and apo B-48 measurements provide very different, but 
very useful information regarding the metabolism of intestinally derived lipoproteins. 
Further investigation using our very specific antiserum will enable the limitations of 
the vitamin A loading method to be determined with respect to transfer of RE to 
higher density lipoprotein particles, and so resolve the origin of the RE in these 
lipoprotein particles.
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APPENDICES
Appendix I - Chapter 2 
Example of the calculation for the conjugation of the Ile-peptide to thyroglobulin 
(TG) using SPDP
1. Addition o f SPDP to thyroglobulin
20 mg TG = 20 x 10'^  = 3.03 x 10'  ^moles
660,000
A 30 mol excess of SPDP is 30 x 3.03 x 10'^= 9.09 x 10'  ^moles
The mass of SPDP was 9.09 x 10’^  x 312 = 0.28 mg. Balance can only accurately 
measure 0.5 mg so the weight of the peptide is 0.5 mg.
2. Estimation o f SPDP coupled to TG
Mercaptoethanol reacts with SPDP bound to TG and liberates 2-thiopyridone. 
The absorbance from 2-thiopyridone was 0.478. This is directly proportional to the 
thiopyridol groups introduced into the TG.
c = A A/s
c = 0.578-0.206 (hlank^ = 3.4 x 10'  ^mol/1
8000
This was from 200 |il of the original TG-SPDP mixture which had a total 
volume of 2.64 ml from the three fractions which were pooled. So the actual amount 
of SPDP bound was
3.4x10'^  X 264 = 4.48 x 10"^  mois SPDP
0.2 1000
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3. Molar ratio ofTG bound to SPDP 
= mois of SPDP
mois of TG
4.48 X 10'^
1.08x10'
1 :41.5
4. Amount o f Ile-peptide added
An 1:1 ratio of peptide to SPDP is required to ensure that the peptide is in 
excess. The molecular weight of the Ile-peptide is 900.
Mass of Ile-peptide added was 4.48 x 10-7 x 900 = 0.40 mg. Balance can 
only accurately measure 0.5 mg so the weight of peptide added is 0.5 mg.
5. Detection o f the amount o f Ile-peptide coupled
When Ile-peptide conjugates to SPDP, already bound to TG, 2-thiopyridone is 
liberated. Thus the absorbance due to 2-thiopyridone is a direct measure of Ile-peptide 
conjugated to SPDP.
A 1:10 dilution of TG-SPDP-Ile-peptide gave an absorbance of 0.211, with the 
sample giving an absorbance of 2 .1 1 0 .
c = A A/s
c = 2.110-0.206 (blanks = 2.4 x 10'  ^mol/1
8000
After removal of 100 pi TG-SPDP and addition of 30 pi of Ile-peptide solution the 
final volume was 2.574 ml.
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The amount of Ile-peptide actually bound to the TG-SPDP-Ile-peptide was
2.4 X 1Q~^  X 2.574 = 6.17 x 10’^  mois
1000
6. The final molar ratio
After the second spectrophotometric test the mois of TG were
1.08 X 10'^  X 2.574 = 10.5x10'^ mois
2.640
Ratio = mois of peptide bound
mois of TG bound
6.17 X 10'^  
10.5 X  1 0 ’ ’
58.8
Therefore final molar ratio of TG : SPDP : Ile-peptide
1: 41.2: 58.8
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Appendix II - data from chapter 3.
Table 3.1. Mean (SEM) TAG concentrations (mmol/1) following consumption of 
meals of varying MUFA content in the plasma, TRL and TPL fractions.
a) Plasma fraction
Time (mins) MUFA meal
12% 17% 24%
0 1.07 0.11 1.04 0.12 1.18 0.12
60 1.12 0.15 1.18 0.11 1.21 0.14
120 1.34 0.19 1.37 0.18 1.59 0.24
180 1.39 0.23 1.35 0.17 1.69 0.35
240 1.39 0.26 1.39 0.21 1.59 0.35
300 1.53 0.21 1.45 0.16 1.58 0.26
360 1.58 0.14 1.44 0.11 1.91 0.27
420 1.57 0.18 1.35 0.20 1.77 0.2^
480 1.30 0.17 1.11 0.17 1.42 0.23
540 1.02 0.10 0.91 0.11 1.09 0.16
b) TRL fraction
Time (mins) MUFA meal
12% 17% 24%
0 0.42 0.09 0.39 0.07 0.46 0.07
60 0.39 0.07 0.49 0.08 0.53 0.10
120 0.68 0.15 0.73 0.11 0.86 0.21
180 0.75 0.25 0.67 0.14 0.94 0.2(3
240 0.62 0.16 0.65 0.13 0.83 0.31
300 0.75 0.13 0.77 0.09 0.66 0.27
360 0.74 0.08 0.74 0.16 1.10 0.26
420 0.74 0.16 0.67 0.13 0.95 0.23
480 0.66 0.10 0.45 0.12 0.57 0.09
540 0.47 0.09 0.31 0.0.3 0.29 0.05
c) TPL fraction
Time (mins) MUFA meal
12% 17% 24%
0 0.64 0.05 0.63 0.06 0.64 0.07
60 0.70 0.10 0.66 0.05 0.62 0.05
120 0.67 0.07 0.64 0.04 0.64 0.06
180 0.71 0.06 0.65 0.03 0.73 0.0&
240 0.73 0.07 0.71 0.08 0.71 0.09
300 0.72 0.04 0.68 0.06 0.74 0.09
360 0.70 0.05 0.72 0.12 0.81 0.06
420 0.71 0.06 0.65 0.04 0.72 0.04
480 0.64 0.06 0.60 0.05 0.69 0.07
540 0.57 0.06 0.59 0.04 0.80 0.14
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Table 3.2. Mean (SEM) RE concentrations (pg/ml) following consumption of meals 
of varying MUFA content (12%, 17% and 24% MUFA meals) in the plasma, TRL and
TPL fractions, 
a) Plasma fraction
Time (mins) MUFA meal
12% 17% 24%
0 0 0 0 0 0 0
60 0.08 0.04 0.24 0.10 0.12 0.06
120 0.38 0.10 0.48 0.11 0.61 0.27
180 0.67 0.23 0.61 0.18 0.70 0.15
240 0.61 0.26 0.77 0.13 0.75 0.22
300 0.80 0.18 1.02 0.13 0.85 0.24
360 0.87 0.08 1.50 0.23 1.27 0.34
420 1.30 0.25 1.83 0.35 1.56 0.26
480 1.06 0.21 1.24 0.37 1.23 0.25
540 0.59 0.07 0.70 0.24 1.00 0.20
b) TRL fraction
Time (mins) MUFA meal
12% 17% 24%
0 0 0 0 0 0 0
60 0.03 0.02 0.08 0.04 0.09 0.05
120 0.36 0.72 0.48 0.13 0.62 0.17
180 0.65 0.27 0.53 0.15 1.03 0.37
240 0.61 0.18 0.74 0.24 1.05 0.57
300 1.00 0.16 1.41 0.30 1.00 0.47
360 1.12 0.19 1.51 0.27 1.43 0.39
420 1.13 0.27 1.55 0.25 1.74 0.42
480 0.87 0.18 0.99 0.26 1.03 0.19
540 0.54 0.13 0.50 0.15 0.77 0.25
c) TPL fraction
Time (mins) MUFA meal
12% 17% 24%
0 0 0 0 0 0 0
60 0.04 0.07 0.05 0.02 0.05 0.02
120 0.14 0.02 0.14 0.04 0.14 0.04
180 0.18 0.05 0.19 0.05 0.25 0.06
240 0.19 0.04 0.29 0.07 0.23 0.05
300 0.22 0.03 0.34 0.08 0.21 0.04
360 0.25 0.06 0.49 0.12 0.25 0.05
420 0.30 0.09 0.48 0.07 0.30 0.05
480 0.29 0.05 0.39 0.05 0.36 0.06
540 0.32 0.05 0.39 0.07 0.35 0.07
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Table 3.3. Mean (SEM) apo B-48 concentrations (pg/ml) following consumption of 
meals of varying MUFA content (12%, 17% and 24% MUFA meals) in the plasma,
TRL and TPL fractions, 
a) Plasma fraction
Time (mins) MUFA meal
12% 17% 24%
0 3.27 0.20 3.24 0.15 3.76 0.2^
60 3.93 0.43 4.39 0.45 4.38 0.32
120 4.74 0.73 4.75 0.32 4.83 0.52
180 5.81 1.20 4.89 0.4(3 6.18 0.51
240 7.64 1.40 6.49 0.86 7.19 0.74
300 6.69 1.41 7.10 0.91 6.97 0.95
360 5.48 0.64 5.28 0.47 5.44 0.74
420 5.49 0.45 4.99 0.59 6.55 1.16
480 4.61 0.32 3.75 0.55 4.06 0.31
540 3.49 0.17 3.44 0.4& 3.53 0.2&
b) TRL fraction
Time (mins) MUFA meal
12% 17% 24%
0 0.42 0.12 0.50 0.11 0.48 0.10
60 0.59 0.16 0.51 0.05 0.70 0.22
120 0.99 0.25 1.04 0.19 1.07 0.25
180 1.15 0.36 1.34 0.40 1.10 0.40
240 1.34 0.40 1.02 0.21 1.37 0.51
300 1.35 0.42 1.38 0.35 1.38 0.44
360 1.41 0.31 1.26 0.18 1.49 0.37
420 0.97 0.24 1.34 0.37 1.16 0.31
480 1.03 0.21 0.70 0.21 0.81 0.25
540 0.55 0.15 0.48 0.22 0.47 0.10
c) TPL fraction
Time (mins) MUFA meal
12% 17% 24%
0 2.95 0.10 2.84 0.25 3.06 0.25
60 3.65 0.21 3.70 0.45 3.24 0.50
120 3.73 0.29 3.34 0.55 3.41 0.21
180 4.19 0.39 3.41 0.31 3.91 0.38
240 4.39 0.26 3.65 0.29 4.46 0.5^
300 4.46 0.42 4.22 0.52 4.76 0.42
360 4.07 0.52 3.77 0.54 3.93 0.25
420 4.14 0.58 3.78 0.59 3.69 0.26
480 3.94 0.45 3.62 0.55 3.84 0.2(5
540 3.29 0.19 3.11 0.24 3.38 0.24
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Table 3.4. Mean (SEM) postheparin plasma LPL and HL activities (mU/ml) following
consumption of meals of varying MUFA content
MUFA meal Enzyme activity (mU/ml)
LPL (15 mins) HL (5 mins)
Fasting 294.40 30.0 60.35 7.0
12% 344.75 27.6 70.98 11.7
17% 331.95 25.6 64.89 7.7
24% 359.34 7&4 71.45 7.4
Table 3.5. a) Mean (SEM) plasma HDL-C responses (mmol/1) following meals of 
varying MUFA content (12%, 17% and 24% MUFA test meals)
Time (mins) MUFA meal
12% 17% 24%
0 0.86 0.05 0.81 0.05 0.87 0.04
60 0.82 0.05 0.80 0.05 0.83 0.04
120 0.80 0.03 0.74 0.04 0.78 0.04
180 0.78 0.04 0.72 0.05 0.77 0.05
240 0.82 0.04 0.75 0.04 0.83 0.05
300 0.81 0.04 0.74 0.06 0.82 0.03
360 0.78 0.04 0.74 0.06 0.77 0.04
420 0.84 0.05 0.79 0.06 0.80 0.03
480 0.82 0.07 0.72 0.07 0.80 0.05
540 0.81 0.07 0.80 0.04 0.84 0.04
b) Mean (SEM) AUC and lAUCs for the plasma HDL-C responses
MUFA meal AUC/IAUC (mmol/l.min)
AUC lAUC
12% 436.92 23.1 -29.6 17.6
17% 408.1 24.6 -29.2 5.4
24% 435.8 18.2 -32.9 &9
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Table 3.6. a) Mean (SEM) plasma NEF A responses (mmol/1) following meals of
varying MUFA content (12%, 17% and 24% MUFA test meals)
Time (mins) MUFA meal
12% 17% 24%
0 0.38 0.06 0.44 0.07 0.42 0.07
60 0.08 0.01 0.10 0.02 0.14 0.04
120 0.12 0.01 0.08 0.02 0.07 0.01
180 0.06 0.01 0.08 0.02 0.09 0.02
240 0.19 0.05. 0.20 0.05 0.12 0.01
300 0.31 0.05 0.33 0.06 0.28 0.05
360 0.58 0.07 0.58 0.09 0.49 0.06
420 0.76 0.05 0.67 0.08 0.62 0.07
480 0.78 0.08 0.76 0.07 0.61 0.12
540 0.75 0.08 0.83 0.12 0.70 0.08
b) Mean (SEM) AUC and lAUCs for the plasma NEFA responses
MUFA meal AUC/IAUC (mmol/l.min)
AUC lAUC
12% 202.9 18.8 -1.9 22.(5
17% 206.9 22.6 -30.9 27.6
24% 178.8 14.1 -45.8 35.7
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Table 3.7. Mean (SEM) plasma GIF (pmol/1), insulin (pmol/1) and glucose (mmol/1) 
responses following consumption of meals of varying MUFA content (12%, 17% and
24% MUFA meals), 
a) GIF response
Time (mins) MUFA meal
12% 17% 24%
0 16.3 2.7 17.0 2.1 21.5 6.1
60 161.3 M 7 166.6 15.7 160.9 10.9
120 181.5 9.4 199.9 74.^ 185.9 75.(5
180 153.8 13.3 187.0 9.2 187.1 74.&
240 140.8 &5 194.7 7&4 145.5 74.7
300 120.1 9.^ 148.2 11.8 134.7 77.7
360 110.3 1&2 123.9 72.2 138.9 20.5
420 97.0 15.1 95.3 20.7 88.5 75.7
480 62.8 12.0 47.3 &6 58.0 (5.9
540 34.8 7.9 42.5 6.1 33.6 5.2
b) Insulin response
Time (mins) MUFA meal
12% 17% 24%
0 41.6 4.7 49.5 &6 47.9 5.1
60 526.9 &2.7 580.5 102.7 905.8 330.1
120 503.1 96.7 491.9 ^&7 926.4 256.2
180 301.9 54.7 287.3 55.1 502.4 76.7
240 101.4 27.^ 97.9 25.^ 142.1 56.5
300 117.5 55.5 78.9 17.1 64.5 14.9
360 53.5 8.1 51.2 (5.9 56.4 15.4
420 50.2 7.7 58.5 12.3 52.7 &4
480 46.2 9.7 43.1 9.9 46.8 5.1
540 43.1 6.4 44.3 10.5 39.9 4.5
c) Glucose responses
Time (mins) MUFA meal
12% 17% 24%
0 4.63 0.15 4.80 6.79 4.80 6.75
60 5.31 6.4^ 5.47 6.27 5.54 6.55
120 5.67 0.49 5.96 6.57 6.02 0.35
180 5.03 6.25 4.64 6.26 5.20 0.43
240 4.26 0.18 4.23 6.22 4.44 0.10
300 4.79 6.29 4.13 6.76 4.45 0.15
360 4.50 6.72 4.63 0.18 4.75 6.7^
420 4.61 6.76 4.82 6.22 4.83 6.77
480 4.32 6.55 4.79 6.27 4.74 6.75
540 4.75 6.76 4.80 6.27 4.96 6.22
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Table 3.8. Mean PL-TRL-TPL (losses from fractions) TAG (mmol/1), RE (pg/ml) and 
apo B-48 (pg/ml) concentrations observed during the postprandial period following 
consumption of meals of varying MUFA content (12%, 17% and 24% MUFA meals)
a) TAG losses
Time (mins) MUFA meal
12% 17% 24%
0 0.04 0.03 0.01
60 0.02 0.04 0.02
120 0.04 -0.02 0.10
180 -0.01 0.04 0.03
240 0.00 0.04 0.01
300 0.01 0.04 -0.03
360 0.06 0.06 0.05
420 0.09 0.04 0.08
480 -0.02 0.09 0.02
540 0.01 -0.03 -0.13
b) Apo B-48 losses
Time (mins) MUFA meal
12% 17% 24%
0 -0.09 -0.09 0.21
60 -0.23 0.18 0.45
120 0.02 0.37 0.34
180 0.46 0.14 1.16
240 1.91 1.79 1.35
300 2.12 1.50 0.83
360 0.00 0.25 0.01
420 0.39 -0.13 1.70
480 -0.35 -0.57 -0.59
540 -0.35 -0.16 -0.32
c) RE losses
Time (mins) MUFA meal
12% 17% 24%
0 0.00 0.00 0.00
60 0.00 0.06 -0.04
120 -0.16 -0.11 -0.17
180 -0.25 -0.20 -0.57
240 -0.27 -0.32 -0.40
300 -0.37 -0.61 -0.31
360 -0.41 -0.35 -0.31
420 -0.18 -0.32 -0.54
480 -0.09 -0.25 -0.29
540 -0.28 -0.25 -0.27
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Appendix III - Data from chapter 4 
Table 4.1. Mean (SEM) TAG concentrations (mmol/1) following consumption of the 
12%, 17% and 24% MUFA tes meals in the plasma fraction, 
a) 12% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 1.07 6.6,^ 1.02 0.08
60 1.24 0.11 1.23 0.11
120 1.36 0.13 1.65 0.16
180 1.32 0.15 1.71 0.18
240 1.31 0.16 1.63 0.19
300 1.41 0.14 1.43 0.18
360 1.53 0.11 1.31 0.15
420 1.60 0.12 1.31 0.19
480 1.31 0.11 1.07 0.11
540 1.03 0.07 0.90 0.07
b) 17% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 0.95 6.65 1.12 0.07
60 1.10 6.67 1.39 0.09
120 1.34 6.72 1.68 0.13
180 1.25 6.77 1.97 0.21
240 1.24 6.72 1.69 0.20
300 1.37 0.12 1.51 0.18
360 1.51 0.11 1.44 0.14
420 1.30 0.11 1.29 0.16
480 1.05 0.09 1.07 0.14
540 0.90 0.07 1.00 0.14
c) 24% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 1.12 0.10 1.17 0.10
60 1.29 0.12 1.41 0.09
120 1.57 0.15 2.02 0.19
180 1.51 0.21 1.93 0.14
240 1.41 6.22 1.51 0.19
300 1.43 0.19 1.37 0.17
360 1.64 0.20 1.46 0.20
420 1.64 0.19 1.20 0.13
480 1.37 0.14 1.14 0.12
540 1.07 0.10 0.96 0.09
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Table 4.2 Mean (SEM) apo B-48 concentrations (pg/ml) following consumption of
the 12%, 17% and 24% MUFA meal in the plasma fraction,
a) 12% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 3.57 0.17 3.01 0.21
60 4.82 0.41 4.31 0.53
120 4.95 0.42 4.71 0.43
180 5.45 0.60 5.77 0.52
240 6.24 0.81 4.43 0.47
300 5.45 0.77 4.03 0.43
360 4.92 0.57 3.76 0.31
420 5.31 0.39 3.51 0.34
480 4.41 0.22 2.74 0.19
540 3.78 0.16 2.44 0.13
b) 17% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 3.56 0.23 2.86 0.18
60 5.16 0.50 4.28 0.45
120 4.91 0.40 5.30 0.42
180 4.95 0.35 6.18 0.70
240 5.54 0.54 5.17 0.75
300 5.61 0.63 4.63 0.75
360 4.93 0.57 4.23 0.61
420 5.32 0.50 3.75 0.40
480 3 j# 0.36 2.71 0.19
540 3.86 0.33 2.64 0.14
a) 24% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 3.84 0.26 3.20 0.30
60 5.08 0.51 4.61 0.49
120 4.82 0.54 4.71 0.44
180 5.46 0.41 6.02 0.51
240 5.92 0.52 5.28 0.61
300 5.54 0.64 4.69 0.54
360 4.89 0.4& 3.85 0.47
420 5.68 0.66 3.46 0.33
480 4.08 0.24 3.12 0.56
540 3.67 0.24 2.94 0.20
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Table 4.3. Mean (SEM) TAG/apo B-48 ratios following consumption of the 12%,
17% and 24% MUFA meals in the plasma fraction
a) 12% MUFA meal
Time (mins) Subject centre
N. E. S.E.
0 0.31 0.03 0.37 0.05
60 0.28 0.03 0.31 0.03
120 0.30 0.04 0.36 0.03
180 0.26 0.03 0.32 0.04
240 0.24 0.04 0.39 0.04
300 0.30 0.04 0.36 0.04
360 0.33 0.03 0.34 0.02
420 0.32 0.03 0.38 0.05
480 0.31 0.03 0.40 0.04
540 0.28 0.02 0.38 0.03
b) 17% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 0.29 0.03 0.42 0.05
60 0.24 0.03 0.35 0.04
120 0.30 0.04 0.35 0.05
180 0.27 0.03 0.35 0.04
240 0.26 0.04 0.38 0.05
300 0.29 0.05 0.37 0.04
360 0.36 0.06 0.39 0.05
420 0.27 0.03 0.37 0.05
480 0.29 0.03 0.43 0.05
540 0.26 0.02 0.40 0.06
c) 24% MUFA meal
Time (mins) Subject centre
N. E. S. E.
0 0.30 0.03 0.38 0.04
60 0.28 0.03 0.35 0.04
120 0.34 0.03 0.45 0.04
180 0.29 0.03 0.34 0.03
240 0.25 0.03 0.30 0.03
300 0.28 0.03 0.30 0.03
360 0.39 0.08 0.38 0.04
420 0.32 0.04 0.35 0.04
480 0.35 0.05 0.38 0.03
540 0.30 0.03 0.33 0.03
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Table 4.4. Mean (SEM) plasma postheparin LPL and HL activities (mU/ml) follovdng
meals of varying MUFA contents
a) LPL activity
MUFA meal Activity (mU/ml)
N. E. S. E.
Fasting 319.8 226 277.5 22.6
12% 335.4 19.7 271.9 15.3
17% 342.5 17.5 305.8 21.4
24% 340.4 15.5 299.9 22.4
b) HL activity
MUFA meal Activity (mU/ml)
N. E. S. E.
Fasting 81.4 8.1 120.9 10.4
12% 87.1 121.1 11.6
17% 81.9 120.6 10.0
24% 85.1 7.4 123.6 11.2
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Table 4.5. Mean (SEM) plasma TC concentrations (mmol/1) following meals of
varying MUFA content (12%, 17% and 24% MUFA test meals)
a) N. E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 4.24 0.26 4.24 0.27 4.15 1.04
60 4.26 0.27 4.11 0.30 4.08 1.02
120 4.13 0.2^ 4.07 0.30 3.97 O.PP
180 4.06 0.24 4.26 0.27 3.94 0.9(9
240 4.11 0.25 4.07 0.23 4.05 1.01
300 4.24 0.26 4.27 0.25 4.05 1.01
360 4.05 0.25 4.28 0.23 4.11 1.03
420 4.07 0.26 4.31 0.20 4.08 7.02
480 4.17 0.29 4.19 0.24 4.15 1.04
540 4.13 0.27 4.38 0.25 4.15 1.04
b) S.E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 4.30 0.22 4.14 0.35 4.08 0.2^
60 4.38 0.22 3.85 0.54 3.61 0.50
120 3.94 0.29 4.17 &27 3.78 0.31
180 3.91 0.22 4.00 0.26 3.55 0.37
240 4.07 0.21 3.88 0.31 3.61 0.32
300 4.09 0.27 3.72 ■ 0.54 3.89 0.35
360 4.20 0.21 3.94 0.27 3.49 0.33
420 4.06 0.25 193 0.31 3.75 0.30
480 3.74 0.35 4.27 0.30 3.77 0.2^
540 4.13 0.23 4.09 0.37 4.32 0.29
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Table 4.6. Mean (SEM) plasma HDL-C concentrations (mmol/1) following meals of
varying MUFA content (12%, 17% and 24% MUFA test meals)
a) N. E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 0.96 0.06 0.94 0.06 0.97 0.06
60 0.93 0.07 0.96 0.06 0.96 0.06
120 0.90 0.06 0.94 0.06 0.93 0.07
180 0.91 0.06 0.95 0.07 0.95 0.07
240 0.95 0.07 0.94 0.06 1.00 0.07
300 0.94 0.06 0.93 0.0(9 1.00 0.07
360 0.90 0.06 0.95 0.07 0.93 0.07
420 0.93 0.06 0.96 0.07 0.94 0.06
480 0.89 0.08 0.92 0.07 0.94 0.0(9
540 0.89 0.0& 0.94 0.06 0.98 0.06
b) S.E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 0.80 0.07 0.85 0.08 0.88 0.06
60 0.84 0.08 0.89 0.10 0.86 0.06
120 0.79 0.07 0.83 0.07 0.83 0.07
180 0.81 0.07 0.87 0.0^ 0.93 0.07
240 0.77 0.06 0.78 0.07 0.85 0.06
300 0.83 0.07 0.82 0.09 0.87 0.06
360 0.81 0.07 0.82 0.07 0.87 0.07
420 0.74 0.06 0.82 0.07 0.85 0.06
480 0.85 0.07 0.80 0.07 0.85 0.06
540 0.86 0.07 0.82 0.08 0.86 0.07
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Table 4.7 a. Mean (SEM) plasma NEF A concentrations (mmol/1) following meals of
varying MUFA test meals (12%, 17% and 24% MUFA test meals)
a) N. E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 0.61 0.13 0.52 0.06 0.42 0.05
60 0.22 0.07 0.15 0.02 0.16 0.02
120 0.19 0.06 0.12 0.02 0.10 0.01
180 0.15 0.05 0.11 0.02 0.08 0.01
240 0.23 0.04 0.23 0.04 0.12 0.01
300 0.34 0.04 0.35 0.07 0.24 0.04
360 0.59 0.05 0.56 0.08 0.40 0.05
420 0.72 0.05 0.67 0.06 0.55 0.05
480 0.71 0.06 0.77 0.06 0.54 0.07
540 0.68 0.05 0.80 0.06 0.65 0.05
b) S.E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 0.73 0.06 0.60 0.06 0.55 0.09
60 0.44 0.06 0.28 0.03 0.29 0.05
120 0.42 0.06 0.28 0.03 0.24 0.05
180 0.37 0.06 0.27 0.03 0.24 0.04
240 0.34 0.06 0.23 0.03 0.22 0.04
300 0.45 0.07 0.30 0.03 0.29 0.05
360 0.60 0.06 0.49 0.05 0.45 0.05
420 0.83 0.07 0.71 0.07 0.60 0.08
480 0.84 0.10 0.81 0.05 0.74 0.08
540 0.92 0.08 0.87 0.08 0.82 0.09
Table 4.7 b. Mean (SEM) AUC and lAUC (mmol/l.min) for t l
responses
le postprandial NEFA
Parameter MUFA meal
12% 17% 24%
N.E. AUC 
lAUC
228.75 25.46 
-98.75 50.25
216.88 18.32 
-66.37 26.03
164.69 11.22 
-64.53 23.28
S.E. AUC 
lAUC
306.89 26.^7 
-88.91 31.17
246.25 15.94 
-79.48 25.21
225.30 25.17 
-73.54 28.54
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Table 4.8 a. Mean (SEM) plasma GIP concentrations (pmol/1) following the 12%
MUFA test meal
Time
(mins)
Subject centre
U.K. S.E.
0 16.3 2 7 70.4 74.7
60 161.3 7&7 241.8 19.9
120 181.5 P.4 316.7 25.P
180 153.8 13.3 293.3 7&P
240 140.8 &5 278.9 22.5
300 120.1 9.(9 247.3 224
360 110.3 78.2 188.4 20.8
420 97.0 15.1 156.3 52.6
480 62.77 12.1 132.5 52.4
540 34.82 7.9 102.1 54.2
Table 4.8 b. Mean (SEM) AUC and lAUC (pmol/1 .min) for the postprandial GIP
responses
Parameter Subject centre
U.K. S.E.
AUC
lAUC
63185.7 3514.28 
54368.9 2301.7
116489.0 7774.7 
78495.3 7418.9
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Table 4.9 a. Mean (SEM) plasma insulin concentrations (pmol/1) following the 12%
MUFA test meal
Time
(mins)
Subject centre
U.K. S.E.
0 41.6 4.1 86.0 74.7
60 527.0 1002.0 19.9
120 503.1 96 7 691.0 229
180 301.9 j j .a 997.0 74.9
240 101.4 224 594.0 22J
300 117.5 53.3 188.0 224
360 53.5 8.1 101.0 20.4
420 50.2 7.7 75.0 42.6
480 46.2 9.7 68.0 42.4
540 43.1 6^^ 102.0 44.2
Table 4.9 b Mean (SEM) AUC and I AUC (pmol/l.min) for the postprandial GIP
responses
Parameter Subject centre
U.K. S.E.
AUC 104592.0 12266.5 228563.0 68522.0
lAUC 82105.8 70979.4 182222.0 65184.0
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Table 4.10. Losses from fractions (TRL and TPL TAG concentrations (mmol/1) 
compared with those for total plasma) for the TAG responses during the postprandial 
period following consumption of meals of varying MUFA content (12%, 17% and
24% MUFA test meals)
a) N. E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 0.16 0.13 0.11
60 0.18 0.21 0.23
120 0.20 0.28 0.34
180 0.14 0.22 0.27
240 0.16 0.20 0.22
300 0.18 0.21 0.23
360 0.23 0.32 0.29
420 0.25 0.23 0.37
480 0.16 0.19 0.22
540 0.15 0.12 0.07
b).S.E. subjects
Time MUFA meal
(mins)
12% 17% 24%
0 0.13 0.16 0.14
60 0.31 0.33 0.31
120 0.43 0.38 0.60
180 0.49 0.48 0.51
240 0.48 0.45 0.33
300 0.27 0.39 0.18
360 0.27 0.34 0.32
420 0.31 0.20 0.13
480 0.20 0.07 0.09
540 0.14 0.13 0.03
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Table 4.11. Losses from fractions (TRL and TPL apo B-48 concentrations (pg/ml) 
compared with those for total plasma) for the apo B-48 responses during the 
postprandial period following consumption of meals of varying MUFA content (12%,
17% and 24% MUFA test meals)
a) N. E. subjects
Time
(mins)
MUFA meal
12% 17% 24%
0 0.46 0.56 0.73
60 0.56 1.01 1.30
120 0.08 0.74 0.72
180 0.59 0.64 1.18
240 1.46 1.39 1.32
300 1.33 1.19 0.76
360 0.01 0.56 0.58
420 0.22 0.63 1.53
480 -0.03 0.25 0.27
540 0.30 0.69 0.38
b) S.E. subjects
Time MUFA meal
(mins)
12% 17% 24%
0 0.13 -0.24 -0.17
60 0.01 0.31 0.15
120 0.72 1.08 0.62
180 1.74 1.78 1.66
240 0.60 1.34 1.33
300 0.59 0.90 0.43
360 0.29 0.66 -0.02
420 0.23 0.23 -0.48
480 -0.13 -0.22 0.13
540 -0.20 -0.28 0.07
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Appendix IV - Data from chapter 5.
Table 5.1. Mean (SEM) TAG concentrations (nmiol/1) following consumption of the 
24% MUFA test meal in the plasma, TRL and TPL fractions.
a) Control diet
Time (mins) Fraction
Plasma TRL TPL
0 1.31 0.11 0.44 0.05 0.83 0.06
60 1.61 0.13 0.60 0.07 0.81 0.06
120 1.88 0.17 0.87 0.12 0.90 0.05
180 2.06 0.20 0.94 0.13 0.93 0.05
240 2.02 0.17 0.87 0.16 0.99 0.04
300 1.98 0.19 0.81 0.13 1.01 0.07
360 2.33 0.24 1.08 0.19 0.99 0.07
420 Z52 0.24 1.07 0.18 1.05 0.08
480 1.84 0.18 0.81 0.14 0.92 0.07
540 1.47 0.11 0.49 0.09 0.87 0.06
b) MUFA-enriehed diet
Time (mins) Fraction
Plasma TRL TPL
0 1.47 0.17 0.45 0.09 0.86 0.07
60 1.73 0.20 0.60 0.08 0.86 0.06
120 2.21 0.25 0.84 0.13 0.90 0.04
180 2.65 0.36 1.15 0.21 0.96 0.06
240 2.64 0.41 1.13 0.19 0.94 0.06
300 2.57 0.44 0.93 0.13 0.99 0.06
360 2 j3 0.24 0.82 0.11 0.93 0.05
420 :129 0.20 1.01 0.15 0.96 0.05
480 1.98 0.22 0.97 0.20 0.89 0.05
540 1.52 0.17 0.54 0.14 0.89 0.06
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Table 5.2. Mean (SEM) apo B-48 concentrations (pg/ml) following consumption of
the 24% MUFA test meal in the plasma, TRL and TPL fractions.
a) Control diet
Time (mins) Fraction
Plasma TRL TPL
0 3.25 0.30 0.13 0.02 2.78 0.29
60 3.50 0.44 0.14 0.01 2.73 0.24
120 L23 0.27 0.21 0.03 3.13 0.29
180 3.47 0.26 0.23 0.02 2.89 0.25
240 3.76 0.44 0.28 0.03 3.06 0.47
300 3.70 0.35 0.29 0.04 3.17 0.27
360 3.76 0.44 0.29 0.03 2.96 0.27
420 3.87 0.40 0.30 0.03 :L99 0.44
480 3.46 0.30 0.24 0.04 2.77 0.27
540 3.59 0.23 0.17 0.03 3.30 0.44
b) MUFA-enriehed diet
Time (mins) Fraction
Plasma TRL TPL
0 2.81 0.45 0.15 0.02 Z39 0.46
60 2.95 0.46 0.27 0.07 2.56 0.44
120 3.34 0.44 0.28 0.04 3.02 0.44
180 3.12 0.42 0.35 0.04 3.13 0.64
240 3.39 0.52 0.42 0.04 Z82 0.49
300 3.51 0.56 0.37 0.06 :L86 0.44
360 3.41 0.46 0.32 0.05 2.46 0.44
420 3.46 0.39 0.34 0.06 2.77 0.49
480 3.47 0.44 0.28 0.04 2.59 0.46
540 3.08 0.46 0.22 0.04 2.94 0.44
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Table 5.3. Mean (SEM) plasma postheparin LPL and HL activities (mU/ml) following
the 24% MUFA test meal
Diet Activity (mU/ml)
LPL (15 mins) HL (5 mins)
Control
MUFA-enriehed
218.90 (19.6) 
200.88(15.9)
144.72 (13.3) 
12.08 (11.2)
Table 5.4. Mean (SEM) plasma TC and HDL-C concentrations (mmol/1) following
the 24% MUFA test meal
a) Control diet
Time (mins) Analyte
TC HDL-C
0 5.04 0.31 0.72 0.10
60 5.05 0.44 0.84 0.05
120 4.93 0.30 0.87 0.06
180 4.81 0.47 0.93 0.10
240 5.19 0.29 0.80 0.13
300 5.08 0.41 0.78 0.09
360 4.68 0.33 0.95 0.09
420 5.33 0.40 0.83 0.11
480 4.87 0.32 0.87 0.07
540 5.26 0.42 0.89 0.11
b) MUFA-enriehed diet
Time (mins) Analyte
TC HDL-C
0 4.53 0.27 0.68 0.07
60 4.76 0.2(9 1.03 0.09
120 4.69 0.26 0.94 0.11
180 4.71 0.26 0.90 0.09
240 4.44 0.24 0.99 0.11
300 4.69 0.24 0.99 0.12
360 4.56 0.21 0.91 0.0(9
420 4.65 0.24 0.96 0.0(9
480 4.60 0.23 0.87 0.10
540 4.38 0.25 0.86 0.06
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Table 5.5. Mean (SEM) AUC and lAUC for the postprandial plasma HDL-C and TC
responses
a) HDL-C responses
Diet AUC/IAUC mmoI/I.min)
AUC lAUC
Control
MUFA-enriehed
410.9 39.6 
446.5 39.2
11.9 29.3
81.9 34.3
b) TC responses
Diet AUC/IAUC [mmoI/l.min)
AUC lAUC
Control
MUFA-enriehed
2715.9 600.8
2498.9 112.9
-22.5 119.6 
51.9 192.3
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Table 5.6. Mean (SEM) plasma NEFA (mmol/1), GIP (pmol/1) and insulin (pmol/1) 
concentrations following the 24% MUFA test meal 
a) Control diet
Time (mins) Analyte
NEFA (mmol/1) GIP (pmol/1) Insulin (pmol/ml)
0 0.51 0.05 97.8 7^.8 61.1 27.7
60 0.182 0.01 241.5 54.0 521.6 2#2.&
120 0.17 0.02 322.1 722 560.1 #2 .P
180 0.14 0.02 319.0 72.7 441.9 2467
240 0.19 0.02 311.9 (92.P 199.6 135.1
300 0.31 0.03 266.5 121.6 ^7.2
360 0.54 0.07 266.3 72^ 71.7 31.0
420 0.73 0.08 173.4 60.7 65.8
480 0.80 0.05 123.9 ^6.6 56.5 2P.7
540 0.78 0.06 96.1 27.2 49.2 22.2
b) MUFA-enriehed diet
Time (mins) Analyte
NEFA (mmol/1) GIF (pmol/1) Insulin (mU/ml)
0 0.51 0.06 74.3 20.2 8&3 59.6
60 0.15 0.01 270.3 7&d 676.9 653.2
120 0.13 0.02 356.3 ^7.0 572.2 536.4
180 0.15 0.02 336J 104.1 525.9 402.6
240 0.22 0.03 325.2 62.2 381.2 268.6
300 0.34 0.04 273.1 (22.P 115.0 02.6
360 0.53 0.05 267.2 102.6 115.6 120.9
420 0.71 0.06 176.3 716 86.5 48.7
480 0.73 0.07 126.3 47.2 78.9 28.7
540 0.70 0.07 92.9 218 76.7 64.4
Table 5.7. Mean (SEM) AUC and lAUC for the postprandial plasma NEFA responses
Diet AUC/IAUC [mmol/l.min)
AUC lAUC
Control
MUFA-enriehed
229.3 15.4
213.4 77.2
-57.7 70.7 
-63.8 26.6
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Abstract
This paper describes the use of an antiserum, specific for apolipoprotein (apo) B-48, in a competitive, enzyme-linked immunosorber 
assay (ELISA) for apo B-48 in triacylglycerol-rich lipoprotein (TRL) fractions prepared from fasting and post-prandial plasma samples 
Previously we showed the antiserum to act as an effective immunoblotting agent following sodium dodecyl sulfate polyacrylamide ge 
electrophoresis (SDS-PAGE). Its use in this ELISA indicates that the antiserum recognises the C-terminal region of the protein on th 
surface of lipoprotein particles. The ELISA had a sensitivity of less than 37 ng/m l and intra- and inter-assay coefficients of variation c 
3.8% and 8.6%, respectively. There was no cross-reaction in the ELISA against serum albumin, ovalbumin, thyroglobulin, or apo B-10 
(purified by immunoaffinity chromatography), and high lipid concentrations (as Intralipid) did not interfere. A low density lipoprotei 
fraction reacted in the ELISA but SDS-PAGE-Westem blot analysis confirmed the presence, in the fraction, of a small amount of ap 
B-48, indicating the existence of low density dietary-derived lipoprotein particles. ELISA and SDS-PAGE-Westem blot analysis wer 
used to measure apo B-48 in 12 series of postprandial samples collected from 4 diabetic and 8 normal subjects, following test meals c 
varying fat content. The mean correlation between the two methods was r =  0.74. The mean fasting concentration of apo B-48 in th 
TRL fractions from 15 healthy men was 0.46 /xg/m l of plasma.
Keywords: Carboxy terminal peptide; Chylomicron; Dietary-derived lipid; Immunoassay; Immunoaffinity chromatography; Post-prandial profile
1. Introduction
Human populations, in general, spend the majority o f  
their day in the post-prandial state. The atherogenic poten­
tial o f post-prandial lipoproteins, chylomicrons (CM) and 
their remnants (CM-r), was postulated as early as 1979 [1]
Abbreviations: CHD, coronary heart disease; CM, chylomicron; CM-r, 
chylomicron remnants; ECL, enhanced chemiluminescence; ELISA, en­
zyme-linked immunosorbent assay; HSA, human serum albumin; LDL, 
low density lipoprotein; PBS, phosphate-buffered saline; PBSGT, phos­
phate-buffered saline containing Tween and gelatin; QC, quality control; 
TAG, triacylglycerol; TRL, triacylglycerol-rich lipoprotein; SDS-PAGE, 
sodium dodecyl sulfate polyacrylamide gel electrophoresis; VLDL, very 
low density lipoprotein.
* Corresponding author. Fax: -+44 1483 576978; e-mail: bsslbg@sur- 
rey.ac.uk.
' Present address: Department of Food Science and Technology, Uni­
versity of Reading, Reading, Berkshire RG6 2AH, UK.
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and CM-r particles are now believed to contribute to th 
risk o f coronary heart disease (CHD) either directly, o 
indirectly, by affecting the concentration and compositio 
o f other lipoprotein particles [2]. However, to date there i 
no simple, reproducible, rapid assay that can be used t 
distinguish between lipids in the circulation that are de 
rived from the diet, CM and CM-r, and those secreted b 
the liver, very low density lipoproteins (VLDL) and lo \ 
density lipoproteins (LDL).
A number o f techniques have been used in an attempt t 
separate or distinguish between these lipoproteins. Ultra 
centrifugation achieves only partial separation with signifi 
cant contamination o f the two types o f  lipoproteins in eac 
fraction. The use o f triacylglycerol (TAG) levels in plasm  
and more commonly in the TAG-rich lipoprotein fractio 
(TRL), has also been used as an indication o f  the contribn 
tion o f dietary-derived lipid to total plasma TAG, but thi 
fraction also contains TAG from VLDL. Retinyl este 
labelling o f CM, by the administration o f retinyl palmitat
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dth a meal, was first described in 1976 [3]. This technique 
ssumes that the retinyl esters are incorporated within the 
M  core, in a similar manner to cholesteryl esters, and that 
le retinyl esters are not transferred to other lipoproteins or 
îsecreted by the liver, so that quantitation o f exogenously 
dministered retinyl ester in plasma gives a measure o f  
ietary-derived lipids in the circulation. Recently, doubts 
bout the validity o f this method have been reported [4,5]. 
hese doubts have stimulated attempts to develop altema- 
ve approaches to specifically monitor lipoproteins of 
itestinal origin.
One alternative is to determine the levels o f apolipo- 
rotein B-48 (apo B-48). This apolipoprotein is uniquely 
5sociated with CM in humans [6] and is therefore the 
leal marker for intestinally derived lipids. However, apo 
-48 has an amino-acid sequence identical to the N-termi- 
al 48% of apolipoprotein B-lOO (apo B-lOO), which is 
îcreted by the liver in association with VLDL and LDL. 
herefore specific assays, especially immunoassays, are 
ifficult. High-performance liquid chromatography (HPLC) 
sing molecular sieving for separation has been described 
,8] but has given exceptionally high values. Another 
aproach is pre-separation of these two proteins by elec- 
ophoresis. Densitometric scanning o f Coomassie brilliant 
ue stained SDS-PAGE gels was first reported by Kane 
id colleagues in 1980 [6]. Since then it has been used 
iccessfully by many investigators [9-11], although the 
quirement for long ultracentrifugation spins and low  
:nsitivity limit the use of this method for large scale 
ast-prandial studies. Immunoblotting o f gels and the ap- 
ication o f specific antisera, against apo B [12] and specif- 
ally against apo B-48 [13,14] has been successfully used
quantify apo B-48 giving greater sensitivity and speci- 
:ity compared with protein staining.
With all o f the techniques described, there are inherent 
oblems with specificity, sensitivity, reproducibility, cost, 
ne and sample throughput. To date, a specific im- 
unoassay has not been developed for routine determina- 
)n o f apo B-48. Brasaemle and colleagues described a 
mi-quantitative enzyme-linked inununosorbent assay 
L ISA ) system for apo B-48. They used a non-specific 
itiserum raised against apo B-lOO, from which they 
lected only those immunoglobulins that bound to apo 
-48. These so-called affinity-purified apo B-48 specific 
)lyclonal antibodies were used in a sandwich ELISA for 
)th capture and detection. Although apo B-48 was the 
ain antigen measured, apo B-lOO was about 50% as 
active [15].
This paper describes a specific ELISA for the quantita- 
)n o f apo B-48 in human TRL fractions using the previ- 
isly described specific polyclonal anti apo- B-48 anti­
rum [13]. Validation o f the assay, comparison with the 
)S-PAG E immunoblot system and its application in the 
termination o f post-prandial apo B-48 profiles in sub- 
:ts after various test meals is presented and discussed.
2. Materials and methods
2.1. Human lymph standard and quantitation o f  apo B-48
Human thoracic duct lymph from a patient undergoing 
thoracic surgery was kindly supplied by Dr. J. Wright 
(Royal Surrey County Hospital, Guildford, UK). This was 
treated with preservative 5% (v /v ) ,  according to the 
method o f Edelstein and Scanu [16], to prevent degradation 
and was stored frozen at — 20°C. The preservative con­
tained; EDTA, sodium azide, sodium chloride (Merck, 
Lutterworth, UK), aprotinin, benzamidine, chloramphe­
nicol and gentamicin sulfate (Sigma, Poole, UK). W e are 
indebted to Dr. Frederik Karpe for quantitating the abso­
lute amount o f apo B-48 and apo B-lOO within the lymph 
standard sample using SDS-PAGE separation followed by 
Coomassie brilliant blue staining [11] o f the lymph sample. 
The values for apo B-48 and apo B-lOO within the stan­
dard lymph sample were 19.1 Atg/ml and 42.9 /xg /m l, 
respectively.
2.2. Raising o f  specific antiserum
The previously described method for raising a specific 
antiserum to apo B-48 was used with minor modifications 
[13]. In brief, a heptapeptide consisting o f an N-terminal 
cysteine residue attached to the C-terminal hexapeptide 
equivalent to residues 2147-2152  o f apo B-48, was cus­
tom-synthesised at the National Institute o f Medical Re­
search (Mill Hill, London, UK). This peptide was conju­
gated to ovalbumin using V-succinyl-6-maleimidocaproate 
(Fluka Biochimika, Buchs, Switzerland) according to the 
protocol described by Peeters et al. [17] so that the nega­
tively charged a-carboxyterminal end, which is combined 
in a peptide bond in apo B-lOO, was freely accessible. 
Conjugate, containing peptide, was emulsified in non­
ulcerative Freund’s incomplete adjuvant (gift from B.A. 
Morris, University o f Surrey, Guildford, UK) and injected 
intradermally into a New Zealand White rabbit. After 24 
months the animal was boosted in 4 intra-muscular sites 
with conjugate containing the equivalent of 100 p g  o f 
peptide. Blood was collected on days 8, 10 and 13 after 
boosting and the antiserum titre was measured by a com­
petitive ELISA system.
2.3. Specific apo B-48 ELISA protocol
The coating conjugate was prepared by conjugating the 
same C-terminal heptapeptide to porcine thyroglobulin 
(Sigma, Poole, UK) using V-succinimidyl 3-(2-pyiidyl- 
dithio)propionate (Fluka Biochimika, Buchs, Switzerland) 
following the method described by Carlsson [18]. The 
inner 60 wells o f a Nunc Maxisorp microtitre plate (Nunc, 
Roskilde, Denmark) were coated with 100 p \  o f coating 
conjugate at a final dilution o f 1:8000 in 0.1 M bicarbon-
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ate/carbonate buffer (pH 9.4). This was incubated at 4°C 
overnight in a humid container. After washing with 0.05 M  
phosphate-buffered saline (PBS) containing 0.05% ( v /v )  
Tween 20 and 0.1% ( w /v )  gelatin pH 7.6 (PBSGT) the 
plate was blocked by incubation with 120 p \  o f PBSGT at 
37°C for 1 h. The wells in the microtitre plate were then 
emptied to receive the preincubated samples (see below). 
Subsequent incubations were at 37°C, unless otherwise 
stated, and all washing steps used PBSGT.
A 9-point standard curve was prepared by serial dilution 
of the neat standard lymph in human serum albumin 
(HSA; Sigma, Poole, UK), 35 mg H S A /m l in PBS, 
resulting in a concentration range of apo B-48 from 19.1 
/L g/m l to 37 n g /m l. Pooled plasma samples were col­
lected from fasting individuals, for the low concentration 
apo B-48 quality control (QC), and post-prandial samples 
for medium and high QC samples. The 9-point standard 
curve, the 3 undiluted quality controls and the undiluted 
TRL samples were pre-incubated with equal volumes of 
the specific anti-apo B-48 antisera (at a final dilution of 
1:250000) at ambient temperature for 1 h. After this 
pre-incubation step, 100 p \  o f the standards, QCs and 
samples were added in duplicate to the appropriate wells 
on the microtitre plate and incubated for 2 h. The plates 
were washed and 100 p \  o f the secondary antibody-en- 
zyme conjugate, donkey anti-rabbit antibody (Clifmar, 
University o f Surrey, Guildford, UK) conjugated to horse 
radish peroxidase (Boehringer Mannheim, Lewes, UK) by 
the method o f Beyzavi et al. [19], were added to the plate 
at a final dilution o f 1:30000. The plate was incubated for 
a further 2 h, washed and 100 p \  o f 3,3',5,5'- tetramethyl- 
benzidine (Boehringer Mannheim, Lewes, UK) substrate 
was added. The plate was incubated for 30 min and, after 
the reaction had been stopped by the addition o f 50 p \  o f 1 
M HCl, the absorbance was read on an automated ELISA 
plate spectrophotometer (Labsystems, Basingstoke, UK) at 
450 nm. A  standard curve was constructed and the amount 
of apo B-48 within the QCs and samples was determined 
by reading from this curve.
2.4. Optimisation o f  ELISA
The optimum incubation temperature and time, buffers, 
plates and analyte concentrations were determined at each 
step o f the competitive ELISA system.
2.5. Validation o f  ELISA
All routine validation tests were performed on the 
ELISA. These included intra- and inter-assay reproducibil­
ity, sensitivity (2 S.D. from zero), parallelism, recovery of 
a known amount o f apo B-48 from a spiked sample and 
1 cross-reactivity/interference o f other materials. The pro- 
\ teins tested for cross-reactivity included: ovalbumin, the 
\  carrier protein used to produce the antisera, from 1 m g /m l
to 3.9 /Lg/m l; HSA, which is structurally similar to oval­
bumin and the most abundant protein in plasma, from 70 
m g /m l to 0.27 m g/m l; thyroglobulin, the protein used to 
produce the coating conjugate for the ELISA, from 1 
m g /m l to 3.9 p g /m [ \  and apo B-lOO, since its first 2152 
amino acid residues are identical to those o f apo B-48, 
from 50 ^ tg /m l to 0.2 pg /vsA  within the assay. The 
possibility o f interference by lipid particles was assessed 
by using Intralipid (Kabi Pharmaceuticals, Milton Keynes, 
UK) in the range from 20 m g /m l to 78 /x g /m l. Since 
pure apo B-lOO is not commercial available a sample foi 
determination o f cross-reactivity was prepared by affinity 
purification (see section below). In addition to this affinity 
purified apo B-lOO, a fasting LDL sample, prepared fol­
lowing the method o f Mackness and Durrington [20], was 
also used to assess cross-reactivity.
2.6. Affinity purification o f  apo B-IOO
C-terminal specific anti-apo B-lOO monoclonal antibod­
ies were used for the preparation o f apo B-lOO lipoproteir 
particles free from contamination by apo B-48 containing 
lipoproteins. The solid phase matrix used for the affinity 
colunms was 3000 A porous amino-activated silica bead: 
(Clifmar, University o f Surrey, Guildford, UK). Specific 
monoclonal antibodies, raised against the C-terminal enc 
of apo B-lOO which therefore did not cross-react with ape 
B-48, were bound to these beads. The monoclonal antibod 
ies were BL3 (gift from Sanofi, Montpellier, France) 
MB43 and MB47 (gift from L.K. Curtiss, Sciipps Re 
search Institute, California, USA). The specificity o f eacl 
of these antibodies has been assessed and reported [21-23]
Plasma prepared from fasting blood samples was usee 
for the isolation o f apo B-lOO associated lipoproteins. The 
columns were washed thoroughly with PBS before 1 ml o 
the plasma was allowed to run into the column bed. Thi 
column was then rolled at ambient temperature for 30 min 
The column was washed thoroughly with excess PBS. T< 
elute the bound apo B-lOO containing lipoprotein particles 
3 M sodium thiocyanate was added to the column and thi 
eluate was collected. This was inunediately dialysed agains 
3 changes o f 0.02 M boric acid buffer (0.02 M boric acid 
0.15 M NaCl, 1 mM EDTA) pH 8.0 [22]. The purity o f th 
eluted samples were then assessed on the SDS-PAGl 
Western blot system using a polyclonal sheep anti-apo I 
antiserum (Boehringer Mannheim, Lewes, Sussex, UK) a 
a dilution o f 1:1500. The samples were pooled and concen 
trated by using a 25 p m  YMIOO membrane in a Diafl 
Ultrafiltration Unit (Amicon, Beverley, USA). The ap 
B-lOO concentration o f the concentrated, purified apo B 
100 sample was assessed by automated turbidimetric anal 
ysis using a Unimate 3 apo B kit (Roche, W elwyn Garde 
City, UK) and the degree o f cross-reactivity was the 
determined using the specific apo B-48 ELISA.
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7 . Correlation with SDS-PAGE and immunoblot
As an additional validation test, 12 post-prandial TRL 
po B-48 profiles (described below) were determined by 
sing the specific apo B-48 antisenim in the SDS-PAGE  
/estem  blot system (at a dilution o f 1:10000) following  
le method of Peel et al. [13]. In this method the blot was 
isualised by an enhanced chemiluminescence system  
ECL), according to the manufacturer’s instructions 
\m ersham . Little Chalfont, UK), and quantitated by den- 
itometry, using a Shimadzu CS-9001 PC (Howe, Ban- 
ury, UK) against an internal standard. The values ob- 
lined were correlated, using the Pearson’s correlation, 
/ith the apo B-48 values determined by the specific 
LISA . Molecular weight markers for SDS Gel Elec- 
rophoresis, high range (29 000 -205  000; from Sigma, 
)orset, UK) were run routinely on all gels. These were 
ised to check for correct running o f the gel electrophoresis 
nd electrotransfer, by reversible staining with Ponceau S 
if the nitrocellulose membranes following transfer.
!.S. Post-prandial samples
The post-prandial profiles consisted o f hourly blood 
amples taken after a test meal over an 8 to 12 h period, 
îamples were taken from 12 subjects: subjects 1 to 4 were 
liabetic men (5 1 -5 6  years), subject 5 was a middle-aged 
lealthy man (56 years) and subjects 6 to 12 were young 
lealthy men (1 8 -3 0  years). The test meals given to the 
lubjects were all mixed meals using normal foods and 
containing protein, fat and carbohydrate with either a high, 
nedium or low  fat content. The diabetic subjects con- 
mmed a standard breakfast, lunch, mid-afternoon snack 
ind then consumed the test meal in the evening. This 
contained: 4.7 MJ energy, 50 g fat, 38 g protein and 140 g 
carbohydrate. The remaining subjects consumed test meals 
after a 12 h overnight fast. Subjects 9 and 10 consumed a 
low fat test meal containing 4.2 MJ energy, 21 g fat, 44 g 
protein and 168 g carbohydrate. Subjects 6, 7 and 8 
consumed a medium fat test meal containing: 4.2 MJ 
energy, 43 g fat, 24 g protein and 150 g carbohydrate. 
Subjects 5, 11 and 12 consumed a high fat test meal 
containing 6.4 MJ energy, 82 g fat, 43 g protein and 167 g 
carbohydrate. A ll meals were consumed within 20 min.
2.9. Triacylglycerol rich lipoprotein fraction (TRL) prepa­
ration
Blood samples were collected into heparinized blood 
tubes and spun immediately for 7000 g  min in a bench 
centrifuge. The plasma sample, 3.5 ml, was collected, 
overlayered with an equal volume o f saline solution (1.006  
g m l“ Q, and ultracentiifuged for 5.0 X 10^ [24]
at 24°C in a 30 ml centrifuge tube to prepare the TRL 
fraction using essentially the method o f Grundy and Mok 
[25]. This allowed the flotation o f larger, less dense TRL 
particles o f densities <  1.006 g /m l. Normally, 1.2 ml of  
the upper layer, the TRL fraction was carefully removed 
and added to preservative 5% (v /v ) ,  prepared by the 
method o f Edelstein and Scanu [16] as described previ­
ously, mixed, aliquotted and frozen at — 20°C for later 
analysis by ELISA and SDS-PAGE Western blot analysis.
2.10. Quantitation o f  apo B-48 in normal TRL
Blood samples were obtained from 15 healthy, non­
smoking Caucasian men, on 3 occasions after a 12 h 
overnight fast. Their age and BMI were (mean ±  S.D.) 
22.3 ( ± 3 .2 )  years and 23.0 ( ± 2 .0 )  k g /n P  respectively, 
whilst 39% of their normal dietary energy intake was 
derived from fat, with a P:S ratio o f 0.46. TRL fractions 
were prepared as described above.
3. Results
3.1. Specific apo B-48 antiserum and ELISA
The method for raising the antiserum to apo B-48 was 
successful. The pooled bleed, taken at day 13 after the 
boost, was used routinely for both the SDS-PAGE Western 
blot system and the ELISA. The antiserum had a high titre 
of 1:100 000 assessed by ELISA. The ELISA was opti­
mised and validated. An acceptable standard curve was 
obtained by using double diluted lymph and this allowed 
all o f the TRL fractions tested to be quantified without 
sample dilution or standard curve extrapolation. Fig. 1 
shows a typical standard curve. The intra- and inter-assay 
coefficient o f variation for the 3 quality control samples
Table 1
Intra-assay and inter-assay coefficient of variation (CV, %) for high, medium and low quality controls, which are routinely included in the apo B-48 
ELISA
Quality
control
sample
Mean
( /rg of apo B-48/ml) + S.D. 
(n = 6)
Intra-assay CV (%)
( pg  of apo B-48/ml) ± S.D. 
(n =  6)
Mean
CV(%)
Inter-assay
Low 4.09 ±0.19 4.5 3.95 ±  0.36 9.0
Medium 13.00 ±  0.50 3.8 12.97 ± 0.97 7.5
High 16.10 ±0.52 3.2 16.12 ± 1.50 9.3
Mean value 3.8 8.6
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Fig. 1. Typical standard curve for the apo B-48 ELISA, prepared by 
diluting human lymph (neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256) 
( - • - ) .  Absorbance values for a serially diluted (neat, 1:2, 1:4, 1:8, 
1:16, 1:32) TRL sample (O), prepared from a blood sample taken 4 
hours after an 80 g fat test meal, are included to illustrate parallelism 
between sample and standard.
was low, with mean values o f 3.8% and 8.6% respectively, 
as shown in Table 1.
As an additional validation test for reproducibility o f  
the ELISA, four series o f  post-prandial TRL-rich samples 
obtained from subjects 1, 4, 6 and 9 were assayed on 2 
different occasions and correlations o f repeat determina­
tions calculated. All o f the profiles were significantly 
correlated with a mean ‘r ’ value o f 0.92 as shown in Table 
2.
A ll TRL fractions tested (n  =  5) ran parallel to the 
standard. An example is shown in Fig. 1. The sensitivity of 
the ELISA, defined as 2 SD from zero, was less than 37 
n g /m l and the recovery o f samples spiked with apo B-48 
containing fractions in the range o f 19 .1-5 .7  / tg /m l  
showed a recovery o f 102 +  10%.
The ELISA showed negligible cross-reactivity to other 
proteins, including HSA, thyroglobulin and ovalbumin, 
and negligible interference by a Hpid emulsion (Fig. 2).
3.2. Apo B-lOO affinity purification and cross-reactivity in 
ELISA
The purification o f apo B-lOO containing lipoprotein 
particles using 3 different C-terminal specific anti-apo
Table 2
The correlation cefficients, r, between the post-prandial TRL apo B-48 
concentration measured by ELISA on 2 separate occasions in 4 subjects 
(each with 14 time points over an 8 h period)
Subject
number
Correlation 
coefficient (r)
Significance
( f )
1 0.98 0.0001
4 0.94 0.0001
6 0.80 0.0011
9 0.94 0.0045
I
<
P ro te in  o r  L ip id  (pg /m i)
Fig. 2. Standard ELISA curve for apo B-48 in diluted human lymp 
( -  #  - )  and the corresponding plots for the much higher concentratior 
of the proteins thyroglobulin ( -  □ -), ovalbumin ( -  ■ - )  and HSj 
( -  ° -) , and a set of values for Intralipid (- ▲ -).
B-lOO monoclonal antibodies bound to amino-activate 
porous silica beads was successful. Elution with 3 h 
thiocyanate and dialysis against 0.02 M boric acid buffe 
proved to be the optimum conditions, after assessing man 
different combinations o f elution and dialysis buffers. Th 
apo B-lOO lipoproteins were not degraded and the sample 
were free from all apo B-48 associated lipoproteins, whe 
assessed on the SDS-PAGE Western blot system [13 
Since the apo B-lOO lipoproteins were isolated from 
plasma sample, it was assumed that a mixture o f différer 
lipoprotein sizes were present. Ultrafiltration concentratio 
of these apo B-lOO lipoprotein particles proved successfu 
resulting in a sample which contained 50 /r .g/m l o f ap 
B-lOO, quantified by immunoturbitimetric analysis. Thi 
value was approximately equivalent to the concentration c 
apo B-lOO found in the TRL fractions. No cross-reactio 
was found when this apo B-lOO-containing sample was ru 
in the ELISA as shown in Fig. 3.
The LDL preparation, which contained 1.1 m g /m l c 
apo B-lOO when quantified by immunoturbidimetric anal) 
sis, was found to contain a small quantity o f apo B-4  
when analysed on the SDS-PAGE Western blot systen 
and this was approximately equivalent to the concentratio 
found in a typical TRL fraction from a fasted subjec 
When tested in the ELISA, both the LDL preparation an 
the fasted TRL fraction showed similar displacement: 
Because o f the clear evidence from the Western blot o f th 
presence in the LDL preparation o f apo B-48 (see Fig. f 
lane 3) it was concluded that the displacement obtained o 
ELISA analysis o f the LDL preparation was caused by th 
presence o f apo B-48 rather than cross-reactivity with th 
apo B -100 in LDL.
3.3. Correlation with SDS PAG E and immunoblot an 
fasting value
Apo B-48 concentrations in the TRL fractions wei 
analysed in 137 samples o f varying apo B-48 concentn
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I
I
2
I
<
g. 3. Standard ELISA curve for apo B-48 in diluted human lymph 
• - )  and the corresponding values for a sample of immunoaffinity- 
rified apo B-lOO containing particles ( -  ° -).
3ns. These were post-prandial samples from 12 subjects 
ho consumed 4 different test meal. Analysis was carried 
It using the same antiserum in both the SDS-PAGE  
'estern blot and the optimised ELISA methods which 
tabled quantitation o f apo B-48 in arbitrary and absolute 
lits, respectively. The values obtained were compared 
ling Pearson’s correlation and were found to be signifr- 
intly correlated as shown in Table 3, with a mean ‘r ’ 
due o f 0.74. An example o f the apo B-48 concentrations, 
;termined by both methods for subject 12, is shown in 
g. 5. A typical post-prandial immunoblot is shown in 
g. 4. The diffuse, low  molecular weight bands in lanes 
-13 were produced by non-specific binding o f the second 
itibody (donkey anti-rabbit IgG conjugated to peroxi- 
ise). These were the only bands visible when the first 
Itibody, rabbit anti-apo B-48, was omitted (result not 
own).
The post-prandial apo B-48 analysed in the ELISA from
ble 3
le correlation coefficients, r, between the post-prandial TRL apo B-48 
ncentrations measured by the quantitative ELISA method and the 
ni-quantitative SDS-PAGE Western blot method in 12 subjects over 
/eral time points
bject Number of Correlation Significance
mber time points coefficient (r) (P )
13 0.76 0.0025
13 0.70 0.0076
13 0.61 0.025
13 0.52 0.07
9 0.84 0.0045
12 0.75 0.005
12 0.80 0.0011
13 0.79 0.001
10 0.73 0.10
7 0.78 0.038
11 0.66 0.0024
11 0.90 0.0002
100
0 1 0 1 2 3 4 5 6 7
T im e (h)
Fig. 4. Comparison of the apo B-48 post-prandial profiles in TRL 
fractions determined using the SDS-PAGE Western blot system followed 
by ECL and densitometry ( -  ° - )  and the specific apo B-48 ELISA 
( -  #  -). The subject was a young male who consumed a test meal 
containing 80 g fat, after a 12 hour overnight fast, at zero time, (r  = 0.9, 
P = 0.0002.)
subjects 5 -1 2  (see Table 3), who were fasted before 
consuming the test meal, showed similar patterns. The 
time o f the peak apo B-48 value varied between individu­
als due to the heterogeneous age range and the different 
amount of fat consumed in the test meal. The mean apo 
B-48 peak was at 263 min, ranging from 120 to 360 min, 
and the mean peak apo B-48 rise from fasting values in the 
TRL fractions was 4.5-fold, ranging from 2.4- to 9.5-fold, 
when assessed using the ELISA.
In 15 healthy men, the mean ( +  S.D.) fasting concentra­
tion o f apo B-48 in their TRL fractions was 0.46 (± 0 .2 7 )  
)Ltg/ml of plasma.
I.a iic  Nmiilx-r
5 A T h V 10 11 12 13
. ■ — — - <— A po JI-48
Fig. 5. Apo B-48 pattern of an LDL preparation and TRL samples before 
and after a test meal. Separation was achieved by SDS-PAGE followed 
by electrotransfer to nitrocellulose membranes, incubation with rabbit 
anti-apo B-48, blocking and washing with phosphate-buffered saline 
containing ‘Marvel’ and Tween, and incubation with donkey-anti-rabbit- 
IgG-peroxidase. The apo B-48 bands were then visualised by ECL. Lane 
1, molecular mass markers; lane 2, internal standard, high in apo B-48; 
lane 3, LDL preparation; lanes 4-13, TRL fractions, fasting sample 
immediately preceding the test meal (lane 4), and 30 min, 1 ,2 ,3 , 4, 5,6, 
7, 8 h after the test meal (lanes 5-13).
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4. Discussion
The specific anti-apo B-48 antiserum raised in a rabbit 
against the C-terminal sequence o f the apo B-48 using the 
appropriate peptide, as a hapten, conjugated to ovalbumin, 
proved very successful. The conjugation procedure al­
lowed the peptide to be specifically conjugated to the 
carrier protein via the sulfhydryl group o f the N-terminal 
cysteine residue o f the heptapeptide to ensure accessibility 
o f the C-terminal. The delay o f 24 months between prim­
ing and boosting the rabbit proved beneficial, producing a 
very specific, high titre antiserum compared with the anti­
serum produced after only a 6 week period [13]. When this 
antiserum was used in the Western blot procedure it 
produced a sharp band which was identified as apo B-48 
due to its size, and position just above the 205 kDa 
molecular mass marker. The absence o f a band o f greater 
size in the Western blot system proved the lack o f cross-re- 
activity o f this antiserum with apo B-lOO, which is present 
in TRL fractions at concentrations o f 50- to 100-fold that 
of apo B-48. The presence o f a more diffuse band o f much 
lower molecular mass, which seemed to run just before 
albumin, and bands in the marker lane were due to non- 
I specific binding o f the anti-rabbit-peroxidase-labelled sec­
ond antibody used prior to the visualisation step.
A  specific, sensitive, robust and easy to use competitive 
ELISA for the accurate quantification o f apo B-48 in TRL 
fractions, in fasting and post-prandial samples, has been 
successfully developed. During the assay development a 
number o f ELISA formats were investigated. The first 
ELISA format attempted was a sandwich ELISA, however, 
this proved ineffective since it resulted in high non-specific 
binding. The competitive ELISA system proved to be the 
most appropriate system to use and was therefore opti­
mised and validated. The results from the validation tests 
performed indicated that a sensitive, reproducible assay 
was developed. The inter- and intra-assay reproducibility 
was very low for an ELISA system and it compares well 
with other assay systems, such as the SDS-PAGE system  
reported by Karpe and Hamsten [11], who reported an 
intra-assay CV of 9.8% for apo B-48 determination in the 
TRL fraction. Sample linearity, or parallelism, was excel­
lent illustrating that if  dilution o f the sample was required 
this would not compromise the accuracy o f the measure­
ment.
Determination o f the cross-reactivity o f other sub­
stances within any assay system is essential. None o f the 
substances tested cross-reacted within our ELISA system, 
even when used in large excess. The proteins chosen for 
cross-reactivity were the two proteins used as conjugation 
partners for the immunogen and coating conjugate, ovalbu­
min and thyroglobulin respectively. HSA was also tested 
as this was of similar structure to ovalbumin and was in 
high concentrations in all o f the TRL samples. Due to the 
high lipid content o f the TRL samples (0 .1 -2 5 .0  m m ol/1) 
it was important to test the effect o f lipid in the assay to
determine whether any non-specific binding or interaction 
with the antibody binding occurred. Intralipid, which is 
routinely used for intravenous feeding, contains 20% fat 
and was used in the ELISA to test the effect o f high lipid 
content. As with the other substances tested, this did not 
cause cross-reaction in the assay.
Due to the identical chemical structure o f apo B-48 with 
the N-terminal 2152 amino acids o f apo B-lOO, it was 
essential to ensure that cross-reactivity o f this lipoprotein 
within the assay was negligible. As reported previously, 
the specific antiserum to apo B-48 did not cross-react with 
apo B-lOO when used in the SDS-PAGE Western blol 
system [13]. The fact that the antiserum reacted with ape 
B-48, and not with apo B-lOO, indicates that the negatively 
charged a-carboxyl group o f the C-terminal ile-2152, 
which is part o f a peptide bond in apo B-lOO, is ar 
essential feature for antibody-antigen recognition. The de­
velopment o f an ELISA, also specific for apo B-48, re­
quires that this charged group is accessible on the surface 
of chylomicron particles.
A  pure apo B-lOO lipoprotein sample was prepared by 
immunoaffinity chromatography. The three apo B-lOO spe­
cific monoclonal antibodies: M B43, M B47 and BL3, al 
directed at the C-terminal half o f apo B-lOO, proved to be 
adequate as ligands on the affinity colunms. Sample: 
purified using these antibodies, when tested on the SDS 
PAGE Western blot system using the polyclonal anti-ape 
B antiserum, were free from apo B-48. This supported dat; 
reported previously on the specificity o f these antiser; 
[21-23]. For elution o f the bound apo B-lOO lipoproteins ■ 
M sodium thiocyanate was found to be the most favourabl( 
reagent, which supported the findings o f other groups [26] 
The solid phase that has been reported to be the mos 
appropriate for lipoprotein purification was cyanogen bro 
mide activated Sepharose 4B-CL (Pharmacia) [26,27]. Al 
though this was used for affinity column preparation in ai 
early part o f this study, the amino-activated 3000 A  porou 
silica was found to be adequate for this application, witl 
the advantage o f being a more robust matrix, and wa 
therefore used routinely for immunoaffinity purification o 
lipoprotein particles. Successful isolation and concentra 
tion o f apo B-lOO lipoproteins was achieved and whe: 
used in the apo B-48 ELISA showed no cross-reaction.
As an additional test, an LDL sample, with an ap 
B-lOO concentration o f 1.1 g /1  which is close to the top c 
the normal range in plasma [28], was also tested in th 
ELISA. When this LDL sample was analysed in the ELlSv 
the value found corresponded to the low  amount o f ap 
B-48 shown to be present within the sample by Wester 
blot analysis and there was no evidence o f cross-reactivit 
with the much higher apo B-lOO compared to apo B-4  
concentration. The novel finding o f apo B-48 in the LD] 
sample is important and illustrates the sensitivity o f th 
two assay methods developed with the specific apo B-4 
antiserum. These low  density apo B-48 containing particle 
warrant further study.
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The last validation step that was used to assess the 
pecificity o f the apo B-48 lipoprotein determination, was 
le correlation between the apo B-48 post-prandial values 
btained utilising the SDS-PAGE Western blot system, 
sing the specific anti-apo B-48 antiserum, and the ELISA.
1 the SDS-PAGE system the lipoprotein particles are 
isrupted and the proteins denatured. Then the proteins are 
sparated according to size, excluding the possible interfer- 
nce o f other substances, such as apo B-lOO, in the 
etermination o f the apo B-48 levels. Statistically signifi­
ant correlations (mean value r =  0.74) were found for the 
ost-prandial profiles which were determined using the 
VO assay systems despite the presence o f significant 
mounts o f apo BIGG in the TRL fractions. Since this 
orrelation was between a semi-quantitative and a quantita- 
ve assay it was very encouraging. This adds further 
vidence that the ELISA is specifically detecting apo B-48 
ither than apo B-IGG. These rigorous tests proved that the 
ntiserum itself, and the ELISA system using this anti- 
3rum, did not significantly cross-react with apo B-lGG 
poproteins present within the samples. This is an impor- 
mt breakthrough in the quest for reliable and accurate 
lethods for the determination o f dietary derived lipids. In 
ddition, due to the minimal sample preparation, loss o f 
po B-48 is prevented, thereby enabling an accurate deter- 
lination o f the level o f this protein in biological samples.
For any assay system an appropriate standard is re- 
uired. The most applicable standard is a purified sample 
lat is in a matrix similar to that o f the samples to be 
nalysed [29]. However there is no widely accepted refer- 
nce material for any lipoprotein [29]. W e believed it was 
nportant to choose a standard for the ELISA that con­
fined apo B-48 which was associated with lipid and in the 
ative lipoprotein form to mimic that o f the chylonficron 
po B-48 in the TRL fraction. Delipidated fractions were 
lerefore not considered as appropriate standards. Instead, 
lymph sample which contained high apo B-48 levels 
ompared with TRL fractions and plasma levels was 
lought to be the most appropriate standard to use. When 
fis sample was used in the ELISA system it resulted in an 
cceptable standard curve. Although the lymph sample was 
Lch in apo B-48, it did contain 2.2 times its concentration 
f  apo B-IGG. However, due to the very rigorous valida- 
on o f the ELISA we were confident that this relatively 
3W concentration o f apo B-IGG would not interfere with 
le  specific detection o f apo B-48 lipoproteins within the 
amples when assessed using the ELISA, and the lymph 
ample was used routinely as the standard in the ELISA, 
'he origin o f the apo B-IGG in human lymph needs further 
tudy. Although apo B-48 is undoubtedly the major form 
f  apo B produced in enterocytes, two studies o f human 
îjunal biopsy tissue suggest that the capacity for apo 
i-lGG synthesis is retained in the small intestine o f chil- 
ren and adults, and that this may represent approximately 
G% of the total apo B production [3G,31]. However, the
apo B-IGG may come by transfer o f lipoprotein particles 
from the plasma [32].
Due to the heterogeneous group o f subjects and the 
differing test meals ingested by the subjects the post-pran- 
dial samples analysed represent a wide range o f typical 
fasting and post-prandial apo B-48 concentrations The 
mean change in apo B-48 concentration from fasting to the 
peak, was approximately 4.5-fold, ranging from 2.4- to 
9.5-fold in subjects who had been fasted for a 12 hour 
period before test meal ingestion. This supports the finding 
o f other groups who have investigated the post-prandial 
apo B-48 response. Cohn and colleagues [33] reported a 
4-fold increase in apo B-48 in peak lipaemia at 3 hours 
post-prandially. Schneeman’s group [IG] found that apo 
B-48 increased from G.15 m g /d l to G.4 m g /d l at the peak 
at 3 h, and Karpe and colleagues [11,34] reported 2- to 
7-fold increases in apo B-48 levels from fasting to peak 
lipaemia, depending on the fraction considered. In most 
studies, the peak apo B-48 concentration was reported to 
occur at 3 h post-prandially. However, in these studies 
blood sampling was only performed every 3 hours and the 
true peak apo B-48 concentration may have been missed. 
In our study, in which sampling was carried out hourly, we 
found the peak apo B-48 concentration between 12G and 
36G min with a mean value o f 263 min. The reported 
changes in apo B-48 concentrations during the post-pran­
dial period using the ELISA were comparable with other 
published figures and those detemfined by our group using 
the SDS-PAGE Western blot system [13].
The fasting value for apo B-48 in the TRL fraction for 
15 healthy men was G.46 / ig /m l  o f plasma. This value is 
directly dependent upon the calibration o f our lymph stan­
dard by Karpe. Our TRL fraction, which was obtained 
using a slight modification of the method of Grundy and 
Mok [25], involved a 3G min spin (5.G X IG  ^ g  min). The 
reason for using this short spin is that we wish to follow  
the postprandial profile o f chylomicrons over an extended 
period at frequent intervals. Other workers have measured 
apo B-48 in fasting TRL fractions or VLDL/chylom icron  
fractions. These workers have used prolonged spins so that 
their fractions contain more chylonficron remnants and 
their values for apo B-48 are larger than ours. In some 
cases it is not clear whether the values quoted are for 
plasma or the TRL fraction. Seishima et al. [35] reported a 
value o f G.68 jxg apo B -4 8 /m l o f plasma after centri­
fuging for l.G X IG  ^ g  min. Schneeman et al. [IG] ob­
tained a value o f 1.5 apo B-48 ^ g /m l,  whilst Kotite et al. 
[36] found a value o f 2.5 ^ g /m l,  in both cases after 
centrifuging for l.G X IG  ^ g min. Another explanation for 
our lower values would be loss o f material. In fact this is 
more likely to occur when small volume, filled and capped 
ultracentrifuge tubes are used rather than the 3G ml open 
tubes used in this study. W e are aware that this loss has 
occurred in samples provided to us from collaborative 
investigators, who have used small volume, capped tubes.
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This paper has described an ELISA which is quick, 
sensitive, easy to perform, reproducible and above all 
specific for the quantitation o f apo B-48 in fasting and 
post-prandial TRL samples. Its application is wide and in 
combination with detailed post-prandial studies has the 
potential o f increasing our understanding o f the influence 
o f dietary derived lipids in the pathogenesis and progres­
sion o f diseases such as CHD. However, the wide range o f  
values reported by different groups for apo B-48 in their 
fasting TRL fractions, prepared and measured by different 
methods, indicates that collaboration between these groups 
is essential so as to give greater confidence in the values 
obtained.
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